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ABSTRACT  
In Vitro Cell Models of Vascular Calcification: Integrative Roles for RANKL and TRAIL 
Emma Harper  
Cardiovascular death remains the leading cause of mortality in type-2 diabetes mellitus, in 
which a high prevalence of vascular calcification (VC) is a significant risk factor. VC 
contributes to cardiovascular burden, with many diabetic sufferers succumbing to cardiac 
disease and stroke. Research indicates that key proteins observed in circulation, namely 
receptor-activator of NF-κB ligand (RANKL) and tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL), interact with each other to regulate the calcification process. Whilst 
it is clear that RANKL promotes VC, in part via endothelial paracrine signalling, the precise 
role of TRAIL in this context remains undefined. Nonetheless, recent studies suggest a 
protective role for TRAIL in a vascular setting. Thus, we hypothesised that TRAIL inhibits VC 
via attenuation of RANKL-induced pro-calcific signalling. We also considered the individual 
effects of RANKL and TRAIL in the presence of relevant pathological stimuli (inflammation, 
hyperglycemia), and investigated how TRAIL may interfere with key pro-calcific pathways in 
the vasculature from a mechanistic perspective.  
Human aortic endothelial cells (HAECs) and smooth muscle cells (HASMCs) were cultured in 
mono- and co-culture formats, the latter approximating the paracrine signalling axis of the 
vasculature. Both cell types were routinely exposed to RANKL +/- TRAIL. Following analysis 
of a wide range of VC-related indices, it was found that TRAIL co-incubation robustly 
attenuated RANKL-induced endothelial paracrine signalling, thereby preventing calcification 
in the underlying smooth muscle. Under inflammatory and hyperglycemic conditions, RANKL 
contributed to the promotion of pro-calcific signalling, whilst TRAIL exhibited a protective 
influence on vascular cells. Furthermore, it was found that RANKL induced non-canonical NF-
κB signalling and oxidative stress in the promotion of VC, whilst TRAIL exerted its protective 
influence via anti-oxidant effects and attenuation of the non-canonical NF-κB pathway. This 
data therefore yields valuable mechanistic information on VC pathogenesis, and on the 





















1.1 Background  
Cardiovascular disease (CVD) remains a leading cause of mortality among patients with type-
2 diabetes mellitus (T2DM), in which a high prevalence of vascular calcification (VC) is a 
significant contributing risk factor (Rubin and Silverberg, 2004). The VC process, analogous 
to that of bone morphogenesis, can generally be described as a form of progressive arterial 
hardening that results in reduced vessel elasticity (Demer, 1991), ultimately increasing the risk 
of future cardiovascular events. There are two major forms of calcification; intimal 
calcification, which involves lipid and cholesterol accumulation under the damaged endothelial 
monolayer, and medial calcification, also known as Mönckeberg’s sclerosis, which involves 
mineral deposition within the vessel smooth muscle layer (Proudfoot and Shanahan, 2001). 
The term “VC” conventionally refers to calcification within the medial arterial layer, the prime 
focus of this thesis, whilst intimal calcification has long been associated with atherosclerotic 
disease (Lehto et al., 1996). It should be noted that, although T2DM-related calcification has 
been well-documented at the clinical level, the molecular mechanisms underlying the 
manifestation and progression of VC are still the subject of much debate. In this respect, this 
literature review will examine the VC phenomenon from three distinct perspectives: (i) to 
provide a concise overview of the pathogenesis of VC and the relevance of osteogenic 
pathways; (ii) to critically assess our understanding of the molecular players and mechanisms 
underpinning VC; and (iii) to consider calcification from a clinical perspective, highlighting 
potential novel therapeutic approaches to VC pathology. Finally, the primary objectives of this 
thesis will be outlined.  
 
1.1.1 Type-2 Diabetes Mellitus (T2DM) and Cardiovascular Disease (CVD) 
Type-2 diabetes mellitus (T2DM) accounts for 90-95% of all diabetes cases worldwide (Harris, 
1998). According to Diabetes Ireland there are over 200,000 people living with T2DM in this 
country alone, a figure which is expected to rise to 278,850 by the year 2030 affecting 7.5% of 
our total population. In addition, according to the Healthy Ireland survey, there are 
approximately 1 million people over the age of 30 that are currently at risk of developing this 
disease if significant lifestyle changes are not made (Diabetes Ireland, 2018). These figures 
make T2DM the fastest growing health pandemic in Ireland, and the situation in this country 
reflects the global picture; T2DM therefore constitutes a major health challenge at both a 
national and international level. Furthermore, type-2 diabetics are much more likely to suffer 
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from conditions of the cardiovascular system, having detrimental consequences on T2DM 
mortality rates. The World Health Organization estimates that T2DM, with these associated 
cardiovascular complications, will be the 7th leading cause of death globally by the year 2030 
(Morrish et al., 2001). Many diabetic patients go on to suffer lethal cardiovascular events, 
including myocardial infarction (MI) or stroke, as underlying cardiovascular conditions often 
go unnoticed for long periods of time. The reasons for the high prevalence of cardiovascular 
issues in T2DM have not yet been fully delineated, and as such, a better understanding of 
disease pathophysiology combined with improvements in disease monitoring and treatment are 
therefore clearly warranted.  
 
1.1.1.1 The Progression of T2DM/CVD 
T2DM, at a most basic level, is a metabolic disorder primarily characterised by elevated blood 
glucose (hyperglycemia) and insulin resistance. In this respect, the hormone insulin controls 
blood sugar levels, enabling cellular glucose uptake from the circulation. During T2DM, this 
insulin may not work efficiently, or the pancreas may secrete insufficient amounts of insulin to 
adequately manage blood sugar levels, thereby resulting in hyperglycemia. While the precise 
explanation for the high prevalence of CVD among type-2 diabetic patients remain unclear, it 
may be attributed in part to the fact that several “modifiable” (i.e. controllable) and “non-
modifiable” (i.e. uncontrollable) risk factors for CVD overlap with those for T2DM (Smulders 












Modifiable Risk Factors Non-Modifiable Risk Factors 
Obesity Family History 
Sedentary Lifestyle Ethnicity 
Smoking Age 
Dyslipidemia eg. High Cholesterol Gender 
Hypertension History of Gestational Diabetes* 
Dietary Factors eg. Alcohol Consumption  
Glucose Intolerance*  
Lack of Sleep*  
 
*Risk factor for type-2 diabetes only.   
 
Table 1.1. Non-exhaustive list of modifiable and non-modifiable risk factors common to type-2 diabetes 
and cardiovascular disease.   
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In addition to these common risk factors (Table 1.1), the presence of hyperglycemia among 
type-2 diabetic patients may also promote the development and progression of coinciding 
vascular complications. In this regard, hyperglycemia has been found to promote endothelial 
injury, rendering the innermost vascular layer dysfunctional; in this respect, endothelial 
dysfunction is a well-established precursor to a number of adverse clinical outcomes, as it 
promotes a pro-inflammatory, pro-atherogenic and pro-oxidant pathological vascular 
environment (Popov, 2010; Shi and Vanhoutte, 2017). Endothelial dysfunction is indeed 
considered a precursor to a number of macrovascular diseases common during T2DM,  
including angina, hypertension, coronary artery disease (CAD), carotid artery disease, 
peripheral artery disease (PAD) and ultimately (potentially fatal) acute MI or stroke (Ganz and 
Hsue, 2013; Versari et al., 2009; Widmer and Lerman, 2013). Similarly, hyperglycemia and 
T2DM are associated with a number of microvascular diseases that can have detrimental effects 
on quality of life (Shi and Vanhoutte, 2017). It is extremely difficult for clinicians in practise 
to treat these conditions, however, given that the precise molecular processes underpinning the 
link between T2DM and CVD remain undefined.  
 
1.1.1.2 Current T2DM/CVD Management 
Currently, there are a number of relatively inefficient disease management options for diabetics 
suffering from CVD, focusing primarily on the concept of “modifiable” and “non-modifiable” 
risk factors as listed in Table 1.1. Non-modifiable risk factors are those that cannot be altered, 
such as a patient’s age, gender, and family history of T2DM/CVD (independently increasing 
diabetes risk by 2-6 fold) (Harrison et al., 2003). Treatment is therefore centred around those 
modifiable factors that can be controlled, including obesity, hypertension, smoking, lack of 
exercise, dyslipidemia and alcohol consumption, with interventions generally consisting of 
both lifestyle changes and pharmaceuticals (eg. statins to control blood cholesterol levels) 
(Eldor and Raz, 2009). However, even with these interventions in place, risk factors are 
difficult to maintain under control, making this an ineffective treatment method for 
T2DM/CVD (Banegas et al., 2011). As an additional point of relevance, there is no definitive 
widespread method of diagnosing cardiovascular complications in T2DM (or the extent of 
CVD) unless a patient suffers a cardiovascular event, in which case it is often too late for 
successful intervention. Therefore, a range of cardiovascular diseases of varying severity 
remain untreated during T2DM, ultimately contributing to the startling morbidity and mortality 
rates associated with this disease.  
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1.2 Vascular Calcification (VC) 
Vascular calcification (VC), or “hardening of the arteries”, is one of the most prevalent 
cardiovascular complications among type-2 diabetics, and yet, this disorder remains 
unchallenged by current T2DM/CVD disease management. In recent years, it has been 
discovered that VC is not only an adverse side-effect of T2DM, but also participates in and 
accelerates the occurrence of acute cardiovascular complications (Demer and Tintut, 2008), 
making it and its mechanism of action a prime target for intervention. Recently, the potential 
of VC as both a biomarker of CVD risk and as a target for the inhibition and reversal of CVD 
has begun to emerge in the literature (Kapustin and Shanahan, 2009; Rennenberg et al., 2009), 
but while considerable information has been gathered thus far on VC mechanisms, there is still 
much that is not understood (Muthu, 2013). If the precise mechanism(s) of action can be 
specified, it will bring us closer to the development and implementation of therapies that can 
either prevent or regress VC in diabetics, and ultimately improve the cardiovascular health and 
reduce the morbidity and mortality associated with T2DM worldwide. 
 
1.2.1 VC – A Brief History 
Calcification is a phenomenon primarily associated with bone formation. It is approximately 
500 years since the first comparison was made between ossification and blood vessel hardening 
(Acierno, 1994), with the first elements of bone confirmed in the vasculature in 1906 (Bunting, 
1906), however it is only in the past number of decades that the factuality of VC has started to 
emerge. Although it has long been appropriately associated with age, CVD and metabolic 
disorders such as diabetes, VC was until recently believed to be a passive degenerative 
disorder, with elevated calcium and phosphate levels resulting in mineral deposition as a form 
of arterial protection (Hayden et al., 2005; Mizobuchi et al., 2009; Valdivielso, 2011). Contrary 
to this belief, it is now known to be an active process involving the differentiation of vascular 
cells into osteoblast-like cells capable of mineralisation (Mizobuchi et al., 2009). A number of 
mineralisation proteins have been identified in vascular cells, alongside mounting evidence that 
vascular smooth muscle cells (VSMCs) have the ability to simultaneously exhibit both 
physiological smooth muscle and pathophysiological osteogenic properties (Shanahan et al., 
2000). The growing evidence supporting this trans-differentiation of VSMCs has resulted in 
widespread recognition that VC is an actively regulated dynamic process sharing many 
similarities with that of bone morphogenesis. 
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1.2.2 Forms of VC and their Location in the Vasculature 
VC can be broadly classified into two distinct 
forms depending upon its location within the 
vascular wall: intimal VC, affecting the tunica 
intima, and medial VC, affecting the tunica 
media; the latter form will be the prime focus of 
this thesis (Figure 1.1). A third form of VC, 
valvular calcification, can also affect aortic 
valves (Mohler et al., 2001), but given the very 
specific nature of this complication, will not be 
included in the current literature review.   
 
1.2.2.1 Intimal Calcification  
Intimal VC is more commonly referred to as atherosclerotic calcification, given that it co-
locates with atherosclerotic plaque in vivo (Figure 1.2A). Atherosclerosis is a progressive 
inflammatory syndrome characterised by the formation of atheromata, or plaques, within the 
vascular intima. This plaque formation involves the gradual deposition and accumulation of 
oxidised low-density lipoprotein (LDL) and macrophages, in conjunction with VSMC 
migration and foam cell formation, to form a potentially rupture-prone plaque within the 
arterial lumen (Ross, 1999). Atherosclerosis (and thus intimal calcification) is generally limited 
to larger arterial vessels (e.g. aortic arch, thoracic aorta, coronary artery), often leading to 
diseases such as angina, CAD, carotid artery disease and PAD (Albrecht, 2013; Ford et al., 
2017; Thapar et al., 2013). Moreover, atherosclerosis is strongly affected by arterial 
haemodynamic forces, and is more likely to develop at sites of disturbed shear stress such as 
that experienced at major arterial curvatures and bifurcations (Cunningham and Gotlieb, 2005). 
Indeed, the aorta is the most common vascular bed for intimal VC (Allison et al., 2004; Doherty 
et al., 2003).  
It is thought that the presence of intimal VC, manifesting as small nodules of calcified material 
within atherosclerotic tissue, renders these plaques more prone to rupture and thus significantly 
increase the risk of a cardiovascular event (e.g. acute MI, stroke) (Abedin et al., 2004; Budoff 
et al., 2003; Johnson et al., 2006; Virmani et al., 1998). At a molecular level, intimal 
calcification is strongly dependent on pro-inflammatory cytokines present within atheromata 
Figure 1.1. Basic representation of the 
three distinct layers of the vascular wall. 
EC, endothelial cell; VSMC, vascular smooth 
muscle cell. 
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(Doherty et al., 2003; Tintut et al., 2000), which originate primarily from macrophages and 
foam cells prevalent in vulnerable plaques (Finn et al., 2010). These infiltrating macrophages 
(and cytokines) can drive other pro-calcific and pro-oxidant signals, as can vascular cells 
themselves (Johnson et al., 2006; Mody et al., 2001), further promoting the progression of 
intimal VC. Whilst atherosclerotic calcification is highly prevalent in the general population 
(Allison et al., 2004), diabetics with poorly-controlled blood glucose levels are at an even 
higher risk of developing intimal VC (Aronson and Rayfield, 2002). 
 
1.2.2.2 Medial Calcification  
Medial calcification, on the other hand, is a hydroxyapatite mineralisation process (Orimo, 
2010) within the VSMC medial layer analogous to the process of endochondral ossification. 
Medial arterial calcification is the most common form of VC in T2DM, wherein arteries lose 
their elasticity due to the circumferential mineral deposition within the smooth muscle cell  
layer (Lehto et al., 1996) (Figure 1.2B). Medial calcification can occur at any point within the 
arterial tree, including smaller vessels unlikely to be affected by atherosclerosis (Trouvin and 
Goëb, 2010). Thus far, medial VC has been implicated in multiple cardiovascular pathologies 
including hypertension, coronary insufficiency, left ventricular hypertrophy and an increased 
risk of atherosclerotic plaque rupture (Panizo et al., 2009; Rubin and Silverberg, 2004; Singh 
et al., 2012). Medial VC can also be driven by many of the same pro-calcific, pro-inflammatory 
and pro-oxidant signals as intimal VC, and also appears to be promoted by hyperglycemic 
conditions, given the higher prevalence of VC observed in diabetic patients (Stabley and 
Towler, 2017). Interestingly, although both intimal and medial VC can occur as independent 
entities, they share many risk factors and mechanistic similarities and often exist alongside one 
another in the same individual (McCullough et al., 2008).  
What makes medial VC a distinctly different process to intimal VC, however, is not only its 
location in the vasculature; the process of medial calcification is particularly similar to the 
process of bone formation, with smooth muscle cells taking on a distinctly “osteoblastic” 
phenotype (Kaden et al., 2004; Ndip et al., 2011; Panizo et al., 2009) capable of inducing 
mineralisation. As such, the process of bone morphogenesis will first be summarised, before 
discussing in-depth the molecular signalling pathways and mechanisms underpinning medial 























Figure 1.2. Intimal and medial calcification. (A) Intimal calcification occurs alongside atherosclerosis in 
vivo, manifesting as small nodules of calcified material rendering plaque vulnerable to rupture. Intimal VC 
coincides with several of the hallmarks of atherosclerotic disease; EC dysfunction and permeability, VSMC 
migration, foam cell formation, macrophage infiltration and platelet aggregation (Ross, 1999). (B) Medial VC 
exists as circumferential mineral deposits within the smooth muscle layer, a process promoted by “osteoblastic” 
VSMCs. This mineral deposition ultimately reducing vessel elasticity and promotes a number of vascular 
pathologies (Lehto et al., 1996). Intimal and medial VC often coincide in the same vessel (McCullough et al., 
2008). EC, endothelial cell; VSMC, vascular smooth muscle cell.   
A: Intimal VC 
B: Medial VC 
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1.2.3 Bone Morphogenesis 
As noted, VC is now known to be a highly dynamic process involving the action of various 
hormones and cytokines upon multiple vascular cell types (Demer, 2001). Many of these 
proteins and their respective functions are traditionally associated with bone morphogenesis, 
and therefore before considering the pathogenesis of VC, it is critical to first understand the 
calcification process within this traditional physiological setting. 
 
1.2.3.1 Bone Morphogenesis – A Balance of Osteoblasts and Osteoclasts  
By way of overview, bone remodelling involves a complex equilibrium between anabolic bone 
formation (osteogenesis, ossification) and catabolic bone resorption, a key dynamic balance 
for healthy bone metabolism. This balance initially enables early bone development and 
thereafter maintains mineral homeostasis of calcium and phosphorus (Trouvin and Goëb, 
2010), allowing continuous removal of old or damaged bone tissue alongside simultaneous 
growth of new bone. There are two cell types at the forefront of bone morphogenesis, namely 
bone-forming osteoblasts and bone-resorbing osteoclasts, which jointly regulate the 
remodelling process in conjunction with various hormones and cytokines. Osteoblasts are 
derivatives of bone marrow stem cells, whilst osteoclasts arise from the cytoplasmic fusion of 
immune precursors of monocyte/macrophage lineage to generate a multi-nucleated pre-
osteoclast that forms a mature osteoclast upon activation (Ducy et al., 2000; Teitelbaum, 2000) 
(Figure 1.3). Over-activation of bone-resorbing osteoclasts can lead to multiple pathological 
conditions including osteoporosis and rheumatoid arthritis (Kearns et al., 2008), whilst 
diminished osteoclast function may result in osteopetrosis (excessive bone formation). These 
respective disease processes highlight the critical importance of maintaining a healthy balance 
between bone formation and resorption. 
Central to this osteogenic balance are the serum glycoproteins, osteoprotegerin (OPG) and 
receptor activator of nuclear factor kappa-B ligand (RANKL), which function as part of a 
signalling triad with the RANK receptor to modulate cell function, differentiation and survival 
during bone morphogenesis (Boyce and Xing, 2007). Osteocytes, mature osteoblasts trapped 
within the bone matrix, are the predominant source of RANKL for the activation of osteoclast 
precursors, whilst osteoblasts are a significant source of OPG (Figure 1.3). RANKL has long 
been implicated in the promotion of osteoclastogenesis and bone resorption (Wada et al., 
2006); this function entails binding of RANKL to its cell surface RANK receptor, which is 
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widely expressed in both precursor and mature osteoclasts (Atkins et al., 2006; Myers et al., 
1999). Within this context, OPG acts as a soluble decoy receptor for RANKL (Luan et al., 
2012), preventing RANK:RANKL interactions and blocking the resulting downstream 
osteoclastogenic cascade. Generally, when RANKL expression is induced, OPG levels are 
downregulated such that the RANKL:OPG ratio promotes osteoclastogenesis (Kearns et al., 
2008). Unsurprisingly, the RANKL:OPG ratio appears to be differentially regulated in 
pathological conditions compared to healthy physiological states (Liu et al., 2010), 














Figure 1.3. Progression of bone morphogenesis. Osteocytes are the primary source of RANKL in bone, a 
ligand with osteoclastic properties when bound to the RANK cell surface receptor (middle). Osteoclasts arise 
from the cytoplasmic fusion of immune precursors of monocyte/macrophage lineage (prefusion osteoclasts) to 
generate a multi-nucleated osteoclast; RANKL:RANK binding can then occur on the surface of this multi-
nucleated osteoclast, to form a mature, activated osteoclast capable of bone resorption (top). Osteoblasts are 
the primary source of OPG in bone, a soluble decoy receptor for RANKL serving to prevent bone resorption. 
High levels of OPG prevent RANKL:RANK binding and prevent bone resorption (thereby promoting bone 
formation) (bottom). RANK, receptor activator of nuclear factor kappa-B; RANKL, receptor activator of 
nuclear factor kappa-B ligand; OPG, osteoprotegerin. Harper et al., 2016. 
 11 
1.2.3.2 Molecular Players in Bone Morphogenesis – RANKL and OPG 
At a molecular level, RANKL is a type-II homotrimeric transmembrane protein (Boyce and 
Xing, 2007) and a member of the tumour necrosis factor (TNF) superfamily. RANKL typically 
remains membrane bound, but also exhibits at least two known active soluble forms that may 
arise either through proteolytic cleavage from the cell membrane or alternate mRNA splicing 
(Ikeda et al., 2001). Both membrane-associated and secreted forms of RANKL are capable of 
promoting osteoclast formation (Lacey et al., 2012). Structurally, RANKL has a small 
intracellular N-terminal domain, a transmembrane anchor, a connecting stalk and an 
extracellular receptor-binding domain, the latter of which typically arranges into a homotrimer 
in both membrane-bound and soluble form (Luan et al., 2012). Whilst many cell types express 
RANKL, osteocytes appear to be the prominent source for in vivo activation of osteoclast 
precursors (Nakashima et al., 2011). Additional sources of RANKL include vascular cells, 
stromal cells, T-cells and immune osteoclast precursors (monocytes, macrophages and 
dendritic cells) (Hofbauer and Schoppet, 2004; Kong et al., 1999; Lacey et al., 1998). 
OPG, the decoy receptor for RANKL, is a soluble TNF receptor family member often referred 
to as an “osteoclastogenesis inhibitory factor” (Yasuda et al., 1998). OPG is synthesized and 
secreted in vivo by most cell types including vascular cells (particularly smooth muscle cells), 
but osteoblasts and stromal cells exhibit the most prominent expression (Hofbauer and 
Schoppet, 2004). Structurally, OPG is a glycosylated cytokine with seven domains; four 
cysteine-rich domains (1-4) at the N-terminus are responsible for attenuating RANKL-induced 
osteoclast activation and activity (Luan et al., 2012), while domains 5 and 6 are apoptosis-
mediating regions. Domain 7 is responsible for cysteine-mediated dimerization, and can also 
bind the anticoagulant heparin (Yamaguchi et al., 1998). OPG can also bind to and neutralise 
TNF-related apoptosis-inducing ligand (TRAIL), a pleiotropic molecule with a dominant role 
in the mediation of apoptosis. OPG is also considered an unusual member of the TNF receptor 
superfamily, as it lacks a transmembrane region and is exclusively secreted as a soluble protein 
(Luan et al., 2012). OPG exists in serum as either a 60 kDa monomer or a 120 kDa disulphide-
linked homodimer, with the latter more biologically active; it can also be detected in complex 





1.2.3.3 Bone Morphogenesis – Key Mechanisms  
At a mechanistic level, the key pathways involved in bone morphogenesis are complex, but 
several of the pathways that mediate ossification are particularly relevant to VC. As a brief 
overview, RANKL in its osteoclastic role in bone, is known to exert its function via NF-κB 
(nuclear factor of activated B-cells) signalling. NF-κB is a rapidly inducible transcription factor 
that exerts diverse functions in almost all animal cell types (Zhang et al., 2017), and can be 
activated via two distinct pathways, canonical and non-canonical, that will be described in more 
detail in Section 1.2.4.5.1. In bone, NF-κB plays a crucial role in osteoclastogenesis when 
activated by RANKL; at a basic level, RANKL binds to its cell surface receptor (RANK) to 
activate both canonical and non-canonical NF-κB pathways, and the respective downstream 
components translocate to the nucleus to mediate osteoclastic gene expression (Boyce et al., 
2010). The role for OPG in bone formation involves the prevention of RANKL:RANK binding, 
therefore attenuating NF-κB activation and the resulting osteoclastic gene upregulation.  
In addition to NF-κB, bone morphogenetic proteins (BMPs) are potent regulators of osteogenic 
differentiation; these osteo-inductive members of the transforming growth factor (TGF)-β 
superfamily function through binding to a heterodimeric transmembrane BMP receptor (I and 
II) complex; when a specific BMP binds to its specific type II receptor, the type I receptor 
becomes activated. Phosphorylation and nuclear translocation of Smad transcription factors 
ensue, resulting in gene transcription alterations (Hruska et al., 2005) that regulate bone 
formation, maintenance and repair (Sykaras and Opperman, 2003). BMP-2, for example, 
functions through increasing the expression of the transcription factors runt-related 
transcription factor-2 (Runx2) (Sage et al., 2010) and osterix (Lee et al., 2003), which follows 
on to induce alkaline phosphatase (ALP), an enzyme involved in the mineralisation of bone.  
Thirdly, oxidative stress plays an important role in bone remodelling, as redox signalling and 
reactive oxygen species (ROS) can regulate the natural balance between osteoblasts and 
osteoclasts (and therefore bone formation and resorption) (Domazetovic et al., 2017). ROS are 
highly reactive chemical species that promote a pathological “pro-oxidant” environment, 
thereby promoting bone resorption (Huh et al., 2006). Anti-oxidant signalling, leading to a 
reduction in ROS levels, therefore prevent bone resorption and allow bone formation to ensue 
(Jun et al., 2008). Indeed, redox signalling in bone is closely associated with RANKL 
signalling and NF-κB activation, as redox status has been found to directly regulate RANKL-
induced osteoclastogenesis (Huh et al., 2006).  
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1.2.4 VC Pathogenesis  
While RANKL and OPG play pertinent roles in the regulation of bone turnover, they are also 
central to the development and progression of VC, as are a number of key mechanisms involved 
in bone morphogenesis. Thus, the role of these ligands and signalling pathways will now be 
discussed in detail from a vascular perspective, again maintaining focus on the VSMC layer 
(the established location of medial VC in vivo).  
 
1.2.4.1 VC Pathogenesis at the Cellular Level   
As a simplistic overview, VC is a gradual mineralisation process that occurs in arterial tissue, 
beginning with vascular wall damage and ultimately progressing to the deposition of 
hydroxyapatite within the medial arterial layer (Orimo, 2010). Many aspects of the metabolic 
syndrome associated with T2DM can promote this process, including oxidative stress, 
endothelial dysfunction, dyslipidemia, irregularities in mineral metabolism, and the heightened 
generation of pro-inflammatory cytokines (Singh et al., 2009; Singh et al., 2010; Singh et al., 
2012). At the cellular level, studies have indicated that VC primarily involves the phenotypic 
trans-differentiation of VSMCs into osteoblastic (bone-forming) or chondrocytic (cartilage-
forming) cells, capable of expressing and releasing osteoblastic proteins that regulate the 
calcification process (Luo et al., 1997; Speer et al., 2009). Proteins in circulation also 
contribute to VSMC calcification, most likely through a combination of direct contact with 
VSMCs (as they diffuse through a dysfunctional endothelial monolayer), and through 
exhibiting their effects directly on healthy (non-dysfunctional) endothelial cells which signal 
in a paracrine manner to underlying VSMCs (Davenport et al., 2016; Panizo et al., 2009).  
In culture, VSMCs are induced to calcify when exposed to elevated levels of calcium and 
phosphate, encouraging the osteochondrogenic phenotype and a loss of natural VSMC markers 
(Steitz et al., 2001). Interestingly, VSMC differentiation is generally referred to as osteoblastic, 
however many recent studies now indicate that VC may more closely resemble a chondrocytic 
process (Speer et al., 2009). Indeed, both osteoblastic and chondrocytic processes involve the 
upregulation of many of the same genes and proteins (Speer et al., 2009; Tyson et al., 2003), 
and as such, chondrocyte-like cells may be considered to have an osteoblastic phenotype when 
assessed in culture. In support of VSMC chondrocytic differentiation, Speer and colleagues 
(2009) used a fate-mapping approach in a murine model of VC to provide evidence that 
VSMCs are the main origin of chondrocytic cells seen in calcified vessels. Medial cells from 
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calcified vessels of 4-week old matrix gla protein (MGP)-deficient mice were shown to lack 
expression of VSMC lineage proteins (smooth muscle myosin heavy chain, smooth muscle α-
actin (SMα-actin), smooth muscle-22α (SM22α)) however they did express osteochondrogenic 
proteins osteopontin (OPN) and type II collagen. These chondrocyte-like cells were involved 
in large calcific medial regions, and had previously expressed these smooth muscle markers, 
providing strong evidence that they had differentiated from VSMCs (Speer et al., 2009). Given 
the similarity in phenotype between osteoblastic and chondrocytic cells, however, both terms 
will be considered to describe a “pro-calcific” VSMC phenotype throughout this thesis.  
While VSMCs may be the main source of “calcifying” cell in the vasculature, a number of 
additional cell types also contribute to the establishment and progression of VC. As noted, the 
intimal endothelial monolayer is now considered to play a major role in the regulation of VC, 
known to communicate with the underlying HASMCs via paracrine signalling (Davenport et 
al., 2016; Osako et al., 2010). Thus, when the endothelium is exposed to pro-calcific proteins 
in circulation, or exposed to a pro-inflammatory, pro-oxidant environment such as that present 
during endothelial dysfunction (Higashi et al., 2009; Zhang, 2008), the secretory profile of 
these cells can be altered to promote calcification within the medial arterial layer (Yao et al., 
2013). Furthermore, as mentioned, intimal VC and atherosclerotic plaque often co-locate with 
medial VC in vivo (McCullough et al., 2008), and macrophages and foam cells within the 
atheroma can secrete pro-inflammatory cytokines that further promote the VC process (Barath 
et al., 1990; McLaren et al., 2011; Moore et al., 2013).  
 
1.2.4.2 VC Pathogenesis at the Molecular Level   
There are numerous molecular components involved in the pathogenesis of calcification, 
described in detail by Sage and colleagues (2010), and a number of proteins relating to 
osteogenesis/chondrogenesis have been identified in arterial vascular cells (Papadopouli et al., 
2008). VC mechanisms are mediated by transcription factors that also control 
osteogenesis/chondrogenesis, such as Runx2, sex-determining region Y box-9 (Sox9) and 
osterix, and their downstream matrix components ALP, bone sialoprotein (BSP) and 
osteocalcin (OCN) (Tintut and Demer, 2006). Furthermore, BMPs, central regulators of 
osteogenic differentiation, are also known to have potent pro-calcific effects in the vasculature, 
as are a number of pro-inflammatory cytokines (e.g. TNF, interleukin (IL)-6) (Al-Aly, 2008; 
Davenport et al., 2016; Hénaut and Massy, 2018). The most relevant of these factors to the 
current research are described in more detail overleaf.  
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1.2.4.2.1 Pro-calcific Transcription Factors  
There are several pro-calcific transcription factors involved in the regulation of bone 
morphogenesis that are also known to regulate VC. Runx2, for example, a “master regulator” 
of osteoblast differentiation and bone development, has been implicated as one of the central 
osteoblastic transcription factors involved in VC pathogenesis (Lin et al., 2015). Runx2 is 
responsible for inducing the expression of a wide range of osteoblastic genes (Byon et al., 
2011; Pratap et al., 2003; Weng and Su, 2013), and also trans-activates another osteoblastic 
transcription factor, osterix (Nishio et al., 2006). Indeed, Runx2 has been shown to be elevated 
in calcified arteries (Moe et al., 2003), and Runx2 deletion has been shown to attenuate 
osteochondrogenic differentiation and subsequent calcification in VSMCs (Lin et al., 2015). 
Another transcription factor, msh homeobox 2 (Msx2) also plays a crucial role in osteoblastic 
differentiation of VSMCs, but is not believed to be necessary for subsequent calcification 
(Andrade et al., 2017).  
Sox9, a chondrocytic transcription factor with a primary role in chondrocyte differentiation, is 
also responsible for driving a number of pro-calcific genes (Akiyama et al., 2002). Unlike 
Runx2, however, Sox9 has only recently been implicated in the VC process (Kauffenstein et 
al., 2014) and is of particular interest given that the calcification process is now thought to 
closely resemble chondrocytic rather than osteoblastic differentiation (Speer et al., 2009). Sox9 
has also been detected in calcified vessels (Kauffenstein et al., 2014) and is known to be 
expressed in cultured VSMCs (Tyson et al., 2003). In a vascular context, the particular stimuli 
that induce Sox9 expression are relatively unclear, but it has been shown to potentiate BMP-2-
induced cartilage formation (Liao et al., 2014). Interestingly, Sox9 prevents Runx2-mediated 
osteoblastic gene expression in bone (Cheng and Genever, 2010), however, the expression of 
osteoblastic targets have been identified alongside Sox9 expression in calcified vascular cells 
(Tyson et al., 2003). Thus, the role of this transcription factor in a vascular setting may vary 
considerably from their traditional roles in osteo/chondrogenesis and remain to be delineated. 
 
1.2.4.2.2 Downstream Protein Mediators 
There are a number of proteins downstream of these transcription factors that regulate the VC 
process. ALP, for example, is a metalloenzyme regulated by Runx2 that is actively involved in 
the mineralisation process, and is known to be highly expressed in calcified vascular tissue 
(Sheen et al., 2015). ALP is localised to the extracellular side of the plasma membrane, but can 
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also be identified intracellularly (attached to matrix vesicles) and in secretory form (Davenport 
et al., 2016; Golub and Boesze-Battaglia, 2007). Extracellular ALP is the most relevant to VC, 
given that it promotes mineralisation by reducing inorganic pyrophosphate (PPi) levels (an 
inhibitor of mineralisation) and increasing inorganic phosphate (Pi) levels (a promoter of 
mineralisation) in the extracellular space (Schoppet and Shanahan, 2008). Budding matrix 
vesicles containing hydroxyapatite crystals (a calcium- and phosphate-containing mineral), 
which are then deposited into the extracellular matrix if the PPi/Pi balance is correct (Orimo, 
2010) (Figure 1.4). In addition to ALP, BSP and OCN, early and late markers of VC, 
respectively (Huang et al., 2007), also promote the mineralisation process in VSMCs by 
promoting nucleation and binding of hydroxyapatite crystals (Hunter and Goldberg, 1994). As 
these osteoblastic markers are upregulated, natural VSMC markers (e.g., SMα-actin, SM22α) 
are downregulated, resulting in a “calcifying” VSMC phenotype. A range of proteins are also 
involved in the negative regulation of VC; for example, MGP inhibits VC in its role as a BMP 
inhibitor (Boström et al., 2001), while OPN binds strongly to calcium atoms to prevent 
mineralisation (Sodek et al., 2000). However, upregulation of the aforementioned pro-calcific 
transcription factors have also been associated with a decrease in the expression of these 
proteins (Schinke et al., 2000; Zhang et al., 2012).  
 
1.2.4.2.3 BMPs 
BMPs are known to play a central role in the regulation of VC, and vascular cells have been 
shown to express BMP receptors (Kim et al., 2013; Yu et al., 2007). There are multiple BMPs 
involved in the regulation of osteoblastogenesis, some of which are particularly relevant in a 
vascular setting. BMP-2, for example, is known to induce the calcification process, and exerts 
its osteoblastic function by increasing the expression of the transcription factors Runx2 (Sage 
et al., 2010) and osterix (Lee et al., 2003), which follow on to induce ALP activity. BMPs exert 
their function via Smad phosphorylation and translocation, promoting osteoblastic gene 
expression (Hruska et al., 2005). Of significant interest is the role for BMP-2 identified in 
endothelial:smooth muscle cell communication; in this respect, endothelial cells directly 
exposed to pro-calcific stimuli in circulation secrete BMP-2 as a pro-calcific paracrine signal 
to the underlying VSMCs (the location of medial VC in vivo) (Davenport et al., 2016; Osako 
et al., 2010). BMP-4 has also been implicated in the promotion of VC in smooth muscle (Panizo 
et al., 2009), whilst BMP-7 has been shown to inhibit calcification (Mathew et al., 2006).  
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1.2.4.2.4 Pro-inflammatory and Pro-oxidant Mediators 
Inflammation is closely related to calcification, as immune/vascular cells at the site of 
atherosclerotic plaque release inflammatory cytokines that contribute to VC regulation 
(Johnson et al., 2006; Mody et al., 2001). In this respect, TNFα and IL-6 have both been shown 
to induce VC (Al-Aly, 2008; Hénaut and Massy, 2018) and can activate many of the 
aforementioned pro-calcific mediators in vascular cells (e.g. Runx2, ALP, BMP-2) (Illiandri et 
al., 2016; Kurozumi et al., 2016). Of further note, oxidative stress (induced by ROS) is a well-
known inducer of pro-calcific and pro-inflammatory proteins in the vasculature (Al-Aly et al., 
2007; Byon et al., 2008), and ROS are also known to be secreted by vascular cells under pro-
calcific conditions (Clempus and Griendling, 2006; Farrar et al., 2015). Of particular relevance 
to T2DM, hyperglycemia (a pro-oxidant, pro-inflammatory stimulus) has also been shown to 
stimulate chondrocytic trans-differentiation of human VSMCs, alongside increased levels of 
















Figure 1.4. The regulation of pro-calcific genes and proteins in calcifying vascular cells. Pro-calcific stimuli, pro-
inflammatory stimuli and pro-oxidant stimuli can induce a number of osteoblastic/chondrocytic transcription factors in 
vascular cells (Runx2, Sox9, osterix, Msx2). These transcription factors drive the expression of pro-calcific proteins 
(ALP, BMPs, BSP, OCN) and downregulate anti-calcific proteins (MGP, OPN) and smooth muscle markers (SMα-
actin, SM22α). ALP is secreted alongside hydroxyapatite (in matrix vesicles), and converts PPi to Pi to promote mineral 
deposition. These osteoblastic vascular cells also secrete BMPs, pro-inflammatory cytokines and reactive oxygen species 
to further promote the calcification process. ALP, alkaline phosphatase; BMP, bone morphogenetic protein; BSP, bone 
sialoprotein; MGP, matrix gla protein; Msx2, msh homeobox 2; OPN, osteopontin; (P)P i, inorganic (pyro)phosphate; 
Runx2, runt-related transcription factor-2; SM, smooth muscle; Sox9, sex determining region Y box-9.  
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1.2.4.3 VC Pathogenesis – a Role for RANKL and OPG 
There is gathering evidence that the OPG/RANKL/RANK signalling axis is central to the 
manifestation and progression of VC (Papadopouli et al., 2008). RANKL in circulation 
primarily originates from bone, but additional sources of vascular RANKL are thought to 
include circulating T-cells and vascular cells themselves (although this expression is believed 
to be relatively low) (Osako et al., 2010; Collin-Osdoby et al., 2001; Hofbauer and Schoppet, 
2004; Ndip et al., 2014). OPG, on the other hand, is expressed to a significant extent by smooth 
muscle cells (Corallini et al., 2009), and to a lesser extent by endothelial cells (Davenport et 
al., 2018), but circulating OPG originating from bone can also contribute to VC regulation 
within the vasculature. Furthermore, the RANK cell surface receptor is known to be expressed 
in vascular cells (Kavurma et al., 2008), and thus RANKL can influence the vasculature by 
inducing endothelial paracrine signals (Davenport et al., 2016), and also by direct contact with 
underlying VSMCs in areas of damage or dysfunctional endothelium. 
As described, the role for RANKL in bone morphogenesis involves the induction of bone 
resorption, while OPG promotes bone formation by preventing RANKL:RANK binding 
(thereby preventing osteoclastic activity). In the vasculature, however, RANKL promotes 
osteoblastic rather than osteoclastic activity, acting as a key driver of VC, while OPG, in its 
vasoprotective role as a RANKL decoy receptor, prevents RANKL-induced pro-calcific 
signalling (Papadopouli et al., 2008). Thus, both RANKL and OPG appear to exhibit 
contradictory effects during vascular calcification to those typically manifested by either of 
these ligands during bone remodelling, an apparent pathophysiological paradox that has yet 
to be fully understood. 
From a mechanistic perspective, RANKL can actively promote the calcification process in the 
vasculature by binding to the RANK receptor, inducing pathological differentiation of healthy 
VSMCs into calcified VSMCs with an osteoblastic phenotype (Kaden et al., 2004; Ndip et al., 
2011; Panizo et al., 2009). RANKL binds to its receptor in homotrimeric form, triggering the 
activation of both canonical and non-canonical NF-κB pathways (Khavandgar et al., 2014), 
although it has been suggested that RANKL exerts its pro-calcification actions primarily via 
non-canonical activation (Panizo et al., 2009). NF-κB then translocates to the nucleus (Ndip et 
al., 2011) where it activates osteogenic gene expression and downregulates smooth muscle 
markers (e.g. smooth muscle α-actin) (Ndip et al., 2014). The VSMC then becomes a calcifying 
cell with an osteochondrogenic phenotype, producing and secreting pro-calcific proteins that 
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drive the formation of a mineralised matrix (Ndip et al., 2014) (Figure 1.5). RANKL has also 
been shown to be upregulated in calcified VSMCs (Kaden et al., 2004) and atheroscleorotic 
tissue (Higgins et al., 2015); these findings indicate that, when serum RANKL levels are high, 
an acceleration of this differentiation process occurs, resulting in an increased mineral 












OPG, on the other hand, binds and neutralises RANKL (Collin-Osdoby, 2004), and this 
neutralization ameliorates the VC process and exerts an anti-calcific effect within the 
vasculature. In this respect, OPG prevents RANKL:RANK interaction and NF-κB 
activation/translocation, resulting in a healthy non-calcified vessel (Figure 1.5, left). When 
RANKL levels are high, however, VSMCs cannot secrete enough OPG to neutralise the excess, 
thereby rendering the vessel prone to RANKL-induced calcification.  
Figure 1.5. Interactions between OPG and RANKL in healthy (left) and calcified (right) vessel. In healthy 
vasculature, VSMCs secrete enough OPG to neutralise excess RANKL, originating from circulation and 
surrounding vascular cells. OPG prevents RANKL binding to the RANK receptor on the VSMC surface, 
thereby preventing RANKL-induced calcification (left). When RANKL levels are high, however, VSMCs 
cannot secrete enough OPG to neutralise RANKL, enabling RANKL:RANK binding and osteoblastic 
activation to ensue. This activation ultimately results in the formation of calcified mineral deposits within the 
medial arterial layer (right). EC, endothelial cell; VSMC, vascular smooth muscle cell; RANK, receptor 
activator of nuclear factor kappa-B; RANKL, receptor activator of nuclear factor kappa-B ligand; OPG, 
osteoprotegerin; NF-κB, nuclear factor kappa-B. Harper et al., 2016.  
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1.2.4.4 VC Pathogenesis – a Role for TRAIL  
In recent years, a novel role has emerged for an additional ligand in the vasculature: namely, 
TRAIL. This ligand has been shown to interact with OPG and RANKL in the modulation of 
the calcification process (Schoppet et al., 2004), and although its precise functions in this 
context are poorly defined, mounting evidence now points to a vasoprotective role for TRAIL 
in the prevention of VC. Prior to discussing the effects of TRAIL in a vascular context, some 
background will first be provided on the function and regulation of this complex ligand in vivo.  
 
1.2.4.4.1 TRAIL – Location, Function and Regulation 
As its name suggests, the primary function for TRAIL is as an inducer of apoptosis, and 
although originally believed to exert this function on malignant or transformed hematopoietic 
cells, it is now known to have diverse pleiotropic roles in multiple cell types (Forde et al., 2016; 
Wiley et al., 1995). TRAIL has been identified in multiple tissue locations including spleen, 
prostate and lung (Wiley et al., 1995), but its mRNA and protein expression has thus far only 
been demonstrated in immune, vascular, hepatocytic and myocytic cells (Falschlehner et al., 
2009; Forde et al., unpublished observations; Gochuico et al., 2000; Sato et al., 2006; Spierings 
et al., 2004). TRAIL is also present in the circulation (albeit in the picomolar range), and 
interestingly, serum TRAIL has been shown to be inversely correlated with a number of 
pathologies including CVD (Volpato et al., 2011). 
At a molecular level, TRAIL, a member of the TNF ligand superfamily, is a type-II 
transmembrane protein with the ability to bind five different receptors found on numerous cell 
types, as well as a C-terminal domain that can also be cleaved from the cell surface (or secreted 
in vesicles) to release a soluble form (Ehrlich et al., 2003). Both membrane-bound and soluble 
TRAIL can induce apoptosis, although soluble TRAIL is thought to exert a more potent 
apoptotic effect (Kim et al., 2004). Two TRAIL receptors (DR4 and DR5) have a cytoplasmic 
death domain, whilst two decoy receptors (DcR1 and DcR2) lack a functional death domain; 
thus TRAIL-induced apoptosis via DR4 and DR5 is antagonised by the competitive inhibitory 
effect of DcR1 and DcR2 (Ravi et al., 2001). OPG acts as an additional soluble decoy receptor 
for TRAIL (and vice-versa); therefore, OPG has a second protective function in addition to its 
ability to block RANKL-induced calcification, by virtue of its ability to block TRAIL-
dependent apoptotic signalling (Emery et al., 1998).  
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The regulation of TRAIL in vivo is mediated by a number of factors including the NF-κB 
family of transcription factors (Wurzer et al., 2004) and interferons (Kayagaki et al., 1999; 
Miura et al., 2006), described in detail by Forde et al. (2016). TRAIL receptor regulation, 
although not yet fully defined, appears to be mediated by many of the same pathways that 
regulate TRAIL (Kamohara et al., 2004; Ravi et al., 2001). TRAIL receptors are expressed at 
varying levels in a wide range of cells and tissues in vivo (hepatocytes, neurons, cardiac 
myocytes, colon, kidney, lung, vasculature, and pancreas among others) (Daniels et al., 2005; 
Pan et al., 1998; Zauli et al., 2006), and as such, it is no surprise that TRAIL exerts complex 
pleiotropic functions dependent on the location-specific expression of death and decoy 
receptors (and the pathways activated by TRAIL:TRAIL receptor binding).  
The mechanisms associated with TRAIL signalling are complex, but, as noted, TRAIL’s 
primary function as an apoptosis-inducing ligand is best defined. Indeed, TRAIL’s apoptotic 
function is initiated by DR4 and DR5 binding, resulting in the formation of the death-inducing 
signalling complex (Almasan et al., 2003) and downstream caspase activation (Suliman et al., 
2001). There are also a number of signalling pathways activated by TRAIL, however, that 
result in anti-apoptotic functions, but these pathways are less understood. As a brief summary, 
TRAIL has the ability to induce NF-κB activation, which can function to either promote cell 
survival or apoptosis depending on the cellular context (Degli-Esposti, 1999; Ravi et al., 2001). 
In this respect, high concentrations of TRAIL (1 µg/mL) cause the NF-κB-dependent 
upregulation of anti-apoptotic proteins which may reduce cellular sensitivity to TRAIL-
induced apoptosis (Almasan et al., 2003). Secondly, TRAIL can initiate the mitogen activated 
protein kinase (MAPK)/extracellular signal-related kinase (ERK) signalling cascade 
(Falschlehner et al., 2007), which results in an anti-apoptotic effect in vascular cells (Secchiero 
et al., 2003). A third non-apoptotic signalling cascade activated by TRAIL is the protein kinase 
B/Akt pathway (Secchiero et al., 2003); Akt activation also indirectly protects from apoptosis 
through P53 degradation and NF-κB activation (Hausenloy et al., 2004). While these pathways 
can be activated by DR4 and DR5 under the correct conditions, the decoy receptor DcR2 (while 
incapable of inducing apoptosis) is capable of activating other signalling pathways (e.g. NF-
κB) which may accentuate the anti-apoptotic role of TRAIL (Delgi-Esposti et al., 1997). 
For a comprehensive review on the pleiotropic roles of TRAIL in vivo, and an in-depth 
summary of the pathways that activate, and are activated by TRAIL, see Forde et al. (2016). 
For the purpose of the current review, however, a focus on the specific role for TRAIL in the 
vasculature will be maintained. 
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1.2.4.4.2 TRAIL in the Vasculature  
The pro-survival role of TRAIL has led to the hypothesis that this ligand may exert pleiotropic 
roles in many cell types, including the circulatory system (Forde et al., 2016). Although there 
is still much debate over whether or not TRAIL is expressed in the vascular endothelium 
(Secchiero and Zauli, 2008), TRAIL receptors are expressed by endothelial cells (Zauli et al., 
2006), and VSMCs express both TRAIL and TRAIL receptors (Cheng et al., 2014; Harith et 
al., 2016; Li et al., 2016). Additionally, immune cells present at sites of atherosclerotic plaque 
and intimal calcification are sources of surface and soluble TRAIL (Ehrlich et al., 2003; 
Kamohara et al., 2004) while the TRAIL receptors on these cells are widely expressed 
(Guicciardi and Gores, 2009). As noted, TRAIL is also present in circulation (Volpato et al., 
2011), further supporting a physiological role for TRAIL in the vasculature.  
An emerging hypothesis within the field of vascular research has proposed a vasoprotective 
role for TRAIL, possibly via the mediation of anti-atherogenic, anti-inflammatory and anti-
oxidant effects. In this respect, TRAIL delivery has been shown to promote anti-atherosclerotic 
activity in diabetic mice, while TRAIL-deficient mice also developed accelerated medial VC 
(di Bartolo et al., 2013). Furthermore, TRAIL deficiency has also been associated with 
increased atherosclerotic plaque size in Apolipoprotein E(ApoE)-/- mice (Watt et al., 2011), 
and Secchiero et al. (2006) also found that TRAIL reduced plaque mass and increased 
macrophage apoptosis within atherosclerotic lesions. Furthermore, TRAIL has been shown to 
exert anti-oxidant and anti-inflammatory effects on the endothelium via the modulation of 
endothelial nitric oxide synthase (eNOS) (Zauli et al., 2003), and endothelial survival and 
proliferation has also been observed in response to TRAIL treatment (Pritzker et al., 2004; 
Secchiero et al., 2003). From a clinical perspective, decreased serum TRAIL levels correlate 
with acute cardiovascular events (including myocardial infarction, heart failure) and resulting 
mortality (Niessner et al., 2009; Secchiero et al., 2009; Volpato et al., 2011), potentially 
implicating lower circulating TRAIL with poorer prognoses.   
Contrastingly, however, some competing theories point to a potential role for TRAIL as an 
inducer of calcification. In this respect, elevated levels of TRAIL have been identified in 
vulnerable atherosclerotic plaque (Michowitz et al., 2005; Schoppet et al., 2004) and both 
TRAIL and its decoy receptor OPG have been identified at elevated levels alongside medial 
VC (Schoppet et al., 2004). There is also evidence that TRAIL induces apoptosis in endothelial 
cells (Li et al., 2003) and VSMCs (Sato et al., 2006) in vitro, yet TRAIL has also been shown 
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to exhibit anti-apoptotic activity in these cells under certain conditions (Kavurma et al., 2008; 
Secchiero et al., 2003; Secchiero et al., 2004). As such, the precise role(s) for TRAIL within 
the vasculature are as of yet unclear, and remain the focus of a complex debate within the field 
of vascular research.  
As mentioned, OPG can also serve as a decoy receptor for TRAIL. Importantly, both TRAIL 
and RANKL compete for OPG with similar binding affinities, with OPG favouring the protein 
of greatest concentration, resulting in a competitive effect between the two ligands (Vitovski 
et al., 2007). With excessive TRAIL levels, OPG:RANKL binding is reduced, allowing 
unopposed RANKL activity to ensue (and vice versa) (Figure 1.6). Therefore, the concentration 
of all three ligands are relevant to the ultimate biological effects within the vascular system, a 
fact which may be relevant in explaining the apparent contradictions in TRAIL function. 
Overall, there is evidence to suggest that TRAIL has substantive yet diverse functional roles 
within the vasculature (which may be dependent on or independent of OPG/RANKL), but 















Figure 1.6. Interactions between OPG, RANKL and TRAIL in the vasculature. (i) OPG is in excess of 
RANKL, preventing RANKL:RANK binding. (ii) OPG is in excess of TRAIL, preventing TRAIL binding 
to its receptors. (iii) RANKL is in excess of OPG, thus excess RANKL can bind to RANK receptors. There 
is no OPG available to prevent TRAIL binding to its receptors. (iv) TRAIL is in excess of OPG, thus excess 
TRAIL can bind to receptors. There is no OPG available to prevent RANKL binding to its receptors. OPG, 
osteoprotegerin, RANK, receptor activator of nuclear factor kappa-B; RANKL, receptor activator of nuclear 
factor kappa-B ligand; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand. 
 24 
1.2.4.5 VC Pathogenesis – Mechanistic Considerations for RANKL and TRAIL  
Whilst the mechanisms for both RANKL and TRAIL are well-established in the context of 
osteogenesis and apoptosis, respectively, the precise signalling pathways activated by these 
ligands in a vascular context remain relatively undefined. Indeed, both RANKL and TRAIL 
are known to activate NF-κB, and there is evidence that they also do so in the vasculature 
(Kavurma et al., 2008; Panizo et al., 2009), but it is somewhat unclear which NF-κB pathway 
(i.e. canonical or non-canonical) mediates their respective pro-calcific and (hypothesised) 
protective effects in vascular cells. Furthermore, evidence also exists pertaining to a role for 
redox signalling in the mediation of RANKL/TRAIL vascular function (Thummuri et al., 2017; 
Zauli et al., 2003), and indeed, VC is known to exist alongside a pro-oxidant environment 
(Byon et al., 2008). These pathways (described in more detail below) have not yet been 
extensively studied in the context of RANKL/TRAIL function in a vascular setting, but further 
clarification of the mechanistic targets of these ligands may aid in the development of 
successful therapeutics to prevent or revert VC.  
 
1.2.4.5.1 NF-κB Signalling  
By way of overview, the NF-κB family of inducible transcription factors are known to mediate 
a number of physiological and pathological cellular processes, particularly with respect to 
inflammation, immunity, cell differentiation and survival (Oeckinghaus and Ghosh, 2009; 
Wong and Tergaonkar, 2009). This family consists of five members, similar in structure, that 
function together in a signalling cascade: p50, p52, p65 (RelA), RelB and c-Rel (Liu et al., 
2017; Moynagh 2005; Hoffmann et al., 2006). These members have a homologous N-terminal 
Rel homology domain that allows for dimerisation and DNA binding, allowing varying 
combinations of hetero- and homodimers to modulate gene transcription via binding to a 
specific DNA element, κB enhancer (Huxford et al., 1999; Liu et al., 2017). The subunits p50 
and p52 are derived from larger precursors p100 and p105, respectively. RelB, c-Rel and p65 
contain transcription activation domains (TADs), allowing them to activate gene expression, 
while p50 and p52 do not have this function; thus, p50 and p52 function to suppress gene 
transcription unless dimerised to a transcription factor containing a TAD (Oeckinghaus and 
Ghosh, 2009). There are also a number of IκB (inhibitor of κB enhancer) proteins in the 
cytoplasm that prevent NF-κB activity, which also include precursor proteins p100 and p105; 
for example, in unstimulated cells, p100 binds to RelB to prevent nuclear translocation 
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(Oeckinghaus and Ghosh, 2009). Thus, NF-κB regulation involves a complex balance of both 
positive and negative feedback mechanisms to achieve the appropriate response. 
The NF-κB family of transcription factors facilitate the activation of two signalling pathways, 
the canonical (classical) pathway, and the non-canonical (alternative) pathway. Both pathways 
involve the formation of an IκB kinase (IKK) complex, which causes phosphorylation-induced 
degradation of IκBs, allowing NF-κB subunits to translocate to the nucleus (Israël, 2010). The 
canonical pathway involves the phosphorylation and nuclear translocation of the p50/p65 
heterodimer, while the non-canonical pathway involves the phosphorylation and cleavage of 
the p100 precursor and subsequent translocation of p52/RelB. In both cases, NF-κB activation 
leads to the expression of IκBα, which functions in a negative feedback manner to terminate 
NF-κB signalling unless a permanent activation signal is present (Ruland, 2011) (Figure 1.7). 
In general, canonical NF-κB mediates diverse cellular functions and can be rapidly activated 
in response to its stimuli; non-canonical activation, on the other hand, is slow and persistent, 
and exerts limited functions mediated by specific ligands (including RANK) (Sun, 2011).  
As noted, RANKL is known to exert its osteoclastic functions in bone via NF-κB signalling 
(Beristain et al., 2012; Boyce et al., 2015), and is also known to activate both NF-κB pathways 
within a vascular setting (Khavandgar et al., 2014; Panizo et al., 2009). At a molecular level, 
RANKL binding to the RANK receptor results in the association of TNF receptor associated 
factors (TRAFs) with the cytoplasmic domain of RANK (Wong et al., 1998). TRAFs are a 
family of adaptor proteins that interact with the intracellular domain of cell surface receptors 
to mediate downstream pathways (Arch et al., 1998), and TRAFs 2, 5 and 6 can activate NF-
κB (Song et al., 1997). TRAF6 appears to be most pertinent with regard to RANKL:RANK 
binding, which can then go on to activate both canonical and non-canonical NF- κB pathways 
(Boyce et al., 2015).  
To activate the canonical pathway, recruited TRAF6 induces the formation of a complex of 
IKKs (specifically, IKKα, IKKβ and IKKγ) that induce the phosphorylation and degradation 
of inhibitory IκBα; thus, the p65/p50 heterodimer is free to translocate to the nucleus. In 
osteoclastogenesis, the p65/p50 heterodimer then induces the expression of c-Fos and nuclear 
factor of activated T-cells cytoplasmic 1 (NFATc1), transcription factors necessary for 
osteoclast differentiation (Boyce et al., 2015) (Figure 1.7, left). In the vasculature, however, 
the specific effects of p65/p50 translocation remain unclear, but NFATc1 has also been 
implicated in the development of oxidised LDL-induced VC (Goettsch et al., 2011). To activate 
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the non-canonical pathway, TRAF6 directly activates the NF-κB-inducing kinase (NIK), the 
first protein of the non-canonical signalling cascade (Darnay et al., 1999). NIK forms a 
complex and activates IKKα, also promoting the binding of IKKα to its substrate, p100 (Xiao 
et al., 2004). Once bound, p100 is cleaved to form p52, which then forms a heterodimer with 
RelB prior to nuclear translocation (Sun, 2011) (Figure 1.7, right). As with canonical 
activation, in osteogenesis, p52/RelB also drive the same osteoclastic genes as p50/p65 (i.e., c-
Fos, NFATc1), but it is as of yet unclear what genes are regulated by RANKL-mediated 



















Figure 1.7. The canonical (left) and non-canonical (right) NF-κB pathways activated by RANKL. (A) 
The canonical NF-κB pathway involves TRAF6 association with the intracellular domain of RANK. This 
association recruits three members of the IKK family to induce the degradation of IκBα, allowing p50/p65 
translocation to the nucleus. (B) The non-canonical pathway also involves TRAF6 association with RANK, 
inducing NIK; NIK complexes with IKKα, promoting p100 binding and processing to p52. The p52/RelB 
heterodimer can then translocate to the nucleus. Once translocated, both p50/p65 and p52/RelB heterodimers 
can regulate gene expression. IKK, IκB kinase; NIK, NF-κB-inducing kinase; RANK(L), receptor activator 




As noted, TRAIL can activate NF-κB via DcR2, DR4 or DR5 binding (Delgi-Esposti et al., 
1997). TRAIL-mediated binding to its death receptors is mostly associated with caspase-
mediated apoptosis (Wang and El-Deiry, 2003), but activation of NF-κB has also been 
associated with both pro-apoptotic and pro-survival functions (Delgi-Esposti, 1999; Ravi et al., 
2001) and the induction of pro-inflammatory cytokines (Tang et al., 2008). Unlike RANKL, 
however, no studies to date have yet associated non-canonical NF-κB activation with TRAIL 
function; furthermore, there is limited data available regarding the downstream targets of 
TRAIL-induced NF-κB outside the context of apoptosis/survival (summarised in detail by 
Forde et al., 2016). TRAIL is known to have diverse pleiotropic functions in many cells and 
tissues, but as mentioned, its precise role(s) in the vasculature (and particularly those mediated 
by NF-κB) remain to be delineated.  
Of particular relevance, NF-κB signalling has been associated with a number of pathological 
conditions relevant to VC. In this respect, NF-κB has been implicated in a number of metabolic 
and vascular diseases due to its close association with the inflammatory response, including 
T2DM and atherosclerosis (Baker et al., 2011; Baumgartl et al., 2006; Rocha and Libby, 2009). 
Indeed, pro-inflammatory cytokines are widely accepted inducers and products of NF-κB 
signalling, and are themselves known to promote VC (Al-Aly, 2008; Hénaut and Massy, 2018). 
Furthermore, these cytokines have been found to be present at high levels in atherosclerotic 
plaque (Barath et al., 1990), the location of intimal VC in vivo, often coinciding with medial 
calcification (McCullough et al., 2008). Interestingly, the NF-κB pathway has previously been 
suggested as a potential therapeutic target for inflammatory vascular diseases (Pamukcu et al., 
2011), and with relevance to RANKL, NF-κB blockade has been shown to prevent 
osteoclastogenesis in vivo (Jimi et al., 2004). Additionally, the glucagon-like peptide-1 receptor 
agonist (GLP-1RA) exenatide has been found to protect from VC via attenuation of 
RANKL/NF-κB activation (Zhan et al., 2014), whilst induced activation of NF-κB has been 
shown to accelerate VC (Zhang et al., 2017; Zhao et al., 2012). Unfortunately, however, these 
studies focus on canonical NF-κB activation (or do not specify which pathway); thus, much 
remains to be delineated regarding the precise role for both canonical and non-canonical NF-
κB during VC pathogenesis. As both RANKL and TRAIL activate NF-κB to modulate 
osteoclastogenesis and apoptosis/survival, respectively, it is highly likely that the 
aforementioned effects of these ligands in the vasculature may be mediated in some way by 
NF-κB; more information on NF-κB signalling may therefore aid in delineating VC 
mechanisms and ultimately developing a successful treatment.  
 28 
1.2.4.5.2 Oxidative Stress   
Oxidative stress has also been implicated in the pathogenesis of vascular diseases, and is known 
to be involved in RANKL/TRAIL signalling. Oxidative stress is exerted in vivo by ROS, 
metabolic by-products resulting from the reduction of oxygen. ROS is a cumulative term used 
to describe a number of chemically reactive oxygen-containing species that are naturally 
produced in the mitochondria during aerobic metabolism, including both free radicals (e.g. 
superoxide, hydroxyl, peroxyl) and non-radicals (e.g. hydrogen peroxide) (Bayir, 2005). Under 
healthy conditions, these species mediate a number of physiological processes (Vara and Pula, 
2014). Under certain pathological conditions, however, ROS may be overproduced (in both 
mitochondria and cytosol) to levels above those required to mediate physiological processes 
(Schieber and Chandel, 2014); elevated ROS then leads to irreversible damage to intracellular 
components (e.g. nucleic acids, proteins) resulting in cell dysfunction or cell death (Pitocco et 
al., 2013). ROS levels are mediated by a number of pro-oxidant and anti-oxidant enzymes 
(Rahal et al., 2014), and some of these enzymes are of particular relevance to the vasculature. 
In vascular cells, ROS are primarily produced by membrane-associated nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases, often referred to as NOX enzymes (Pitocco et al., 
2013). There are multiple NOX isoforms, many of which are expressed by vascular cells 
(Meyer and Schmitt, 2000), and these isoforms are determined based on the specific 
arrangement of their phagocytic oxidase (phox) subunits (gp91, p22, p40, p47, p67) (Brandes 
and Kreuzer, 2005). Following assembly at the plasma membrane, NOX enzymes catalyse 
ROS generation by transferring electrons from NADPH to molecular oxygen, and can release 
ROS both intra- and extracellularly (Lassègue et al., 2010; Raaz et al., 2014). Xanthine 
oxidase, another enzyme involved in ROS generation in endothelial cells, produced ROS when 
converting (hypo)xanthine to uric acid (Madamanchi et al., 2005). The third main source of 
ROS in the vasculature involves the uncoupling of endothelial nitric oxide synthase (eNOS)-
mediated nitric oxide (NO) production from oxygen reduction; eNOS can then produce ROS 
in the form of superoxide and hydrogen peroxide (Yang et al., 2009). 
Interestingly, eNOS, under normal conditions, produces NO, a free radical responsible for the 
regulation of vascular homeostasis, VSMC proliferation and vasodilation (Sena et al., 2013).  
As such, eNOS generally confers a protective influence on the vasculature (Albrecht et al., 
2003), highlighting a dual role for this enzyme in the regulation of ROS. Superoxide dismutase 
(SOD) enzymes also exert an anti-oxidant effect on the vasculature by converting superoxide 
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anions into less harmful compounds (Ighodaro and Akinloye, 2017; Zhang et al., 2003). There 
are three isoforms of SOD; SOD1, responsible for scavenging cytosolic ROS, SOD2, 
responsible for scavenging mitochondrial ROS, and SOD3, responsible for scavenging 
extracellular ROS (Faraci and Didion, 2004; Fukai et al., 2002; Zelko et al., 2002). Finally, 
heme oxygenase-1 (HMOX1) exerts an anti-oxidant effect on the vasculature via the 
degradation of heme, a potent pro-oxidant (Jeney et al., 2002) in response to oxidative stress 
and inflammation (True et al., 2007). Thus, the regulation of ROS in the vasculature involves 
a complex balance of both pro- and anti-oxidant enzymes.  
From a pathological perspective, many of these enzymes have been associated with vascular 
pathologies. In this respect, NADPH oxidases have been associated with the progression of 
endothelial dysfunction and CVD/T2DM (Higashi et al., 2009; Kayama et al., 2015; Pitocco 
et al., 2013). More specifically, the expression of both gp91 and p47 phox subunits have been 
positively correlated with atherosclerosis and intimal calcification (Barry-Lane et al., 2001; 
Meyer and Schmitt, 2000; Sorescu et al., 2002), and p47 has been shown to be induced in 
endothelial cells under pro-inflammatory conditions common during VC (Li et al., 2002). 
Furthermore, eNOS uncoupling has been shown to be prevalent in CVD/T2DM, contributing 
to vascular ROS (Guzik et al., 2002; Yang et al., 2009). Indeed, elevated ROS has been 
associated with the pathology of endothelial dysfunction and VC (Byon et al., 2008; Faraci and 
Didion, 2004; Li and Shah, 2004; Madamanchi et al., 2007; Towler, 2008), and with particular 
respect to T2DM, is known to be induced by hyperglycemia (Callaghan et al., 2005). 
Of relevance, RANKL has been shown to induce ROS formation in osteoclastogenesis 
(Thummuri et al., 2017), and TRAIL is thought to exert its apoptotic function via the induction 
of oxidative stress in malignant cells (Lee et al., 2002). Interestingly, an anti-oxidant role for 
TRAIL has also been considered in the vasculature (Zauli et al., 2003), indicating that TRAIL 
may exert varying roles in normal versus tumour cells. No literature to date has yet investigated 
the effects of these ligands on oxidative stress in vascular cells, however, or assessed what the 
implications of this might be for VC. Of further note, redox signalling and NF-κB have been 
shown to reciprocally interact (Morgan and Liu, 2011), and Zhao and colleagues (2011) have 
presented pertinent evidence describing the dual activation of both ROS and NF-κB during 
VC. Pro-inflammatory cytokines, known activators of NF-κB, are also well established pro-
oxidant stimuli, and given that both RANKL and TRAIL can also activate NF-κB, may 
highlight a role for RANKL/TRAIL-mediated oxidative stress during VC pathogenesis.  
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1.3 VC Models  
There have been numerous vascular cell culture and animal models employed to date to 
highlight the critical importance of RANKL, TRAIL and their common decoy receptor OPG 
in the VC process, contributing to the overall mechanistic understanding of calcification. 
Although some data is conflicting, most studies endorse the pro-calcific effects of RANKL and 
the protective effects of both TRAIL and OPG within the vasculature. A summary of in vitro 
and in vivo models and their corresponding findings are discussed in the following sections 
1.3.1 and 1.3.2, respectively.  
 
1.3.1 In vitro Studies  
There is a considerable body of in vitro evidence to support the proposed pro-calcific actions 
of RANKL and anti-calcification actions of OPG/TRAIL in vascular cells, as summarised in 
Table 1.2 overleaf. Firstly, Panizo and co-workers have provided clear evidence in cell culture 
models that RANKL directly increases VSMC calcification in a dose-dependent manner, a 
process that can be counteracted through co-incubation with OPG (Ndip et al., 2011; Panizo et 
al., 2009). Additionally, di Bartolo and colleagues have demonstrated OPG’s ability to prevent 
calcium-induced calcification in cultured VSMCs (di Bartolo et al., 2011). Anti-calcific effects 
are also a feature of TRAIL-mediated protection. As noted in Section 1.2.4.4, a considerable 
body of evidence points to an ant-atherogenic role for TRAIL. Specifically with respect to VC, 
studies employing VSMCs isolated from both wild-type and TRAIL-deficient mice revealed 
accelerated calcification in the latter, pointing to a putative role for TRAIL in preventing 
calcium-induced calcification of VSMCs. Moreover, this effect was shown to be calcium dose-
dependent. After 24 hours of calcium exposure, wild-type VSMCs significantly increased 
RANKL mRNA with simultaneous inhibition of both OPG and TRAIL, demonstrating the 
differential regulation of RANKL, OPG and TRAIL in the modulation of VC in vitro (di 
Bartolo et al., 2013). Furthermore, although not directly relevant in a vascular setting, Zauli 
and colleagues have pertinently illustrated that TRAIL can prevent bone resorptive activity 
induced by RANKL plus macrophage colony stimulating factor in vitro (Zauli et al., 2004), 
potentially indicating a role for TRAIL in the mediation of RANKL function.  
In contrast to these observations, it has also been claimed that neither OPG, RANKL nor 
TRAIL have any effect on VSMC calcification in vitro (Olesen et al., 2012). In addition, it has 
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been noted that RANKL has no direct effect on VSMCs (Byon et al., 2011), while Chasseraud 
and colleagues have demonstrated that TRAIL can actually enhance VSMC mineralisation in 
the presence of phosphate (Chasseraud et al., 2011). The methodological approach of the 
investigator may therefore be pertinent to explaining these discrepancies. Many previous 
studies have employed phosphate-containing “calcifying” growth media to enhance 
calcification. However, phosphate itself induces osteoblastic activity, possibly confounding the 
observed cellular effects of OPG, RANKL and/or TRAIL. Additionally, calcium deposition is 
often relied upon as a calcification end-point assay, despite wide variability and lack of 
reproducibility across VSMC populations (Olesen et al., 2012). Furthermore, endogenous OPG 
secretion (primarily by VSMCs (Corallini et al., 2009)) leading to RANKL and TRAIL 
neutralization is often overlooked, whilst commonly-used static VSMC monocultures lack 
endothelial paracrine signalling inputs and shear-mediated conditioning effects that are 
undoubtedly present in the corresponding in vivo environment (Chiu et al., 2009; Eddahibi et 
al., 2006). Some or all of these confounders are features in many of the studies within the 














Study Protein Outcome 
Panizo et al., 2009 
OPG Anti-calcification 
RANKL Pro-calcification 
Di Bartolo et al., 2011 OPG Anti-calcification 
Zauli et al., 2004 
RANKL Pro-calcification 
TRAIL Anti-calcification 




Olesen et al., 2012 
OPG No effect 
RANKL No effect 
TRAIL No effect 
Byon et al., 2011 RANKL No effect 
Chasseraud et al., 2011 TRAIL Pro-calcification 
Davenport et al. 2016 RANKL Pro-calcification* 
Osako et al., 2010 RANKL Pro-calcification* 
 *Exerts this effect through endothelial cell paracrine signalling. 
Table 1.2. Summary of the most relevant in vitro studies regarding the effects of RANKL, TRAIL and 
OPG in the vasculature. 
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Using an advanced perfused capillary co-culture model approach that specifically addresses 
some of these confounders, our research group have recently determined that RANKL does not 
appear to directly affect osteogenic activity and/or calcification in VSMCs, rather it appears to 
stimulate ECs to release paracrine factors capable of inducing VSMC osteochondrogenic 
transformation (Davenport et al., 2016). This is somewhat consistent with Osako and 
colleagues, who have provided evidence that RANKL may act indirectly on VSMCs through 
stimulating endothelial release of osteogenic paracrine signals including BMP-2 (Osako et al., 
2010). Thus, whilst the majority of in vitro research completed to date supports the respective 
pro-calcific and anti-calcific effects of RANKL and OPG/TRAIL (Table 1.2), the precise 
mechanisms through which this occurs are likely more complex than previously believed. 
 
1.3.2 In vivo Studies  
Numerous murine models have also been employed to illustrate the effects of OPG, RANKL 
and TRAIL in the VC process. In an early study by Bucay and colleagues, it was noted that 
OPG-deficient mice developed accelerated medial VC in large arteries (aortic and renal), where 
endogenous OPG production is typically prevalent, indicating a protective role for OPG in 
these locations (Bucay et al., 1998). More recently, Callegari and colleagues have 
demonstrated that recombinant OPG delivery to OPG-deficient ApoE-/- mice can reduce 
calcification in addition to reducing atherosclerotic lesion size (Callegari et al., 2013), and 
further demonstrated that OPG inactivation increases calcification and lesion size in the same 
murine model (Callegari et al., 2014). Interestingly, inactivation of RANKL signalling in OPG-
deficient ApoE-/- VSMCs counteracted this effect (Callegari et al., 2014), whilst murine serum 
OPG has also been shown to be inversely correlated with free/unbound levels of RANKL 
(Secchiero et al., 2006). To further support the proposed OPG/RANKL relationship, isolated 
murine OPG-/-ApoE-/- VSMCs developed increased calcification and exerted an upregulation 
of osteochondrogenic genes following RANKL treatment, while OPG+/+ApoE-/- VSMCs 
exhibited no such response (Callegari et al., 2014). This basic model highlights the protective 
effect of OPG on VC through the modulation of RANKL’s pro-calcific effects.  
Although OPG can also act as a soluble decoy receptor for TRAIL, many in vivo studies have 
also highlighted the protective effects of TRAIL on the vasculature. For example, it has 
previously been shown that systemic delivery (both single/repeated injection) of recombinant 
TRAIL to ApoE-/- diabetic mice demonstrated anti-atherosclerotic activity (Secchiero et al., 
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2006). Elevated diabetic risk has also been linked to TRAIL deficiency, as high fat diet (HFD)-
fed TRAIL-/-ApoE-/- and TRAIL-/-ApoE+/+ mice showed multiple indicators of diabetes 
development after 12 weeks when compared to TRAIL+/+ApoE-/- mice (including increased 
weight, hyperglycemia and reduced plasma insulin) (di Bartolo et al., 2011). In the 
aforementioned study by di Bartolo et al. (Section 1.3.1), advanced atherosclerotic lesions in 
HFD-fed TRAIL-/-ApoE-/- and ApoE-/- mice were also monitored, revealing an increase in 
calcification and cartilaginous metaplasia at 20 weeks and an upregulation of pro-calcification 
proteins (including RANKL and BMP-2) at 12 weeks in TRAIL-/-ApoE-/-  when compared to 
ApoE-/- mice (di Bartolo et al., 2013). On a final note, the previously reported ability of TRAIL 
to counteract RANKL’s osteoclastic signals in vitro (Zauli et al., 2004) was verified in a murine 
model (Zauli et al., 2008), pointing to a vasoprotective role for TRAIL in the modulation of 












1.3.3 Clinical Research  
It is now widely accepted that VC constitutes a major risk factor in CVD-associated morbidity 
and mortality. In this respect, previous studies have specifically linked VC to cardiac death, as 
coronary artery calcification (CAC) in CAD has been shown to be significantly associated with 
mortality (Budoff et al., 2010). Moreover, atherosclerotic calcification has been claimed to be 
an independent risk factor for cardiovascular death (Detrano et al., 2008), often occurring 
Study Protein  Outcome  
Bucay et al., 1998 OPG Anti-calcification 
Callegari et al., 2013 OPG Anti-calcification 
Callegari et al., 2014 OPG Anti-calcification 
RANKL Pro-calcification 
Secchiero et al., 2006 TRAIL Anti-calcification 
Di Bartolo et al., 2011 TRAIL Anti-calcification 
Di Bartolo et al., 2013 RANKL Pro-calcification 
TRAIL Anti-calcification 
Zauli et al., 2008 RANKL Pro-calcification 
TRAIL Anti-calcification 
 
Table 1.3. Summary of the most relevant in vivo studies regarding the effects of RANKL, TRAIL and 
OPG in the vasculature.  
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alongside medial VC (McCullough et al., 2008). As CVD is the major cause of mortality 
among diabetes subjects (Morrish et al., 2001), it is unsurprising that VC is a pathological 
condition frequently accelerated in this patient population (Sage et al., 2010; Shao et al., 2010). 
Additionally, clinical evidence is continuously emerging regarding the involvement of 
RANKL, TRAIL and their decoy receptor OPG in VC and associated cardiovascular events. 
Importantly, all three glycoproteins have been identified within vascular tissues, circulating 
blood, and calcified atherosclerotic lesions (Higgins et al., 2015; Schoppet et al., 2004; Van 
Campenhout and Golledge, 2009), with clinical observations supporting a likely role for these 
regulatory proteins in the VC process in patients with T2DM/CVD. Careful analysis of these 
protein targets within a clinical setting (addressed below) may unlock their potential value to 
CVD and T2DM with respect to risk assessment and disease management (di Bartolo and 
Kavurma, 2014; Sage et al., 2010). A joint focus will be maintained on both T2DM and 




Circulating OPG has thus far been positively correlated with a number of T2DM/CVD 
pathologies. High levels of plasma OPG have been shown to positively predict CVD morbidity 
and mortality (Reinhard et al., 2010; Vik et al., 2011), while circulating OPG is increased in 
patient groups with high levels of arterial calcification (O’Sullivan et al., 2010). As part of the 
Dallas Heart Study, it was observed that CAC and aortic plaque volume could be independently 
(positively) associated with circulating OPG in an unselected population, thereby indicating its 
possible use as a biomarker for atherosclerosis (Abedin et al., 2007). Moreover, high levels of 
OPG have been positively correlated with CAD (Schoppet et al., 2003) and peripheral vascular 
disease (Zielger et al., 2005), whilst Omland and co-workers have highlighted its potential use 
as a predictor of heart failure in patients who suffer from acute coronary syndromes (Omland 
et al., 2008). Most recently, Higgins and colleagues have demonstrated that both tissue and 
serum OPG are strongly and inversely associated with calcification in human carotid 
atherosclerosis (Higgins et al., 2015). Since OPG is a proposed inhibitor of RANKL-induced 
VSMC osteogenic differentiation (Morony et al., 2008), increased circulating OPG levels may 
represent a protective phenomenon to tackle pro-inflammatory and pro-calcific events (Singh 
et al., 2012); the role of this ligand as a decoy receptor for TRAIL, in this respect, is less clear. 
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Elevated serum OPG has also been linked to T2DM. In murine models for example, it has been 
shown that OPG levels increase shortly after induction of diabetes (Secchiero et al., 2006), 
with a similar trend noted in clinical studies. Many studies have significantly correlated serum 
OPG elevation with worsening cardiovascular burden in T2DM, including CAC (Jung et al., 
2010), carotid intimal-medial thickness (Gaudio et al., 2014), hypertension (Rozas Moreno et 
al., 2013), CAD/PAD (Poulsen et al., 2011), metabolic syndrome and microvascular 
complications (Tavintharan et al., 2014). Elevated OPG has also been shown to invariably 
predict coronary artery VC progression in diabetics, and furthermore can be used to predict 
future cardiovascular events (Anand et al., 2006; Anand et al., 2007). Finally, a 2012 study 
into advanced carotid atherosclerosis illustrated that a history of diabetes and CAD (among 
other diseases) could independently predict circulatory plasma OPG levels (Giaginis et al., 
2012). Therefore, it is highly likely that serum OPG concentration may constitute an important 
and specific CVD biomarker in T2DM, but it is unclear what the potential therapeutic value of 
this protein may be given that OPG levels are already elevated in T2DM/CVD patients.  
 
1.3.3.2 RANKL 
Despite strong evidence supporting a role for OPG as a T2DM/CVD biomarker, clinical 
investigations focusing on RANKL have proven much more divisive, with varying clinical 
observations across the T2DM/CVD spectrum. It has been claimed for example that circulating 
RANKL levels exhibit no correlation with either advanced carotid atherosclerosis (Giaginis et 
al., 2012) or carotid intimal-medial thickness (Gaudio et al., 2014). More recently however, 
both serum and tissue RANKL have been positively correlated with carotid calcification in 
atherosclerotic lesions (Higgins et al., 2015). With respect to T2DM, Gaudio and co-workers 
have reported that circulating RANKL levels were lower in diabetics than in control subjects 
(Gaudio et al., 2014), whilst O’Sullivan and co-workers reported no change in plasma RANKL 
levels in T2DM (O’Sullivan et al., 2010). In another recent study, the authors identified an 
inverse association between higher levels of total RANKL and CAC/triglycerides in post-
menopausal women (Poornima et al., 2014). It has also been reported that RANKL expression 
is upregulated and localized to areas displaying medial arterial calcification in patients with 
charcot neuroarthropathy (Ndip et al., 2011), whilst soluble RANKL (sRANKL) has also been 
positively co-associated with well-known biomarkers of heart failure (Loncar et al., 2010). 
Overall, however, based on these recent clinical findings, a definitive role for RANKL as a 
serum biomarker for T2DM/CVD remains inconclusive, and the primary clinical relevance for 
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this ligand may lie in the prevention of RANKL-mediated pro-calcific events during VC (well-
defined both in vitro and in vivo).  
 
1.3.3.3 TRAIL 
There has been considerable clinical focus on circulating TRAIL levels in CVD. Secchiero and 
co-workers have found that levels of circulating TRAIL are decreased after acute MI and that 
lower TRAIL levels are independently associated with increased levels of cardiac death in the 
year following patient discharge (Secchiero et al., 2009) - observations consistent with the 
vasoprotective anti-calcific role for TRAIL previously postulated from in vitro and animal 
studies. Furthermore, due to elevated OPG and decreased TRAIL in acute MI patients, these 
researchers proposed that the ratio between OPG/TRAIL may have potential use as a 
biomarker, as this balance was significantly associated with CAD. In support of its efficacy as 
a biomarker, follow-up patients who developed heart failure had a significantly elevated 
OPG/TRAIL ratio than those who did not, indicating that this ratio may be used to predict heart 
failure in acute MI patients (Secchiero et al., 2009). TRAIL levels have also inversely predicted 
all-cause mortality in patients with advanced heart failure (Niessner et al., 2009).  
In other research, Mori and co-workers reported that serum TRAIL levels were significantly 
lower in CAD patients, and were inversely associated with CAD severity independently of 
other coronary risk factors (Mori et al., 2010), while Volpato and colleagues found a significant 
inverse relationship between baseline serum TRAIL levels and all-cause CVD mortality 
(Volpato et al., 2011). Kawano and co-workers have also previously reported that serum 
TRAIL levels were significantly and inversely correlated with carotid intimal-medial thickness 
in a subset of T2DM patients with macrovascular diseases (Kawano et al., 2011). 
Notwithstanding these observations, inconsistencies between study findings are also evident 
from the literature. In this regard, O’Sullivan et al. found no change in TRAIL levels in T2DM 
subjects (2010), whilst Galeone et al. (2013) detected high levels of TRAIL in calcified aortic 
valves, as well as elevated levels of circulating TRAIL in these CVD patients compared to 
control subjects. The balance of clinical evidence, however, suggests that serum TRAIL levels 
may constitute an important predictor of CV burden in patients with T2DM and CVD. Thus, 
given the previously reported potential therapeutic value for TRAIL identified in vivo, it 
appears that this ligand’s translational potential may be multi-faceted.  
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1.4 Therapeutic Considerations  
The dynamic nature of VC offers significant potential for clinical intervention in patients with 
T2DM manifesting cardiovascular complications. Thus far, however, there are no treatment 
options available for VC across the T2DM/CVD patient spectrum, most likely due to an 
insufficient understanding of the precise molecular and cellular mechanisms involved, in 
conjunction with a lack of clinical studies. It is clear that the dynamic pathways involving 
RANKL, TRAIL and their decoy receptor OPG represent potential therapeutic targets for 
interference of the calcification process. To date, however, progress in exploring these 
therapeutic options (which could play a key role in the development of an effective treatment 
for VC) has been limited. Nonetheless, the anti-calcific effects of OPG/TRAIL, as well as the 
pro-calcific effects of RANKL, have been considered by some authors in the context of 
generating targets for VC intervention.  
 
1.4.1 Recombinant OPG Therapy 
Unsurprisingly, in view of its mechanism of action, OPG administration has been suggested as 
one potential treatment option for VC (Wu et al., 2013). OPG functions to prevent 
osteoclastogenesis and resorption in bone, whilst also having a paradoxical function in 
preventing osteochondroblastic calcification within the vasculature, thus resulting in a context-
specific dual protective function. In support of this, numerous murine studies have illustrated 
that OPG deficiency tends to increase the extent of VC and cardiovascular complications, and 
promisingly, a recombinant OPG fusion protein (Fc-OPG) has been shown to inhibit VC in an 
animal study (Morony et al., 2008). In this latter study, ldlr-/- mice were fed an atherogenic diet 
alongside Fc-OPG administration; calcification (as measured by the Von Kossa silver stain for 
calcium deposition) was specifically inhibited with no effect on atherosclerotic lesion number 
or size. It can be noted that Fc-OPG has also been safely employed in rat models to treat arthritis 
(Bolon et al., 2002) and orthodontic issues (Fernández-González et al., 2015), and administered 
to dogs (alongside BMP-2) to increase bone formation and healing (Yao et al., 2011), although 
its specific pleiotropic effects on VC were not considered during these particular investigations. 
As noted, however, circulating OPG is significantly elevated during T2DM/CVD, and as such, 
the precise benefit of recombinant OPG treatment in human clinical studies remains to be 
determined.  
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1.4.2 Anti-RANKL Therapy  
Due to the cross-over in molecular mechanisms between bone morphogenesis and VC, it is 
possible that a second prospective treatment for VC could be adapted from currently existing 
osteoporosis therapy (Wu et al., 2013). Osteoporosis is a systemic skeletal disease in which the 
level of bone resorption is greater than that of bone formation, leading to continuous bone 
degradation and ultimately resulting in low bone mass and fragility (Miyazaki et al., 2014). 
Denosumab, a human monoclonal antibody for RANKL, is one of the latest approved treatment 
options for osteoporosis (Suresh et al., 2015; Wu et al., 2013), although its effects on VC have 
not yet been fully assessed. Mimicking the natural actions of OPG, Denosumab binds and 
neutralizes RANKL (but not TRAIL), attenuating its osteoclastic effects and allowing 
osteoblastic build-up of bone to ensue (Kostenuik et al., 2009). As RANKL promotes 
osteochondroblastic activity in VSMCs, anti-RANKL therapy could theoretically function to 
reduce the extent of calcification in the vasculature.  
In support of this theory, it has been demonstrated that Denosumab reduced aortic calcium 
levels by half in a murine model of osteoporosis (Helas et al., 2009), but contrastingly, the only 
corresponding human study completed to date has noted no influence of this therapy on aortic 
calcification progression over a three-year period (Samelson et al., 2014). It is possible that 
this disparity is due to inconsistencies in calcification measurement, as Samelson and 
colleagues utilized a semi-quantitative method (lateral spine X-rays) as opposed to the 
quantitative measurement of aortic calcium deposition employed by Helas and co-workers 
(2009). However, as noted, the natural increase in circulating OPG during T2DM likely exerts 
the same influence as Denosumab in vivo, and (given that VC progresses alongside this 
elevated OPG) may not be sufficient to attenuate RANKL-mediated pro-calcific effects 
(indeed, it must be remembered that in both bone and vasculature, RANKL exerts its function 
despite the presence of endogenous OPG production). The potential of anti-RANKL therapy 
in VC treatment therefore awaits further clinical investigation, but it is likely that successful 
intervention for VC may lie outside of the RANKL:OPG axis.   
 
1.4.3 TRAIL Administration 
Although its potential therapeutic use in cardiovascular protection has been suggested (Volpato 
et al., 2011), there have been no human clinical investigations conducted to date that address 
the potential of TRAIL for the treatment of VC. As noted however, recombinant TRAIL 
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administration to ApoE-/- diabetic mice has been shown to significantly reduce atherosclerosis 
progression (Secchiero et al., 2006), whilst TRAIL delivery protects against diabetic vascular 
injury in rats (Liu et al., 2014). Also of relevance, TRAIL deficiency appears to promote VC 
and diabetes in vivo (di Bartolo et al., 2011; di Bartolo et al., 2013), and most relevantly, has 
been shown to attenuate RANKL-mediated function both in vitro and in vivo (Zauli et al., 2004; 
Zauli et al., 2008). Thus, the potential therapeutic value of TRAIL in the treatment of VC 
cannot be ignored, but further basic research is necessary to determine the precise 
mechanism(s) of TRAIL-mediated protection before clinical trials can be conducted.  
 
1.4.4 Additional Therapeutic Possibilities 
A range of potential therapeutic possibilities for VC unrelated to the OPG/RANKL/TRAIL 
axis have emerged in the literature, some of which are related to current treatments for 
osteoporosis, CVD, and chronic kidney disease (CKD) (Wu et al., 2013). Firstly, like 
Denosumab, bisphosphonates (pyrophosphate analogs) are a successful osteoporosis treatment 
that have been considered as a potential VC therapy option due to their inhibitory effect on 
hydroxyapatite crystal formation (Boskey et al., 2003). Additionally, teriparatide, a shortened 
recombinant human parathyroid hormone also employed for osteoporosis treatment, has been 
shown to reduce VC in ldlr-/- mice (Shao et al., 2003). Secondly, statins, which have been 
routinely employed to lower blood cholesterol and prevent vascular complications during 
CVD/T2DM, have also been considered as a potential treatment option for VC, in view of their 
inherent pleiotropic properties (Wu et al., 2013). Indeed, statins have been shown to reduce 
levels of pro-calcific serum RANKL (Lenglet et al, 2014) and to increase anti-calcific serum 
OPG (Mori et al., 2010). Thirdly, GLP-1RAs, a new class of injectable glucose-lowering drugs, 
are currently employed in T2DM treatment (Mafong et al., 2008), and thus far, the potential 
for GLP-1RAs in VC prevention have been promising (Zhan et al., 2014). Furthermore, 
endothelin receptor agonists used to treat hypertension have also been shown to be effective 
against VC in vitro (Wu et al., 2003) and in vivo (Essalihi et al., 2004), while a monoclonal 
antibody to IL-1β (01BSUR, Novartis) has been noted to reduce aortic calcification in ldlr-/- 
mice (Awan et al., 2016). Finally, owing to the similarity in calcification-driven pathogenesis, 
the range of existing therapies for CKD may also hold promise in the development of a 
successful VC treatment (Wu et al., 2013). An extensive list of treatment options for VC are 
summarised in Appendix 1.1 for perusal (Harper et al., 2016). 
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1.5 Study Hypotheses and Objectives 
Accelerated VC observed during T2DM is a leading cause of morbidity and mortality, 
however, the key molecular events and signalling pathways underpinning this process remain 
to be fully defined. Evidence now points to a role for the signalling triad RANKL, TRAIL and 
their common decoy receptor OPG in the regulation of VC; in this respect, the pro-calcific and 
protective effects of RANKL and OPG, respectively, are well documented, but the role for 
TRAIL in a vascular setting remains under debate. Despite this, compelling evidence now 
points to a vasoprotective role for TRAIL, but further research is required to confirm its 
potential therapeutic relevance to VC. Furthermore, whilst the precise mechanisms underlying 
the physiological roles for RANKL and TRAIL are well defined, the interrelated mechanisms 
by which these ligands exert their function in the vasculature remain to be explored.  
 
1.5.1 Study 1: Profiling the Effects of RANKL +/- TRAIL in the Vasculature 
The pro-calcific effects of RANKL in the vasculature have been well described, exerting both 
direct effects on vascular cells (Panizo et al., 2009) and indirect effects on VSMCs via 
endothelial paracrine signalling (Davenport et al., 2016; Osako et al., 2010). Furthermore, we 
note an interesting piece of evidence presented by Zauli and colleagues (2004; 2008) that 
TRAIL can attenuate RANKL-induced osteoclastogenesis, suggesting that TRAIL has the 
ability to regulate RANKL signalling. Thus, given the proposed vasoprotective properties of 
TRAIL, we hypothesise that TRAIL may exert an anti-calcific influence on the vasculature via 
attenuation of RANKL-induced pro-calcific signalling. As RANKL is known to promote VC 
both directly and via paracrine communication, the effects of RANKL +/- TRAIL on vascular 
cells in monoculture (endothelial/smooth muscle cells separately) and in co-culture 
(endothelial/smooth muscle cells in indirect contact) will be assessed (Figure 1.8A). A range 
of VC-related indices will be analysed following RANKL +/- TRAIL treatment at an mRNA 
and/or protein level by RT-qPCR, ELISA and Western blotting where appropriate.  
 
1.5.2 Study 2: Profiling the Effects of RANKL and TRAIL under Pathological Conditions  
We notice that the vast majority of studies to date assess the effects of RANKL and TRAIL 
under “healthy” conditions in vitro. In reality, however, RANKL and TRAIL during 
CVD/T2DM exert their function in the presence of pathological stimuli, primarily 
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hyperglycemia and inflammation. Thus, we hypothesise that the influence of RANKL and 
TRAIL may vary considerably under pathological compared to healthy conditions. In this 
respect, the effects of RANKL/TRAIL on the vasculature under pathological conditions will 
be analysed, which may aid in delineating the roles of RANKL and TRAIL during VC. Again, 
both monoculture and co-culture models will be included in order to recapitulate the paracrine 
signalling element of physiological vasculature (Figure 1.8B), and a range of VC-related 

















1.5.3 Study 3: Investigating the Mechanisms of RANKL and TRAIL Function during VC  
From a mechanistic perspective, both RANKL and TRAIL function are known to involve NF-
κB signalling and oxidative stress, both of which have been implicated in vascular pathologies 
(Byon et al., 2008; Folli et al., 2011; Patel and Santani, 2009). However, the signalling 
pathways activated by these ligands during VC remain to be clarified. We therefore hypothesise 
that both NF-κB activation and redox signalling may regulate RANKL/TRAIL function during 
Figure 1.8. Representation of the in vitro co-culture model to be employed for studies 1 and 2. (A) 
Endothelial cells will be treated with RANKL +/- TRAIL, and (B) endothelial cells will be treated with 
RANKL or TRAIL under pathological conditions. (i) Endothelial:smooth muscle paracrine signalling and (iii) 
smooth muscle cell responses will be assessed in each case. RANKL, receptor activator of NF-κB ligand; 
TRAIL, tumour necrosis factor-related apoptosis-inducing ligand. Image adapted from Harper et al., 2018. 
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VC. Thus, we chose to investigate these pathways in the aforementioned in vitro models via 
analysis of a range of both VC-related and redox indices via RT-qPCR, ELISA and Western 
blotting where appropriate. Oxidative stress will also be assessed via analysis of reactive 
oxygen species by flow cytometry and fluorescence microscopy. Furthermore, the potential for 
the involvement of additional protein mediators not yet implicated in the VC process will be 
assessed via bioinformatics analyses (Section 2.2.8). Identifying the precise molecular 
mechanisms underpinning VC may ultimately lead to therapeutic development that will reduce 






































2.1 Materials  
2.1.1 Consumables and Plasticware 
Becton Dickinson (New Jersey, USA) 
Falcon® round-bottomed test tubes for flow cytometry 352054 
 
Digital Bio Technology (Seoul, South Korea)  
Accuchip 4x Kit AD4K-200 
 
Merck Millipore (Massachusetts, USA)  
Immobilon®-PSQ polyvinylidene fluoride 0.2 μm membrane ISEQ00010 
Millicell® hanging cell culture transwell insert 0.4 µm MCHT06H48 
 
Roche Diagnostics (Basel, Switzerland) 
LightCycler® 480 plates 96-well 04729692001 
 
Sarstedt AG & Co. (Nümbrecht, Germany)  
10 μL pipette tips 70.1130 
200 μL pipette tips 70.760.002 
1000 μL pipette tips 70.762 
0.2 mL PCR tubes 72.737.002 
0.5 mL PCR tubes 72.735.002 
1.5 mL microtubes 72.706.200  
2 mL microtubes 72.695.500 
15 mL centrifuge tubes 62.554.502  
50 mL centrifuge tubes 62.559.001  
10 mL serological pipettes 86.1254.001  
100 x 20 mm tissue culture dishes 83.3902  
6-well tissue culture plates 83.3920 
12-well tissue culture plates 83.3921 
24-well tissue culture plates 83.3922 
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96-well tissue culture plates 83.3924 
Cell scrapers 83.1830  
CryoPure tubes 72.380.992  
Filtopur 0.2 μm syringe filters 83.1826.001  
 
Thermo Fisher Scientific (Massachusetts, USA)  
MicroAmp™ Optical adhesive film 4311971 
Nunc® Immuno MaxiSorp™ 96-well plates 439454 
White Microtiter™ plates 611F96WT 
 
Terumo Medical (New Jersey, USA) 
Terumo® 10 mL syringe without needle SS-10ES 
 
2.1.2 Reagents and Chemicals  
Becton Dickinson (New Jersey, USA)  
FACS rinse solution 340346  
FACSFlow™ sheath fluid 342003  
 
BioAssay Systems (California, USA) 
QuantiChrom™ alkaline phosphatase assay kit DALP-250 
 
Bio-Rad (California, USA)  
Coomassie Brilliant Blue R-250 161-0400 
 
Cell Signalling Technologies (Massachusetts, USA) 
Anti-human NF-κB p65 (D14E12) XP® rabbit monoclonal antibody 8242S 
Anti-human phospho-NF-κB p65 (Ser536) rabbit monoclonal antibody 3031S 
Anti-mouse HRP-linked antibody 7076S  




Dharmacon Inc. (Colorado, USA)  
DharmaFECT™ 1 transfection reagent 11571731 
ON-TARGETplus™ GAPDH control siRNA D-001830-01-05 
siGENOME™ non-targetting siRNA pool D-001206-13-05 
SMARTpool™ ON-TARGETplus™ NF-κB2 siRNA L-003918-00-0005 
Sterile RNase-free water B-003000-WB-100 
 
Eurofins Genomics GmbH (Ebersberg, Germany) 
Custom DNA primer oligonucleotides  
 
Fisher Scientific (New Hampshire, USA)  
Acetic acid glacial A35-500 
Buffer solution pH 4 (phthalate) J/2825/15  
Buffer solution pH 7 (phosphate) J/2855/15  
Buffer solution pH 10 (borate) J/2885/15 
Propan-2-ol/Isopropanol P/7490/15 
 
InvivoGen (California, USA) 
Primocin™ antimicrobial agent for primary cells ANT-PM-1 
 
Lennox Laboratories Supplies (Dublin, Ireland)  
Industrial methylated spirits CRTSI0330716 
 
Merck Millipore (Massachusetts, USA)  
Alizarin Red staining solution TMS-008-C 
Anti-human NF-κB p52 rabbit monoclonal antibody 06-413 
Anti-human SOD2 rabbit polyclonal antibody AB10346 
Luminata™ Forte Western HRP substrate WBLUF0100 




PromoCell GmbH (Heidelberg, Germany) 
Endothelial cell growth medium MV C-22020 
Smooth muscle cell growth medium 2 C-22062 
CryoSFM freezing medium C-29910 
 
Research and Diagnostic (R&D) Systems Inc. (Minnesota, USA) 
Human BMP-2 DuoSet® ELISA DY355 
Human IL-6 DuoSet® ELISA DY206 
Human OPG DuoSet® ELISA DY805 
Human RANKL DuoSet® ELISA DY626 
Human TNFα DuoSet® ELISA DY210 
Human TRAIL DuoSet® ELISA DY375 
Normal goat serum DY005 
Recombinant human noggin protein 6057-NG 
Recombinant human RANKL protein 390-TN 
Recombinant human TRAIL protein 375-TL 
Anti-human TRACP5 sheep polyclonal antibody AF3948 
Anti-human GAPDH mouse monoclonal antibody MAB5718 
Anti-human SOD1 mouse monoclonal antibody MAB3418 
 
Roche Diagnostics (Basel, Switzerland) 
Complete EDTA-free protease inhibitor cocktail tablets 04693132001  
Fast Start essential DNA green master 06924204001 
 
Santa Cruz Biotechnology (Texas, USA)  
Anti-human RANKL mouse monoclonal antibody sc-377079 





Sigma-Aldrich (Dorset, UK) 
Acrylamide/bis-acrylamide solution A3574  
Agarose A5093  
Albumin from bovine serum A2153  
Ammonium bicarbonate A6141  
Ammonium hydroxide 338818 
Ammonium persulfate A9164  
Ascorbic acid 2-phosphate 49752 
Bovine serum albumin (for ELISA) A7638 
Brilliant blue R B0149  
Chloroform C2432  
Custom DNA primer oligonucleotides  
Deoxynucleotide set DNTP100 
Dexamethasone D4902 
D-glucose G8644 
Dihydroethidium 37291  
Dimethyl sulfoxide D8418 
D-mannitol M4125 
DNase 1 kit AMPD1  
Dulbecco’s phosphate-buffered saline D8537 
Ethanol E7023 
Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) E5134  
Fluorescein Isothiocyanate-Dextran 40kDa (FITC-Dextran) FD40S  
Glycerol G6279  
Glycine G8898  
HEPES H4034 
Human recombinant TNFα H8916 
Hydrochloric acid H1758 
L-glutamine G6392 
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Methanol 34860  
Minimum Essential Medium Eagle, alpha modification (αMEM) M8042 
N,N,N’,N’-tetramethylethylenediamine (TEMED) T9281  
N-acetyl-L-cysteine A9165  
Paraformaldehyde P6148  
Penicillin-streptomycin P0781  
Phosphate-buffered saline tablets P4417  
Ponceau S solution P7170  
Potassium chloride P9541 
Potassium phosphate monobasic P5655 
Sodium azide 13412 
Sodium chloride S3014  
Sodium deoxycholate D6750  
Sodium dodecyl sulphate L3771  
Sodium fluoride S7920  
Sodium hydroxide 72068 
Sodium orthovanadate S6508  
Sodium phosphate dibasic S3264  
Tris acetate-EDTA buffer, 50X T9650  
Tris base T1503 
Triton™X-100 X100  
Trizma® base T6066  
Trypsin-EDTA solution T4174  
Tween®20 P1379 
β-glycerophosphate G9422 
2-mercaptoethanol M6250  




Thermo Fisher Scientific (Massachusetts, USA)  
Dead Cell Apoptosis Kit with Annexin V Alexa Fluor® 488 & Propidium Iodide V13241 
DreamTaq DNA polymerase kit EP0702 
Fetal bovine serum 10106169 
GeneRuler 100 bp plus DNA ladder SM0321 
High capacity cDNA reverse transcription kit 4368814 
MultiScribe™ reverse transcriptase 4311235 
PageRuler™ Plus prestained protein ladder 26619 
Pierce™ BCA protein assay kit 23225 
Recombinant human BMP-2 PHC7145 
RNaseZap™ RNase decontamination solution AM9780 
SYBR Safe® DNA gel stain S33102 
Trizol™ reagent 15596018 
Western blot stripping reagent 10057103 
 
2.1.3 Apparatus and Equipment   
ADAM™ cell counter (Digital Bio, Seoul, South Korea) 
Agarose gel rig (Apollo Scientific, Stockport, UK) 
Benchtop pH meter SevenCompact™ (Mettler Toledo, Ohio, USA) 
Block heater SBH130D (Stuart Scientific, Staffordshire, UK) 
Clifton™ water bath (Nickel-Electro Ltd., Weston-super-Mare, UK) 
ELx800 microplate reader (Biotek, Vermont, USA) 
FACSAria™ flow cytometer (Becton Dickinson, New Jersey, USA) 
G-Box chemi-luminescence analysis system (Syngene, Cambridge, UK) 
HeraCell™ 150 incubator (Thermo Fisher Scientific, Massachusetts, USA) 
HERASafe™ laminar flow cabinet class II (Thermo Fisher Scientific, Massachusetts, USA)  
Large volume centrifuge 5804R (Eppendorf, Cambridge, UK) 
LightCycler®96 real-time PCR system (Roche Diagnostics, Basel, Switzerland) 
Liquid nitrogen storage container (Taylor-Wharton Cryogenics, Borehamwood, UK) 
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Mini orbital shaker SSM1 (Stuart Scientific, Staffordshire, UK) 
Mini-PROTEAN® Tetra-cell gel casting module (Bio-Rad, California, USA) 
Mini-PROTEAN® Tetra-Cell SDS-PAGE and transfer module (Bio-Rad, California, USA) 
MJ Mini thermal cycler (Bio-Rad, California, USA) 
Multiskan™ EX microplate reader (Thermo Fisher Scientific, Massachusetts, USA) 
Nalgene® Mr. Frosty cryo-freezing container (Thermo Fisher Scientific, Massachusetts, USA)  
Nanodrop™ 1000 spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA) 
Nikon Eclipse Ti fluorescent microscope (Nikon, Tokyo, Japan) 
Nikon Eclipse TS100 phase-contrast microscope (Nikon, Tokyo, Japan)  
PowerPac™ basic electrophoresis power supply (Bio-Rad, California, USA) 
See-saw rocker SSL4 (Stuart Scientific, Staffordshire, UK)  
Small volume centrifuge 5430R (Eppendorf, Cambridge, UK) 
Synergy™ HT Fluorescent microplate reader (Bio-Tek, Vermont, USA) 
 
2.1.4 Buffer Preparation  
Radio Immunoprecipitation Assay (RIPA) stock (1.28X)  
HEPES, pH7.5, 64 mM  
Sodium chloride, 192 mM  
Triton X-100, 1.28% (v/v)  
Sodium deoxycholate, 0.64% (v/v)  
SDS, 0.128% (w/v)  
 
RIPA cell lysis buffer  
1.28X RIPA stock, 1X 
Sodium fluoride, 10 mM  
EDTA, pH 8.0, 5 mM  
Sodium phosphate, 10 mM  
Sodium orthovanadate, 1 mM  
Protease inhibitor cocktail, 1X 
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Running buffer for SDS-PAGE  
Trizma® base, 25 mM  
Glycine, 192 mM  
SDS, 0.1% (w/v)  
 
Transfer buffer  
Tris-HCl, pH6.8, 25 mM  
Glycine, 192 mM  
Methanol, 20% (v/v)  
 
Sample solubilisation buffer (SSB) 
Tris-HCl, pH6.8, 250 mM  
SDS, 8% (w/v)  
Glycerol, 40% (v/v)  
2-mercaptoethanol, 4% (v/v)  
Bromophenol blue, 0.008% (w/v)  
0.2 μm filter  
 
Phosphate buffered saline (PBS) stock, 10X concentrate  
Sodium chloride, 1.37 M 
Potassium chloride, 27 mM 
Sodium phosphate dibasic, 81 mM 
Potassium phosphate monobasic, 15 mM 
Adjust to pH 7.4 
 
Tris buffered saline (TBS) stock, 10X concentrate   
Tris base, 0.5 M  
Sodium chloride, 1.5 M  





Tris base, 1.5 M  
Adjust to pH 6.8/pH 8.8 with HCl 
 
Coomassie R-250 staining solution  
Coomassie brilliant blue R250, 1% (w/v)  
Glacial acetic acid, 10% (v/v)  
Methanol, 40% (v/v)  
Distilled water, 50% (v/v)  
0.2 μm filter 
 
Coomassie R-250 de-staining solution  
Methanol, 20% (v/v)  
Glacial acetic acid, 10% (v/v)  
Distilled water, 70% (v/v) 
 
FACS buffer  
Fetal bovine serum, 2% (v/v)  
Sodium azide, 0.1% (w/v)  
PBS, 98% (v/v)  











2.2 Methods  
2.2.1 Cell Culture Methods  
2.2.1.1 Sterile Conditions 
All cell culture work was carried out in a validated HERASafe™ laminar flow Class II 
biological safety cabinet. Equipment was routinely sanitised with 70% industrial methylated 
spirits (IMS) before use. All materials used in cell culture work, including pipette tips, 
microtubes and phosphate-buffered saline (PBS) were autoclaved as required, and 
reconstitution buffers for recombinant proteins subject to 0.2 µm filtration. Tissue culture 
plates, pipettes and centrifuge tubes were pre-sterilised. Standard aseptic technique was 
routinely employed.  
 
2.2.1.2 Growth and Maintenance of Cells  
Human aortic endothelial cells (HAECs) and human aortic smooth muscle cells (HASMCs) 
were obtained from PromoCell GmbH (Heidelberg, Germany). HAECs were donated by a 23 
year-old Caucasian male and were cultured in endothelial cell growth medium MV 
(Promocell), with final concentrations of 0.05 mL/mL fetal bovine serum (FBS), 0.004 mL/mL 
endothelial cell growth supplement, 10 ng/mL recombinant human epidermal growth factor, 
90 µg/mL heparin and 1 µg/mL hydrocortisone. HASMCs were donated by a 19 year-old 
Caucasian male and were cultured in smooth muscle cell medium 2 (Promocell) with final 
concentrations of 0.05 mL/mL FBS, 0.5 ng/mL recombinant human epidermal growth factor, 
2 ng/mL recombinant human basic fibroblast growth factor and 5 µg/mL recombinant human 
insulin. Penicillin (100 U/mL) and streptomycin (100 µg/mL) were added to both growth 
media. Primocin™ antimicrobial agent, at a final concentration of 100 µg/mL, was included in 
place of these antibiotics for long-term incubation periods (providing protection from bacteria, 
mycoplasma and fungi). Primocin™ is validated for primary cell culture, and no differences 
were noted in cell morphology or viability when compared to antibiotic treatment.  
HAECs/HASMCs of passage 5 to 12 were used for experimental procedures. Cells were 
maintained at 37°C and 5% CO2. Fresh media was added to cells in culture every 2-3 days, and 
passaged at 80-90% confluency unless otherwise described. HAECs and HASMCs were 
visually analysed daily to monitor confluency and morphological changes using a Nikon 
Eclipse TS100 microscope at 10X and 40X magnification.  
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2.2.1.3 Trypsinisation 
Trypsinisation is required to passage both HAEC and HASMC adherent cells.  Spent media 
was removed from the cell culture dish and cells were washed twice with sterile Dulbecco’s 
PBS to remove trypsin inhibitors. A small volume of pre-warmed 10% (v/v) trypsin-EDTA 
was added to cover the cell monolayer and incubated at 37°C for 2-3 minutes until the cells 
had visibly detached from the surface. An equal volume of culture media was then added to 
deactivate the trypsin enzyme. The cell suspension was transferred to a 15 mL centrifuge tube 
and subject to centrifugation at 50 xg for 5 minutes, supernatant media removed, and the 
resulting cell pellet re-suspended in fresh growth media. For both HAECs and HASMCs, the 
ratio of passage was 1:3. 
 
2.2.1.4 Cryopreservation and Cryorecovery 
To cryopreserve cell stocks, approximately 1x106 cells were trypsinised and subject to 
centrifugation at 100 xg. The resulting cell pellet was then re-suspended in 1 mL CryoSFM 
cryopreservation medium (Promocell), which contains a number of cryoprotectants including 
methylcellulose and dimethyl sulfoxide (DMSO). Re-suspended cells were transferred to a 
sterile CryoPure cryovial and placed in a Mr. FrostyTM isopropanol chamber at -80°C to ensure 
a cooling rate of -1°C per minute. The following day, cryovials were transferred to liquid 
nitrogen storage. When required, cells were recovered by rapid thawing of the vial in a 37°C 
water bath and immediate transfer to pre-warmed media, which was replaced with fresh media 
after 24 hours.  
 
2.2.1.5 Cell Counting  
Cells were routinely counted during trypsinisation to ensure appropriate seeding densities, or 
at the point of harvesting for viability measurement and data normalisation after experimental 
procedures. All cell counts were carried out using an Advanced Detection and Accurate 
Measurement (ADAM™) counter (Digital Bio), as pictured in Figure 2.1. The ADAM™ 
counter method applies fluorescent propidium iodide (PI) staining to cell suspensions in order 
to calculate: (i) total cell number (T), (ii) non-viable cell number (N), (iii) viable cell number 
(T-N), and (iv) percentage viability. PI intercalates with available DNA, but cannot penetrate 
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undamaged cell membranes. A small volume (15 
µL) of cell suspension was mixed with an equal 
volume of both solution N, containing PI only, 
and solution T, which contains both PI and lysis 
buffer to ensure disruption of intact membranes. 
A 15 µL aliquot of each mixture was added to the 
appropriate channel in a microfluidic Accuchip, 
and the Accuchip loaded into the ADAM™ 
counter. Multiple images of the channels are 
taken, and the ADAM™ image analysis software 
determines average values for total and viable cell 
counts which are then displayed digitally.  
 
2.2.2 Cell Models and Treatments 
2.2.2.1 Monoculture Models 
To identify direct effects of soluble factors on HAECs and HASMCs, standard monoculture 
experiments were employed. Cells were seeded into 6-well, 12-well or 24-well culture dishes 
at the required seeding density. At confluency, cells were washed with sterile PBS and fresh 
pre-warmed media added containing soluble factors at experimental concentrations. The 
following recombinant proteins were employed for cell exposures (Table 2.1):  
 
Soluble factor Source Concentration 
TNFα Sigma-Aldrich 100 ng/mL 
RANKL R&D Systems 5-50 ng/mL 
TRAIL R&D Systems 5-50 ng/mL 
BMP-2 Thermo Fisher Scientific 5 ng/mL  
Noggin R&D Systems 100 ng/mL 
Glucose Sigma-Aldrich 15-30 mM 
Mannitol Sigma-Aldrich 30 mM 
NAC Sigma-Aldrich 5 mM 
 
Figure 2.1. The ADAM™ Counter with an 
Accuchip resting in the loading bay. Image 
courtesy of www.digital-bio.com.  
TNF, tumour necrosis factor; RANKL, receptor activator of NF-κB ligand; TRAIL; TNF-related apoptosis 
inducing ligand; BMP, bone morphogenetic protein; NAC, N-acetyl-L-cysteine.  
 
Table 2.1.  Soluble factors, their source and concentrations employed for cell exposures.  
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2.2.2.2 Co-Culture Models 
In vivo, both HAECs and HASMCs thrive in close proximity to each other; thus, a co-culture 
model was employed to better recapitulate the paracrine signalling properties of the vessel wall. 
Representing the intimal layer of the vasculature, HAECs were directly treated with soluble 
factors and the resulting paracrine influences on underlying co-cultured HASMCs were 
monitored. ECs and VSMCs have been successfully employed in similar non-contact co-
culture studies (Liu et al., 2007; Nam et al., 2011; Wang et al., 2011). 
For the majority of HAEC:HASMC co-culture experiments, HASMCs were first grown in 
standard 6-well culture dishes as described above. At confluency, transwell culture inserts 
(Merck Millipore) were placed in HASMC wells, and HAECs seeded into the wells at a density 
of 2x105 cells/insert to ensure tight monolayer formation. Transwell inserts support the 
endothelial monolayer above a 0.4 µm porous membrane, allowing HAEC:HASMC 
communication while maintaining separate luminal and subluminal compartments. A 
combination of HAEC and HASMC media was used for co-culture experiments (1:1 ratio) to 
ensure healthy maintenance of both cells, and a total of 6 mL media was required per well (2 
mL apical/luminal, 4 mL basolateral/subluminal). After seeding, the co-culture was incubated 
for 24 hours pre-treatment to ensure endothelial monolayer formation and media volume 
equilibration. This method was altered for gene knockdown experiments (Section 2.2.2.4).  
To initiate experimental conditions, relevant concentrations of soluble factors were added to 
the apical compartment. HAECs are in direct contact with these factors, as endothelial cells are 
exposed to circulating soluble factors in the vasculature, while HASMCs rely on the paracrine 
signalling of HAECs (through the subluminal compartment in vitro or through the intercellular 
space in vivo) to induce a response. After incubation, spent media from both luminal and 
subluminal compartments, along with protein/RNA from the HASMC culture, were harvested 
for analysis. A schematic diagram of the non-contact co-culture model is illustrated overleaf in 
Figure 2.2. 
During co-culture development, a simple conditioned media transfer model was utilised 
(previously employed by Davenport et al., 2016) to confirm consistency with previously 
published results. In this case, HAECs in standard 6-well culture dishes were exposed to 
soluble factors for 72 hours, and 50% endothelial conditioned media (+ 50% fresh HASMC 
media) was transferred to confluent reporter HASMCs for a further 72 hours. HASMCs were 






2.2.2.3 Calcification Models  
In order to investigate end-point calcification, HASMCs were subject to high phosphate-
induced osteoblastic differentiation. Pro-osteogenic differentiation medium was employed, 
consisting of minimum essential medium eagle alpha modification (αMEM) supplemented 
with 0.292 g/L L-glutamine, 10% FBS and 1% penicillin/streptomycin, and the pro-osteogenic 
factors dexamethasone (100 nM), ascorbic acid 2-phosphate (50 μM), and β-glycerophosphate 
(10 mM) (Langenbach and Handschel, 2013; Shioi et al., 1995). This medium has previously 
been successfully employed for osteoblastic differentiation (Ghali et al., 2015; Westhrin et al., 
2015). HASMCs were exposed to differentiation medium at approximately 60% confluency, 
and remained in culture for 21 days prior to treatment with soluble factors.  
A murine osteoblastic precursor cell line (MC3T3-E1) was also employed as a positive control 
for osteogenic differentiation/mineral deposition. MC3T3-E1 cells, kindly donated for use by 
Dr. Steve Kerrigan (Cardiovascular Infection Research Group, RCSI), were cultured in 
standard αMEM supplemented with L-glutamine, FBS and antibiotics prior to differentiation. 
Cells were trypsinised and cryopreserved according to sections 2.2.1.3 and 2.2.1.4 respectively, 
and passages 24-28 were used for experimental purposes. MC3T3-E1 cells were exposed to 
differentiation medium for 21 days prior to analysis.  
Control medium, consisting of αMEM supplemented with L-glutamine, FBS and antibiotics in 
the absence of pro-osteogenic factors, was routinely employed as a negative control for both 
HASMCs and MC3T3-E1 cells. 
Figure 2.2.  Schematic representation of the HAEC:HASMC co-culture model. Image 
adapted from Harper et al., 2017. HAEC, human aortic endothelial cell; HASMC, 
human aortic smooth muscle cell. 
 
 59 
2.2.2.4 siRNA Gene Knockdown Models 
HAECs were subject to small interfering (si) RNA 
knockdown of the NFκB2 gene, coding for the p100 
subunit of the non-canonical NF-κB pathway (and thus 
the p52 cleaved product). siRNA knockdown, or gene 
‘silencing’, involves the exogenous introduction of 
synthesised short double-stranded RNA sequences 
(~20-24 bp) into the cell cytoplasm. This siRNA, 
complementary to the target gene mRNA sequence, is 
processed by the RNA-induced silencing complex 
(RISC), and ultimately used to locate and bind the 
mRNA of interest. The target mRNA is then cleaved by 
argonaute 2 endonuclease (Chendrimada et al., 2005), 
reducing mRNA copy number and thus transcription and 
translation of the target protein (Figure 2.3). 
DharmaFECT™ transfection reagents (Dharmacon), with self-reported minimal reagent 
toxicity, were chosen for transient lipid-based transfection. An intact endothelial monolayer is 
required for co-culture, and alternative physical techniques (eg. electroporation) can induce 
leakage of intracellular components and high percentage of cell death (Tsong et al., 1991). 
HAECs were trypsinised and seeded into 6-well dishes (optimisation) or transwell inserts (co-
culture) for siRNA knockdown. In all cases, cells were re-suspended and plated in antibiotic-
free medium, and left to adhere overnight. For the siRNA transfection procedure, 5 µM siRNA 
solution was prepared in sterile molecular grade water. DharmaFECT™ 1 transfection reagent 
and siRNA (Dharmacon) were individually diluted in antibiotic- and serum-free medium and 
incubated for 5 minutes at room temperature. Diluted DharmaFECT™ 1 and siRNA were 
mixed and incubated for a further 20 minutes at room temperature. The resulting mix was 
diluted with antibiotic-free complete medium, achieving a final concentration of 50 nM siRNA 
and a final volume of 10 µL DharmaFECT™ 1 per well. Spent media was removed from 
cultured HAECs, transfection medium added and cells were incubated for 48 hours (mRNA 
analysis) or 72 hours (protein analysis) unless otherwise described. DharmaFECT™ 1 has 
previously been used for the transfection of human primary cells (Chiang et al., 2016; 
Dharmacon, 2015), while both GAPDH and NFκB2 siRNA sequences have been successfully 
employed for gene silencing (Bryant et al., 2012; Nguyen et al., 2015). 
Figure 2.3. The process of siRNA 
gene silencing.  RISC, RNA-induced 




2.2.2.4.1 siRNA Transfection Optimisation 
HAECs were seeded at a density of 2.5x106 cells per well for optimisation purposes. Initially, 
cells were assessed for gene knockdown receptivity using positive control siRNA for 
endogenous GAPDH. HAECs were exposed to the recommended 25 nM GAPDH siRNA 
across a range of 2.5-10 µL/well DharmaFECT™ 1 reagent volumes in order to assess reagent 
toxicity and suitability. For NFκB2 gene knockdown optimisation, HAECs were exposed to 25 
nM and 50 nM pooled NFκB2 siRNA across a DharmaFECT™ 1 volume range of 2.5-10 
µL/well to determine optimal transfection conditions. A non-targetting scrambled siRNA 
control pool was also included to expose non-specific effects. Cell viability, NFκB2 mRNA 
expression and NF-κB p100/p52 protein expression were measured post-knockdown to assess 
reagent toxicity and transfection/knockdown efficiency. Untransfected cells and non-targetting 
siRNA controls were included under all experimental conditions for comparison purposes.  
 
2.2.2.4.2 Co-culture Experiments: NFκB2 Knockdown 
HASMCs were grown to confluency in standard 6-well culture dishes. HAECs were seeded 
into semi-permeable transwell inserts at a lower density of 1.5x106 cells per insert, and allowed 
to incubate for 24 hours before commencing siRNA knockdown in optimal transfection media. 
After 48 hours in culture, transwell inserts were removed from the transfection media and 
transferred to the dish of confluent HASMCs. Cells were allowed to recover for 6 hours in 
fresh media prior to treatment with recombinant RANKL. HAECs and HASMCs were co-
cultured for a further 72 hours, prior to harvesting for analysis. Additionally, HAECs were 
assessed for responses post-exposure to both NFκB2 siRNA and non-targetting siRNA, 
alongside HASMC responses to endothelial non-targetting siRNA treatment. 
 
2.2.3 Gene Expression Analysis  
2.2.3.1 RNA Isolation 
To prevent RNA degradation by natural RNases, all surfaces, equipment and gloves were 
sprayed with RNaseZap™ and all pipette tips, centrifuge tubes and PBS were autoclaved for 
use in RNA work. If cell counting was not required, cells were washed three times with sterile 
PBS and Trizol™ reagent then added directly to the cell culture dish to a total of 1 mL per 
condition. If cell counting was required, cells were trypsinised and counted via ADAM™ 
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counter before the addition of Trizol™ to the cell pellet after centrifugation. Trizol™ reagent 
degrades cellular components (including cell membranes), whilst maintaining RNA integrity, 
allowing the separation of high quality total RNA from DNA and protein. Trizol™ monophasic 
solution contains a mixture of phenol and guanidine isothiocyanate (among other proprietary 
components), and improves on the RNA isolation method originally developed by 
Chomczynski & Sacchi (1987). 
After incubation, cells were scraped using a sterile cell scraper to ensure all cells were lysed 
and detached from the plate surface, and the total volume of Trizol™ was transferred to a 
centrifuge tube. If trypsinised, it was ensured that the resulting cell pellet was fully re-
suspended in Trizol™ solution. In both cases, a 5-minute incubation at room temperature was 
included at this stage to ensure maximum RNA separation from protein complexes. 
Subsequently, 0.2 mL chloroform was added per 1 mL Trizol™ solution, samples were shaken 
vigorously for 15 seconds and incubated at room temperature for 15 minutes. Samples were 
then subject to centrifugation at 15,000 xg for 15 minutes at 4ºC, resulting in sample separation 
into three phases (Figure 2.4): (i) a lower organic 
phenol-chloroform phase containing DNA and 
protein, (ii) a thick white interphase, and (iii) an 
upper aqueous phase containing RNA. The aqueous 
phase was then carefully transferred into a fresh 
centrifuge tube and an equal volume of isopropanol 
(IPA) added to precipitate out the total RNA. 
Samples were then gently inverted 5-10 times to 
ensure equal mixing and stored overnight at -20ºC.  
After re-equilibrating to room temperature, samples were centrifuged at 15,000 xg for 10 
minutes at 4ºC and the supernatant removed leaving a small precipitated RNA pellet. The pellet 
was detached from the wall of the centrifuge tube, washed with 100% ethanol to remove 
impurities, and then re-centrifuged (5 minutes, 15,000 xg, 4ºC) to enable removal of the ethanol 
supernatant. After allowing the RNA pellet to air-dry, it was re-suspended in a small volume 
of RNase-free water and incubated at 60ºC for 10 minutes to ensure sample homogenisation, 
then placed on ice prior to quantification/quality assessment with Nanodrop™ (Section 
2.2.3.3). RNA samples were stored long-term at -80ºC and were sporadically subject to RNA 
integrity checks via agarose gel electrophoresis (Section 2.2.3.6).  
Figure 2.4. The three distinct phases of 
Trizol™ extractions. DNA, deoxyribonucleic 
acid; RNA, ribonucleic acid. 
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2.2.3.2 DNase Treatment and cDNA Synthesis 
Prior to cDNA synthesis, RNA samples were subject to treatment with deoxyribonuclease 1 
(DNase 1) enzyme to ensure degradation of any contaminating genomic double- or single-
stranded DNA.  First, 8 µL of 100 ng/µL RNA was treated with 1 µL DNase 1 enzyme (10X) 
and 1 µL DNase buffer (10X), and incubated at room temperature for 15 minutes. Next, 1 µL 
of DNase stop solution was then added followed by a 10-minute incubation at 60ºC to denature 
the DNase enzyme. Treated RNA samples were stored on ice for cDNA processing (final 
volume 11 µL). A High-capacity cDNA Reverse Transcription Kit (Applied Biosystems) was 
used to convert these RNA samples into cDNA using reverse transcriptase (RT) enzyme. For 
a final reaction volume of 20 µL, 9 µL of reaction mixture was added to each RNA sample 
containing the following:  
 
 
Reagent Volume (20 µL) 
10X RT buffer 2 µL 
10X random primers 2 µL 
Multiscribe™ RT (50 U/µL) 1 µL 
25X dNTP mix (100 mM) 0.8 µL 
RNase-free water 3.2 µL 
 
 
Samples were well mixed before placing on a thermal cycler and run on the specified RT 
programme of 25ºC for 10 minutes, 37ºC for 120 minutes and 85ºC for 5 minutes. Samples 
were held at 4ºC before Nanodrop™ quantification and final storage at -20ºC.  
 
2.2.3.3 RNA and DNA Quantification  
The Nanodrop™ ND-1000 spectrophotometer (Thermo Fischer Scientific) was employed for 
nucleic acid analysis of both quantity and purity. RNA/cDNA (1 µL sample) is placed in 
between two fibre optic cables, and the light passed through is subject to spectrophotometric 
analysis at a range of wavelengths. The Nanodrop™ provides a concentration reading in ng/µL 
and the ratio of absorbance at 260/280 and 260/230 nm is used to assess sample purity. 
Inaccurate ratios suggest the presence of impurities such as proteins or solvents used during 
RNA extraction. An example of the Nanodrop™ output for cDNA is illustrated in Figure 2.5.  
RT, reverse transcriptase. dNTP, deoxynucleotide triphosphate. 











2.2.3.4 Primer Design and Optimisation  
For polymerase chain reaction (PCR), primer sequences were designed for BMP-2. The online 
Primer3 tool (http://primer3.ut.ee/) was used to identify potential primer sets for the coding 
region of human BMP-2, specifying optimal primer parameters for product size, primer size, 
melting temperature and GC content. The Northwestern BioTools OligoCalc website 
(http://www.basic.northwestern.edu/biotools/OligoCalc.html) was then used to confirm primer 
characteristics, ensure specificity for BMP-2 using BLAST, and check their structural integrity. 
Primer sets for GAPDH, 18S, IL-6, ALP, Runx2, OPG, RANKL and TRAIL were pre-
published by our research group while Sox9 primers were designed and published by Alesutan 
et al. (2015). Primer sets for TRAIL receptors, SOD1, SOD2, HMOX1, gp91 and p47 were 
sourced from a colleague, Dr. Hannah Forde. All other primers utilised were sourced from the 
PrimerBank website and confirmed against the human mRNA sequence 
(https://pga.mgh.harvard.edu/primerbank/).  
Standard PCR was employed for primer optimisation and to test primer specificity (i.e., to 
confirm no non-specific secondary product amplification or extensive primer-dimer 
formation). Annealing temperature and primer concentration were optimised for BMP-2 and 
re-confirmed for previously optimised primer sets. All primer product sizes were confirmed by 
agarose gel electrophoresis (Section 2.2.3.6) and assessed for efficiency via real-time PCR 
(Section 2.2.3.7). Primer sequences, their respective product sizes and optimal annealing 
temperatures are detailed overleaf in Table 2.5; primer efficiencies are listed in Appendix 2.1. 
Figure 2.5. Example of a Nanodrop™ spectrophotometric reading for cDNA quantification. The final 
cDNA concentration is presented as ng/µL, while the purity is determined by 260/280 and 260/230 nm ratio. 
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2.2.3.5 Standard PCR 
Using the Nanodrop™ reading, cDNA samples were diluted to a final concentration of 500 
ng/µL and the 25 µL PCR reaction mix was made up as follows (Table 2.3):  
 
 
Reagent Volume (25 µL) 
10X reaction buffer 2.5 µL 
10 mM dNTPs 2 µL 
DreamTaq DNA polymerase (5 U/µL) 0.2 µL 
25 mM magnesium chloride 1.5 µL 
cDNA (500 ng/µL) 2 µL 
Forward/reverse primer (10 mM) 2 x 1µL 
RNase-free water 14.8 µL 
 
For each PCR reaction, two controls were included; a negative control containing water in 
place of cDNA, and a non-RT control (in which RT enzyme was omitted from cDNA synthesis 
reaction mix). PCR product in the non-RT control indicates the presence of contaminating 
genomic DNA in the sample preparation. Each reaction mix was then placed in a thermal cycler 
and subject to the following standard PCR temperature cycle (Table 2.4) before a cooling hold 




Denature  95ºC 5 minutes  
 
Cycling 
Denature 95ºC 15 seconds  
Repeat x40-45  Annealing See Table 2.5 30 seconds 
Extension 72ºC 15 seconds 





dNTP, deoxynucleotide triphosphate. 
Table 2.3. Standard PCR reaction components. 
Table 2.4. Standard PCR reaction parameters.  
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GAPDH F GAGTCAACGGATTTGGTCGT   
GAPDH R TTGATTTTGGAGGGATCTCG 238 60 
18S F CAGCCACCCGAGATTGAGCA   
18S R TAGTAGCGACGGGCGGTGTG 250 60 
OPG F GGCAACACAGCTCACAAGAA   
OPG R CTGGGTTTGCATGCCTTTAT 241 58 
RANKL F AGAGCGCAGATGGATCCTAA   
RANKL R TTCCTTTTGCACAGCTCCTT 180 58 
TRAIL F TTCACAGTGCTCCTGCAGTC   
TRAIL R ACGGAGTTGCCACTTGACTT 170 60 
ALP F GCCTGGCTACAAGGTGGTG   
ALP R GGCCAGAGCGAGCAGC 293 58 
BMP-2 F CAAGCCAAACACAAACAGCG   
BMP-2 R CCAACGTCTGAACAATGGCA 199 57 
Runx2 F GGTACCAGATGGGACTGTGG   
Runx2 R GAGGCGGTCAGAGAACAAAC 315 59 
Sox9 F AGCGAACGCACATCAAGAC   
Sox9 R CTGTAGGCGATCTGTTGGGG 85 60 
IL-6 F AAAGAGGCACTGGCAGAAAA   
IL-6 R AGCTCTGGCTTGTTCCTCAC 183 60 
p52/p100 F AGAGGCTTCCGATTTCGATATGG   
p52/p100 R GGATAGGTCTTTCGGCCCTTC 89 60 
TRACP5 F GATCCCACAGACCAATGTGTC   
TRACP5 R CCAGCACGTAGTCCTCCCT 179 60 
SOD1 F GTGGGGAAGCATTAAAGGACTGAC   
SOD1 R CAATTACAGCACAAGCCAAACGAC   355 60 
SOD2 F GGGAGATGTTACAGCCCAGA   
SOD2 R AGTCACGTTTGATGGCTTCC 149 60 
eNOS F TGATGGCGAAGCGAGTGAAG   
eNOS R ACTCATCCATACACAGGACCC 129 60 
Table 2.5. Forward/reverse (F/R) primer sequences employed in standard PCR and qPCR.  
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SMα-actin F CTATGAGGGCTATGCCTTGCC   
SMα-actin R GCTCAGCAGTAGTAACGAAGGA 122 61 
SM22α F CCGTGGAGATCCCAACTGG   
SM22α R CCATCTGAAGGCCAATGACAT 104 61 
RANK F CACCAAATGAACCCCATGTTTAC   
RANK R GGACTCCTTATCTCCACTTAGGC 182 60 
DcR1 F TCCCCAAGACCCTAAAGTTCG   
DcR1 R CAGTGGTGGCAGAGTAAGC 75 60 
DcR2 F GTTGGCTTTTCATGTCGGAAGA   
DcR2 R CCCAGGAACTCGTGAAGGAC 129 60 
DR4 F ACCTTCAAGTTTGTCGTCGTC   
DR4 R CCAAAGGGCTATGTTCCCATT 115 60 
DR5 F GCCCCACAACAAAAGAGGTC   
DR5 R AGGTCATTCCAGTGAGTGCTA 128 61 
gp91 F GCTGTTCAATGCTTGTGGCT   
gp91 R TCTCCTCATCATGGTGCACA 403 62 
p47 F AAGTGGTTTGACGGGCAG   
p47 R TGGACGGAAAGTAGCCTG 597 62 
HMOX 1 F ATTGCCAGTGCCACCAAGTTCAAG   
HMOX 1 R ACGCAGTCTTGGCCTCTTCTATCA 103 61 
BSP F GAACCTCGTGGGGACAATTAC   
BSP R CATCATAGCCATCGTAGCCTTG 79 61 
OCN F GGCGCTACCTGTATCAATGG   
OCN R GTGGTCAGCCAACTCGTCA 110 60 
BSP (murine) F ATGGAGACGGCGATAGTTCC   
BSP (murine) R CTAGCTGTTACACCCGAGAGT 148 60 
OCN (murine) F CTGACCTCACAGATCCCAAGC   





GAPDH, glyceraldehyde 3-phosphate dehydrogenase; OPG, osteoprotegerin; RANK(L), receptor activator 
of NF-κB (ligand); TRAIL, tumour necrosis factor-related apoptosis-inducing ligand; ALP, alkaline 
phosphatase; BMP, bone morphogenetic protein; Runx2, runt-related transcription factor-2; Sox9, sex 
determining region Y box-9; IL, interleukin; TRACP5, tartrate resistant acid phosphatase 5; SOD, superoxide 
dismutase; eNOS, endothelial nitric oxide synthase; SM, smooth muscle; DcR, decoy receptor; DR, death 
receptor; HMOX1, heme oxygenase 1; BSP, bone sialoprotein; OCN, osteocalcin. Respective primer 
efficiencies are presented in Appendix 2.1. 
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2.2.3.6 Agarose Gel Electrophoresis  
Agarose gel electrophoresis was used to assess PCR products from standard PCR reactions. A 
1% agarose gel was made by adding 1 g agarose to 100 mL TAE buffer (40 mM Tris-Acetate 
pH 8.2, 1 mM EDTA) and heating to dissolve. After cooling, 10 µL SYBR Safe® gel stain was 
added to the liquid agarose, mixed well and transferred into a casting gel rig with the 
appropriate well comb. The gel was left to polymerise at room temperature in the dark (as 
SYBR Safe® is light sensitive) for approximately 30 minutes. The rig was then filled with TAE 
buffer and the comb removed to allow sample loading.  
For PCR product visualisation, 10 µL of PCR product was loaded into each well; wells 
containing 5 µL GeneRuler™ 100 bp DNA Ladder was included for PCR product size 
determination. The gel was electrophoresed at 100 V, and when the PCR products had been 
sufficiently resolved, the bands was visualised using the Syngene G-Box imaging system.  
For RNA integrity checks, 1 µg RNA (diluted in 8 µL RNase-free water) was loaded into each 
well for electrophoresis. Intact RNA can be visualised as two distinct bands: the 18S ribosomal 
RNA (rRNA) at 1.9 kb and the 28S rRNA at 4.5 kb (1:2 ratio). Degraded RNA will appear as 
a smear at the bottom of the gel.  
 
2.2.3.7 Quantitative Reverse Transcription PCR (RT-qPCR) 
After optimisation, the primer sets were employed in quantitative real-time PCR (qPCR) to 
assess reverse transcribed mRNA levels using the LightCycler®96 System (Roche 
Diagnostics). In qPCR, the level of gene amplification is tracked in real-time via the binding 
of SYBR Green 1 nucleic acid stain to double-stranded DNA. SYBR Green dye emits a green 
fluorescent signal when bound to DNA, and thus as PCR cycles progress and the product is 
amplified, this fluorescence accumulates. This signal is then graphed as a means of quantifying 
the level of gene amplification. To conduct relative gene quantification between samples, 
LightCycler® systems employ the second derivative maximum method, in which the 
quantification cycle (Cq) number acts as a measure of gene copy abundance. The Cq is defined 
as the point at which the curvature of the amplification plot is maximal. In this case, in contrast 
to the threshold cycle (Ct) method, no arbitrary threshold value needs to be assigned. The 
methodological principle is the same, as illustrated overleaf in Figure 2.6: the higher the 
expression of a gene in a sample, the faster the amplification of that gene will reach the Cq. The 
principles of the comparative Ct method (ΔΔCt) as described by Livak and Schmittgen (2001), 
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are first used to calculate the sample- and gene-specific ratio against the reference gene, and 
secondly to calculate the normalised ratio (or fold change) compared to the control sample. The 
same negative controls as used in standard PCR were also included in each qPCR run.  






For each qPCR reaction, samples were assayed in duplicate or triplicate for both the gene of 
interest and the endogenous reference gene (GAPDH or 18S).  Reaction constituents were as 
follows, according to the manufacturer’s specifications (Table 2.6). This mix was then subject 
to thermocycling under the conditions listed in Table 2.7.  
 
 
Reagent Volume (10 µL) 
Fast Start Essential DNA Green Master   5 µL 
cDNA (500 ng/µL) 2.5 µL 
F/R primer (10 µM) 2 x 1 µL 
RNase-free water 1.5 µL 
Figure 2.6.  Examples of amplification curves on the LightCycler®96 software 
demonstrating the principle of qPCR. The gene of interest has a lower quantification 
cycle (Cq), and therefore higher expression levels, in the treated sample.  
Volumes listed are for one well of a 96-well PCR reaction plate.   
Table 2.6.  Employed volumes of qPCR reaction components.  
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Pre-incubation  95ºC 10 minutes  
 
Amplification 
Denature 95ºC 10 seconds  
Repeat x45-55 Annealing See Table 2.5 10 seconds 
Extension 72ºC 10 seconds 
 
 
To ensure primer specificity, PCR amplicons were routinely checked via agarose gel 
electrophoresis to ensure correct product formation. In addition, melt curve analysis was 
carried out for every qPCR run. A single melting curve peak indicates single and specific 
product formation with no non-specific PCR products or primer-dimers present (Figure 2.7). 
Once product specificity was confirmed, results were analysed in accordance with The 











2.2.3.8 Primer Efficiencies 
Standard curve analysis was employed using the LightCycler® system to calculate primer 
efficiencies. After PCR amplification, the PCR product was subject to 1/1000-fold dilution in 
RNase-free water. A further 7-point 1/10 serial dilution followed. Each dilution was subject to 
qPCR according to the reaction mix and parameters detailed in Tables 2.6 and 2.7 respectively, 
in addition to a negative control (RNase-free water in place of cDNA). The resulting values 
Table 2.7. qPCR reaction parameters.  
Figure 2.7.  Representative melting curve (OPG primers).  
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were used to plot a standard curve of Cq versus the relative number of gene copies. The primer 
efficiency, in percentage, was then calculated from the following formula:  
𝑃𝑟𝑖𝑚𝑒𝑟 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 10
−
1
𝑠𝑙𝑜𝑝𝑒 − 1  
As specified in the MIQE guidelines, all primer sets were confirmed to have an acceptable 
efficiency of between 90% and 105% and were deemed suitable for gene expression analysis. 
The percentage efficiency of all primer sets are presented in Appendix 2.1. 
 
2.2.4. Protein Analysis  
2.2.4.1 Protein Extraction  
Following exposure to soluble factors, cells were harvested for total intracellular protein. For 
routine analyses, if counting was not required, cells were washed 3 times with PBS and a small 
volume of 1X radioimmunoprecipitation assay (RIPA) buffer was added on ice. A cell scraper 
was used to aid in cellular lysis and to detach cells from the surface of the dish. The full volume 
was transferred to a centrifuge tube and the samples subject to rotation at 4ºC for 1 hour. 
Samples were then centrifuged for 20 minutes at 10,000 xg at 4ºC to remove any insoluble 
cellular debris. The protein supernatant was then removed to a fresh tube and stored at -80ºC. 
If cell counting was required, cells were first trypsinised for the purpose of ADAM™ counter 
analysis, and then centrifuged to gather the cell pellet. RIPA buffer was added directly to the 
cell pellet, and re-suspended before rotation, centrifugation and storage. 
For the purpose of ALP enzyme activity assay analysis, cells were harvested in the same 
manner but with 0.2% Triton X-100 in place of RIPA lysis buffer. The components of RIPA 
(chelating/denaturing agents, detergents) will inhibit enzyme activity and therefore should be 
avoided in sample preparation.  
 
2.2.4.2 BCA Assay 
The bicinchoninic acid (BCA) biochemical assay originally employed by Smith et al. (1985) 
is required prior to protein analysis for the purpose of data normalisation. This assay determines 
total protein concentration in whole cell lysates. For analysis, lysate samples are diluted 1:5 in 
RIPA lysis buffer to ensure they fall within the 0-2 mg/mL bovine serum albumin (BSA) 
standard curve. The samples and standards are then added in triplicate to a 96-well plate, and 
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200 µL BCA working reagent (1:50 dilution of reagent B (copper sulphate solution) in reagent 
A (alkaline bicarbonate solution), as part of a commercially available kit (ThermoScientific)) 
is added to each well. The plate is then incubated for 30 minutes in the dark at 37ºC to allow 
two reactions to occur: the reaction of Cu2+ with protein in an alkaline environment to form 
Cu+, and a second reaction between Cu+ and bicinchoninic acid. The latter results in a colour 
change from green to purple, the extent of which is dependent on the amount of copper ions 
(and therefore protein) present. The plate is then read at 570 nm, the wavelength at which this 
purple complex absorbs light, on a colorimetric plate reader and the unknown protein 
concentrations determined via standard curve.  
 
2.2.4.3 SDS-PAGE 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out using a 12% (v/v) 
resolving gel and a 5% (v/v) stacking gel, made up of the components listed in Table 2.8 below: 
 
Component 12% Resolving Gel 5% Stacking Gel 
Distilled water 3345 µL 5990 µL 
1.5 M Tris-HCl, pH 8.8 2500 µL - 
1.5 M Tris-HCl, pH 6.8 - 2500 µL 
30% Acrylamide/bis-acrylamide 4000 µL 1300 µL 
10% SDS 100 µL 100 µL 
10% Ammonium persulfate 50 µL 100 µL 
TEMED 5 µL 10 µL 




Immediately after mixing, 5-6 ml of the resolving gel mixture was added between two 10x100 
mm glass plates with a 1 mm spacer held in a Mini-PROTEAN® gel casting module (Bio-
Rad). Once the gel was set, after approximately 45 minutes, the dH2O was removed, the 
stacking gel was mixed and 1-2 mL poured on top of the resolving gel. The comb was 
immediately inserted, providing the sample wells, and the stacking gel allowed to polymerise 
for 15-30 minutes. SDS-PAGE was carried out using the Mini-PROTEAN® Tetra-Cell system 
(Bio-Rad) using the method of Laemmli (1970), all components of which were assembled as 
SDS, sodium dodecyl sulfate; TEMED, tetramethylethylenediamine. 
Table 2.8.  Components of resolving and stacking gels for SDS-PAGE.  
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described by the manufacturer. Once polymerised, the gels were placed in running buffer in a 
1 L electrophoresis tank. Samples were diluted with distilled water as determined by the BCA 
assay and made up to a final volume of 25 µL, containing 25% (6.25 µL) sample solubilisation 
buffer (SSB). Samples were then boiled for 5 minutes at 95°C on a block heater and stored on 
ice until ready to load.  
Before loading, the comb was gently removed to allow running buffer to fill the wells. The full 
sample volume was loaded into each well, ruled on either side by 2 µL PageRuler™ protein 
ladder (10-250 kDa). Samples were subject to electrophoretic separation for approximately 2 
hours at 80 V. 
 
2.2.4.4 Electrophoretic Transfer and Western Immunoblotting  
A Mini-PROTEAN® Trans Blot module (Bio-Rad) was used for protein transfer to an 
Immobilon®-PSQ polyvinylidene fluoride (PVDF) 0.2 μm membrane (Millipore) according to 
the wet transfer method of Towbin et al. (1979). After separation, the resolving gel was 
removed from the glass plates, separated from the stacking gel, and placed in an assembled wet 
transfer cassette soaked in transfer buffer. The PVDF membrane, previously soaked in 
methanol and cut to the correct size, was placed on top, ensuring no air bubbles were present 
to affect successful protein transfer. The cassette, as illustrated in Figure 2.8, was then placed 
in the module in transfer buffer and the protein was transferred at 50 V overnight at 4°C.  
 
 
Figure 2.8.  Layout of the fully assembled transfer cassette. Image courtesy of www.bio-rad.com. 
Foam pad 
Blot absorbant paper 
Membrane 
Gel 
Blot absorbant paper 
Foam pad 
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On completion of wet transfer, the PVDF membrane was stained with Ponceau S solution 
(Sigma-Aldrich) to ensure successful and even transfer of the protein bands. Ponceau S 
negative stain interacts with the positively charged amino groups of proteins, staining them 
red, and can be unstained with repeated distilled water rinses for further analysis after 
visualisation of the protein bands. The resolving gel was also removed from the transfer 
cassette at this point and stained with Coomassie R-250 staining solution for 1 hour on a see-
saw rocker, and a further 1 hour in Coomassie de-staining solution to confirm successful 
protein transfer.  
After staining, the membrane was blocked for 1 hour in a 5% BSA tris-buffered saline solution 
plus 0.1% Tween®-20 detergent (TBS-T) with gentle rocking. The membrane was then cut 
into separate sections depending on the size of the protein of interest, and incubated overnight 
at 4ºC on a see-saw rocker in the relevant primary antibody (diluted in 1% BSA in TBS-T) 




Antibody Target Protein Size 1º Species 1º Dilution 2º Dilution 
GAPDH 37 kDa Mouse 1:10,000 1:5000 
Phospho-NF-κB p65 65 kDa Rabbit 1:1000 1:1000 
NF-κB p65 65 kDa Rabbit 1:1000 1:1000 
NF-κB p52/p100 52/100 kDa Rabbit 1:1000 1:1000 
SOD1 16 kDa Mouse 1:1000 1:1000 
SOD2 28 kDa Rabbit 1:1000 1:1000 
TRACP5 35-42 kDa Sheep 1:2000 1:1000 
RANKL 43-55 kDa Mouse 1:1000 1:1000 
TRAIL 32 kDa Mouse 1:1000 1:1000 
Prior to probing, primary and secondary antibody concentrations were optimised for use across a number of 
parameters: dilution factor, secondary antibody incubation time, and chemiluminescent exposure duration.  
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NF-κB, nuclear factor-κB; SOD, superoxide dismutase; 
TRACP5, tartrate-resistant acid phosphatase-5; RANKL, receptor-activator of NF-κB ligand; TRAIL, tumour 
necrosis factor-related apoptosis-inducing ligand. 
 
Table 2.9. Details of the antibodies employed in Western immunoblotting.  
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Once the primary antibody was removed, the membrane was washed three times with TBS-T 
for 5 minutes each, and the relevant secondary antibodies (Cell Signalling) added and incubated 
on a see-saw rocker at room temperature for 2-3 hours. After this incubation, the wash steps 
were repeated. Antibodies were stored at -20ºC and re-used up to 5 times. Luminata™ Forte 
Western Horseradish Peroxidase (HRP) chemiluminescent substrate (Millipore) was used for 
visualisation of the bound HRP-conjugated secondary antibodies. A minimal amount of this 
substrate was added to the membrane and imaged using GeneSnap software on a Syngene G-
Box. Images were saved for densitometric analysis using freely available Image J software. 
For proteins with a molecular weight in the range of 30-45 kDa, Western blot stripping reagent 
(Thermo Fisher) was employed to enable a second analysis for visualisation of overlapping 
GAPDH endogenous control bands. The stripping process was optimised to ensure complete 
removal of both primary and secondary antibodies. After imaging, membranes were incubated 
for 15 minutes in stripping buffer to remove bound antibodies, washed three times with TBS-
T, and then re-blocked for 1 hour with 5% BSA in TBS-T. Primary and secondary antibodies 
for GAPDH were employed as normal and the blot subject to a second chemiluminescent 
analysis.  
 
2.2.4.5 Enzyme-linked Immunosorbent Assay (ELISA) 
An enzyme-linked immunosorbent assay (ELISA) was used for the quantification of OPG, 
BMP-2, RANKL and TRAIL in media and lysate samples, and IL-6 in media samples, using 
DuoSet® ELISA kits (R&D Systems). These kits are designed for the development of 
sandwich ELISAs to measure antigens from cell culture preparations, and their specificity and 
calibration confirmed by the manufacturer. Materials provided in the DuoSet® ELISA kit 
include capture antibody, detection antibody, recombinant human standard and Streptavidin-
HRP (streptavidin conjugated to horseradish peroxidase). Additional solutions required 
included PBS, wash buffer (0.05% Tween®-20 in PBS, pH 7.2-7.4), normal goat serum (NGS), 
reagent diluent (1% BSA in PBS), tetramethylbenzidine (TMB) substrate solution, and stop 
solution (1 M sulfuric acid). Nunc® Microtitre 96-well plates were used for each assay.  
All DuoSet® ELISA kits measure total levels of the protein target, including both free and 
bound forms. As OPG can act as a decoy receptor for RANKL and TRAIL, additional 
experiments were performed to confirm that endogenous OPG production or recombinant 
RANKL/TRAIL treatment did not interfere with ELISA measurements.  
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2.2.4.5.1 Standard ELISA protocol 
 For ELISA preparation, microtitre plates were first coated with capture antibody, sealed and 
incubated overnight at room temperature. The plate was then washed three times with wash 
buffer and blocked with reagent diluent for 1 hour to prevent non-specific binding. The plate 
was subject to a second wash step before the addition of samples and standards in duplicate or 
triplicate, and incubated overnight at 4°C. Samples were diluted in reagent diluent where 




After this incubation, the plate was re-washed and loaded with the appropriate dilution of 
detection antibody for a 2-hour incubation at room temperature. Both OPG and TRAIL ELISA 
kits require an additional 2% NGS to aid stability of the detection antibody. After a subsequent 
wash, streptavidin-HRP was added to each well and incubated for 20 minutes, followed by the 
final wash step and TMB addition. The plate was 
incubated for approximately 20 minutes in the 
dark (TMB is light sensitive) before the addition 
of stop solution. These steps and the associated 
colour changes are illustrated in Figure 2.9. The 
plate was read immediately at dual wavelengths 
450 nm and 570 nm; this wavelength correction 
allows for optical interference of the Nunc® plate.  
Concentrations were subsequently determined 
using standard curve analysis; a typical standard 
curve for each ELISA DuoSet® kit employed is 
presented in Appendix 2.2A. 
Protein Target Detection Range 
OPG 62.5 - 2000 pg/mL 
RANKL 78.1 - 5000 pg/mL 
TRAIL 23.4 - 1500 pg/mL 
BMP-2 46.9 - 3000 pg/mL 
IL-6 9.38 - 600 pg/mL 
TNFα 15.6 - 1000 pg/mL 
Table 2.10. Detection limits for DuoSet® ELISA kits. 
 Figure 2.9. The final steps of the ELISA 
protocol. TMB, tetramethylbenzidine. Image 
courtesy of www.rndsystems.com.  
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 2.2.5 Functional and Physiological Analysis 
2.2.5.1 ALP Enzyme Activity Assay 
A colorimetric Quantichrom™ ALP activity kit (Bioassay Systems) was employed to directly 
quantify ALP activity in media supernatant and lysate samples, as in previous publications 
(Davenport et al., 2015, 2016). This assay is based on the following kinetic reaction: ALP 
hydrolyses p-Nitrophenyl phosphate (pNPP) into p-nitrophenol and phosphate, forming a 
yellow product with a maximum absorbance at 405 nm. The working solution for the assay 
consists of assay buffer pH 10.5, 0.2 M magnesium acetate and 1 M pNPP, which when added 
to the sample is subject to a 4-minute incubation at 37ºC. The plate is read at 0 and 4 minutes, 
with distilled H2O (negative control) and tartrazine (yellow liquid with a fixed absorbance) 
loaded for run calibration. All samples were assayed in duplicate. ALP activity (IU/L) is 
calculated from the colour change over the fixed time period using the following equation:  
 
ODSAMPLE 0 and ODSAMPLE t are average absorbance values at 0 minutes and 4 minutes 
respectively; ODH2O and ODCALIBRATOR are the average absorbance values of dH2O and 
tartrazine; reaction volume is 200 µL; sample volume is 50 µL volume for media supernatants 
and 5 µL volume for lysates; t is the incubation time (4 minutes). The multiplication factor is 
determined by a number of factors including light path length, incubation time, molar 
absorbance and sample volume, and is calculated by the kit manufacturer. Results are expressed 
as fold change to experimental control to account for microplate reader variations.  
 
2.2.5.2 Permeability Assay   
The trans-endothelial permeability/barrier assay was employed for physiological analysis of 
HAEC monolayers in transwell inserts, i.e., to assess the effect of soluble factors on endothelial 
monolayer integrity in co-culture. This method has been successfully implemented in previous 
publications (Rochfort et al., 2014; Walsh et al., 2011). HAECs were seeded into transwell 
inserts in usual co-culture format, and allowed to incubate for 24 hours to ensure tight 
monolayer formation. Following a 72-hour incubation period with the relevant soluble factors, 
spent media was removed and 4 mL fresh media added to the basolateral compartment. 
x 35.3 (media supernatant) 
x 353 (lysate) 
ALP Activity 
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Fluorophore media, containing 250 µg/mL FITC-labelled Dextran (40 kDa), was prepared and 
2 mL added to the apical compartment. Immediately, a small sample volume was collected 
from the basolateral compartment and diluted as necessary in fresh media. Samples were taken 
from the basal compartment every 30 minutes for 3 hours, diluted and loaded in triplicate on a 
white 96-well microplate (Figure 2.10). A positive control (diluted fluorophore media) and 
negative control (fresh media) were included on each plate. Samples were read on a 
fluorospectrophotometer (Bio-Tek), with an excitation wavelength of 490 nm and an emission 
of 520 nm. Results are expressed as percentage trans-endothelial exchange (TEE) of FITC-







2.2.6 Cell Staining  
2.2.6.1 Alizarin Red S: Calcium Staining  
Alizarin Red (AR) S, an anthraquinone derivative, is routinely employed as a marker of matrix 
mineralisation in vitro, as it is a potent stain for calcific deposits (and other minerals) in bone 
and other tissues (Puchtler et al., 1969). Calcium forms an AR S-calcium complex through 
chelation, resulting in a bright red stain. AR staining was employed to identify and quantify 
crystalline and non-crystalline calcific deposits in differentiated HASMC and MC3T3-E1 cells.   
 
2.2.6.1.1 Alizarin Red Staining for Microscopy 
Post-treatment, spent media was removed and cells were washed three times with calcium- and 
magnesium-free PBS. Cells were then fixed with 3.7% paraformaldehyde for 15 minutes at 
room temperature, before being washed a further three times with distilled water. AR staining 
Figure 2.10. Principle of the trans-endothelial permeability assay. HAEC, human aortic endothelial cell; 
t, time. 
t = 0 hours t = 3 hours 
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solution (40 mM), at the optimal pH of 4.1 - 4.3, was added to the cells and incubated for 30 
minutes in the dark with gentle agitation. After removal of the staining solution, cells were 
washed three times with distilled water and imaged at 0X, 4X, 10X and 40X magnification on 
a Nikon Eclipse phase-contrast microscope.  
 
2.2.6.1.2 Alizarin Red Staining for Quantification by Absorbance 
Following microscopic imaging, AR stain was quantified by absorbance. Acetic acid (10% 
(v/v)) was added to each well and incubated for 30 minutes in the dark with gentle agitation 
(stain extraction). Cells were scraped, transferred to microtubes, and vortexed for 30 seconds, 
before heating at 85ºC for 10 minutes on a block heater. AR stain extractions were then cooled 
on ice, subject to centrifugation at 20,000 xg for 15 minutes, and the supernatant transferred to 
a fresh tube. Ammonium hydroxide solution (25% (v/v)) was then added to the sample for 
neutralisation, and 150 µL sample added in triplicate to an opaque wall plate for analysis. An 
AR standard curve (0 - 4 mM) was included alongside the samples in triplicate for 
quantification (Appendix 2.2B), and the plate read at 405 nm.   
 
2.2.6.2 Immunofluorescence Microscopy: Oxidative Stress 
In order to measure active reactive oxygen species (ROS) levels, HAECs were stained with 
dihydroethidium (DHE) and analysed via immunofluorescent microscopy. DHE, a superoxide 
indicator, can enter the cytoplasm of living cells where it stains blue until it is oxidised by ROS. 
When oxidised, this reaction yields ethidium, which can intercalate with available DNA. In 
order to assess ROS levels via immunofluorescence (IF), HAECs were exposed to experimental 
treatments as required, and DHE added at 3 µM concentration 30 minutes prior to the end of 
the incubation period. Media was then removed, cells washed three times with PBS and fixed 
for 15 minutes with 3.7% paraformaldehyde. Cells were washed a further three times and 4',6-
diamidino-2-phenylindole dihydrochloride (DAPI) nuclear counterstain added for 3 minutes at 
1/3000 dilution. The cells were re-washed before being coated in a thin layer of distilled water. 
Stained HAECs were imaged on a Nikon Eclipse Ti fluorescent microscope at 4X, 10X and 
40X magnification, with exposure time kept constant for each condition. An unstained control 
was included for all microscopy work.  
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2.2.7 Flow Cytometry 
Flow cytometry, a laser-based technology enabling single-cell analysis, was employed to 
investigate apoptosis and oxidative stress in response to soluble factors in vitro. In flow 
cytometry, the characteristics of each cell in suspension are investigated as they flow through 
a hydrodynamically-focused stream of liquid (sheath fluid); each particle or cell (“event”) is 
interrogated by a single-wavelength light beam. Detectors surrounding the laser beam measure 
a number of characteristics of each event at the point where the liquid stream and light beam 
meet. Forward light scatter (FSC), a measure of light refraction directly proportional to cell 
size, is measured by a detector in line with the light beam. Side light scatter (SSC), a measure 
of cell granularity, is measured by a number of detectors perpendicular to the light beam (as 
intracellular components can disperse light in all directions). Thus, FSC and SSC 
measurements help to identify cell populations based on size and internal complexity.  
 
 
Figure 2.11. The flow cell of a flow cytometer. The cell suspension, which may be fluorescently 
labelled, enters the flow cell and is hydrodynamically focused in a stream of sheath fluid. Cells pass 
the laser light source where they are interrogated for fluorescence and light scattering, and the light and 
fluorescence emission collected by a number of detectors. Image courtesy of www.abcam.com.  
Sample 
(stained cells in suspension) Sheath fluid 
Nozzle 
Laser light source 
Hydrodynamic focusing  
(cells pass through in single file) 
Fluorescence emitted 
from stained cells 
detected  
Forward and side 
scattered light from all 
cells detected  
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In addition, cells can be specifically interrogated for the presence of fluorophores when 
fluorescent dyes (e.g. intercalating dyes for nucleic acids, fluorescence-linked antibodies) are 
employed in sample preparation. These fluorophores can be excited by the laser as the event 
passes through the beam, and fluorescent detectors measure scattered emissions at a longer 
wavelength. Optimised laser parameters (e.g. voltage and gain), specific FSC/SSC settings, 
and a strategic gating technique help to develop a biochemical profile of the cell suspension, 
as the signals are amplified and visualised digitally on the FACSAria™ flow cytometer. The 
flow cell of a flow cytometer is depicted in Figure 2.11. 
 
2.2.7.1 Apoptosis Assay  
The Dead Cell Apoptosis Kit with Annexin V and PI (Thermo Fisher) was employed as in 
previous publications (Rochfort et al., 2014) for apoptosis and viability measurements in 
HAECs and HASMCs following exposure to soluble factors. This kit not only distinguishes 
between live and dead cells, but measures the degree of apoptosis at the point of interrogation. 
This kit employs two fluorescent labels; first, PI, a red fluorescent dye that intercalates with 
available nucleic acid is used to distinguish between live and dead cells. Using the same logic 
as for cell counting (Section 2.2.1.5), PI cannot penetrate undamaged cell membranes and 
therefore is a suitable measure of the non-viable cell population. The second fluorescent dye, 
green Alexa Fluor®-488, is conjugated to recombinant Annexin V anticoagulant. In healthy 
live cells, a protein called phosphatidylserine (PS) is expressed on the inner surface cell 
membrane, while in apoptotic cells, PS is translocated to the extracellular surface. Annexin V 
phospholipid-binding protein has a high affinity for PS, and thus fluorescence-conjugated 
Annexin V acts as a suitable identifier of apoptotic cells. Using this dye combination in flow 
cytometry, viable non-apoptotic cells can be identified as having negligible fluorescence, 
viable apoptotic cells will have green fluorescence, and non-viable post-apoptotic cells have 
both red and green fluorescence (Figure 2.12). These distinct cell populations can be visualised 
using the 488 nm laser on the FACSAria™, exciting both PI and Alexa Fluor®-488 dyes which 
have differing emission spectra.  
For the apoptosis assay, cells were first exposed to experimental treatments as required; two 
untreated negative controls (stained, unstained) and one apoptotic positive control (20% 
DMSO, 30 minutes) were also included. Cells were trypsinised and washed in PBS while the 
Annexin V binding buffer (BB) (1/5 dilution of stock in dH2O) and 100 µg/mL PI (1/20 dilution 





100 µL BB. Alexa Fluor®-488 Annexin V (5 µL) and PI (1 µL) were added to the suspension 
and incubated for 15 minutes at room temperature in the dark, with the exception of one 
untreated control. BB (400 µL) was then added and the suspension transferred to sterile 
Falcon® tubes. Tubes were kept on ice in the dark until ready to read. 
The negative unstained control was first processed to determine the optimal FSC/SSC settings 
for each cell type. The positive control was run to ensure all three cell populations (healthy, 
apoptotic and non-viable) were clearly within range. All samples were read on the FITC (~530 
nm) and PE-Texas Red (~610 nm) detection channels to 10,000 events. As PI and Alexa 
Fluor®-488 have relatively close emission maxima, a compensation protocol was employed to 
remove bleed-through fluorescence between channels. To do this, single-stained cell 
suspensions for both PI and Alexa Fluor®-488 were analysed alongside a double-stained 
sample. The auto-compensation settings on the Becton-Dickinson FACSDIVA™ software 
automatically calculates and eliminates the percentage of overlapping fluorescence, improving 
result specificity. Quadrant and gating strategies (e.g. doublet discrimination) were employed 









Figure 2.12. Example output of the apoptosis assay. (A) unstained live cells. (B) 
Alexa Fluor®-488 stained apoptotic cells. (C) Alexa Fluor®-488 and PI stained post-
apoptotic non-viable cells. Image adapted from www.thermofisher.com.  
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2.2.7.2 Oxidative Stress  
As for IF microscopy (Section 2.2.6.2), ROS levels were investigated using DHE staining by 
flow cytometry. Unlike qualitative microscopic analyses, ROS levels can be quantified using 
this technique by measuring the relative intensity of ethidium fluorescence, after DHE is 
oxidised, in control versus treated samples. In this case, HAECs were again exposed to 3 µM 
DHE prior to the completion of the incubation period (an unstained control was also included). 
HAECs were then trypsinised and centrifuged to gather the cell pellet, washed in FACS buffer, 
re-centrifuged and re-suspended in 500 µL FACS buffer. After transferring to Falcon® tubes, 
samples were excited using the 488 nm laser and emission spectra read on the PE-Texas Red 
channel for 10,000 events. No compensation settings were required for DHE single stain 
analysis. Gating strategies were employed as required and data analysed via FACSDIVA™ 
and Cyflogic.  
 
2.2.8 Bioinformatics Search 
In order to identify novel targets that may be involved in RANKL/TRAIL-mediated VC 
signalling, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database 
(version 10.0; accessed November 2016; https://string-db.org/) was primarily employed. The 
STRING database, developed by a consortium of academic institutions including the Swiss 
institute of Bioinformatics, the Novo Nordisk Foundation Centre for Protein Research, and the 
European Molecular Biology Laboratory, obtains protein association knowledge principally 
from experimental literature curation. Computational predictions of protein-protein 
interactions are also included in the STRING database, obtained via text mining methods and 
orthology. STRING provides a colour-coded network of known and predicted interactions for 
any given protein; the data is weighted and integrated and a confidence score calculated for 
each interaction based on available evidence. This confidence score represents how likely an 
interaction is to be true, with values ranging from 0 to 1 (with 1 being the highest possible 
confidence). Proteins interacting with RANKL, TRAIL and their soluble decoy receptor OPG 
were first investigated using the STRING database, while further analyses were conducted for 
additional pro-calcific proteins of interest. Searches were conducted within both homo sapiens 
and mus musculus species databases, and the 20 highest scored interactions for each database 
reviewed. The minimum required interaction score for each search was 0.900 (high 
confidence), with results identified experimentally or via text mining.  
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Secondly, the Biological General Repository for Interaction Datasets (BioGRID) database 
(version 3.4.142; accessed November 2016; https://thebiogrid.org/) was employed as a 
secondary search tool to confirm and expand on the protein-protein interactions identified via 
the STRING database. BioGRID is a public database of protein, chemical and genetic 
interactions curated from over 1.5 million entries within the biomedical literature. Searches 
conducted within BioGRID were filtered for physical rather than genetic interactions, and for 
interactions identified via high-throughput methods, a high confidence score (>0.900) was 
required.  
Following protein identification, the Universal Protein Resource Knowledgebase (UniProtKB), 
a consortium consisting of the European Bioinformatics Institute, the Swiss Institute of 
Bioinformatics and the Protein Information Resource, was employed to compare the functions 
of proteins identified as potential interactants with RANKL and TRAIL. UniProtKB (accessed 
November 2016; https://www.uniprot.org/) contains functional protein information derived 
from the literature and genome sequencing projects, and biological functions identified via this 
database were used to direct further literature investigations. 
 
2.2.9 Data Normalisation 
For conditioned media analyses, absolute values for ELISA and enzyme activity assay were 
normalised to 105 cells, as measured by ADAM™ cell counter. For lysate analyses by ELISA 
and enzyme activity assay, absolute values were normalised to pg total cell lysate, as measured 
by BCA assay. For lysate analyses by Western blotting, samples were diluted to equal 
concentrations of total cell protein prior to SDS-PAGE, and further normalised post-analysis 
to endogenous control (GAPDH). For NF-κB analyses, phosphorylated-p65 was also 
normalised to total p65, and the p52 cleaved subunit normalised to p100, to accurately 
determine pathway activation for canonical and non-canonical NF-κB, respectively. 
 
2.2.10 Statistical Analysis 
All data was analysed and graphed using Microsoft Excel, expressed as the mean ± standard 
error of the mean (SEM). Independent experiments were conducted to a minimum of n = 3. 
Control versus treated groups were analysed by analysis of variance (ANOVA) in conjunction 
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with a Dunnett’s post-hoc test for multiple comparisons, and a Student’s t-test was utilised for 
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3.1 Introduction  
3.1.1 Background and Hypothesis Development 
Accelerated VC observed in systemic diseases (eg. T2DM) is widely associated with 
cardiovascular morbidity/mortality; however, the key pathological events driving this process 
have yet to be fully delineated. Accordingly, improved knowledge of the molecular and 
mechanistic pathways underpinning VC are essential if successful therapeutic interventions are 
to be developed.  
A number of studies to date have considered the functions of RANKL and TRAIL in the 
vasculature, several of which form the basis of this chapter. As detailed in Chapter 1, RANKL 
has long been implicated as a promoter of medial VC, as it exhibits pro-calcific/osteoblastic 
actions in vascular smooth muscle (Kaden et al., 2004; Ndip et al., 2011; Panizo et al., 2009). 
Furthermore, RANKL has been noted to exert pro-calcific effects on endothelial cells, inducing 
the release of osteoblastic paracrine signals such as BMP-2/4 to underlying VSMCs (Davenport 
et al., 2016; Osako et al., 2010). Correspondingly, RANKL expression has been observed in 
vascular cells and in circulation (Cheng et al., 2015; Osako et al., 2010), with elevated levels 
detected in calcified/atherosclerotic tissue (Higgins et al., 2015). From a mechanistic 
perspective, RANKL function is known to involve NF-κB signalling, and the non-canonical 
NF-κB pathway has been implicated in pro-calcific events (Panizo et al., 2009). Although the 
functions of RANKL in VC are well established, the precise role(s) of TRAIL in this process, 
and its mechanism of action, remain undefined.  
Like RANKL, TRAIL has also been identified in serum and in vascular cells (Cheng et al., 
2014; Volpato et al., 2011; Zauli et al., 2006), and a growing body of evidence now points to 
a protective role for TRAIL in VC. From a clinical perspective, decreased serum TRAIL levels 
correlate with acute cardiovascular events (including myocardial infarction, heart failure) and 
resulting mortality (Niessner et al., 2009; Secchiero et al., 2009; Volpato et al., 2011). In vivo, 
TRAIL administration has demonstrated anti-atherosclerotic activity in diabetic mice, with 
TRAIL deficiency promoting VC in TRAIL-null mice (di Bartolo et al., 2013). Moreover, 
Zauli and colleagues have found that TRAIL has the ability to interfere with RANKL function, 
attenuating its role in bone resorption (Zauli et al., 2004; Zauli et al., 2008). Despite this, 
however, no such concept has been investigated in the vasculature to date. We therefore 
hypothesise that TRAIL exerts protective anti-calcific effects on the vasculature, in part via 
attenuation of RANKL-induced pro-calcific signalling.  
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3.1.2 Study Aims  
As noted, the function of TRAIL in the vasculature remains the subject of much debate. Former 
VC investigations in the literature rely heavily on cell models of minimal relevance in vivo (for 
example, vascular beds that are not susceptible to calcification), and limit their studies to a 
narrow range of pro-calcific markers (Corallini et al., 2011; Osako et al., 2010; Secchiero et 
al., 2003). As the aorta is a long-established location for VC in vivo (Mackey et al., 2007; 
Wexler et al., 1996), primary human arterial endothelial/smooth muscle cells will be employed 
in this study, within which a wide range of recognised pro-calcific indices will be monitored 
in physiologically relevant in vitro models. Within these models, the hypothesised protective 
role of TRAIL on RANKL-induced pro-calcific signalling will be thoroughly evaluated. 
To better understand the signalling processes surrounding VC, a number of specific study aims 
were defined:  
 
1. To delineate the direct effects of RANKL and TRAIL on the intimal vascular 
endothelium, the primary target for circulatory protein interaction, and to 
investigate the potential for TRAIL protection in the intimal layer.  
2. To define the direct effects of RANKL and TRAIL on medial vascular smooth 
muscle cells, the primary location of mineral deposition in vivo, and to investigate 
the potential for TRAIL protection in the medial layer.  
3. To implement a physiologically relevant co-culture model in which to investigate 
the effects of RANKL and TRAIL on endothelial:smooth muscle paracrine 
signalling, and to monitor the potential for TRAIL protection within this model.  
 
3.1.3 Experimental Design  
To address study aims 1 and 2, primary 
human aortic endothelial cells (HAECs) 
and human aortic smooth muscle cells 
(HASMCs) respectively were cultured in 
standard 6-well dishes (Figure 3.1) and 
exposed to RANKL (5-25 ng/mL), 
TRAIL (5 ng/mL), or both for 72 hours. 
To address study aim 3, a non-contact 
Figure 3.1. Typical morphology of HAECs and 
HASMCs in culture. (A) Cultured HAECs under control 
conditions displaying typical cobblestone morphology. (B) 
Cultured HASMCs under control conditions displaying 
their characteristic spindle shape. Images were taken using 
a Nikon Eclipse TS100 phase-contrast light microscope.  
 88 
co-culture model was developed in which HASMCs were grown to confluency in standard 6-
well culture dishes (subluminal compartment), while HAECs were seeded in semi-permeable 
transwell inserts (luminal compartment). Transwell inserts were suspended above confluent 
smooth muscle cells and exposed to RANKL (5-25 ng/mL), TRAIL (5 ng/mL) or co-incubated 
with both for 72 hours (Figure 3.2). In each case, mRNA, protein lysate and conditioned media 
were harvested as required for analyses by RT-qPCR, ELISA, enzyme activity assay and 
Western blotting where appropriate (n = 3). The following gene/protein targets previously 
implicated in the VC process were monitored in both mono- and co-culture: 
 
(i) BMP-2, an endothelial paracrine signalling molecule induced by RANKL 
(Davenport et al., 2016); 
(ii) ALP, an enzyme involved in matrix mineralisation in the VC process (Hui and 
Tenenbaum, 1998); 
(iii) OPG, a soluble decoy receptor for both RANKL and TRAIL, shown to have 
cardioprotective properties (Van Campenhout and Golledge, 2009); 
(iv) IL-6, a pro-inflammatory cytokine, evidenced as a key driver of pro-calcific genes 
(Kurozumi et al., 2016);  
(v) Runx2, an osteoblastic transcription factor responsible for driving pro-calcific 
genes (Pratap et al., 2003); 
(vi) Sox9, a chondrocytic transcription factor responsible for driving pro-
calcific/chondroblastic genes (Akiyama et al., 2002);  
(vii) Canonical and non-canonical NF-κB activation, central pathways involved in 








Figure 3.2. Representation of the transwell co-culture model. HASMCs were grown to confluency in 
standard 6-well culture dishes. HAECs were cultured in semi-permeable transwell inserts and suspended above 
the confluent smooth muscle layer when confluent. HAECs were exposed to RANKL (5-25 ng/mL), TRAIL 
(5 ng/mL) or both in the luminal compartment for 72 hours. Conditioned media in the subluminal compartment 
was assessed for BMP-2, IL-6, ALP and OPG release; HASMC protein lysates were harvested and analysed 
for BMP-2, ALP, OPG and NF-κB p52/p65; the HASMC transcriptome was harvested and assessed for BMP-
2, IL-6, ALP, OPG, Runx2 and Sox9 mRNA expression. Image adapted from Harper et al., 2017.  
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3.2 Preliminary Investigations  
This chapter will focus primarily on the effects of recombinant RANKL and TRAIL exposure 
on HAECs and HASMCs. A number of preliminary investigations were conducted to ensure 
suitable experimental design and correct interpretation of analyses: establishing optimal 
treatment conditions, determining basal expression levels of RANKL, TRAIL and their 
receptors, highlighting potential adverse cellular effects of recombinant protein exposure, and 
ensuring a valid methodological approach.  
 
3.2.1 Establishing Treatment Conditions  
Prior to implementing experimental conditions, raw HAEC and HASMC unconditioned media 
was subject to ELISA analysis to ensure negligible RANKL/TRAIL levels prior to recombinant 
protein addition. Both proteins proved undetectable in endothelial and smooth muscle media, 
with measurements below the lower limit of detection (data not shown). 
In consideration of the experimental aims and the HAEC:HASMC co-culture investigations 
conducted by Davenport et al. (2016), optimal exposure conditions were primarily determined 
based on maximal RANKL-induced endothelial BMP-2 secretion. In this respect, Davenport et 
al. (2016) identified a role for BMP-2, but not BMP-4, in EC paracrine signalling in response 
to RANKL. Additional paracrine factors (extracellular ALP activity, OPG and IL-6 release) 
were also considered. Minimal direct effects of TRAIL on these paracrine factors was 
preferential so as not to disguise the pro-calcific effects of RANKL. As VC is a chronic process, 
an exposure duration of 72 hours was implemented to reflect in vivo pathological conditions 
while maintaining cell culture integrity. This duration has been successfully employed in 
previous VC signalling studies (Davenport et al., 2016; Freise et al., 2016). 
By way of optimisation, RANKL concentrations that elicited measurable changes in VC 
parameters were required, to provide a model in which to investigate TRAIL-mediated 
protection. In this respect, physiological RANKL circulating levels of approximately 50 pg/mL 
as reported by Bilgir et al. (2018) were first investigated for suitability in vitro. HAECs and 
HASMCs were subject to treatment with 50 pg/mL of RANKL for 72 hours, however, no 
effects were noted in the release profiles of any of the paracrine signalling molecules measured 
(data not shown). Therefore, the higher dose range of 5-50 ng/mL previously utilised by 


























Figure 3.3. Optimisation of RANKL and TRAIL exposure concentrations in HAEC monoculture. HAECs 
were exposed to 5-50 ng/mL (A) RANKL or (B) TRAIL for 72 hours. (i) BMP-2, (ii) OPG and (iii) IL-6 release 
were monitored by ELISA; (iv) extracellular ALP activity was determined by activity assay. Absolute values 
normalised to 105
 
cells. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to 0 ng/mL control. 
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Following endothelial exposure to 5, 25 and 50 ng/mL RANKL, it was determined that 25 
ng/mL RANKL elicited maximal BMP-2 release while also significantly increasing pro-
calcific ALP activity in the conditioned media (Figure 3.3A). As such, this concentration was 
deemed optimal for in vitro studies. With respect to TRAIL, however, concentrations that 
elicited minimal effects on the measured indices were optimal, to ensure that RANKL-induced 
pro-calcific effects could be clearly monitored. In this regard, it was noted that TRAIL 
significantly increased BMP-2 and OPG secretion from HAECs at 25 ng/mL and above (Figure 
3.3B). As such, a concentration of 5 ng/mL TRAIL was deemed optimal for in vitro studies. 
Given that the optimal RANKL concentration (25 ng/mL) was in excess of the optimal TRAIL 
concentration (5 ng/mL), a lower RANKL concentration of 5 ng/mL was also included; this 
ensured that the pro-calcific effects of RANKL would not overwhelm the potential protective 
influence of TRAIL. Neither RANKL nor TRAIL induced significant inflammatory IL-6 
release under any of the optimal conditions chosen.  
 
3.2.2 Expression of RANKL and TRAIL  
In order to ensure accuracy of treatment concentrations, basal mRNA and protein expression 
of RANKL and TRAIL in HAECs and HASMCs was examined, alongside any potential 
differential effects when exposed to recombinant RANKL (25 ng/mL) or TRAIL (5 ng/mL) 
for 72 hours.  
 
3.2.2.1 HAECs  
With regard to mRNA expression, RANKL and TRAIL levels were undetectable both at basal 
levels and following RANKL/TRAIL exposure (data not shown). In endothelial conditioned 
media, soluble RANKL was detected by ELISA at an average concentration of 61.9 pg/mL per 
105 cells, with TRAIL release approximately ten times less; neither RANKL (25 ng/mL) nor 
TRAIL (5 ng/mL) treatment exerted any observable effects on RANKL/TRAIL release into 
the conditioned media. Secreted RANKL and TRAIL levels were therefore deemed too low to 
affect treatment conditions in the 5-25 ng/mL range. Intracellular RANKL and TRAIL 
averaged 584.6 and 157.3 pg/mg lysate, respectively, and again no significant variations were 
noted in intracellular RANKL/TRAIL following exposure to  these ligands. Furthermore, 
Western blotting analysis identified low-level expression of RANKL and undetectable levels 




In HASMCs, RANKL and TRAIL mRNA were expressed at transcriptionally relevant levels 
compared to endogenous control, with no significant deviations in expression following 
exposure to RANKL/TRAIL (data not shown). In HASMC-conditioned media, secreted 
RANKL and TRAIL levels averaged 96.2 pg/mL and 212.5 pg/mL per 105 cells, respectively; 
RANKL treatment elevated TRAIL release by 23% and TRAIL induced a 31% increase in 
RANKL secretion. While these levels were deemed relatively insignificant compared to the 
excess ng/mL experimental concentrations, endogenous RANKL and TRAIL production was 
noted for subsequent HASMC analyses. Intracellular levels of RANKL (1329.5 pg/mL) and 
TRAIL (6188.4 pg/mL), were not altered by recombinant ligand exposure. Again, Western 
blotting confirmed the presence of both RANKL and TRAIL protein in HASMC lysate, at 
significantly higher levels than that of HAECs (Appendix 3.1).  
 
3.2.3 Expression of RANKL and TRAIL Receptors 
The mRNA expression of RANKL and TRAIL surface receptors were also confirmed in 
HAECs and HASMCs to ensure these recombinant ligands could exert direct physiological 
effects in culture. TRAIL receptors (decoy receptors DcR1 and DcR2, death receptors DR4 
and DR5) were expressed at similar levels in both cell types compared to endogenous controls, 
while RANK receptor mRNA was approximately 104 fold more abundant in HASMCs than 
HAECs (data not shown). Indeed, all four cell surface receptors for TRAIL, along with the 
RANK receptor, are known to be expressed in both HAECs and HASMCs (Kavurma et al., 
2008; Secchiero et al., 2003).  
 
3.2.4 Effects of RANKL and TRAIL on Cellular Integrity  
The potential adverse effects of recombinant RANKL and TRAIL on cellular integrity were 
also assessed prior to experimental treatment. To this end, cell morphology, viability and 
apoptosis, endothelial barrier function and the expression of phenotypic markers in smooth 




3.2.4.1 Cell Morphology  
HAECs and HASMCs were assessed via light microscopy pre- and post- exposure to RANKL 
and TRAIL for 72 hours. No changes in HAECs were noted with recombinant protein treatment 
or co-treatment, exhibiting a typical “cobblestone” morphology (Figure 3.1A). Similarly, no 
physical variations were noted in treated or co-cultured HASMCs which retained their 
characteristic spindle shape (Figure 3.1B). Morphological assessment was routinely employed 
throughout experimental procedures.  
 
3.2.4.2 Viability and Apoptosis  
Routine viability measurements were conducted via ADAM™ counter as required. Cell 
viability for both HAECs and HASMCs were maintained above 90% for all recombinant ligand 
treatments and co-treatments in mono- and co-culture (data not shown). Apoptosis was also 
monitored via flow cytometry as described in Section 2.2.7.1 to ensure that neither RANKL 
nor TRAIL at the employed concentrations were potent apoptotic inducers in HAECs or 
HASMCs. In HAECs, TRAIL treatment resulted in a very small but statistically significant 
1.2% increase in apoptosis, while in HASMCs, RANKL exposure decreased apoptotic cells by 
6.4% compared to control (Figure 3.4). Average values for viability and apoptotic 
measurements are summarised overleaf in Table 3.1.  
 
3.2.4.3 Endothelial Barrier Function  
As endothelial cells will ultimately be employed in co-culture, HAEC barrier function was 
assessed to ensure that RANKL nor TRAIL did not alter monolayer integrity or permeability 
over the 72-hour exposure time. HAECs were exposed to RANKL and/or TRAIL in transwell 
inserts for 72 hours. FITC-dextran was then added to the apical compartment as described in 
Section 2.2.5.2, and the percentage trans-endothelial exchange (TEE) monitored over a three-
hour period. Untreated control cells permitted an average TEE of 3.0% FITC-dextran, and 
neither RANKL nor TRAIL treatment exhibited any significant difference on endothelial 

























  Viable (%) Non-viable (%) Apoptotic (%) 
HAECs Untreated 96.58 3.41 7.23 
 25 ng/mL RANKL 96.63 3.34 6.59 
 5 ng/mL TRAIL 96.36 3.62 8.42** 
 DMSO  48.42 49.15 17.8 
HASMCs Untreated 95.60 3.32 17.01 
 25 ng/mL RANKL 98.36*** 1.52*** 10.60* 
 5 ng/mL TRAIL 96.29 3.00 19.11 
 DMSO 88.20 11.43 44.63 
* p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control.  
 
Table 3.1.  Average percentages of viable, non-viable, and apoptotic HAECs and HASMCs post-
treatment.  
Figure 3.4. The effect of RANKL and TRAIL exposure on HAEC and HASMC apoptosis. (A) HAECs 
and (B) HASMCs were exposed to experimental concentrations of RANKL (25 ng/mL) and TRAIL (5 ng/mL) 
for 72 hours, or 20% DMSO for 30 minutes, prior to analysis by flow cytometry. Dot plots are presented for 
apoptosis measurements of (i) control, (ii) RANKL, (iii) TRAIL and (iv) DMSO. Quadrants determined by 
unstained control. Bar charts represent percentage apoptosis when (C) HAECs and (D) HASMCs were 
exposed to (i) RANKL and (ii) TRAIL for 72 hours. * p < 0.05; ** p < 0.01 compared to untreated control.  
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3.2.4.4 Phenotypic Analysis of Smooth Muscle Cells 
As noted, trans-differentiation of HASMCs away from smooth muscle and towards a pro-
osteoblastic phenotype can occur under the correct conditions, particularly in the presence of 
pro-calcific factors such as RANKL. Thus, HASMCs were characterised for specific 
phenotypic markers under both control conditions and following exposure to recombinant 
ligands. In this respect, HASMCs were analysed for mRNA expression levels of two core 
smooth muscle markers: SMα-actin and SM22α, and two markers of osteoblastic 
differentiation: BSP and OCN. No changes were noted in the expression levels of either smooth 
muscle or osteoblastic markers after 72 hours’ treatment with RANKL or TRAIL (Appendix 
3.2B), confirming that HASMCs maintain a characteristic smooth muscle phenotype for the 
experimental duration. Furthermore, no changes in the above phenotypic markers were noted 
in HASMCs in co-culture, despite the potential presence of pro-calcific endothelial paracrine 
signalling (data not shown).  
 
3.2.5 Methodological Validation  
Prior to experimentation, confirmatory experiments were carried out to ensure a valid 
methodological approach for RT-qPCR, ELISA and co-culture cell models. Validations were 
carried out at the optimal determined experimental concentrations for RANKL and TRAIL 
recombinant ligands.  
 
3.2.5.1 qPCR  
Prior to conducting gene expression analysis on experimental samples, it was confirmed that 
both GAPDH and 18S were appropriate endogenous controls for the treatment conditions 
employed. To this end, both reference genes were assessed for changes in expression levels in 
response to RANKL or TRAIL exposure for 72 hours. Both ligands were noted to have no 
effect on either GAPDH or S18 gene expression in HAECs or HASMCs (Appendix 3.3A), 
confirming their suitability in experimental qPCR analyses. 
 
3.2.5.2 ELISA  
As OPG can function as a soluble decoy receptor for both RANKL and TRAIL, it was 
considered that recombinant protein addition may interfere with extracellular OPG ELISA 
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readings. Reciprocally, endogenous OPG production may alter the analysis of RANKL and/or 
TRAIL release. In this regard, experimental concentrations of both RANKL and TRAIL were 
“spiked” into untreated HASMC conditioned media after 72 hours and subject to OPG ELISA 
analysis. Meanwhile, conditioned HASMC media was also spiked with recombinant human 
OPG at 20 ng/mL (doubling secreted OPG concentration), and RANKL/TRAIL release 
monitored by ELISA. No neutralisation effects were noted in RANKL, TRAIL, or OPG levels 
between control and spiked conditioned media (Appendix 3.3B, C), highlighting that neither 
recombinant protein addition nor endogenous OPG production interfere with ELISA analyses.  
 
3.2.5.3 Co-culture  
In addition to the endothelial permeability assay (Section 3.2.4.3), further validation was 
conducted prior to co-culture; namely, calculating recombinant protein leakage into the basal 
HASMC compartment. HAECs were exposed to recombinant ligands at experimental 
concentrations, and basal concentrations of RANKL and TRAIL determined by ELISA 
analysis at 24 and 72 hours. RANKL- and TRAIL-treated endothelial cells permitted an 
approximate 1.8% and 5.4% transfer, respectively, of total ligand from the luminal to the 
subluminal compartment after 72 hours in culture (Appendix 3.3D). In consideration of the 
larger media volume present in the subluminal compartment, these percentage values equate to 
absolute concentrations of 224.9 pg/mL RANKL and 135.7 pg/mL TRAIL at the termination 











3.2.6 Discussion: Preliminary Investigations  
Extensive efforts were made to ensure robust and relevant in vitro models were employed 
alongside a sound methodological approach. In this respect, preliminary investigations 
primarily involved the optimisation of exposure conditions, identification of potential adverse 
effects, and the validation of experimental controls.  
 
3.2.6.1 Selection of Optimal Treatment Conditions in HAECs  
As noted, exposure conditions were primarily chosen based on optimal RANKL-induced BMP-
2 release from HAECs, as previously characterised by Davenport et al. (2016), representing 
endothelial paracrine signalling to HASMCs in the vascular wall. Endothelial release of active 
ALP, a critical marker of osteoblastic activity, were also assessed; ALP promotes matrix 
mineralisation via PPi clearance/increasing Pi levels in the extracellular space (Schoppet and 
Shanahan, 2008), and thus may contribute to RANKL-induced pro-calcific events in 
underlying HASMCs in co-culture. As HAECs have been previously noted to release low but 
detectable quantities of OPG decoy receptor under basal conditions (Davenport et al., 2016), 
minimal extracellular OPG levels were preferential to facilitate uninterrupted RANKL/TRAIL 
function. Furthermore, negligible endothelial IL-6 release was required for multiple reasons: 
firstly, IL-6 has been shown to increase vascular permeability through VEGF production 
(Hashizume et al., 2009; Tanaka et al., 2014), an undesirable outcome in co-culture where a 
tight endothelial barrier is desired. Secondly, research indicates that IL-6 can directly induce 
ALP and Runx2 expression in VSMCs (Kurozumi et al., 2016), an effect which may hinder 
the identification of RANKL-induced pro-calcific signalling. Thirdly, IL-6 has been shown to 
suppress RANK signalling during osteoclastic differentiation (Yoshitake et al., 2008); although 
not directly relevant in a vascular setting, the overlapping functions of RANKL in bone and in 
the VC process (and thus the potential for interference in the employed cell models) must be 
considered. An exposure concentration of 25 ng/mL RANKL satisfied the above requirements, 
achieving substantial BMP-2/ALP secretion alongside negligible OPG/IL-6.  
TRAIL’s optimal exposure concentration was also determined by BMP-2/IL-6, as elevated 
release of both soluble markers was noted at 25 ng/mL and above. Thus, 5 ng/mL TRAIL was 
required so as not to interfere with RANKL-specific pro-calcific effects. This concentration-
dependent BMP-2/IL-6 induction further supports the complex pleiotropic role of TRAIL in 
the vasculature (Forde et al., 2016), and may go towards explaining some of the contrasting 
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effects noted with TRAIL exposure in the literature (Chasseraud et al., 2011; Olesen et al., 
2012). Crucially, no significant effects on OPG/ALP secretion were detected at the optimal 
TRAIL dose. A significant and novel finding of this preliminary investigation is the dose-
dependent release of cardioprotective OPG in response to TRAIL treatment, possibly the result 
of self-regulation in response to abundant extracellular TRAIL, but also a potential contributor 
to the growing theory of TRAIL-mediated vasoprotection. Interestingly, OPG (co-localised 
with von-Willebrand Factor) is subject to rapid release from Wiebel-Palade bodies in response 
to endothelial inflammation (Zannettino et al., 2005), potentially revealing an additional role 
for TRAIL at higher concentrations. This finding may also be of relevance in explaining 
TRAIL-induced BMP-2/IL-6 release, however this conjecture requires further research and is 
beyond the scope of the current study.  
On an additional note, it is no surprise that reported circulating levels of RANKL (~50 pg/mL) 
did not induce endothelial pro-calcific paracrine responses in culture. Recorded concentrations 
of basal RANKL production in HAECs were of a similar magnitude, and low-level endogenous 
OPG production may contribute to RANKL neutralisation. Subsequently, the higher dose range 
of 5-50 ng/mL was considered suitable as it has previously been employed to investigate the 
effects of RANKL in HAECs, particularly regarding BMP-2 secretion (Davenport et al. 2016, 
Osako et al., 2010). Moreover, higher levels of RANKL than that measured in circulation have 
been detected in atherosclerotic and calcified lesions (Dhore et al., 2001; Morony et al., 2008; 
Schoppet et al., 2004) enhancing the physiological relevance of the employed RANKL 
concentration in the current study.  
 
3.2.6.2 Expression of RANKL and TRAIL in HAECs and HASMCs  
There are varying reports in the literature regarding the expression of RANKL and TRAIL in 
vascular cells. While both proteins have been identified in calcified arteries in vivo, whether 
this originates from circulating immune cells (Falschlehner et al., 2009; Hofbauer and 
Schoppet, 2004) or from the vasculature itself is long under debate. Regarding the endothelium, 
RANKL mRNA/protein has been detected in HAECs (Osako et al., 2010) and microvascular 
ECs (Collin-Osdoby et al., 2001), while TRAIL mRNA/protein has been detected in 
microvascular ECs (Pritzker et al., 2004) and pulmonary arteries (Spierings et al., 2004). 
Contrastingly, the absence of RANKL (Zannettino et al., 2005) and TRAIL (Secchiero et al., 
2006) in HUVECs has been reported at both transcriptional and translational level. To account 
for these divergences, Zannettino and colleagues (2005) highlight the potential differences in 
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microvascular EC and HUVEC responses, while Spierings et al. (2004) suggest that the 
expression of TRAIL is both tissue and cell-specific. Interestingly, previous studies in our own 
lab indicate that neither protein is expressed at detectable quantities in HAECs, despite the 
presence of mRNA transcripts (Davenport et al., unpublished observations). While these cells 
were cultured under similar conditions, these studies by Davenport et al. employed primary 
HAECs from a different donor to those employed in the current investigation. Together with 
the findings from the present study in which low-level RANKL/TRAIL protein (but not 
transcript expression) was detected, we further support the proposition by Spierings et al. 
(2004) that while ECs in general can produce RANKL and TRAIL, their expression may be 
cell-specific and should be evaluated for each endothelial population.  
There are more consistent reports in the literature regarding VSMC expression of RANKL and 
TRAIL. Concurring with our study, both RANKL mRNA and protein expression have been 
detected in murine aortic VSMCs (Chang et al., 2015; Tseng et al., 2010), while TRAIL 
transcripts/protein have been quantified in VSMCs (Harith et al., 2016; Li et al., 2016). In 
supernatant media, low concentrations of RANKL and TRAIL bound to OPG in human VSMC 
supernatant media have also been discovered (Nguyen et al., 2007). Contrastingly, however, 
previous studies by Davenport et al. (2016) within our own research group have revealed a lack 
of RANKL/TRAIL production by HASMCs; this discrepancy may also be explained by the 
proposition of a VSMC population-specific production profile, as different HASMC donors 
were employed in each case. Moreover, primary HASMCs are notoriously heterogeneous in 
culture, with phenotypic characteristics dependent on the specific differentiation state of the 
explanted populations (Speer et al., 2009). As with HAECs, RANKL and TRAIL produced by 
VSMCs may therefore contribute to that detected in calcified lesions in vivo (Dhore et al., 
2001; Morony et al., 2008; Schoppet et al., 2004), however, given the relatively overwhelming 
concentrations of OPG produced by HASMCs (Davenport et al., 2016), their biologically 
significant effects at these levels are likely negated in culture. Nonetheless, the induction of 
RANKL/TRAIL secretion observed with TRAIL and RANKL exposure, respectively, is 
considered a significant finding of this study, providing, to our knowledge, the first evidence 
of inter-regulation between the two ligands in the vasculature.  
 
3.2.6.3 The Effects of RANKL and TRAIL on Cellular Integrity  
Despite the notorious roles of RANKL and TRAIL as potent inducers of calcification and 
apoptosis, respectively, both proteins exerted minimal effects on HAEC/HASMC viability and 
 100 
integrity. No detrimental effects of recombinant ligand exposure on endothelial barrier function 
were noted, despite the claim that RANKL induces vascular permeability (Min et al. 2007). In 
HAECs exposed to TRAIL, a slight but significant increase in apoptosis was noted after 72 
hours, an effect considered inconsequential for current cell models. Despite TRAIL’s historical 
function as an “apoptosis-inducing ligand”, the literature reveals conflicting results. While 
Cheng et al. (2014) have previously generalised that excessive TRAIL stimulates EC apoptosis, 
concurrent with studies by Li et al. (2013) and Sato et al. (2006), TRAIL has in some cases 
been shown to promote endothelial survival (Secchiero et al., 2003). Unpublished studies in 
our lab have however revealed that higher concentrations of TRAIL (100 ng/mL) over a shorter 
exposure period (24 hours) induce an approximate 5% increase in apoptosis, potentially 
revealing concentration- and time-dependency in TRAIL’s apoptotic function (Forde et al., 
unpublished observations). While responses to TRAIL are likely to be somewhat 
concentration-dependent, varying responses to TRAIL treatment have been considered 
(Spencer et al., 2009), further supporting a complex pleiotropic role for this protein in vivo. 
Therefore, the effects of TRAIL on endothelial integrity likely vary widely and involve a 
complex balance of both pro- and anti-apoptotic signalling pathways, a subject for further 
investigation outside the scope of this thesis (for review, see Forde et al., 2016).  
As an additional novel finding, RANKL exposure significantly decreased smooth muscle 
apoptosis and cell death. Although Bharti et al. (2003) present opposing evidence of RANKL-
induced apoptosis, their study employed a murine monocytic cell line, and no comprehensive 
investigations have since clarified the role of RANKL in VSMC apoptosis. While not covered 
in the current study, further research is necessary to delineate the pro-survival properties of 
RANKL in smooth muscle.  
As expected, neither RANKL nor TRAIL were noted to affect the expression of smooth muscle 
markers SMα-actin and SM22α or the early (BSP) and late (OCN) markers of osteogenic 
differentiation in HASMCs after 72 hours’ exposure. Despite RANKL’s well-defined roles in 
pro-calcific signalling, differentiation processes generally require 14-21 days’ differentiation 
in complex pro-osteogenic media to induce phenotypic changes in VSMCs (Patel et al., 2016, 
Yang et al., 2005). Therefore, transcriptional and translational variations pre-and post-exposure 





3.2.6.4 Methodological Validation  
Regarding the choice of endogenous control, GAPDH and 18S were confirmed to be suitable 
for mRNA analysis post-exposure to RANKL/TRAIL, as no changes in these genes were noted 
in HAECs/HASMCs. These reference genes have also been previously employed following 
RANKL/TRAIL exposure in vascular cells (Davenport et al., 2016; Panizo et al., 2009; Patel 
et al., 2013). On a separate note, no neutralisation effects were noted in RANKL, TRAIL, or 
OPG levels between control and spiked conditioned media following ELISA analyses. In 
agreement with the manufacturer’s specifications, this suggests that these DuoSet™ ELISA 
systems measure both free and bound protein, a finding previously confirmed for the RANKL 
DuoSet™ kit by Davenport et al. (unpublished observations).  
In relation to co-culture models, transwell inserts have been successfully employed in VC 
studies to demonstrate the paracrine interaction between VSMCs and various cell types 
(Hénaut et al., 2016; Zhang et al., 2014). However, additional efforts were made in this case 
to confirm a tight endothelial monolayer in co-culture, to ensure that recombinant 
RANKL/TRAIL could not leak through into the subluminal compartment in significant 
quantities to cause direct effects on underlying HASMCs. In consideration of the endothelial 
barrier function in vitro, endothelial protein uptake and degradation by natural proteases, 
minimal recombinant RANKL/TRAIL was expected to cross the HAEC monolayer. Indeed, 
after 72 hours, less than 2% and 6% total RANKL and TRAIL respectively were detected in 
the subluminal compartment; in combination with neutralising OPG secretion, these low 
pg/mL concentrations are unlikely to exert direct physiological effects on HASMCs in co-
culture. The aforementioned permeability assay, viability and apoptosis measurements, and 
morphological assessments also support a robust physiologically relevant co-culture model in 








3.3 HAEC Monoculture  
As noted, HAECs were first employed in monoculture to investigate the effects of RANKL +/- 
TRAIL, in order to profile the pro-calcific effects of RANKL and the potential protective 
effects of TRAIL on the vascular intima. A number of gene and protein targets were analysed 
as part of this study, listed in Section 3.1.3.  
 
3.3.1 The Effects of RANKL +/- TRAIL on the Expression of HAEC Gene Targets  
Following analyses by RT-qPCR, neither RANKL nor TRAIL altered the mRNA expression 
levels of BMP-2, ALP, Runx2 or IL-6 gene targets in endothelial monoculture after 72 hours 
(Appendix 3.4A). Both OPG and Sox9 mRNA were deemed undetectable in the HAEC 
transcriptome, with levels below that required for accurate detection. However, as elevated 
levels of BMP-2 and ALP protein were detected in the endothelial secretome in response to 25 
ng/mL RANKL (Figure 3.3), the mRNA levels of these genes following 24 hours’ incubation 
with RANKL were also investigated (in the event that mRNA changes had normalised after 72 
hours). Again, no notable differences were detected in BMP-2 mRNA levels, but both ALP 
and Runx2 transcripts were significantly more abundant at the earlier time-point before 
returning to baseline levels at 72 hours (Appendix 3.5B).  
 
3.3.2 The Effects of RANKL +/- TRAIL on the Expression of HAEC Protein Targets 
With regard to protein release, RANKL was again confirmed to dose-dependently increase 
paracrine BMP-2 secretion and extracellular ALP activity. TRAIL had no effect on secretory 
BMP-2 levels, but reduced active ALP release by approximately 20%. Co-incubation with both 
RANKL and TRAIL resulted in complete attenuation of RANKL-induced BMP-2 release at 
both concentrations, while TRAIL significantly reduced ALP activity when compared to 
RANKL treatment alone (Figure 3.5A (i), (iii)). Regarding intracellular protein, again dose-
dependent increases of BMP-2 and active ALP were noted in response to RANKL. In the case 
of BMP-2, while TRAIL treatment alone had no effect, co-incubation with both recombinant 
proteins significantly increased BMP-2 production when compared to RANKL exposure 
(Figure 3.5A (ii)). In the case of ALP, however, TRAIL co-incubation fully attenuated 
RANKL-induced activity at both concentrations (Figure 3.5A (iv)). No changes were noted at 





Figure 3.5. Protein analyses in HAEC monoculture. HAECs were exposed to RANKL (5-25 ng/mL) +/- TRAIL 
(5 ng/mL) for 72 hours. (A) (i) BMP-2 release and (ii) intracellular BMP-2 levels were analysed by ELISA. (iii) 
extracellular and (iv) intracellular ALP activity were determined by activity assay. (B) (i) Canonical and (ii) non-
canonical NF-κB activation were determined by Western blotting, analysed by scanning densitometry and 
normalised to GAPDH. Blots are representative. Absolute values for media and lysate analysis are and normalised 
to 105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control 
unless otherwise stated; bars indicate statistical significance between treatment groups.  
A 
(i)  (ii)  
B 
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3.3.3 The Effects of RANKL +/- TRAIL on HAEC NF-κB Activation 
Both canonical and non-canonical NF-κB pathways were activated in response to RANKL. 
Phosphorylated p65 levels were similarly elevated in response to both 5 and 25 ng/mL 
RANKL, while cleaved p52 levels increased in a dose-dependent manner (Figure 3.5B). 
TRAIL itself had no effect on either NF-κB pathway at the employed concentration in 
endothelial cells, and did not interfere with RANKL-induced canonical activation. However, 
TRAIL completely attenuated non-canonical signalling induced by RANKL exposure, at both 
5 and 25 ng/mL concentrations. As an additional investigation, non-canonical activation was 
monitored over the earlier time course of 0-24 hours, to better profile pro-calcific NF-κB 
signalling responses to RANKL. It was found that cleaved p52 levels are elevated as early as 
15 minutes’ post-exposure, peaking at approximately 6 hours, and this pathway remains active 
after 24 hours of treatment (Appendix 3.5A). Furthermore, β-glycerophosphate, a well-
established inducer of calcification, was noted to significantly induce non-canonical NF-κB 
activation while exerting minimal effect on canonical signalling after 72 hours’ exposure. 
Elevated BMP-2 release and extracellular ALP activity were noted alongside this activation 
(Appendix 3.6). 
 
3.3.4 HAEC Monoculture: Summary of Results 
Differentially expressed indices in response to RANKL +/- TRAIL treatment in HAEC 
monoculture are summarised in Table 3.2 below.  
 
 






BMP-2 Extracellular Protein ↑ − − 
 Intracellular Protein ↑ − ↑↑ 
ALP Extracellular Activity ↑ ↓ − 
 Intracellular Activity ↑ − − 
NF-κB (p52/p100) Activation ↑ − − 
NF-κB (p-p65/t-p65) Activation ↑ ↑ ↑ 
 ↑, upregulation; ↑↑, further upregulation relative to corresponding treatment conditions; ↓, downregulation; −, 
no change. p-p65, phospho-p65; t-p65, total p65.  
Table 3.2. The effects of RANKL +/- TRAIL in HAEC monoculture.  
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3.3.5 Discussion: HAEC Monoculture  
Firstly, the pro-calcific effects of RANKL and the proposed protective effects of TRAIL were 
explored in endothelial monolayer. Thus far, limited data exists regarding the process of VC in 
large artery ECs, as the majority of calcification studies to date employing RANKL and TRAIL 
have been completed in VSMC models. As such, there is minimal research data available to 
which our findings can be compared, and we present a number of novel findings regarding pro-
calcific indices never before explored in human endothelial cell models. These studies are vital 
in addressing the current hypothesis as they aid in defining the endothelial contribution to 
vascular paracrine signalling, enhancing our ultimate understanding of more complex co-
culture models. Given the comprehensive nature of this investigation, only the key findings of 
the presented HAEC monoculture studies (summarised in Table 3.2) will be discussed. 
 
3.3.5.1 The Effects of RANKL +/- TRAIL on BMP-2 Regulation 
BMP-2 has been defined as a pro-osteogenic protein known to act in a paracrine manner on 
underlying VSMCs in the vasculature. In this respect, and in agreement with the literature, 
RANKL was noted to dose-dependently induce BMP-2 release in HAEC monoculture 
(Davenport et al., 2016; Osako et al., 2010). At a translational level, this trend was maintained, 
however no concurrent transcriptional changes were observed. Given the induction of BMP-2 
protein, BMP-2 mRNA levels were also investigated following 24 hours’ RANKL treatment, 
and again no changes were detected in BMP-2 transcript expression at this earlier time point. 
Osako and colleagues, to our knowledge the only other research group to assess the effects of 
RANKL on BMP-2 expression in HAECs, noted an upregulation of BMP-2 mRNA expression 
at 6 hours, however they fail to report on gene expression levels at 24 hours and beyond. 
Additionally, while not directly relevant to our VC model, early-stage (6 hours) BMP-2 mRNA 
expression has also been induced by RANKL exposure in osteosarcoma cells (Wittrant et al., 
2006). It is therefore possible that BMP-2 mRNA transcription may be subject to early 
upregulation before returning to baseline levels, but this hypothesis requires further 
confirmation. This inconsistency between mRNA and protein levels also suggests that RANKL 
modulates long-term BMP-2 production at a translational rather than a transcriptional level, 
with BMP-2 mRNA levels likely irrelevant to chronic conditions such as VC.  
With regard to TRAIL, no effects were observed in BMP-2 mRNA/protein following 72 hours’ 
exposure, in agreement with our hypothesis. Indeed, despite the known pro-calcific effects of 
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RANKL and the ability of TRAIL to counteract RANKL function in osteoclastogenesis (Zauli 
et al., 2004; Zauli et al., 2008), no studies to date have investigated the combined effects of 
these ligands on BMP-2 release. We therefore present, for the first time, the ability of TRAIL 
to completely attenuate RANKL-induced BMP-2 paracrine signalling in HAECs, even when 
RANKL is greatly in excess. This novel finding provides the first evidence of TRAIL-mediated 
protection within the context of VC. Furthermore, with co-exposure to TRAIL, we report that 
TRAIL enhanced RANKL-induced intracellular BMP-2 levels (while blocking its release). 
Thus, TRAIL may exert an inhibitory effect on chronic RANKL-induced BMP-2 secretion, 
rather than production, having no effect on total protein turnover.  
 
3.3.5.2 The Effects of RANKL +/- TRAIL on Pro-Calcific Markers 
Interestingly, alongside BMP-2, RANKL is known to exert its pro-calcific function in the 
vasculature via upregulation of osteogenic transcription factors (eg. Runx2), subsequently 
increasing ALP expression/activity (Sage et al., 2010). ALP is also independently recognised 
as an extracellular inducer of calcification, and is often used to assess mineralisation in vascular 
settings (Liberman et al., 2013). However, what the majority of the literature fails to address is 
the effect of RANKL on these pro-calcific indices in ECs, focusing instead on VSMC models. 
While VSMCs are indeed the primary location for mineralisation in vivo, the endothelium is in 
direct contact with pro-calcific stimuli in circulation, and so ECs are likely to exert their own 
osteogenic response to condition underlying VSMCs within the medial layer. This study aimed 
to address these limitations by defining multiple endothelial pro-calcific responses to RANKL, 
and assessing the potential for TRAIL protection in this respect.  
At an mRNA level, both ALP and its upstream transcription factor Runx2 were induced by 
RANKL at 24 hours, but this upregulation was not sustained at 72 hours. Interestingly, 
however, both intra- and extra-cellular ALP activity were elevated following 72 hours’ 
RANKL exposure, a trend previously highlighted in HASMCs (Osako et al., 2010) but never 
before clarified in the endothelial monolayer. We therefore highlight the novel finding that 
endothelial exposure to RANKL induces active ALP, potentially contributing to VSMC 
extracellular matrix mineralisation and/or elevated circulating ALP noted in chronic T2DM 
(Hussein, 2017). Taken together, these data may suggest that, like BMP-2, early transcriptional 
changes in ALP/Runx2 may affect sustained responses at a protein level. Also of relevance, 
Sox9 chondrogenic transcription factor expression was not present in detectable quantities in 
 107 
HAECs, either untreated or exposed to RANKL, suggesting a specific role for the endothelium 
in pro-osteogenic rather than chondrogenic processes.  
With regard to TRAIL, no effect was noted on ALP/Runx2 transcription at either time point. 
TRAIL did, however, significantly reduce extracellular ALP activity at 72 hours, and more 
pertinently, completely attenuated RANKL-induced active ALP. In the first study to our 
knowledge to consider endothelial ALP as a paracrine factor, or more specifically a core 
contributor to VSMC matrix crystallisation, we present further novel evidence to support the 
protective role for TRAIL in attenuating RANKL-induced endothelial pro-calcific signalling.  
 
3.3.5.3 The Effects of RANKL +/- TRAIL on OPG Regulation 
Following quantification of extracellular OPG, neither RANKL nor TRAIL were found to 
affect the release of their own decoy receptor from HAECs at the employed concentrations. It 
has long been reported that OPG, with its well-defined cardioprotective properties, is secreted 
by endothelial cells (Malyankar et al., 2000; Zannettino et al., 2005), although many claims to 
date have been based on less physiologically relevant cell models (eg. HUVECs). More 
relevantly, previous studies in our own lab have identified endothelial release in the 20-30 
pg/mL range, consistent with our own reports (Davenport et al., 2016). To date, few studies 
have investigated the effects of RANKL/TRAIL on OPG release, potentially due to its role as 
a potent decoy receptor for these ligands. However, endothelial OPG secretion in the low 
pg/mL range is highly unlikely to exert any biologically relevant neutralising effects on 
excessive ng/mL concentrations of recombinant ligands employed in this case. Furthermore, 
anti-OPG antibodies are often employed in RANKL studies in vitro, in order to negate this 
neutralising function (Davenport et al., 2016; Osako et al., 2010). However, both RANKL and 
TRAIL exert biologically significant effects in vivo even in the presence of circulating OPG 
(Carbone et al., 2016; Secchiero et al., 2006). Therefore, we chose to maintain physiological 
relevance and exclude OPG neutralisation from our in vitro models.  
Despite the detection of OPG protein, OPG mRNA was deemed too low to be accurately 
quantified in HAECs. In this regard, our finding contradicts the literature, as Osako et al. (2010) 
and Davenport et al. (2018) have previously identified OPG mRNA in HAECs. While the 
discrepancy in RANKL/TRAIL expression (whereby protein but not mRNA transcripts were 
detected) may be explained by population heterogeneity, we propose an environment-specific 
explanation for the same discrepancy with OPG. Due to the high concentration of intracellular 
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protein, HAECs appear to maintain a “store” of OPG for release under the appropriate 
conditions, and thus OPG transcription levels may not be required in measurable amounts.  
Furthermore, the qPCR “cut-off point” employed in this study (40 Cq) may not have been 
employed by the aforementioned authors, resulting in low but quantifiable OPG expression in 
those studies. As a final consideration, this proposed induction of stored OPG alongside the 
apparent low transcription rate may result in the eventual attenuation of OPG release, leaving 
the vasculature open to injury. Therefore, the protective effects of OPG may be short-term, 
rendering OPG nothing more than a marker of early endothelial dysfunction with minimal 
biologically significant effects. The precise nature of OPG regulation in endothelial cells, 
relatively understudied to date, therefore requires further clarification.  
 
3.3.5.4 The Effects of RANKL +/- TRAIL on NF-κB Activation 
The activation of NF-κB by RANKL and TRAIL under certain conditions is well established. 
RANKL binding to the RANK cell surface receptor is known to involve NF-κB signalling in 
osteoclastogenesis and vascular disease (Abu-Amer 2013; Boyce et al., 2015; Otero et al., 
2012), and NF-κB has previously been implicated in diabetic vascular complications 
(Suryavanshi and Kulkarni, 2017; Zhan et al., 2014; Zhao et al., 2012). The literature, however, 
lacks clarity with respect to which pathway exerts pro-calcific functions. While the non-
canonical pathway has been implicated in VC pathogenesis in VSMCs (Panizo et al., 2009), 
no studies to our knowledge have investigated RANKL-induced NF-κB activation in vascular 
endothelial cells. In the current study, we note that RANKL activates both the canonical and 
non-canonical NF-κB pathway in HAECs, suggesting a potential role for both pathways in 
RANKL endothelial function. Interestingly, Feng and colleagues (2003) have previously linked 
NF-κB activation and BMP-2 gene expression in chondrocytes, involving both canonical and 
non-canonical signalling elements (p50/p65, p52), but this study failed to assess BMP-2 protein 
levels nor is it directly relevant to paracrine communication in the vasculature. 
TRAIL, which can activate NF-κB through its surface receptors DcR2, DR4 and DR5 (Juan et 
al., 2001) (all of which are expressed by HAECs), is widely known to hold a complex 
relationship with NF-κB signalling (Forde et al., 2016). In this case, TRAIL had no effect on 
either the canonical or non-canonical pathway, in agreement with the same finding in HUVECs 
(Secchiero et al., 2003), however, TRAIL has previously been shown to activate NF-κB 
signalling in the endothelium at higher concentrations (20 – 50 ng/mL) (Li et al., 2003). 
Furthermore, previous research in our lab has indicated that 100 ng/mL TRAIL induces a strong 
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trend towards canonical activation (Forde et al., unpublished observations), which may suggest 
a concentration-dependent NF-κB response to TRAIL. However, the major limitation of the 
literature to date is the lack of specification on which NF-κB pathway is activated, in our view 
a vital piece information in determining TRAIL function.  
Moreover, we noted for the first time that endothelial co-incubation with RANKL + TRAIL 
can completely attenuate RANKL-induced non-canonical, but not canonical, activation, a 
finding for which the mechanism will be explored in Chapter 5. Interestingly, this coincides 
with TRAIL blockade of RANKL-induced paracrine BMP-2 release and ALP activity. As we 
know that RANKL can function via non-canonical signalling (Panizo et al., 2009), this 
pathway may also be responsible for RANKL-induced pro-calcific action in the endothelium, 
and TRAIL may exert its protective effects by attenuating RANKL-induced non-canonical 
activation. Moreover, HAEC exposure to the calcification inducer β-glycerophosphate was 
noted to induce non-canonical (but not canonical) signalling alongside BMP-2/ALP induction, 
further implicating the former pathway in RANKL pro-calcific function.  
As NF-κB is a well-known “early responder” to its stimuli (Healy et al., 2013), non-canonical 
signalling was monitored following 15 minutes-24 hours’ exposure to RANKL to gain a better 
insight into the RANKL/NF-κB pro-calcific mechanism. We noted maximum activation at 1 
hour, with an increase apparent as early as 15 minutes’ exposure. Interestingly, as NF-κB/p52 
translocation to the nucleus regulates gene transcription (Oeckinghaus and Ghosh, 2009), this 
may explain the early upregulation of pro-calcific genes before eventually returning to baseline 
alongside low-level non-canonical activation. Furthermore, RANKL-induced NF-κB, although 
somewhat diminished, remains steadily active at 24-72 hours, supporting the ability of RANKL 
to exert sustained effects on HAECs in its role during chronic VC.  
 
3.3.5.5 Summary: HAEC Monoculture 
Overall, we present novel evidence that RANKL induces endothelial paracrine BMP-2/ALP 
signalling via NF-κB non-canonical activation, and that TRAIL has the ability to attenuate 
these effects. While RANKL induces early maximal NF-κB/pro-calcific gene expression, 
longer term protein responses are sustained at 72 hours, remaining relevant to chronic VC. This 
novel evidence provides valuable insight on the pro-calcific function and mechanism of 
RANKL in the endothelial monolayer, and supports the valuable therapeutic potential for 
TRAIL in the modulation of these pathophysiological effects. 
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3.4 HASMC Monoculture  
HASMCs were also employed in monoculture, in which the same range of mRNA and protein 
targets were assessed for differential expression in response to RANKL +/- TRAIL. Additional 
investigations, incorporating the pro-calcific inducer β-glycerophosphate and the key paracrine 
signalling molecule BMP-2, were also employed to better define the pro-calcific events 
surrounding RANKL exposure in the vascular media.  
 
3.4.1 The Effects of RANKL +/- TRAIL on the Expression of HASMC Gene Targets  
RANKL +/- TRAIL exposure exerted several effects on the expression of HASMC gene targets 
following 72 hours’ incubation. RANKL treatment was found to dose-dependently decrease 
OPG mRNA, and increase Runx2 transcription factor expression at 25 ng/mL (Figure 3.6A), 
while having no effect on ALP/BMP-2 transcript levels (Appendix 3.7A (i), (ii)) or Sox9 
mRNA expression (data not shown). TRAIL treatment, on the other hand, had no effect on 
OPG mRNA expression, nor did it interfere with the RANKL-induced downregulation of OPG. 
TRAIL did, however, decrease Runx2 mRNA by approximately 40%, and maintained a 30% 
decrease in Runx2 expression following co-incubation with 5 ng/mL RANKL. Again, no 
changes in ALP or Sox9 transcript expression were noted in response to TRAIL, but TRAIL 
significantly decreased the abundance of BMP-2 transcripts by approximately 30% (although 
this trend was not maintained with RANKL co-incubation). Interestingly, with regard to IL-6, 
both RANKL (25 ng/mL) and TRAIL (5 ng/mL) increased mRNA levels by approximately 
1.5-fold, inducing an additive effect with co-treatment (Appendix 3.7A (iii)).  
Core gene targets were also assessed following 24 hours’ exposure to RANKL, to address 
inconsistencies between mRNA and protein trends (see Section 3.4.2). Interestingly, while 
BMP-2, ALP and Sox9 mRNA showed no change at 72 hours, all three pro-calcific genes were 
upregulated following 24 hours’ exposure. While BMP-2 and Runx2 transcripts were 
decreased in response to TRAIL at 72 hours, no change was noted in either gene at the earlier 
time-point of 24 hours (Appendix 3.8A). With regard to OPG, a more detailed investigation 
(including a 48-hour time point) was executed in an attempt to explain the complex regulation 
of OPG at a protein level (see Section 3.4.2). In this case, while TRAIL had no effect, RANKL 
induced an increase in OPG expression at 24 hours, returned to baseline at 48 hours, and 



























Figure 3.6. mRNA and protein analyses in HASMC monoculture. HASMCs were exposed to RANKL (5-25 
ng/mL) +/- TRAIL (5 ng/mL) for 72 hours. (A) mRNA expression of (i) OPG and (ii) Runx2 were analysed by 
RT-qPCR; GAPDH was employed as an endogenous control. (B) (i) OPG and (ii) active ALP release were 
analysed by ELISA and activity assay respectively, and normalised to 105 cells. Intracellular levels of (iii) OPG 
and (iv) BMP-2 were analysed by ELISA, normalised to total protein. * p < 0.05; ** p < 0.01; *** p < 0.001 




3.4.2 The Effects of RANKL +/- TRAIL on the Expression of HASMC Protein Targets 
Pertaining to extracellular protein trends, OPG (released at substantially higher levels in 
HASMCs than HAECs) was noted to be significantly decreased following exposure to 25 
ng/mL RANKL (Figure 3.6B (i)). TRAIL treatment had no effect on OPG release, either alone 
or in combination with RANKL. Active ALP was also increased in the conditioned media 
following 25 ng/mL RANKL exposure, both alone and following co-exposure with TRAIL 
(Figure 3.6B (ii)). BMP-2, secreted at lower levels from HASMCs than in the vascular 
endothelium, remained unchanged in all cases, while extracellular IL-6 levels were elevated by 
25 ng/mL RANKL both alone and in combination with TRAIL (Appendix 3.7C).  
Intracellularly, RANKL exposure dose-dependently increased OPG production. OPG was also 
induced by TRAIL, but no additive effect was noted with co-treatment; rather, TRAIL 
significantly diminished the effect of 25 ng/mL RANKL in this case (Figure 3.6B (iii)). 
Interestingly, RANKL induced BMP-2 protein levels at 25 ng/mL concentration, and while 
TRAIL itself had no effect, co-treatment resulted in complete attenuation of RANKL-induced 
BMP-2 translation (Figure 3.6B (iv)). No effects were noted in intracellular ALP activity under 
any of the conditions tested (Appendix 3.7B).  
 
3.4.3 The Effects of RANKL +/- TRAIL on NF-κB Activation 
Recombinant RANKL, at both 5 and 25 ng/mL concentrations, significantly induced activation 
of both canonical and non-canonical NF-κB signalling in smooth muscle cells after 72 hours. 
TRAIL treatment significantly induced canonical activation, but did not exert any significant 
effects on the non-canonical pathway. Both pathways remained similarly activated in the 
presence of RANKL + TRAIL (Figure 3.7).  
 
3.4.4 The Effects of β-glycerophosphate on the Expression of Gene/Protein Targets 
In order to profile an established pro-calcific response, HASMCs were exposed to 10 mM β-
glycerophosphate, a key driver of calcification, for 72 hours. In this way, the effects of RANKL 
can be compared to that of a recognised inducer of mineralisation in vascular smooth muscle. 
As expected, β-glycerophosphate exposure significantly upregulated BMP-2, ALP, Runx2 and 
Sox9 at an mRNA level (Appendix 3.9A), while also increasing intracellular and extracellular 





activation of either the canonical or non-canonical NF-κB pathways or IL-6 regulation in 
HASMCs (data not shown). Interestingly, OPG release, intracellular production, and mRNA 
expression were significantly increased following β-glycerophosphate exposure (Appendix 
3.9D). HASMC exposure to β-glycerophosphate for 72 hours did not exert any significant 
effects on cell morphology, viability or apoptosis, nor did it affect the suitability of 
GAPDH/S18 endogenous controls employed in qPCR (data not shown).  
 
3.4.5 The Effects of BMP-2 +/- Noggin on the Expression of HASMC Gene/Protein Targets 
To confirm the pro-calcific effects of paracrine BMP-2 signalling from the endothelium to 
smooth muscle, recombinant BMP-2 and the BMP inhibitor, noggin, were employed in 
HASMC monoculture. Recombinant BMP-2, at 5 ng/mL, was found to significantly increase 
ALP, Runx2 and Sox9 mRNA in HASMCs after 72 hours. Co-incubation with noggin (100 
ng/mL) was found to completely attenuate the pro-calcific influence of BMP-2 at a 
transcriptional level (Appendix 3.10A). Interestingly, while a non-significant increase was 
noted in extracellular ALP activity following BMP-2 exposure, co-treatment with noggin 
Figure 3.7. NF-κB activation in HASMC monoculture following RANKL +/- TRAIL treatment. HASMCs 
were exposed to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours. (i) Non-canonical and (ii) canonical 
NF-κB activation were determined by Western blotting, and analysed by scanning densitometry normalised to 
GAPDH. Blots are representative. * p < 0.05; *** p < 0.001 compared to untreated control.  
(i)  (ii)  
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reduced active ALP by approximately 50% compared to control (Appendix 3.10B). Post-
treatment increases in intracellular ALP and BMP-2 were also significantly reduced and 
completely attenuated by noggin co-exposure, respectively (Appendix 3.10C). BMP-2 
exposure did not induce activation of either the canonical or non-canonical NF-κB pathway 
(Appendix 3.10D), nor did it affect OPG (mRNA/protein) or IL-6 release (data not shown). 
Again, regarding preliminary controls, BMP-2 and/or noggin did not exert any significant 
effects on cell morphology, viability, apoptosis, or the expression of smooth muscle markers 
SMα-actin and SM22α. GAPDH/S18 were also confirmed to be suitable reference genes for 
BMP-2/noggin analyses.  
 
3.4.6 HASMC Monoculture: Summary of Results 
The expression levels of several indices were altered in response to RANKL +/- TRAIL 
treatment in HASMCs, as summarised in Table 3.3 below.  
 
 






BMP-2 mRNA  − ↓ − 
 Intracellular Protein ↑ − − 
ALP Extracellular Activity ↑ − ↑ 
OPG mRNA ↓ − ↓ 
 Extracellular Protein ↓ − ↓ 
 Intracellular Protein  ↑↑ ↑ ↑ 
IL-6  mRNA  ↑ ↑ ↑↑ 
 Extracellular Protein  ↑ − ↑ 
Runx2  mRNA  ↑ ↓ − 
NF-κB (p52/p100) Activation ↑ − ↑ 




↑, upregulation; ↑↑, further upregulation relative to corresponding treatment conditions; ↓, downregulation; −, 
no change. p-p65, phospho-p65; t-p65, total-p65.  
Table 3.3. The effects of RANKL +/- TRAIL in HASMC monoculture.  
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3.4.7 Discussion: HASMC Monoculture  
The clear majority of VC research to date has been carried out in VSMCs, with varying reports. 
To our knowledge, however, this study is the first to assess an expansive range of indices within 
a human primary HASMC population. Although smooth muscle is not generally in direct 
contact with circulating proteins under healthy physiological conditions, in pathophysiological 
areas of vascular damage and EC dysfunction in vivo, these proteins may penetrate to the 
medial layer due to an increased endothelial permeability (Review: Sena et al., 2013). Elevated 
levels of RANKL/TRAIL have been identified in calcified arteries and atherosclerotic plaque 
(Dhore et al., 2001; Michowitz et al., 2005; Morony et al., 2008; Schoppet et al., 2004). 
Therefore, it is vital to understand the function of RANKL and TRAIL in the VSMC layer, 
whereby these proteins may exert direct effects in addition to those paracrine signals induced 
by HAECs. The key findings from this study (Table 3.3) also aid our understanding of 
subsequent co-culture models.  
There is a large body of literature regarding the effect of RANKL and TRAIL in VSMCs; 
however, many of these studies will not be drawn on in the current discussion (Byon et al., 
2011; Chasseraud et al., 2011; Olesen et al., 2012; Tseng et al., 2010). While some divergences 
may be explained by a combination of methodological differences (eg. anti-OPG), variations 
in exposure time/dosage, donor heterogeneity and limitations in the range of calcification 
indices assessed, we highlight an additional confounder often employed in VC research. A 
number of researchers employ “calcifying” media with high levels of calcium/phosphate in 
VSMC studies, in order to induce/enhance mineralisation and pro-calcific responses. The 
inclusion of these confounders may interfere with the analysis of pro-calcific indices, as they 
themselves have been shown to induce Runx2, Sox9 and ALP levels (Alesutan et al., 2015). 
As such, our own series of experiments were specifically conducted in the absence of calcifying 
media, in order to facilitate a clearer interpretation of HASMC responses to RANKL/TRAIL.  
 
3.4.7.1 The Effects of RANKL +/- TRAIL on Pro-Calcific Targets  
BMP-2 is primarily known to act in a paracrine manner on smooth muscle when released from 
ECs. In agreement with Davenport et al. (2016) and Osako et al. (2010), we found that BMP-
2 is released at significantly lower levels in HASMCs compared to HAECs, and incubation 
with RANKL and/or TRAIL had no effect on these release levels. Again, RANKL exerted no 
effect on BMP-2 mRNA level at 72 hours, but significantly elevated these levels at the earlier 
 116 
time point of 24 hours. In agreement, Panizo and colleagues (2009) reported no change in 
BMP-2 expression in rat VSMCs following 48 hours’ RANKL exposure, further suggesting 
short-term transcriptional regulation. TRAIL, on the other hand, exerted a later response in 
BMP-2 mRNA and induced a down-regulation at 72 hours. While this reduction in BMP-2 
mRNA was not observed in co-incubation with RANKL, TRAIL completely attenuated 
RANKL-induced intracellular accumulation. This novel finding may indicate a potential 
storage mechanism for BMP-2 in VSMCs, released under certain inflammatory/atherogenic 
conditions (Ikeda et al., 2012; Nakagawa et al., 2010; Simões Sato et al., 2014), and although 
RANKL itself induces BMP-2 production, it does not induce this release. As with HAECs, 
BMP-2 appears to be regulated at a translational rather than a transcriptional level in HASMCs.  
In agreement with Davenport et al. (2016), no effects were noted in ALP mRNA expression in 
response to RANKL/TRAIL in HASMCs at 72 hours, despite significant upregulation at 24 
hours. Interestingly, extracellular (but not intracellular) ALP activity was also induced 
following 72-hour RANKL exposure, both in the presence and absence of TRAIL. Thus, while 
ALP is induced by RANKL in VSMCs in accordance with the literature (Liu et al., 2014; 
Morony et al., 2012; Panizo et al., 2009; Yuan et al., 2011; Zhan et al., 2014), this induction 
is not modulated at a long-term transcriptional level. Furthermore, the observation that ALP 
activity is only increased following exposure to higher concentrations of RANKL may suggest 
a dose-dependent response, but may also highlight the significance of endogenous OPG 
protection in the vasculature in vivo. Overall, this data is supportive of a direct role for RANKL 
in VSMC calcification and more specifically a role in paracrine ALP regulation, although 
TRAIL does not exert a protective influence on RANKL function in VSMCs.  We also 
demonstrate that TRAIL downregulates Runx2 mRNA expression at 72 hours, even in the 
presence of 5 ng/mL RANKL; while Runx2 has previously been implicated in the VC 
process/RANKL function in VSMCs (Sun et al., 2012; Zhan et al., 2014), we highlight for the 
first time the ability of TRAIL to downregulate this osteoblastic transcription factor in vitro.  
Sox9 chondrocytic transcription factor, although undetectable at an mRNA level in HAECs, 
was readily detectable in HASMCs. Sox9 has been shown to occur in VSMC calcification, and 
is associated with many of the same gene/protein alterations as osteogenic differentiation 
(Speer et al., 2009; Tyson et al., 2003). Despite this knowledge, and as a major limitation of 
the literature to date, Sox9 is rarely employed as a marker of pro-calcific events in VC studies. 
In this series of experiments, while a non-significant increase was observed at 24 hours 
following RANKL exposure, neither recombinant protein affected Sox9 transcript expression 
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at 72 hours. This may suggest that HASMCs are not directly induced to express chondrocytic 
genes/proteins following exposure RANKL, or it may suggest a complete dependence on 
osteoblastic (rather than chondroblastic) transcription factors for calcifying VSMCs. To date, 
the role of Sox9 in the calcification process remains under debate (Speer et al., 2009), but we 
propose that RANKL does not induce long-term Sox9 upregulation in VSMCs. 
In order to profile a well-defined pro-calcific insult on HASMCs in monoculture, the 
calcification inducer β-glycerophosphate was employed for a series of control experiments 
(Shioi et al., 1995). β-glycerophosphate was found to significantly induce all pro-calcific 
indices, confirming the suitability of these targets in assessing osteoblastic activity in smooth 
muscle.  As an additional control, we investigated the effects of BMP-2 directly on HASMCs 
to provide preliminary insight into the potential for endothelial BMP-2 paracrine regulation in 
co-culture. In this case, ALP, Runx2 and Sox9 mRNA, alongside ALP/BMP-2 protein, were 
upregulated, and subsequently reduced/abrogated by the BMP inhibitor noggin (Krause et al., 
2011). Thus, endothelial paracrine BMP-2 signalling is likely to regulate these pro-calcific 
indices in smooth muscle both in co-culture and in vivo.   
 
3.4.7.2 The Effects of RANKL +/- TRAIL on OPG Regulation  
OPG, given its established role as a cardioprotective decoy receptor for RANKL and TRAIL 
(Collin-Osdoby, 2004; Emery et al., 1998), was also assessed in HASMCs. Initially, HASMCs 
were noted to produce and release far greater amounts of OPG than HAECs after 72 hours, 
supporting the common observation that the VSMC layer is the dominant source of vascular 
OPG (Corallini et al., 2009; Davenport et al., 2016). However, as optimal RANKL/TRAIL 
conditions were determined in endothelial monoculture (with co-culture in mind as an end 
goal), and both proteins have also been shown to exert physiological responses in vivo despite 
the presence of endogenous OPG (Carbone et al., 2016; Secchiero et al., 2006), no action was 
taken to neutralise this decoy ligand. Moreover, the expression of multiple pro-calcific indices 
were altered in response to treatment, further supporting the ability of RANKL/TRAIL to 
function in the presence of substantial OPG release. Therefore, while OPG can readily bind 
and neutralise these proteins, recombinant RANKL/TRAIL likely exert their function 
uninhibited prior to OPG release and subsequent neutralisation.  
In the current study, RANKL was found to decrease OPG mRNA and release, while TRAIL 
exposure had no effect either alone or in combination with RANKL. Interestingly, however, 
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RANKL and TRAIL both induced intracellular OPG production. This data may suggest 
alternate OPG regulatory mechanisms for both RANKL and TRAIL; as such, we propose that 
RANKL may block OPG release without affecting protein turnover, while TRAIL may 
enhance intracellular production as part of a protective storage mechanism. While TRAIL 
somewhat depletes RANKL-dependent intracellular accumulation of OPG, it has no effect on 
RANKL-inhibited OPG release, and therefore exerts minimal biological significance by way 
of protection against RANKL. However, no studies to our knowledge yet describe the effects 
of RANKL/TRAIL on OPG production in VSMCs, and so this theory cannot be confirmed.  
In order to further delineate these complex trends, we assessed OPG mRNA expression at the 
shorter time-point of 24 hours. In this instance, while TRAIL alone had no influence, RANKL 
exerted a clear bimodal effect on OPG transcription, inducing OPG mRNA at 24 hours and 
decreasing it at 72 hours. This novel finding may highlight the potential differential effects of 
RANKL on OPG regulation over time, inducing a protective upregulation in acute vascular 
injury (potentially to protect from further damage), but exerting a long-term downregulation 
and depletion of OPG in chronic conditions such as VC. As a further point of interest, the 
calcification inducer β-glycerophosphate was noted to induce OPG at both a transcriptional 
and translational level, most likely as a protective mechanism to prevent inflammation and 
blood vessel damage similar to that of early RANKL exposure. Of importance, circulating OPG 
has been widely claimed to be elevated in vascular pathologies (Abedin et al., 2007; O’Sullivan 
et al., 2010; Schoppet et al., 2003), consistent with that of β-glycerophosphate exposure. In 
this way, elevated OPG may function as a biomarker for VC while its depletion in the 
vasculature contributes to damage and calcification. Also of note, BMP-2 exposure had no 
effect on HASMCs, suggesting that OPG is not regulated by endothelial paracrine signalling.   
Upon reflection, we present the first novel evidence that RANKL exerts a clear pro-calcific 
effect in HASMCs through maintained suppression of its own decoy receptor, allowing 
unopposed RANKL function to ensue. TRAIL, on the other hand, exerts minimal effect on 
OPG regulation in HASMCs, and does not attenuate RANKL-induced OPG depletion. It is 
unlikely that the proposed protective nature of TRAIL is attributable to OPG regulation, as this 
intracellular OPG is unavailable to bind to recombinant RANKL. However, both RANKL and 
TRAIL play a clear role in the complex modulation of OPG in HASMCs, in a different manner 
to their role in the endothelium. It is obvious that, due to the quantity of OPG produced and 
released, HASMCs are a key influencer in the development and progression of vascular 
complications.  
 119 
3.4.7.3 The Effects of RANKL +/- TRAIL on NF-κB Activation 
Although we suggest a role for the non-canonical NF-κB/p52 pathway in RANKL-induced 
calcification and TRAIL-mediated vasoprotection in HAECs, the function of NF-κB in 
HASMCs is less clear. Both RANKL and TRAIL were shown to activate both the canonical 
and non-canonical NF-κB pathway in smooth muscle, with TRAIL exerting no inhibition on 
RANKL-induced activation. We have confirmed that HASMCs express surface receptors for 
RANKL/TRAIL binding and NF-κB activation, however, due to the inflammatory and 
proliferative roles for NF-κB in VSMCs (Brasier, 2010; Mehrhof et al., 2005), it is difficult to 
determine if the result of this activation is pro-calcific. We did, however, note that the 
calcification inducer β-glycerophosphate did not activate either pathway in HASMCs, nor did 
BMP-2, which may be suggestive that NF-κB is not involved in VSMC calcification, although 
this finding would contradict the literature (Hénaut et al., 2016; Landry et al., 1997; Song et 
al., 2017). While this may hold true for TRAIL, with its pre-established role in VSMC 
inflammation and proliferation (Kavurma et al., 2008; Song et al., 2011), RANKL activation 
of NF-κB has already been implicated in VSMC calcification (Panizo et al., 2009; Zhan et al., 
2014). What therefore appears more likely is that both NF-κB pathways may be involved in 
RANKL-induced pro-calcific induction in HASMCs, but not involved in β-glycerophosphate 
induction (perhaps due to the absence of direct RANKL:RANK binding).  
 
3.4.7.4 Summary: HASMC Monoculture 
In a study assessing the widest range of calcification indices to date, we note that the pro-
calcific nature of RANKL and the proposed protective effect of TRAIL in HASMCs is minimal 
compared to that observed in HAECs. We further note that, while TRAIL attenuates RANKL-
induced NF-κB signalling in endothelial cells, it does not exert the same effect in HASMCs, 
instead activating both NF-κB pathways alongside RANKL. The absence of BMP-2 release 
was also noted in HASMCs in response to RANKL, supporting the one-way paracrine 
relationship between the endothelium and smooth muscle as proposed by Davenport et al. 
(2016) and Osako et al. (2010). We conclude that RANKL and TRAIL exert direct effects on 
VSMCs when in contact during vascular damage, even in the presence of excess endogenous 




3.5 HAEC:HASMC Co-culture 
Finally, HAECs and HASMCs were employed in co-
culture to better recapitulate the paracrine 
communication that exists between the endothelium 
and smooth muscle in vivo. Within the semi-
permeable transwell insert, HAECs were exposed to 
RANKL +/- TRAIL (Figure 3.8), and the underlying 
smooth muscle cells in the basal compartment were 
harvested for analysis. Paracrine signalling proteins 
present in the subluminal conditioned media, along with HASMC mRNA/lysate, were analysed 
as appropriate for transcriptional and translational changes in response to endothelial 
communication. Additional control investigations, including the incorporation of the BMP 
inhibitor noggin, were also employed to support the theoretical basis surrounding this model.  
 
3.5.1 The Effects of RANKL +/- TRAIL on the Expression of HASMC Gene Targets 
Endothelial RANKL +/- TRAIL treatment was found to regulate several gene targets in the 
underlying HASMC layer. Firstly, RANKL exposure significantly increased ALP transcript 
expression; TRAIL treatment alone downregulated ALP mRNA by approximately 10%, and 
completely attenuated RANKL-induced expression at both concentrations (Figure 3.9 (i)). 
Similarly, Sox9 mRNA expression was also dose-dependently upregulated in HASMCs 
following endothelial RANKL treatment, and co-exposure with TRAIL exhibited complete 
blockade of this effect (Figure 3.9 (iii)). Thirdly, OPG mRNA levels were dose-dependently 
decreased following RANKL exposure, and again this expression was entirely recovered with 
TRAIL co-treatment (Figure 3.9 (ii)). RANKL/TRAIL treatment had no effect on BMP-
2/Runx2 mRNA expression in co-culture (Appendix 3.11A).  
 
3.5.2 The Effects of RANKL +/- TRAIL on the Expression of HASMC Protein Targets 
With regard to extracellular protein in the subluminal space, endothelial treatment with 
RANKL was found to induce ALP and BMP-2 secretion at 5 and 25 ng/mL respectively, while 
TRAIL co-treatment attenuated these effects (Figure 3.10A (i), (ii)). As expected, these trends 
resemble that of endothelial treatment in monoculture, but may be altered by the co-secretion 
Figure 3.8. The co-culture model. HAECs in 
semi-permeable transwell inserts, suspended 
above a confluent smooth muscle layer, were 
exposed to RANKL +/- TRAIL for 72 hours.   

























of these molecules from underlying HASMCs. RANKL was also found to induce OPG 
secretion at both 5 and 25 ng/mL (Figure 3.10A (iii)), and while TRAIL alone had no effect, 
co-exposure with TRAIL completely attenuated RANKL-induced OPG release. Due to the 
almost negligible levels of OPG secreted by HAECs when exposed to RANKL +/- TRAIL, it 
can be expected that this trend is due to smooth muscle OPG release rather than that of the 
endothelial monolayer. Furthermore, while RANKL (25 ng/mL) and TRAIL (5 ng/mL) 
induced an apparent increase and decrease in IL-6 release respectively, no change was noted 
in co-treatment compared to control, and these effects remained non-significant (Figure 3.10A 
(iv)). It is noteworthy that both BMP-2 and IL-6 release levels are present at considerably 
elevated levels compared to that measured in endothelial/smooth muscle monocultures; this  
highlights the combined secretion of these proteins from both ECs and VSMCs in co-culture. 
(i)  (ii)  
(iii)  (iv)  
Figure 3.9. mRNA analyses of HASMCs in co-culture. HAECs in transwell inserts were exposed to RANKL 
(5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours. HASMCs in the subluminal compartment were assessed for 
mRNA expression of (i) ALP, (ii) OPG, (iii) Sox9 and (iv) IL-6 by RT-qPCR; GAPDH was employed as an 
endogenous control. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise 
































Regarding intracellular protein, active ALP levels in HASMCs were dose-dependently induced 
by RANKL, while TRAIL co-treatment again abrogated this effect (Figure 3.10B (i)). 
However, the reduction in smooth muscle OPG intracellular production following RANKL 
treatment was not significantly affected by TRAIL (Figure 3.10B (ii)). Furthermore, 
intracellular BMP-2 levels in HASMCs were not affected by endothelial exposure to either 
recombinant ligand either alone or in co-treatment (Appendix 3.11B).  
Figure 3.10. Analysis of protein targets in co-cultured HASMCs. HAECs in transwell inserts were exposed to 
RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours. In the subluminal HASMC compartment, (A) (i) BMP-
2, (ii) ALP, (iii) OPG and (iv) IL-6 release levels were measured, while (B) intracellular (i) ALP and (ii) OPG 
were determined in HASMC lysate. BMP-2, OPG and IL-6 levels were analysed by ELISA, while ALP activity 
was determined by activity assay. Conditioned media and lysate analyses were normalised to 105 cells and total 
intracellular protein respectively. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless 
otherwise stated; bars indicate statistical significance between treatment groups.  
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As an additional control, endothelial conditioned media transfer experiments were employed 
as an alternative to non-contact co-culture, to confirm that endothelial paracrine signalling was 
indeed responsible for the observed HASMC responses. In this case, HAECs were exposed to 
RANKL (5-25 ng/mL) for 72 hours, conditioned media harvested and applied at a 1:1 ratio to 
reporter HASMCs for a further 72 hours prior to media/lysate harvesting. Following HASMC 
exposure, extracellular BMP-2 and ALP were dose-dependently induced by RANKL exposure, 
exhibiting the same trends as noted in both endothelial monoculture and co-culture. OPG 
release trends, however, mirrored that of HASMC monoculture, and were decreased following 
endothelial treatment with 25 ng/mL RANKL (Appendix 3.12A). Intracellular levels of BMP-
2, ALP and OPG were dose-dependently increased following HAEC exposure to RANKL, 
reflecting trends noted in smooth muscle monoculture (BMP-2, OPG) and co-cultured 
HASMCs (ALP) (Appendix 3.12B).  
 
3.5.3 The Effects of RANKL +/- TRAIL on HASMC NF-κB Activation 
Despite potent effects of RANKL and TRAIL exposure on NF-κB activation in 
endothelial/smooth muscle monocultures, no significant effects on either canonical or non-
canonical pathways were noted in co-cultured HASMCs (Appendix 3.11C). Furthermore, in 
the aforementioned conditioned media transfer control, no effects were noted in either 
canonical or non-canonical NF-κB activation when exposed to endothelial conditioned media 
(Appendix 3.12C). 
 
3.5.4 The Effects of RANKL +/- Noggin on the Expression of HASMC Targets 
To determine the extent to which endothelial-secreted BMPs are responsible for smooth muscle 
responses in co-culture, noggin BMP inhibitor was employed. As before, HAECs cultured in 
transwell inserts were exposed to RANKL (5-25 ng/mL) for 72 hours, while noggin (100 
ng/mL) was added to the subluminal compartment to neutralise BMP paracrine signals. Again, 
endothelial exposure to RANKL dose-dependently increased ALP and decreased OPG mRNA 
expression in HASMCs; co-incubation with noggin BMP inhibitor neutralised the effects of 
RANKL on ALP, but not OPG, at a transcriptional level (Appendix 3.13A).  
With regard to extracellular protein, a similar trend was observed; while RANKL dose-
dependently increased and decreased active ALP and OPG release respectively, noggin co-
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treatment in the subluminal compartment completely abrogated RANKL-induced ALP activity 
but did not affect depletion of extracellular OPG (Appendix 3.13B). Interestingly, both 
RANKL-induced ALP activity and OPG production in HASMC lysate were completely 
attenuated by co-incubation with noggin in co-culture (Appendix 3.13C). No effects were noted 
in Runx2 or Sox9 mRNA expression with noggin addition (data not shown).  
 
3.5.5 HAEC:HASMC Co-culture: Summary of Results 
The expression of several pro-calcific indices were altered in HASMCs in response to 
endothelial RANKL +/- TRAIL treatment, as summarised in Table 3.4 below.  
 
 






BMP-2 Extracellular Protein ↑ − − 
ALP mRNA  ↑ ↓ − 
 Extracellular Activity ↑δ − − 
 Intracellular Activity ↑ − − 
OPG mRNA  ↓ − − 
 Extracellular Activity ↓ − − 
 Intracellular Activity ↓ − ↓ 
IL-6 mRNA ↓δ ↑ ↓δ 
 Extracellular Activity ↑δ ↓δ − 







↑, upregulation; ↓, downregulation; −, no change. δ, not significant. 
 
Table 3.4. The effects of RANKL +/- TRAIL in HAEC:HASMC co-culture.  
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3.5.6 Discussion: Co-culture  
Co-culture models have previously been employed to investigate the paracrine contribution of 
various cell types to VSMC calcification (Deuell et al., 2012; Shin et al., 2004), overcoming 
important limitations of traditional monoculture investigations (Chiu et al., 2009; Eddahibi et 
al., 2006; Redmond et al., 1995). The importance of paracrine mediation in maintaining 
vascular function has been highlighted previously, both in (patho-)physiological processes in 
general and more specifically within the context of RANKL signalling (Ardanaz et al., 2006; 
Davenport et al., 2016; Osako et al., 2010; Rongen et al., 1994). Given the conflicting evidence 
reported across endothelial and smooth muscle cell monoculture studies, a comprehensive co-
culture model employing primary human vascular cells was clearly warranted. Again, co-
culture experiments were conducted in the absence of pro-calcifying media and anti-OPG, 
maintaining maximal physiological relevance. As circulating RANKL and TRAIL are 
primarily in contact with the endothelial layer in vivo, and calcification ultimately occurs in 
medial smooth muscle, crucial paracrine signalling elements between the two cell types are 
undoubtedly central to the manifestation and progression of VC. These paracrine signals 
(released from the apical endothelial monolayer and functioning on the underlying smooth 
muscle) were assessed, alongside the effects of these signals on smooth muscle pro-calcific 
indices. In this respect, the pro-calcific role of RANKL and the potential protective role for 
TRAIL in the vasculature were investigated (results summarised in Table 3.4). 
 
3.5.6.1 The Effects of RANKL +/- TRAIL on Endothelial Paracrine Signalling  
Although the presence of paracrine communication within the vascular wall is well established, 
few studies to date have directly implicated endothelial BMP-2 as a potent mediator of 
RANKL-induced VSMC calcification. Two key studies in EC/VSMC monoculture and co-
culture, by Osako et al. (2010) and Davenport et al. (2016) respectively, contributed greatly to 
the formation of our hypothesis. Both studies agree that endothelial release of paracrine 
proteins in response to RANKL subsequently induce a pro-calcific response in smooth muscle, 
attributable (at least in part) to BMP-2. As expected in this case, and in agreement with these 
studies, RANKL-induced endothelial BMP-2 release observed in HAEC monoculture was also 
apparent in the subluminal space in co-culture, although at a higher baseline level due to 
HASMC secretion. Furthermore, RANKL-induced ALP activity in the conditioned media, as 
a potential influencer of HASMC calcification, also displayed a similar trend in co-culture. As 
a key finding of this study, TRAIL co-incubation in co-culture was found to completely 
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attenuate RANKL-induced BMP-2/ALP release, enhancing the physiological relevance of this 
novel finding. As noted, Osako and colleagues (2010) were the first research group to study in 
detail the role of BMP-2 in the calcification process, providing evidence that RANKL induces 
endothelial BMP-2 secretion while HASMCs separately stimulated by BMP-2 acquire 
significant osteoblastic phenotypic alterations after 72 hours. In the study by Osako and 
colleagues (2010), however, a number of limitations were observed; calcifying growth media 
was employed, cells were assessed in isolation rather than in co-culture, and a small range of 
calcification indices were analysed at a transcriptional level only. Furthermore, the potential 
protective effects of TRAIL on HASMC calcification were not considered.  
In light of these limitations, Davenport and co-workers (2016) completed a more advanced 
series of experiments with a focus on BMP-2 signalling. Firstly, a conditioned media model 
was employed whereby reporter HASMCs were exposed to HAEC conditioned media 
previously treated with RANKL; elevated BMP-2 release was noted from HAECs in response 
to RANKL, while HASMCs exposed to endothelial conditioned media displayed an increase 
in pro-calcific indices. Indeed, the conditioned media controls employed in the current study 
confirmed these results. Secondly, Davenport et al. (2016) also employed an advanced perfused 
capillary co-culture system using the CellMax®Duo bioreactor to investigate endothelial 
BMP-2 secretion in response to RANKL on HASMC calcification. Again, endothelial RANKL 
exposure was associated with increased BMP-2 release, and subsequent intracellular pro-
calcific responses (ALP, Runx2, BSP upregulation) in co-cultured HASMCs. While our 
findings agree with these data regarding RANKL/BMP-2, Davenport et al. (2016) did not 
consider co-incubation with TRAIL in these models; we therefore expand on this study by 
including this co-incubation, and further extending the range of pro-calcific indices examined 
in both endothelial and smooth muscle cells. Within the current co-culture model, we now 
highlight for the first time the ability of TRAIL to completely attenuate RANKL-induced 
endothelial paracrine communication reported by Osako et al. (2010) and Davenport et al. 
(2016), shedding novel light on this complex signalling mechanism.  
 
3.5.6.2 The Effects of Endothelial Paracrine Signalling on HASMC Pro-Calcific Indices 
Firstly, despite the induction of endothelial BMP-2 when exposed to RANKL, we noted that 
smooth muscle cell BMP-2 remained unaffected by endothelial paracrine signalling at the 
transcriptional or the translational level. Also of interest, BMP blockade by the addition of 
noggin in co-culture induced BMP-2 mRNA and protein production, which may suggest that 
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HASMCs are not totally exempt from BMP-2 regulation in the vasculature. Regarding ALP, 
both mRNA expression and intracellular activity in HASMCs were induced by endothelial 
RANKL and subsequently attenuated by TRAIL co-treatment. This trend was also noted in the 
subluminal compartment, with ALP levels ascribed to both luminal HAECs and subluminal 
HASMCs. Intracellular ALP was similarly induced by HAEC conditioned media transfer in 
response to RANKL and attenuated at both a transcriptional and translational level when 
noggin was employed in co-culture. Taken together, this data strongly indicates that BMP 
signalling mediates the expression and production of ALP in medial HASMCs, with RANKL 
inducing endothelial BMP-2 paracrine signalling and ultimately smooth muscle ALP activity. 
We also illustrate for the first time that endothelial co-incubation with TRAIL completely 
attenuates RANKL-induced ALP activity in the underlying smooth muscle, most likely due to 
blockade of paracrine BMP-2. Comparatively, Osako et al. (2010) have previously noted that 
smooth muscle ALP mRNA was significantly increased following exposure to BMP-2, while 
Davenport et al. (2016) illustrated that smooth muscle exposure to endothelial conditioned 
media (+ RANKL) induced extracellular ALP activity and mRNA expression (subsequently 
blocked by noggin).  
Runx2 expression, unlike ALP, was not mediated in the smooth muscle cell layer by 
endothelial paracrine signalling nor was it affected by noggin co-incubation; this finding 
indicates that HAEC communication does not modulate this osteogenic transcription factor in 
medial smooth muscle. Contrastingly, however, Runx2 was found to be induced in HASMCs 
following exposure to HAEC-conditioned media and in RANKL-treated capillary co-culture 
(Davenport et al., 2016). This starkly conflicting data in extremely similar cell models is 
difficult to interpret. Focusing on the conditioned media model in isolation, it may be again 
possible that residual RANKL in the media is exerting direct effects on HASMC Runx2 
expression, given that RANKL directly upregulates this transcription factor in monoculture. 
Indeed, given the extensive preliminary experiments conducted, the employed co-culture 
model does not allow the transfer of RANKL into the subluminal compartment. Moreover, 
with regard to the CellMax®Duo model, a higher concentration of RANKL was employed (50 
ng/mL), potentially suggesting a dose-dependent effect for Runx2 in co-cultured HASMCs that 
we do not detect at 25 ng/mL in the current study. Phenotypic variation and donor differences 
between primary cells employed may also may be pertinent in explaining these inconsistencies.  
While RANKL-induced endothelial paracrine signalling did not affect osteogenic Runx2 
expression in HASMCs, Sox9 chondrogenic transcription factor was significantly upregulated 
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in smooth muscle following co-culture. Furthermore, this RANKL-induced induction in Sox9 
mRNA was completely attenuated by endothelial co-incubation with TRAIL, although TRAIL 
alone had no effect. Inclusion of noggin in the basal compartment, however, did not attenuate 
RANKL-induced Sox9 induction. As Sox9 was not induced following direct smooth muscle 
exposure to RANKL (unlike Runx2), it appears that this factor may be regulated solely through 
endothelial paracrine signalling. We therefore propose the following: in areas of intact 
endothelium in the vasculature, the initial differentiation of VSMCs in response to RANKL is 
predominantly chondrogenic, mediated by endothelial signalling. In areas of damaged 
endothelium (such as atherosclerotic plaque) where circulating RANKL may be in direct 
contact with HASMCs, Runx2 expression and resulting osteogenic activity may be prominent. 
In support of this theory, phenotypic alteration of smooth muscle cells in VC has been 
previously accepted to be chondrogenic rather than osteogenic, and as Runx2 and Sox9 exert 
many of the same pro-calcific functions (Luo et al., 1997; Speer et al., 2009; Tyson et al., 
2003), it may be possible that effects induced by Sox9 may be mistaken for specifically 
osteoblastic activity. Given that vascular monoculture studies involving Sox9 are extremely 
limited, and to the best of our knowledge, this is the only vascular co-culture model to date to 
investigate this protein, there is minimal data available with which to compare this result. 
Nonetheless, we present novel evidence that TRAIL has the ability to block RANKL-induced 
Sox9 expression in HASMCs in co-culture, not only supporting TRAIL’s protective function 
but implicating Sox9 for the first time in VC pathogenesis.   
 
3.5.6.3 The Effects of Endothelial Paracrine Signalling on HASMC OPG Regulation  
In the case of co-culture, the majority of OPG is produced and secreted by HASMCs 
(Davenport et al., 2016), but again notably different trends were observed when compared to 
HASMC monoculture. While OPG mRNA levels were similarly downregulated in HASMCs 
exposed to RANKL, TRAIL co-incubation completely attenuated this effect in co-culture. 
Furthermore, the opposite effects were noted in both intra- and extra-cellular OPG in response 
to endothelial RANKL exposure in co-culture; RANKL significantly induced OPG release 
while simultaneously reducing cellular concentration. TRAIL co-incubation fully attenuated 
this RANKL-induced OPG release, but interestingly, the observed depletion in intracellular 
protein remained. Given this data, we believe it is possible that OPG release and production 
are regulated by different paracrine signalling mechanisms in the smooth muscle layer. 
Interestingly, the inclusion of noggin in the subluminal compartment in co-culture does not 
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affect RANKL-induced depletion of OPG mRNA/intracellular protein, but does attenuate 
RANKL-induced OPG release. This finding implicates BMP paracrine signalling in the 
regulation of OPG secretion (but not transcription/total protein) in HASMCs, and highlights 
the mechanism by which TRAIL may block this effect. The observed effect of RANKL on 
intracellular OPG levels, however, remains to be explained, but it is possible that these levels 
are regulated by another paracrine molecule upon which TRAIL exerts no effect. What is also 
notable is that RANKL induces the release of neutralising OPG, while TRAIL inhibits this 
release, despite the “cardioprotective” nature of this protein. It appears, therefore, that 
endothelial paracrine signalling regulates a natural protective mechanism in HASMCs in 
response to RANKL (i.e., inducing OPG release), and TRAIL-mediated blockade of these 
paracrine signals eliminates this effect. This finding therefore uncovers an inherent protective 
response to counteract RANKL-mediated calcification, in the natural release of a potent decoy 
receptor for this ligand.  
Of interest, neither Osako et al. (2010) nor Davenport et al. (2016) chose to assess the effects 
of RANKL/TRAIL on OPG in their models, and indeed both included a neutralising antibody 
for this protein. While OPG can bind to and attenuate the functions of both RANKL and TRAIL 
in vivo, this neutralisation is dependent on relative circulating concentrations of all three 
proteins in the triad (Vitovski et al., 2007). We therefore believe that this co-culture study (the 
first to allow unimpeded OPG regulation) is the most physiologically representative study to 
date in which the effects of RANKL/TRAIL on the vasculature are assessed. We present novel 
evidence that smooth muscle OPG may be induced by RANKL via endothelial paracrine 
signalling, and that TRAIL co-incubation can attenuate this effect. This finding may also shed 
additional light on the regulation of circulating OPG in its role as a biomarker for vascular 
pathologies (Abedin et al., 2007; O’Sullivan et al., 2010; Schoppet et al., 2003).  
 
3.5.6.4 The Effects of Endothelial Paracrine Signalling on HASMC NF-κB Activation  
To the extent of our knowledge, while many researchers have investigated the direct activation 
of NF-κB in response to RANKL and TRAIL in smooth muscle, this is the first study to date 
to assess these effects on HASMCs in co-culture. In this respect, neither the canonical nor the 
non-canonical pathway were activated in co-cultured HASMCs or in HASMCs exposed to 
HAEC-conditioned media. This data demonstrates that while endothelial paracrine signalling 
to the underlying smooth muscle may regulate multiple pro-calcific effects, these signals do 
not function via activation of NF-κB. Furthermore, there have been no studies to date 
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implicating BMP-2 as a modulator of NF-κB in vascular cells; instead, BMPs are known to 
function through BMP receptors and activate SMAD signalling (Hruska et al., 2005). While 
SMAD/NF-κB crosstalk has been reported in osteoblastic differentiation (Huang et al., 2014; 
Mao et al., 2016), no studies to date have provided significant evidence of cross-activation in 
smooth muscle. NF-κB (particularly the non-canonical pathway) therefore appears to be 
responsible for the induction of endothelial paracrine signalling in response to RANKL, but is 
not involved in underlying smooth muscle pro-calcific responses to HAEC communication.  
 
3.5.6.5 Summary: Co-culture 
Overall, in the first physiologically relevant co-culture model to assess such a wide range of 
VC-related indices, we provide strong evidence that RANKL treatment of HAECs has putative 
pro-calcific consequences for osteoblastic activation in underlying smooth muscle, reinforcing 
the significance of BMP-2 communication made by Osako et al. (2010) and Davenport et al. 
(2016). We also present novel and translationally pertinent evidence that TRAIL can block the 
key paracrine signalling actions of RANKL, exerting a strong protective effect on the 
vasculature as a whole. We further propose that, while NF-κB plays a key role in the induction 
of endothelial pro-calcific signalling, these paracrine signals do not directly activate NF-κB in 
the underlying HASMC layer; this paracrine signalling does, however, mediate a number of 











Figure 3.11. Summary of the key responses following endothelial exposure to RANKL +/- TRAIL in co-
culture. Endothelial exposure to RANKL activates the non-canonical NF-κB pathway, and induces BMP-2 and ALP 
release. These paracrine signals then act on the underlying smooth muscle cells to induce pro-calcific genes. The co-
addition of TRAIL, however, attenuates endothelial non-canonical NF-κB activation and paracrine signalling, 






3.6 Alizarin Red S Staining for End-point Calcification   
Research presented in the previous sections has profiled the pro-calcific signalling events that 
occur in the vasculature, ultimately driving calcium deposition and vascular mineralisation. 
Therefore, Alizarin Red S staining for calcium deposition was next employed, in an attempt to 
quantify this “end-point” calcification in response to RANKL, and the potential protective 
effects of TRAIL co-treatment in this respect. Staining was assessed at 0X, 4X and 10X 
magnification to enable visualisation of extracellular matrix crystallisation.  
 
3.6.1 Alizarin Red S Staining: MC3T3-E1 Pre-osteoblasts  
To confirm successful staining, MC3T3-E1 murine pre-osteoblasts were employed as a 
positive control. Following osteoblastic differentiation, MC3T3-E1 cells were stained, 
visualised by microscopy, and quantified by absorbance (Figure 3.12A (i), B (i)) as described 
in Section 2.2.6.1. Compared to undifferentiated controls, differentiated MC3T3-E1 cells 
displayed significantly higher levels of Alizarin Red S calcium staining. This was accompanied 
by an increase in pro-calcific ALP, Runx2, BSP and OCN mRNA (Appendix 3.14A) and 
intracellular ALP activity (Figure 3.12C (i)). Extracellular activity was significantly elevated 
from day 7 of differentiation (Appendix 3.14B (i)).  
 
3.6.2 Alizarin Red S Staining: HASMCs 
HASMCs were also subject to 21 days’ differentiation prior to staining. Differentiated 
HASMCs revealed a significant 1.4-fold increase in calcium deposition (Figure 3.12A (ii), B 
(ii)). Again, this was concurrent with elevated intracellular ALP activity (Figure 3.12C (ii)) 
and extracellular activity from day 7 of differentiation (Appendix 3.14B (ii)). Differentiated 
HASMCs revealed significant transcriptional downregulation of smooth muscle phenotypic 
markers SMα-actin and SM22α, alongside an upregulation of early osteoblastic marker BSP 
(but not late-stage marker OCN) at 21 days (Figure 3.12D). HASMCs were also exposed to 
RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for the final 72 hours of differentiation, both in 
monoculture and co-cultured with HAECs. In each case, neither RANKL nor TRAIL exerted 
any effect on alizarin red S staining/quantification, and thus calcium deposition (Appendix 
3.14C). Moreover, no differential effects were noted in calcium deposition following exposure 


























Figure 3.12. Alizarin red staining of differentiated MC3T3-E1 and HASMC cells. MC3T3-E1 and 
HASMCs were exposed to osteogenic differentiation media for  days prior to Alizarin Red S staining and 
(A) analysis by light microscopy, (B) quantification of staining by absorbance, and (C) analysis of 
intracellular ALP activity via enzyme assay. (D) mRNA analysis of smooth muscle markers (i) SM22α 
and (ii) SMα-actin, and osteogenic differentiation markers (iii) BSP and (iv) OCN, were also analysed by 
RT-qPCR in HASMCs; GAPDH was employed as an endogenous control. * p < 0.05; ** p < 0.01; *** p 
< 0.001 compared to undifferentiated cells cultured in control media for 21 days.  
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3.6.3 Discussion: End-point Calcification  
In addition to the wide range of indices assessed at a gene/protein level in mono- and co-culture, 
Alizarin Red S staining for calcium deposition was also attempted in order to assess the effect 
of RANKL/TRAIL on end-point calcification in these models. For both MC3T3-E1 pre-
osteoblasts and HASMCs, osteoblastic differentiation was carried out for 21 days prior to 
staining to ensure a positive staining response; indeed, it has been previously shown in the 
literature that this differentiation step is required to promote a “calcifying” phenotype 
(Westhrin et al., 2015). Positive staining was achieved in differentiated MC3T3-E1 pre-
osteoblasts, indicating a successful staining protocol and the presence of mineral deposits, 
however staining achieved in HASMCs following 21 days’ osteoblastic differentiation was less 
robust. Furthermore, no significant differences in calcium deposition were noted in 
differentiated HASMCs exposed directly to RANKL +/- TRAIL following differentiation 
either in mono- or co-culture. As noted, a 21-day incubation period has previously been 
employed for successful staining in VSMCs, and differentiation media components employed 
have been shown to induce calcification in culture (Ghali et al., 2015; Westhrin et al., 2015).  
In light of these controls, it is likely that culture heterogeneity may be a primary contributing 
factor to the absence of mineralisation in our models. As discussed, HASMCs can vary 
considerably in their phenotypic state (Speer et al., 2009), and some cultures (donor/location 
specific) may be more prone to calcification than others. This issue has been raised previously 
by Olesen et al. (2010), who label calcium deposition as an unreliable and unreproducible 
endpoint with a high degree of variability among donors. Additionally, many Alizarin Red 
studies to date employ a subset of HASMCs labelled “calcifying” VSMCs that have either been 
clonally selected for the pro-calcific phenotype or have been directly isolated from previously 
calcified artery (Luo et al., 2009; Zhan et al., 2014). While these cultures may ensure positive 
staining, they may mask potential pro-calcific/protective effects of RANKL and TRAIL in the 
development and progression of VC, as these cells are already in a calcific state.  
Despite the absence of positive staining in the current study, the effects of the differentiation 
process highlight the transition of healthy HASMCs to pro-calcific HASMCs with an 
osteoblastic phenotype. In this respect, both early (BSP) and late (OCN) markers of this 
osteogenic process were assessed (Huang et al., 2007), alongside smooth muscle markers SMα-
actin and SM22α (Zhang et al., 2014). Following 21 days’ differentiation, we noted a 
significant decrease in both smooth muscle markers and an increase in early marker BSP but 
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not late marker OCN. MC3T3-E1 cells also displayed significant osteoblastic induction, with 
an increase in ALP, Runx2, BSP and OCN mRNA following differentiation. Both MC3T3-E1 
and HASMCs also displayed substantially elevated ALP activity, a crucial marker of 
osteoblastic function (Shioi et al., 1995), throughout the differentiation process. While both 
cell types therefore display a clear phenotypic transition towards an osteoblastic calcified cell, 
we identified an upregulation of the late calcification marker OCN (upregulated alongside 
mineralisation) only in MC3T3-E1 cells. The lack of OCN expression in HASMCs may further 
explain the less pronounced staining and end-point calcification, as these cells remain in the 
early stages of differentiation. Furthermore, in observing the Alizarin Red staining distribution 
for both cell types post-differentiation, it appears that calcium deposition is distributed evenly 
throughout the extracellular space. Perhaps with the employment of calcifying VSMCs and/or 
elevated levels of calcium and phosphate, larger mineralised nodules (such as that previously 
observed in VSMCs by Hénaut et al. (2016)) may become more apparent.  
Of additional note, primary mesenchymal stem cells (MSCs) are a common ancestor of both 
myocytes (muscle cells) and osteocytes/chondrocytes in vivo. Differentiation of MSCs are 
dependent on their location and extracellular environment, and involve distinct processes for 
each cell type (Chen et al., 2015; Galli et al., 2014; Ullah et al., 2015). It is likely that, once 
VSMCs differentiate towards a myocytic lineage, they can no longer return to a “pre-
differentiated” state to then take on a new calcifying phenotype. Following differentiation/pro-
calcific treatment (e.g. β-glycerophosphate, RANKL), these cells may instead display certain 
characteristics of “pro-calcific” cells  (da Silva Meirelles et al., 2006), including the 
upregulation of osteoblastic/chondroblastic genes/proteins identified throughout this chapter. 
To establish VC, pro-calcific paracrine signals (e.g., BMP-2) may then go on to influence the 
osteoblastic differentiation of pre-differentiated MSCs in the vasculature (Wei et al., 2006). 
Despite the absence of Alizarin Red staining, our analysis of a wide range of relevant indices 
provide a well-rounded view of the signalling processes that occur during VC. Assessment of 
these gene/protein markers are likely more reliable than end-point calcification (Olesen et al., 
2010), particularly at the exposure durations employed. While we can confirm that these 
HASMCs are responsive to an established mineralising stimulus (β-glycerophosphate), it is 
likely that calcium deposition may take much longer, and the differential effects of RANKL 
and TRAIL longer still. Undeniably, VC as a chronic condition in type-2 diabetics may take 
years to develop, but we provide novel evidence profiling the effects of RANKL/TRAIL on 
the genotypic/phenotypic alterations that contribute to its progression.  
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3.7 Summary and Conclusions 
To summarise, this chapter profiles the effects of RANKL +/- TRAIL on the widest range of 
pro-calcific indices to date in primary human vascular cells. Not only do we clarify the role of 
these proteins (both alone and in combination) on the endothelial and smooth muscle layer in 
isolation, but we integrate the effects of endothelial paracrine signalling in a co-culture model 
that more closely resembles the structure of the vasculature. Furthermore, we attempt to assess 
the effects of RANKL and TRAIL on end-point calcium deposition in both cell models. Within 
these experiments, we eliminate a number of common confounders and limitations of the 
literature to date, adding novel credibility and physiological pertinence to our findings.  
We have confirmed in this chapter that RANKL exerts its previously defined pro-calcific 
function in endothelial cells, through induction of BMP-2/ALP paracrine signalling to the 
underlying smooth muscle (Davenport et al., 2016; Osako et al., 2010). We further implicate 
the non-canonical NF-κB signalling pathway as the mechanism by which RANKL induces 
these pro-calcific paracrine signals in the endothelium. Furthermore, and most prominently, we 
demonstrate for the first time that TRAIL can completely attenuate RANKL-induced endothelial 
paracrine signalling, most likely via interference with the non-canonical NF-κB pathway. The 
direct effects of RANKL and TRAIL on HASMCs are vastly different however, with RANKL 
exerting several direct pro-calcific effects, and TRAIL exerting minimal protection; HASMCs 
are only in direct contact with circulating proteins in areas of endothelial damage, however, 
limiting the relevance of this finding to pathologies such as atherosclerosis.  
Of relevance, the vast majority of VC research to date does not account for real-time 
communication between the endothelium and smooth muscle. We therefore employ the first 
in-depth physiologically relevant vascular model in which to clarify the function of RANKL 
and TRAIL in calcification. Within this model, we note for the first time that RANKL-induced 
endothelial paracrine signalling to the underlying smooth muscle layer induces strong pro-
calcific effects in the underlying HASMCs, while TRAIL co-incubation completely attenuates 
the majority of these effects.  
While end-point calcium staining was also attempted, this data was inconclusive, likely due to 
the “healthy” nature of our primary HASMCs. As the nature of VC is chronic, however, the 
pro-calcific effects of RANKL and TRAIL observed may ultimately influence long-term 
development and progression of calcium deposition. Overall, we provide novel evidence of 
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RANKL-induced pro-calcific signalling and TRAIL-mediated protection in VC, highlighting 
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4.1 Introduction  
4.1.1 Background and Hypothesis Development 
Accelerated calcification often accompanying chronic systemic diseases has long been 
correlated with increased mortality rates, yet the molecular mechanisms underlying this process 
(that may ultimately lead to timely interventions) have yet to be defined. In Chapter 3, we 
profiled the pro-calcific effects of RANKL and the hypothesised protective role for TRAIL in 
the vasculature, highlighting the ability of TRAIL to counteract RANKL-induced calcification. 
Medial VC, however, in its pathogenesis in type-2 diabetes in particular, occurs alongside 
elevated blood glucose (hyperglycemia) and often in conjunction with atherosclerotic plaque 
formation (McCullough et al., 2008). As such, while the effects of RANKL and TRAIL have 
been profiled in a “healthy” (i.e. non-pathological) environment in Chapter 3, their roles under 
hyperglycemic (common in diabetes) and pro-inflammatory (present in atherosclerotic plaque) 
conditions may vary.  
Both intimal and medial VC are known to be accelerated among the T2DM population (Rubin 
and Silverberg, 2004); despite this, the vast majority of in vitro research to date assesses the 
effects of RANKL and TRAIL on the VC process in the absence of relevant pathological 
stimuli. In the context of bone turnover, glucose has been shown to induce RANKL mRNA 
expression alongside mineralisation in osteoblastic cells (García-Hernández et al., 2012). In a 
vascular setting, elevated RANKL has been correlated with carotid calcification in 
atherosclerotic lesions (Higgins et al., 2015) and RANKL inactivation reduces calcification 
and lesion size in OPG-/- ApoE-/- mice (Callegari et al., 2014). We therefore hypothesise that 
elevated levels of RANKL may accelerate VC under established pathological conditions.  
With regard to TRAIL, recombinant delivery to ApoE-/- diabetic mice has been shown to 
significantly reduce atherosclerosis progression (Secchiero et al., 2006) whilst TRAIL delivery 
also protects against diabetic vascular injury in rats (Liu et al., 2014). Also of relevance, TRAIL 
deficiency promotes VC and diabetes development in vivo (di Bartolo et al., 2011; di Bartolo 
et al., 2013). It is possible therefore that TRAIL-mediated protection from RANKL-induced 
pro-calcific signalling may also exist for other pro-calcific stimuli that accelerate VC during 
T2DM and CVD. Thus, we also hypothesise that TRAIL may abrogate pro-calcific signalling 
induced by inflammation and hyperglycemia. 
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4.1.2 Study Aims  
As discussed, the role for TRAIL in VC remains to be clarified, and while RANKL is a clear 
promoter of VC, its effects in the presence of established pathological stimuli observed in 
T2DM (hyperglycemia, inflammation) have not yet been considered in vitro. To date, the 
majority of VC studies employing RANKL and TRAIL have been carried out in “healthy” 
models, employing cell types of minimal physiological relevance, and analysing a limited 
range of pro-calcific markers (Corallini et al., 2011; Osako et al., 2010; Secchiero et al., 2003). 
We therefore employ, as in Chapter 3, human primary aortic vascular cells in both mono- and 
co-culture models in order to thoroughly investigate the proposed roles for RANKL and TRAIL 
in VC under pathological conditions. This study advances on findings observed in Chapter 3, 
adding relevance to pathophysiological environments often present in T2DM.  
A number of specific study aims were defined to address the aforementioned hypotheses: 
1. To delineate the effects of hyperglycemia and inflammation on pro-calcific indices in 
the endothelial monolayer, the established location of intimal VC in vivo, and to 
investigate if RANKL and TRAIL can respectively accelerate or attenuate the 
pathological effects of these stimuli. 
2. To investigate the effects of hyperglycemia and inflammation on pro-calcific indices in 
vascular smooth muscle, the established location of medial VC in vivo, and to 
investigate the proposed effects of RANKL and TRAIL on these stimuli.  
3. To investigate the effects of hyperglycemia and inflammation on endothelial:smooth 
muscle paracrine signalling in our physiological co-culture model, and to profile the 
effects of RANKL and TRAIL under these conditions.   
 
4.1.3. Experimental Design  
To investigate study aims 1 and 2, HAECs and HASMCs were cultured in standard 6-well 
culture dishes, and exposed to 100 ng/mL TNF (an established pro-inflammatory stimulus) 
or 15-30 mM glucose (to simulate hyperglycemia). Cells were then exposed to these 
pathological stimuli in the presence of RANKL (25 ng/mL) or TRAIL (5 ng/mL). To 
investigate study aim 3, a non-contact co-culture model was again employed to approximate 
the structure of the vasculature. To reiterate, HASMCs were grown in standard 6-well culture 
dishes, while HAECs were seeded at confluency into semi-permeable transwell inserts. HAECs 
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in the luminal compartment were then exposed to TNF or glucose, in the presence of RANKL 
or TRAIL, and the underlying HASMCs in the subluminal compartment harvested for analysis 
(Figure 4.1). As previously described, mRNA, protein lysate and conditioned media were 
harvested for RT-qPCR, ELISA, enzyme assay and Western blotting (n = 3 independent 
experiments). A comprehensive range of calcification indices, as previously listed in Section 
3.1.3, were assessed (BMP-2, ALP, OPG, IL-6, Runx2, Sox9 and NF-B p52/p65).  
To further clarify, TNF, a well-established inflammatory cytokine, will be employed to 
represent the pro-inflammatory environment of an atherosclerotic plaque, alongside which 
medial VC often develops (McCullough et al., 2008). With regard to the concentration chosen, 
TNF at 100 ng/mL has previously been employed in in vitro vascular models of inflammation 
(Rastogi et al., 2012; Rochfort and Cummins, 2015) and has recently been successfully used 
within our research group (Forde et al., unpublished observations). Hyperglycemia, an intrinsic 
aspect of type-2 diabetes, will be utilised at two concentrations: 15 mM, representing 
circulatory glucose during moderate “pre-diabetes”, and 30 mM, levels common in severe 
diabetes. Both concentrations have been previously employed by our group in vascular cell 
models (Davenport et al., 2018). The optimal concentrations of both RANKL and TRAIL as 
determined in Section 3.2.1 were preserved, alongside the 72-hour exposure time to reflect the 





Figure 4.1. Representation of the transwell co-culture model under inflammatory and hyperglycemic 
conditions. HASMCs were grown to confluency in standard 6-well culture dishes. HAECs were grown to 
confluency in semi-permeable transwell inserts and suspended above the confluent smooth muscle layer. HAECs 
in the luminal compartment were exposed to 100 ng/mL TNF (left) to simulate pro-inflammatory conditions, 
whereby endothelial damage/leakage may enable TNF to act directly on underlying HASMCs. HAECs were 
exposed to 15-30 mM glucose (right) to simulate hyperglycemia, whereby active glucose transport across the 
endothelial monolayer may act directly on underlying HASMCs. Cells were incubated under these conditions for 
72 hours, in the presence and absence of RANKL or TRAIL, prior to analysis of pro-calcific indices. Image adapted 
from Harper et al., 2017.  
 141 
4.2 Preliminary Investigations  
As in Chapter 3, initial preliminary investigations were conducted to ensure correct 
interpretation of results; as such, the expression of RANKL and TRAIL in response to the 
employed pathological stimuli (inflammation, hyperglycemia) were assessed, alongside any 
potential adverse cellular effects of exposure to these stimuli. Essential methodological 
validations were also considered.  
 
4.2.1 Expression of RANKL and TRAIL  
RANKL and TRAIL have been shown to be expressed at a protein level in HAECs and 
HASMCs (Section 3.2.2). Thus, the potential effects of 100 ng/mL TNF and 30 mM glucose 
on RANKL and TRAIL expression was first examined to ensure accuracy of treatment 
conditions during co-exposure with recombinant proteins.  
 
4.2.1.1 HAECs  
In HAECs, RANKL and TRAIL mRNA were not expressed at quantifiable levels following 
exposure to either TNF or glucose (data not shown). Regarding release, RANKL levels in 
endothelial conditioned media were not altered following treatment with either pathological 
stimulus (data not shown), however, TRAIL release was induced under both inflammatory and 
hyperglycemic conditions (Appendix 4.1B). Furthermore, intracellular TRAIL protein 
production was significantly decreased by ~30% following TNF exposure, while RANKL 
protein approximately doubled in both cases (Appendix 4.1D).  
 
4.2.1.2 HASMCs 
While no effect was noted in TRAIL mRNA expression, RANKL transcripts were influenced 
by treatment, with an approximate 2.5-fold increase and 70% decrease noted with TNF and 
hyperglycemia respectively (Appendix 4.1A). A slight but insignificant increase in TRAIL 
release was observed in response to TNF, alongside a significant increase in response to 
glucose (Appendix 4.1C). No changes were noted with regard to RANKL release (data not 
shown), but intracellular protein was induced by approximately one third following exposure 
to both pathological stimuli; TRAIL protein production was also slightly elevated following 
TNF exposure (Appendix 4.1E).  
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4.2.2 Effects of RANKL and TRAIL on Cellular Integrity  
Due to the employment of well-established injurious stimuli, the adverse effects of both TNF 
and high glucose on cellular integrity were monitored. In this regard, the effects of 
inflammation and hyperglycemia on morphology, viability/apoptosis, endothelial barrier 
function and the expression of smooth muscle phenotypic markers were assessed.  
 
4.2.2.1 Cell Morphology  
HAECs and HASMCs were observed via light 
microscopy prior to and following exposure to 
TNF and glucose for 72 hours. While no 
morphological differences were noted in 
response to glucose in either endothelial or 
smooth muscle cell cultures, TNF exposure 
significantly altered the typical “cobblestone” 
morphology of HAECs (Figure 4.2). After 72 
hours, HAECs exposed to this cytokine 
appeared contracted, elongated, and the 
integrity of the endothelial barrier was compromised in several areas (Figure 4.2B, left hand 
side). No variations were noted in HASMCs following exposure to TNF, as they retained 
their typical spindle shape.  
 
4.2.2.2 Viability and Apoptosis  
Routine viability measurements were conducted as required. Cell viability measurements for 
HAECs and HASMCs (in both mono- and co-culture) were maintained above 89% for all 
treatments employed. Due to the potent injurious nature of TNF and hyperglycemia, apoptosis 
was also monitored via flow cytometry for both stimuli. In both HAECs and HASMCs, TNF 
exposure induced apoptosis by approximately 10.3% and 4.3% respectively, whilst upper 
concentrations of glucose elicited a respective 1.7% and 4.2% increase in apoptotic cells 
(Figure 4.3). Average values for viability and apoptosis measurements are presented in Table 
4.1.  
 
Figure 4.2. HAECs under control conditions and 
following exposure to TNF. (A) Cultured HAECs 
under control conditions displaying typical cobblestone 
morphology. (B) Cultured HAECs following exposure 
to 100 ng/mL TNF for 72 hours appear contracted and 
elongated. Images were taken using a Nikon Eclipse 




































  Viable (%) Non-viable (%) Apoptotic (%) 
HAECs Untreated 96.58 3.41 7.23 
 100 ng/mL TNF 94.05 5.94** 17.56*** 
 30 mM glucose 96.52 3.47 8.96* 
 DMSO  48.42 49.15 17.8 
HASMCs Untreated 95.60 3.32 17.01 
 100 ng/mL TNF 89.63** 9.54*** 21.31 
 30 mM glucose 97.05 2.72 21.17 
 DMSO 88.20 11.43 44.63 
Figure 4.3. The effect of TNF⍺ and glucose exposure on HAEC and HASMC apoptosis. (A) HAECs 
and (B) HASMCs were exposed to experimental concentrations of TNF⍺ (100 ng/mL) and glucose (30 
mM) for 72 hours, or 20% DMSO for 30 minutes, prior to analysis by flow cytometry. Quadrants 
determined by unstained control. Bar charts represent percentage apoptosis when (C) HAECs and (D) 
HASMCs were exposed to TNF⍺ and glucose for 72 hours. Control and DMSO data were previously 
presented in Figure 3.4, included here for comparison purposes.** p < 0.01 compared to untreated control.  





























C: HAEC  D: HASMC 
(i) Control  (ii) TNFα 
(iii) Glucose (iv) DMSO 
(i) Control  (ii) TNFα 
(iii) Glucose 
Table 4.1.  Average percentages of viable, non-viable, and apoptotic cells post-treatment.  
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4.2.2.3 Endothelial Barrier Function  
Again, as HAECs will be employed in co-culture, endothelial permeability was assessed in 
response to inflammatory and hyperglycemic conditions. HAECs, following 72-hour exposure 
to TNF or glucose in transwell inserts, were tested for barrier function using the FITC-
Dextran/TEE method described in Section 2.2.5.2. Untreated cells permitted an average TEE 
of 3.0% FITC-dextran to the subluminal compartment after 3 hours, while TNF and glucose 
treatment resulted in non-significant increases of 4.9% and 3.7% transfer respectively 
(Appendix 4.2A).  
 
4.2.2.4 Phenotypic Analysis of Smooth Muscle Cells 
HASMCs were characterised for both smooth muscle and osteoblastic phenotypic markers at 
an mRNA level following exposure to TNFα and glucose. SMα-actin and SM22α, core smooth 
muscle markers, remained constitutively expressed following treatment (Appendix 4.2B (i), 
(ii)). BSP mRNA expression, an early marker of osteoblastic differentiation, was not affected 
by exposure to inflammation or hyperglycemia, while OCN, a marker of late differentiation, 
was significantly reduced in both cases (Appendix 4.2B (iii), (iv)). Transcript levels for all four 
markers remained unaffected by treatment in co-culture (data not shown).  
 
4.2.3 Methodological Validation  
Prior to exposure, it was observed that neither HAECs nor HASMCs released detectable levels 
of TNFα under any of the conditions tested. Regarding hyperglycemic treatments, the media 
formulation employed did not contain glucose prior to manual addition at the required 
concentrations. With respect to RT-qPCR analyses, it was confirmed that the addition of TNFα 
or glucose for 72 hours did not affect the mRNA expression of endogenous control genes 
(GAPDH, 18S) (data not shown). Furthermore, as TNFα exposure is widely known to affect 
endothelial barrier integrity (Marcos-Romiro et al., 2014), and glucose can be subject to active 
transport across the endothelial monolayer (Mann et al., 2003), it was expected that both 
conditions would allow transfer to the subluminal compartment in co-culture. While percentage 
TEE was not quantified, this transfer acts as an integral part of inflammatory/hyperglycemic 
models as both pathophysiological conditions are associated with endothelial dysfunction 
(Hadi and Suwaidi, 2007; Marcos-Romiro et al., 2014).  
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4.2.5 Discussion: Preliminary Investigations  
4.2.5.1 Expression of RANKL and TRAIL under Inflammatory/Hyperglycemic Conditions 
As endothelial RANKL and TRAIL mRNA proved undetectable in Chapter 3, it is therefore 
unsurprising that neither transcript were quantifiable under inflammatory or hyperglycemic 
conditions in HAECs. As discussed, there are conflicting reports in the literature regarding the 
expression of these ligands in the endothelium (Collin-Osdoby et al., 2001; Osako et al., 2010; 
Pritzker et al., 2004; Secchiero et al., 2006; Zannettino et al., 2005). Conclusions regarding 
RANKL mRNA responses to TNF in ECs appear equally divisive (Collin-Osdoby et al., 
2001; Davenport et al., unpublished observations), whilst for TRAIL are completely lacking. 
More relevantly, at a transcriptional level, the observed induction of RANKL protein 
production under inflammatory conditions has been noted previously (Collin-Osdoby et al., 
2001). While the effects of hyperglycemia on RANKL expression have not yet been defined in 
HAECs, glucose uptake has been shown to be required for RANKL protein production in 
osteocytic cells (Takeno et al., 2018) which may partly explain the increase in RANKL 
observed in this study. Despite this increase, extracellular RANKL levels remained unchanged, 
and so are inconsequential for recombinant ligand treatment. Similarly, the release of TRAIL 
induced by both pathological stimuli is a significant finding, and may potentially reveal a novel 
aspect of endothelial vasculo-protection; however, in this case, extracellular TRAIL levels 
were deemed too low to affect ligand exposure in the ng/mL range. Overall, the effects of 
RANKL/TRAIL in response to these stimuli (TNF, glucose) have not yet been extensively 
investigated in HAECs, but due to the conflicting literature listed above, we further reiterate 
that specific responses should be characterised for each application (Spierings et al., 2004).  
The expression of both RANKL and TRAIL are more widely recognised in smooth muscle 
(Chang et al., 2015; Harith et al., 2016; Li et al., 2016; Tseng et al., 2010). Previous 
unpublished studies in our laboratory have highlighted an increase in both RANKL and TRAIL 
mRNA in response to TNF treatment in HASMCs, and while our findings agree with that of 
RANKL, the utilisation of ten-fold less recombinant TRAIL in the current study may explain 
the discrepancy regarding this ligand (Davenport et al., unpublished observations). 
Interestingly, Davenport and colleagues noted that glucose exposure had no effect on 
RANKL/TRAIL mRNA, but hyperglycemia has previously been shown to reduce RANKL 
transcript expression in rat aortic VSMCs (Chang et al., 2015) in agreement with our findings. 
Chang and colleagues (2015) did, however, report a decrease in RANKL protein production 
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following glucose exposure, in contrast to the increase detected in this case. Also of note, Kang 
et al. (2015) reported no effect in RANKL/TRAIL mRNA or (intracellular) protein expression 
following long-term hyperglycemia. It is obvious therefore that, while the expression of both 
ligands have been confirmed in smooth muscle, their expression under the current pathological 
conditions have not, with a significant level of variation still existing in the literature. It again 
appears likely that the expression of RANKL and TRAIL may be species, tissue and 
environment specific and (as for endothelial cells) should be specified prior to use.  
 
4.2.5.2 The Effects of TNF and Glucose on Cellular Integrity  
As mentioned, TNF, in its well-established role as a pro-inflammatory cytokine, was 
employed at a pre-determined concentration of 100 ng/mL often utilised in in vitro models of 
endothelial inflammation and atherosclerosis (Rastogi et al., 2012; Rochfort and Cummins, 
2015). Similarly, glucose was employed at both 15 and 30 mM concentrations to represent 
circulating concentrations during moderate “pre-diabetes” and severe diabetes respectively, 
levels that are again common in hyperglycemic studies (Davenport et al., 2018; Kang et al., 
2015; Liu et al., 2010). Therefore, as dosage optimisations were not required, the adverse 
effects of these conditions on primary HAECs and HASMCs after 72 hours were defined, 
similar to that of RANKL and TRAIL in Section 3.2.6.3.  
As an important point central to the design of this study, it was expected that both inflammatory 
and hyperglycemic conditions would induce potent injurious effects on HAECs and HASMCs 
due to their notorious roles in multiple T2DM/CVD pathologies (Duckworth, 2001; Liu et al., 
2010; Popa et al., 2007; Tintut et al., 2000; Zhang et al., 2009). Unlike Chapter 3, where a key 
design element was the retention of endothelial barrier integrity (and thus distinctly separate 
luminal and subluminal components), in this case the induced pathophysiological 
environments are likely to disrupt this barrier and encourage endothelial leakage (Hadi and 
Suwaidi, 2007; Marcos-Romiro et al., 2014). Not only is this damage expected, but is pertinent 
to the pathological relevance of these models. Furthermore, active glucose transport through 
the endothelial layer predominantly via glucose transporter (GLUT)-1 is prevalent in aortic 
ECs (Mann et al., 2003; Viator and Fouty, 2009) and another mechanism by which glucose 
may transfer to the subluminal space in co-culture.  
Firstly, with regard to HAECs under inflammatory conditions, morphological differences were 
observed following 72 hours’ TNF exposure, with clear barrier degradation and breakdown 
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evident. As noted by Stroka and colleagues (2012), this morphological response is usual 
following long-term exposure to TNF. Following these observations, it is unsurprising that 
an approximate 10% induction in apoptosis was measured in TNF-treated samples compared 
to control; in fact, TNF is a known inducer of apoptosis in vascular ECs (Xia et al., 2006) 
and endothelial dysfunction responses to this pro-inflammatory cytokine are well characterised 
(Zhang et al., 2009). Endothelial barrier integrity was also significantly compromised, albeit 
less than 2%, but again, TNF has long been known to enhance vascular permeability (Royall 
et al., 1989). Overall, the potent injurious effects of HAEC exposure to TNF are consistent 
with the literature, and it is clear that this model suitably represents areas of endothelial injury 
that occur during (predominantly intimal) VC. Despite the employed supra-physiological 
concentration of 100 ng/mL TNF, the levels of this cytokine have been shown to be 
significantly elevated in atherosclerotic plaque alongside which medial VC often co-develops 
(Barath et al., 1990; McCullough et al., 2008; Tintut et al., 2000). On a separate note, HAECs 
fared well under hyperglycemic conditions, with no morphological changes and minimal 
apoptotic/permeability effects noted. This observation may support the more subtle effects of 
circulating glucose on the vasculature during chronic type-2 diabetes, whereby the endothelium 
remains functional despite a slight deterioration in endothelial health. Glucose therefore may 
not affect the integrity of the endothelial barrier in co-culture to any great extent, but due to the 
aforementioned nature of glucose transport through the aortic endothelium, the underlying 
HASMCs are likely to experience some level of hyperglycemia as they would under diabetic 
conditions in vivo.  
Interestingly, no morphological effects were noted in HASMCs in response to either stimulus, 
nor any significant induction in apoptotic cells. Core smooth muscle markers SM-actin and 
SM22 remained constitutively expressed as part of a typical smooth muscle phenotype, 
despite evidence that inflammation and hyperglycemia can induce pro-calcific differentiation 
in VSMCs (Lee et al., 2010; Liu et al., 2010; Tintut et al., 2000). Also of note, BSP (an early 
marker of osteoblastic differentiation) remained unaffected, while OCN (a late marker), was 
significantly downregulated under both inflammatory and hyperglycemic conditions. This 
novel finding has, to our knowledge, not been disclosed to date, but it is unclear as of yet what 
the significance of this is. This phenomenon was absent from subluminal HASMCs in co-
culture, however, more physiologically representative of the vasculature in vivo. To conclude, 
therefore, HASMCs do not display any significant changes when conditioned with TNF or 
glucose in culture, substantiating any potential responses in the upcoming study.  
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4.3 HAEC Monoculture  
HAECs were first employed in standard monoculture to assess the proposed effects of RANKL 
and TRAIL on the endothelium under pathological (inflammatory, hyperglycemic) conditions 
associated with VC in T2DM. The comprehensive range of gene/protein targets employed in 
Chapter 3 were investigated. Given the large volume of data accrued, only the key findings will 
be highlighted in text, while the readers’ attention will be drawn to the relevant figure panels.  
 
4.3.1 The Effects of TNFα and Glucose on Pro-Calcific Targets in HAECs  
Due to the complexity of the current model, the effects of TNFα (an inflammatory stimulus) 
and glucose (a hyperglycemic stimulus) were first profiled in the absence of RANKL and 
TRAIL recombinant ligands. As cultured cells are exposed to enhanced osmotic pressure when 
exposed to glucose, an osmotic control was also included. Mannitol, an organic sugar alcohol, 
was employed at 30 mM to mimic the osmotic pressure of glucose at upper experimental 
concentrations, as previously utilised by Liu et al. (2010). Mannitol was found to have no effect 
on any of the measured pro-calcific indices in HAECs (Appendix 4.3).  
Following endothelial exposure to 100 ng/mL TNFα, all measured pro-calcific indices at an 
mRNA level were found to be upregulated (Figure 4.4A). Similarly, BMP-2, OPG and ALP 
activity levels were increased both in HAEC-conditioned media (Figure 4.4B) and in HAEC 
lysate (Figure 4.4C), alongside both canonical and non-canonical NF-B activation (Figure 
4.4D). Following hyperglycemic treatment, BMP-2 and ALP mRNA expression levels were 
elevated, while Runx2 was decreased (Figure 4.5A). All measured indices in the conditioned 
media were elevated (Figure 4.5B), while only OPG levels were increased in endothelial lysate 
(Figure 4.5C). Canonical (but not non-canonical) NF-B activation was also significantly 
reduced compared to control (Figure 4.5D). 
 
4.3.2 The Effects of RANKL and TRAIL under Inflammatory Conditions in HAECs 
Next, the effects of RANKL and TRAIL on pro-calcific indices were assessed under pro-
inflammatory conditions in HAECs. Both ALP and Runx2 mRNA levels were significantly 
downregulated by the separate addition of both ligands, with TRAIL co-incubation reducing 


























Figure 4.4. The effects of TNF on pro-calcific indices in HAEC monoculture. HAECs were exposed to TNF⍺ (100 
ng/mL) for 72 hours. (A) (i) BMP-2, (ii) ALP, (iii) Runx2 and (iv) IL-6 mRNA were assessed by RT-qPCR, employing 
GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP, (iii) OPG and (iv) IL-6 release, and (C) intracellular (i) BMP-
2, (ii) ALP and (iii) OPG protein levels were quantified by ELISA and enzyme assay where appropriate. (D) (i) Canonical 
and (ii) non-canonical NF-κB activation were determined by Western blotting, quantified by scanning densitometry and 
normalised to GAPDH. Blots are representative. Absolute values for media and protein lysate analyses are normalised to 
105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control. 
(i)  (ii)  (iii)  (iv)  
(i)  (ii)  (iii)  (iv)  
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Figure 4.5. The effects of glucose on pro-calcific indices in HAEC monoculture. HAECs were exposed to glucose (15-
30 mM) for 72 hours. (A) (i) BMP-2, (ii) ALP, (iii) Runx2 and (iv) IL-6 mRNA were assessed by RT-qPCR, employing 
GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP, (iii) OPG and (iv) IL-6 release, and (C) intracellular (i) BMP-
2, (ii) ALP and (iii) OPG protein levels were quantified by ELISA and enzyme assay where appropriate. (D) (i) Canonical 
and (ii) non-canonical NF-κB activation were determined by Western blotting, quantified by scanning densitometry and 
normalised to GAPDH. Blots are representative (control bands previously presented in Figure 4.4). Absolute values for 
media and protein lysate analyses are normalised to 105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p < 





































Furthermore, RANKL in the presence of TNFα significantly promoted the release of BMP-2 
and non-significantly accelerated ALP activity, while TRAIL did not exert any significant 
effects on the release profile of endothelial cells under inflammatory conditions (Figure 4.6C). 
Interestingly, endothelial exposure to TNFα + RANKL also significantly promoted non-
canonical NF-B activation when compared to exposure with TNFα alone (Figure 4.6B), and 
further induced intracellular BMP-2 production (Figure 4.6D). Moreover, TRAIL treatment 
under pro-inflammatory conditions significantly reduced non-canonical NF-B signalling to 
below that of TNFα exposure alone (Figure 4.6B). Supporting material for the additional 
measured indices is presented in Appendix 4.4 and 4.6. 
Figure 4.6. The effects of TNF +/- RANKL/TRAIL on pro-calcific indices in HAEC monoculture. 
HAECs were exposed to TNF⍺ (100 ng/mL) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) 
mRNA expression of (i) ALP and (ii) Runx2 were analysed by RT-qPCR employing GAPDH as an endogenous 
control. (B) Non-canonical NF-κB activation was determined by Western blotting, quantified by scanning 
densitometry and normalised to GAPDH. Representative blots are presented in Appendix 4.6.  (C) (i) BMP-2 
and (ii) ALP in the conditioned media and (D) intracellular BMP-2 were analysed by ELISA and activity assay 
where appropriate. Absolute values for media and lysate are normalised to 105 cells and total protein 
respectively. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars 
indicate statistical significance between treatment groups.  
A 
(i)  (ii)  B 
C 
(i)  (ii)  (ii)  D 
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4.3.3 The Effects of RANKL and TRAIL under Hyperglycemic Conditions in HAECs 
With regard to mRNA, both RANKL and TRAIL exposure under hyperglycemic conditions 
reduced ALP transcript expression when compared to that of glucose treatment alone (but 
TRAIL to a greater extent). Moreover, incubation with RANKL significantly induced Runx2 
compared to control, while TRAIL co-incubation recovered expression to basal levels (Figure 
4.7A). Interestingly, RANKL-induced BMP-2 release was maintained under hyperglycemic 
conditions, while TRAIL exposure did not affect glucose-induced BMP-2 secretion. RANKL 
also non-significantly promoted glucose-induced ALP activity in the conditioned media, while 
TRAIL attenuated this activity following severe hyperglycemia (Figure 4.7B). Supplementary 


















Figure 4.7. The effects of glucose +/- RANKL/TRAIL on pro-calcific indices in HAEC monoculture. 
HAECs were exposed to glucose (15-30 mM) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) 
mRNA expression of (i) ALP and (ii) Runx2 were analysed by RT-qPCR employing GAPDH as an endogenous 
control. (B) (i) BMP-2 release and (ii) extracellular activity were quantified by ELISA and activity assay where 
appropriate. Absolute values are normalised to 105 cells. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to 
untreated control unless otherwise stated; bars indicate statistical significance between treatment groups.  
A 
(i)  (ii)  
B 
(i)  (ii)  
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4.3.4 HAEC Monoculture: Summary of Results  
The effects of endothelial exposure to RANKL and TRAIL under inflammatory and 
hyperglycemic conditions are summarised below in Table 4.2. 
 
 
Inflammation   RANKL TRAIL 
BMP-2 Extracellular Protein ↑ ↑↑ ↑ 
 Intracellular Protein ↑ ↑↑ ↑ 
ALP mRNA ↑↑ ↑ ↓ 
 Extracellular Activity ↑ ↑↑δ ↑ 
OPG Intracellular Protein ↑ ↑↑ ↑ 
Runx2 mRNA ↑↑ ↑ − 
NF-κB (p52/p100) Activation ↑↑ ↑↑↑ ↑ 
 
Hyperglycemia     
BMP-2 mRNA ↑ − − 
 Extracellular Protein ↑ ↑↑ ↑ 
 Intracellular Protein − ↑ − 
ALP mRNA ↑ ↑ − 
 Extracellular Activity ↑↑ ↑↑ ↑ 
OPG Extracellular Protein ↓ ↓ − 
 Intracellular Protein ↑ ↑↑ − 
IL-6 mRNA  − − ↓ 
Runx2 mRNA ↓ ↑ − 







p-p65, phospho-p65; t-p65, total-p65. ↑, upregulation; ↑↑/↑↑↑, further upregulation relative to corresponding 
treatment conditions; ↓, downregulation; −, no change; δ, not significant.  
 
 




4.3.5 Discussion: HAEC Monoculture  
The effects of RANKL and TRAIL on the endothelial monolayer under inflammatory and 
hyperglycemic conditions were first assessed. Although the pathological effects of TNF and 
glucose on the vasculature (particularly VSMCs) have been described previously, there is 
limited data regarding the specific role for these stimuli in the endothelium of large arteries 
during VC. Furthermore, the effects of RANKL and TRAIL have not yet been clarified in the 
presence of pro-inflammatory or hyperglycemic conditions common in type-2 diabetes and 
vascular injury. This in vitro study is the first to our knowledge to investigate such a 
comprehensive range of pro-calcific indices in human primary-derived endothelial cells under 
pathological conditions, and is certainly the first to incorporate RANKL and TRAIL in such 
models. In addition, profiling HAEC responses to these stimuli will aid in discerning the extent 
of endothelial pro-calcific paracrine signalling ultimately relevant in co-culture. This 
discussion will focus on some of the key pertinent findings regarding the endothelial response 
to pathological conditions (summarised in Table 4.2), beginning with the effects of TNF and 
high glucose alone before focusing on the effects of RANKL and TRAIL on these stimuli.  
 
4.3.5.1 The Effects of TNF on VC Indices in HAECs  
The process of inflammation is closely related to that of VC, as immune cells at the site of 
atherosclerotic plaque release inflammatory cytokines (including TNF) that contribute to pro-
calcific events. In this respect, it is known that circulating TNF levels are elevated during 
T2DM/CVD (Olson et al., 2012; Levine et al., 1990; Mirza et al., 2012), and TNF has been 
shown to be highly expressed in intimal atherosclerotic plaque (Barath et al., 1990). 
Furthermore, TNF has been shown to induce endothelial injury/dysfunction (Zhang et al., 
2009), and as such, has been widely used as a model of vascular injury in many studies drawn 
on in this chapter. While TNF is predominantly employed as a pro-inflammatory stimulus, 
the pro-calcific effects of this cytokine are also well documented (Illiandri et al., 2016), but the 
vast majority of relevant VC research focuses on intimal rather than medial calcification. 
However, it should be taken into account that medial VC often coincides with atherosclerosis 
in vivo (McCullough et al., 2008), leaving the role for endothelial paracrine signalling in the 
presence of these inflammatory conditions unclear. 
Following analysis of a wide range of pro-calcific indices that regulate medial VC, TNF was 
found to induce all measured targets in HAECs. Of particular interest, BMP-2 and active ALP 
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release were significantly increased, paracrine signalling elements that promote calcification 
in the underlying VSMC layer (Davenport et al., 2016; Osako et al., 2010). In support of this 
finding, albeit in less relevant models, TNF has been shown to induce BMP-2 release in 
HUVECs (Illiandri et al., 2016), while ALP activity is increased by IL-6 in pulmonary aortic 
ECs (Nakazato et al., 1997), in turn itself upregulated by TNF. Contrastingly, however, 
Illiandri and colleagues (2016) have recently reported that TNF does not induce BMP-2 in 
ECs above a concentration of 5 ng/mL, although these authors note excessive levels of 
apoptosis in response to TNF which may explain this discrepancy. Of additional note, whilst 
RANKL exposure elicited similar paracrine responses (Section 3.3.5.1), these effects did not 
coincide with transcriptional upregulation as seen in the case of TNF, potentially indicating 
that this cytokine exerts a more potent pro-calcific phenotypic influence on HAECs. 
Also noteworthy, TNF significantly induced OPG mRNA/release from endothelial cells in 
accordance with the literature (Collin-Osdoby et al., 2001; Olesen et al., 2005); as previously 
noted, OPG (stored in Weibel-Palade bodies) can be rapidly released in response to 
inflammation (Zannettino et al., 2005), which may highlight both a natural cardioprotective 
response to TNF and partly explain the increase in circulating OPG observed in vascular 
disorders (Abedin et al., 2007; O’Sullivan et al., 2010; Schoppet et al., 2003). Furthermore, 
IL-6, well known to be induced by TNF, has also been implicated in the pathogenesis of EC 
dysfunction and CVD (Qu et al., 2014) and has been considered a pro-calcific cytokine (Hénaut 
and Massy, 2018). Of further note, while TNF is well known to function via the canonical 
NF-B pathway, the precise role for TNF-induced non-canonical activation requires clarity, 
particularly with respect to VC (Kim et al., 2011).  
 
4.3.5.2 The Effects of RANKL on VC Indices under Inflammatory Conditions in HAECs 
The effects of RANKL on HAECs under these conditions (i.e. RANKL + TNF) were next 
assessed. As noted, RANKL has been identified in vascular cells, and has been shown to be 
elevated in atherosclerotic tissue (Cheng et al., 2015, Higgins et al., 2015; Osako et al., 2010). 
Indeed, both RANKL and inflammatory cytokines (eg. TNF, IL-6) can activate overlapping 
signalling pathways, highlighting an inter-related function for these pro-calcific stimuli (Ndip 
et al., 2014). Of note, the current study is novel in a vascular context, with the majority of 
existing RANKL/TNF studies completed with an osteoclastic focus (Kwan et al., 2004; Vitale 
and Ribeiro, 2007). At an mRNA level, pro-calcific (ALP, Runx2) expression was upregulated 
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following exposure to RANKL under inflammatory conditions, although to a lesser extent than 
with TNF treatment alone. It is possible, therefore, that RANKL may induce the switching of 
HAECs from a pro-inflammatory state to a more sustainable pro-calcific phenotype emulating 
the natural sequence of events in atherosclerosis (Joshi et al., 2016). This effect is not reflected 
at a translational level, rendering this data of limited physiological value.  
The observed increase in BMP-2 release and extracellular ALP activity (alongside non-
canonical NF-B activation) following exposure to RANKL + TNF is particularly interesting. 
These levels are not only accelerated compared to RANKL treatment alone, but also compared 
to that of TNF exposure. It appears, therefore, that RANKL and TNF exert an additive effect 
on pro-calcific (paracrine) signalling in the endothelial layer, a trend previously observed in 
osteoclastogenesis (Fuller et al., 2002; Yamashita et al. 2015), and these pro-calcific responses 
may be exerted via the non-canonical NF-B pathway. RANKL’s contribution to TNF-
induced BMP-2/ALP release likely enhances the VC process in the medial HASMC layer. 
TNF also strongly induces BMP-2 production, accompanying the observed increase in BMP-
2 release. This additive trend may be explained by the overlapping mechanisms involved in 
both RANKL and TNF function, in particular the activation of pro-calcific NF-B activation 
previously associated with BMP-2 (Feng et al., 2003; Kim et al., 2011; Panizo et al., 2009).  
 
4.3.5.3 The Effects of TRAIL on VC Indices under Inflammatory Conditions in HAECs 
As noted, TRAIL has also been identified in vascular cells, and TRAIL administration has been 
shown to exert a protective influence particularly during (pro-inflammatory) atherosclerotic 
calcification (di Bartolo et al., 2013; Liu et al., 2014; Secchiero et al., 2006). Despite this, no 
studies have yet clarified the effects of TRAIL on medial VC in areas of vascular inflammation, 
or the role of the endothelium in this process. Under inflammatory conditions, TRAIL was 
found to completely attenuate TNF-induced pro-calcific gene expression (ALP, Runx2) while 
also reducing non-canonical NF-B activation. TRAIL did not, however, attenuate TNF-
induced pro-calcific paracrine signalling, as it did when co-incubated with RANKL in Chapter 
3. It seems, therefore, that TRAIL-mediated atherosclerotic protection previously observed 
(Liu et al., 2014; Secchiero et al., 2006) may not result from the attenuation of TNF-induced 
endothelial ALP/BMP-2 release. Also of note, intracellular BMP-2 production levels remained 
unaffected by TRAIL, supporting a key observation from Chapter 3 that TRAIL does not affect 
total BMP-2 turnover but rather specifically prevents RANKL-induced release.  
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It remains possible that TRAIL-mediated anti-atherosclerotic activity may involve a reduction 
in non-canonical NF-B signalling, influencing genes/proteins not measured in the current 
study. Additionally, several signalling processes have previously been linked to TRAIL 
function in atherosclerosis, including anti-oxidant mechanisms and MAPK signalling (Forde 
et al., 2016), which remain to be fully investigated in the context of TRAIL-induced protection. 
Interestingly, preliminary investigations within our own research group have highlighted the 
potential for an anti-oxidant role for TRAIL in the endothelium, which may be involved in 
TRAIL-mediated anti-atherosclerotic activity (Forde et al., unpublished observations).  
 
4.3.5.4 The Effects of Hyperglycemia on VC Indices in HAECs 
Hyperglycemia is best recognised in a clinical setting as a key circulatory hallmark of type-2 
diabetics, among which VC is particularly prevalent. Elevated glucose is a recognised promoter 
of endothelial dysfunction and sustained vascular inflammation, and T2DM has indeed been 
shown to coincide with increased risk of arterial hardening (Stabley and Towler, 2017) and 
atherosclerosis (Mirza et al., 2012). Furthermore, elevated glucose has been shown to induce 
pro-calcific effects in vascular/osteoblastic cells in vitro (García-Hernández et al., 2012; Liu et 
al., 2010), but no studies to date have clarified the effect of hyperglycemia on pro-calcific 
indices in HAECs, a major contributor to vascular paracrine signalling.  
Following the simulation of hyperglycemic conditions, high glucose did not promote BMP-2 
protein production but slightly induced its release. Of note, BMP-2 was induced by both 
RANKL and TNF alongside NF-B activation (not seen in response to hyperglycemia), 
which suggests that BMP-2 can also be induced by an NF-B-independent mechanism. Of 
note, circulating BMP-2 has been correlated with T2DM in clinical studies (Zhang et al., 2015), 
but non-endothelial sources (eg. HASMCs) and/or the presence of other pathological stimuli 
(eg. RANKL, TNF) likely contribute to this correlation. Extracellular ALP activity was also 
elevated, and to a much greater extent under severe hyperglycemia. Thus, endothelial BMP-
2/ALP may act in a paracrine manner on the underlying HASMCs during T2DM, promoting 
extracellular matrix calcification and contributing to the long-established correlation between 
elevated circulating BMP-2/ALP and hyperglycemia in clinical studies (Rao and Morghom, 
1986; Zhang et al., 2015). Interestingly, OPG protein production/release were also significantly 
increased following high glucose exposure, albeit to a lesser extent than TNF, again likely as 
a natural response to endothelial injury/inflammation and contributory to elevated circulating 
OPG in diabetics (Secchiero et al., 2006).  
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4.3.5.5 The Effects of RANKL on VC Indices under Hyperglycemic Conditions in HAECs 
The effects of RANKL under hyperglycemic conditions were next assessed. As discussed, 
RANKL has long been associated with the progression of VC, but the pro-calcific effects of 
RANKL in the endothelium have not yet been clarified in the presence of high glucose. In the 
presence of hyperglycemia, ALP mRNA levels were dose-dependently upregulated following 
RANKL treatment, but (as with TNF) not to the same extent as with high glucose alone. 
Furthermore, Runx2 mRNA expression was significantly upregulated following glucose + 
RANKL exposure, despite being downregulated by glucose alone. This finding suggests that, 
while hyperglycemia alone does not promote Runx2-mediated pro-calcific activity, RANKL-
induced Runx2 expression may promote VC during both moderate and severe hyperglycemia. 
Runx2 is responsible for the upregulation of several pro-calcific genes (Byon et al., 2008), 
implicating RANKL once more in the promotion of calcification in the endothelium. Also of 
note, RANKL-induced non-canonical NF-B activation is not observed in the presence of high 
glucose, again implicating an NF-B independent mechanism for glucose-induced pro-calcific 
effects. Wittrant and colleagues (2008) have previously found that high glucose inhibited 
osteoclast formation in response to RANKL via inhibition of NF-κB activity, suggesting that 
glucose-induced pro-calcific functions remain independent of NF-κB. Thus, RANKL-induced 
non-canonical NF-κB activation described in Chapter 3 may be more relevant under 
normoglycemic conditions. 
 
4.3.5.6 The Effects of TRAIL on VC Indices under Hyperglycemic Conditions in HAECs 
Finally, the effects of high glucose + TRAIL were assessed. As mentioned, the protective 
effects of TRAIL in CVD have been observed (di Bartolo et al., 2013), and in Chapter 3, the 
ability of TRAIL to counteract RANKL-induced endothelial pro-calcific signalling was 
described. Thus, we investigate for the first time if TRAIL can exert anti-calcific effects on the 
endothelium under hyperglycemic conditions associated with T2DM. In this case, TRAIL was 
found to completely attenuate glucose-induced ALP mRNA expression and significantly reduce 
extracellular ALP activity during severe hyperglycemia. This observation highlights a clear 
protective effect of TRAIL on glucose-induced calcification, ultimately protecting from 
extracellular matrix calcification in the underlying HASMC layer. Interestingly, TRAIL did 
not attenuate glucose-induced BMP-2 release, further supporting the hypothesis that the 
attenuation of BMP-2 paracrine signalling is achieved via a RANKL-specific mechanism. 
Moreover, TRAIL attenuates glucose-induced OPG production and restores OPG release, 
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while also returning Runx2 expression to baseline. Taking this data together, it appears that 
TRAIL may be responsible for maintaining endothelial homeostasis under hyperglycemic 
conditions, counteracting glucose-specific effects. Despite this, TRAIL exerts a much more 
potent protective effect on RANKL-induced calcification than it does under either 
inflammatory or hyperglycemic conditions in vitro.  
 
4.3.5.7 HAEC Monoculture: Summary  
To summarise the key findings of this chapter, illustrated in Figure 4.8, TNF and high glucose 
were found to exert the expected pro-calcific effects in HAECs. Pertinently, RANKL functions 
together with TNF to drive BMP-2/ALP paracrine signalling, ultimately promoting 
calcification within the underlying smooth muscle layer. This effect coincides with elevated 
non-canonical NF-κB signalling, implicating this pathway once again in the VC process, while 
TRAIL again attenuates TNF-induced non-canonical activation. Both RANKL and TRAIL 
also exert a weakly pro-calcific and protective influence respectively on the endothelium 
during hyperglycemia (although to a lesser extent than that observed under inflammatory 
conditions), in the absence of non-canonical NF-κB activation. It must be considered, however, 
that utilising HAECs in isolation only provides a one-dimensional view of the vascular 
environment; as such, the effects of these stimuli on HASMCs in mono- and co-culture may 











Figure 4.8. Summary of the key findings following endothelial exposure to RANKL/TRAIL +/- TNF 
(inflammation) and high glucose. RANKL was found to further upregulate (red arrow) a number of pro-calcific 
indices when compared to TNF or glucose treatment alone. TRAIL was found to reduce (green arrow) a number 




















4.4 HASMC Monoculture  
HASMCs were next employed to profile the effects of RANKL and TRAIL on pro-calcific 
indices under pathological (inflammatory, hyperglycemic) conditions commonly associated 
with calcification in the vascular media. Again, only key findings will be alluded to in-text, 
and the readers’ attention will be drawn to the corresponding figures. No notable trends were 
observed in cases where data is not presented.  
 
4.4.1 The Effects of TNFα and Glucose on Pro-Calcific Targets in HASMCs 
Once again, the effects of inflammation (TNFα) and hyperglycemia (glucose) were first 
assessed in the absence of RANKL and TRAIL to better understand natural HASMC responses 
to these stimuli. Mannitol was again included as a control to ensure the observed effects in 
response to glucose were not due to an increase in osmotic pressure. Mannitol (at 30 mM) was 
confirmed to have no effect on any of the measured indices in HASMCs (Appendix 4.7). At an 
mRNA level, ALP, OPG and Sox9 transcripts were significantly upregulated under 
inflammatory conditions; BMP-2 mRNA, however, was downregulated by approximately 90% 
(Figure 4.9A). At a protein level, TNFα induced all measured extra- and intracellular indices 
in HASMCs (Figure 4.9B-D). Under hyperglycemic conditions, ALP and Sox9 mRNA 
expression were elevated, while BMP-2 transcript expression was once again dramatically 
reduced (Figure 4.10A). High glucose induced the release of all measured indices in the 
conditioned media, while only OPG levels were increased intracellularly. Hyperglycemia also 
reduced activation of the canonical NF-κB pathway (Figure 4.10B-D). 
 
4.4.2 The Effects of RANKL and TRAIL under Inflammatory Conditions in HASMCs 
Regarding mRNA, co-treatment with both TNFα and RANKL significantly reduced ALP, 
Runx2 and Sox9 transcript expression (Figure 4.11A) but further promoted BMP-2, OPG and 
IL-6 mRNA levels (Appendix 4.8A). Interestingly, the addition of TRAIL exerted a similar 
effect (with the exception of OPG). With respect to protein levels, co-incubation of TNFα with 
both RANKL and TRAIL (separately) reduced smooth muscle cell OPG release, while TNFα 
+ TRAIL also significantly reduced extracellular ALP activity (Figure 4.11B). Both ligands 
exerted minimal effects on the TNFα-mediation of intracellular indices. Supporting material is 


























Figure 4.9. The effects of TNF on pro-calcific indices in HASMC monoculture. HASMCs were exposed to TNF⍺ (100 
ng/mL) for 72 hours. (A) (i) BMP-2, (ii) ALP, (iii) OPG and (iv) Sox9 mRNA were assessed by RT-qPCR, employing 
GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP, (iii) OPG and (iv) IL-6 release, and (C) intracellular (i) BMP-
2, (ii) ALP and (iii) OPG protein levels were quantified by ELISA and enzyme assay where appropriate. (D) (i) Canonical 
and (ii) non-canonical NF-κB activation were determined by Western blotting, quantified by scanning densitometry and 
normalised to GAPDH. Blots are representative. Absolute values for media and protein lysate analyses are normalised to 












































Figure 4.10. The effects of glucose on pro-calcific indices in HASMC monoculture. HASMCs were exposed to glucose 
(15-30 mM) for 72 hours. (A) (i) BMP-2, (ii) ALP, (iii) OPG and (iv) Sox9 mRNA were assessed by RT-qPCR, employing 
GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP, (iii) OPG and (iv) IL-6 release, and (C) intracellular (i) BMP-
2, (ii) ALP and (iii) OPG protein levels were quantified by ELISA and enzyme assay where appropriate. (D) (i) Canonical 
and (ii) non-canonical NF-κB activation were determined by Western blotting, quantified by scanning densitometry and 
normalised to GAPDH. Blots are representative (control bands previously presented in Figure 4.9). Absolute values for 
media and protein lysate analyses are normalised to 105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p < 




































4.4.3 The Effects of RANKL and TRAIL under Hyperglycemic Conditions in HASMCs 
At a transcriptional level, both RANKL and TRAIL attenuated the upregulation of glucose-
induced ALP/Sox9 mRNA, while TRAIL also reduced Runx2 expression. Interestingly, OPG 
mRNA was upregulated by the co-addition of both RANKL and TRAIL under hyperglycemic 
conditions (Figure 4.12A). Both ligands reduced OPG release induced by hyperglycemia, while 
TRAIL significantly reduced IL-6 release into the conditioned media (Figure 4.12B). Neither 
RANKL nor TRAIL exerted any relevant effects on glucose-mediated BMP-2/ALP release or 
intracellular pro-calcific indices (Appendix 4.9B, C), while canonical NF-κB induced by both 
ligands alone was completely attenuated in the presence of high glucose. Furthermore, non-
canonical NF-κB activation induced by RANKL was also attenuated under hyperglycemic 
conditions (Appendix 4.11C). 
Figure 4.11. The effects of TNF +/- RANKL/TRAIL on pro-calcific indices in HASMC monoculture. HASMCs 
were exposed to TNF⍺ (100 ng/mL) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) mRNA expression 
of (i) ALP, (ii) Runx2 and (iii) Sox9 were analysed by RT-qPCR employing GAPDH as an endogenous control. (B) 
(i) Extracellular ALP activity was quantified by activity assay and (ii) OPG release was quantified by ELISA, 
normalised to 105 cells. (C) Non-canonical NF-κB activation was determined by Western blotting, quantified by 
scanning densitometry and normalised to GAPDH. Representative blots are presented in Appendix 4.10. * p < 0.05; 
** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance 
between treatment groups.  
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Figure 4.12. The effects of glucose +/- RANKL/TRAIL on pro-calcific indices in HASMC monoculture. 
HASMCs were exposed to glucose (15-30 mM) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) 
mRNA expression of (i) ALP, (ii) Runx2, (iii) OPG and (iv) Sox9 were analysed by RT-qPCR employing 
GAPDH as an endogenous control. (B) (i) OPG and (ii) IL-6 release were quantified by ELISA, normalised to 
105 cells. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars 
indicate statistical significance between treatment groups.  
A 
(i)  (ii)  
(iii)  (iv)  
B 
(i)  (ii)  
 165 
4.4.4 HASMC Monoculture: Summary of Results  
HASMC exposure to RANKL and TRAIL under inflammatory and hyperglycemic conditions 
influenced a number of pro-calcific indices, summarised below in Table 4.3. 
 
 
Inflammation   RANKL TRAIL 
BMP-2 mRNA ↓ ↑↑ ↑ 
ALP mRNA ↑ ↓ ↓ 
 Extracellular Activity ↑↑ ↑↑ ↑ 
OPG mRNA ↑ ↑↑ ↓ 
 Extracellular Protein ↑↑↑ ↑↑ ↑ 
IL-6 mRNA  ↓ ↑ ↑↑ 
Runx2 mRNA − ↓ ↓ 
Sox9 mRNA ↑ ↓ ↓↓ 
 
Hyperglycemia     
BMP-2 mRNA ↓ − − 
 Intracellular Protein − ↑ − 
ALP mRNA ↑ ↓ ↓ 
OPG mRNA − ↑ ↑ 
 Extracellular Protein ↑↑ ↑ ↑ 
 Intracellular Protein ↑↑ ↑ ↑↑ 
IL-6 mRNA  ↓ ↑ ↑↑ 
 Extracellular Protein ↑↑ ↑↑ ↑ 
Runx2 mRNA − ↓ ↓↓ 
Sox9 mRNA ↑ ↓ ↓ 






p-p65, phospho-p65; t-p65, total-p65. ↑, upregulation; ↑↑, further upregulation relative to corresponding 
treatment conditions; ↓, downregulation; ↓↓, further downregulation relative to corresponding treatment 
conditions; −, no change. 
 
Table 4.3. The effects of TNF or glucose +/- RANKL or TRAIL in HASMCs.  
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4.4.5 HASMC Monoculture: Discussion   
The pathological effects of TNF and high glucose have previously been described in the 
vasculature, but few studies attempt to clarify the role of RANKL and TRAIL under 
inflammatory and hyperglycemic conditions in VSMCs, the primary location of medial VC in 
vivo. In this respect, we profile the most comprehensive range of pro-calcific indices in primary 
HASMCs under these common pathological conditions in T2DM/CVD, for the first time 
incorporating key ligands involved in the VC process. As noted, during TNF-induced 
inflammation, the endothelial monolayer is rendered permeable to circulating proteins, while 
during hyperglycemia, glucose transport is facilitated by GLUT-1 transporters across the 
endothelial monolayer (Viator and Fouty, 2009). These pathological conditions in the 
vasculature may therefore exert direct pro-calcific effects on the underlying smooth muscle cell 
layer, and prior to analysis in co-culture, the direct effects of both TNF and glucose must be 
clarified in HASMCs. Again, due to the comprehensive nature of this study, this discussion 
will first focus on the key relevant findings regarding the effects of inflammation and high 
glucose on HASMCs, prior to the incorporation of RANKL and TRAIL into these models.  
 
4.4.5.1 The Effects of TNF on VC Indices in HASMCs  
As discussed, inflammatory cytokines such as TNF may allow circulating proteins to exert 
direct effects on the medial smooth muscle layer. In this respect, serum TNF levels are 
particularly elevated during T2DM/CVD (Olson et al., 2012; Levine et al., 1990; Mirza et al., 
2012) and this cytokine is highly expressed alongside atherosclerotic calcification (Barath et 
al., 1990). Medial arterial hardening, the prime focus of this study, is indeed known to co-exist 
with atherosclerosis (McCullough et al., 2008), and thus the pro-calcific effects of the involved 
cytokines at these sites cannot be ignored. Of interest, pro-inflammatory cytokines (eg. TNF, 
IL-6) have been implicated in key osteogenic processes in the vasculature that drive medial VC 
(Al-Aly, 2008; Illiandri et al., 2016; Shao et al., 2010), and have been shown to induce 
osteogenic differentiation and mineralisation of calcifying vascular cells (Aikawa et al., 2007). 
More specifically, TNF has been shown to directly induce osteogenic responses and 
calcification in VSMCs (Liu et al., 2010; Tintut et al., 2000).  
Following assessment of a wide range of pro-calcific indices, TNF was found to induce the 
vast majority of pro-calcific indices in HASMCs, both at an mRNA and protein level. In 
consideration of the documented pro-calcific effects of this cytokine (Lee et al., 2010; Tintut 
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et al., 2000), this result is unsurprising. Interesting trends were observed, however, regarding 
BMP-2, as the concurrent increase in BMP-2 release and downregulation of mRNA expression 
may suggest only a temporary induction of BMP-2 release in response to TNF. Indeed, 
HAECs, and not HASMCs, are thought to be the primary source of BMP-2 paracrine signalling 
in the vasculature (Osako et al., 2010; Davenport et al., 2016), and minimal BMP-2 was found 
to be released from HASMCs (under basal conditions or following RANKL exposure) in 
Chapter 3. TNF, however, strongly induced BMP-2 release, and thus HASMCs may release 
pro-calcific autocrine signals under pro-inflammatory conditions to promote VC. Nonetheless, 
further experimentation is necessary to determine if this release is maintained longer-term. 
OPG levels were significantly upregulated both at an mRNA and protein level following TNF 
exposure in HASMCs, a finding previously reported by multiple authors in smooth muscle 
(Ben-Tal Cohen et al., 2007; Davenport et al., 2018; Olesen et al., 2005). This observation is 
perhaps more physiologically relevant, given that OPG release from smooth muscle is 
significantly greater than from the endothelium (Davenport et al., 2016). It is again likely that 
OPG is released as part of a cardioprotective mechanism in response to vascular injury, and 
contributing significantly to the elevated circulating OPG noted in diabetic patients (Abedin et 
al., 2007; O’Sullivan et al., 2010; Schoppet et al., 2003). On an additional note, the well-
defined induction of IL-6 release in response to TNF exposure may also contribute to the 
observed pro-calcific effects, as this cytokine has also been shown to induce calcification and 
mineralisation of vascular cells (Aikawa et al., 2007).  
 
4.4.5.2 The Effects of RANKL on VC Indices under Inflammatory Conditions in HASMCs 
Of interest, many similarities in the effects of TNF and RANKL have been observed in 
osteogenic and calcific processes (Shao et al., 2010). While the role for RANKL in 
osteoclastogenesis has been described in detail, TNF has long been known to regulate bone 
turnover, inhibiting osteoblastic function and promoting bone resorption (Azuma et al., 2000; 
Gaspersic et al., 2003). The upregulation of osteoblastic genes in the vasculature are 
responsible for driving VC, however, it seems that the paradoxical effects of RANKL in bone 
versus vessel (i.e. RANKL exerts osteoclastic/resorptive functions in bone, but promotes 
calcification in an osteoblastic role during VC) appear also relevant to TNF.  
Interestingly, the observed decrease in BMP-2 mRNA expression was significantly reversed 
following RANKL co-treatment, although paracrine levels of BMP-2 remained unchanged 
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compared to that induced by TNF alone; this finding may be suggestive that the combination 
of both proteins exerts a longer-term upregulation of BMP-2 as part of a pro-calcific phenotypic 
change. The relevance of this finding is augmented by the fact that RANKL treatment alone 
did not induce BMP-2 expression or release in HASMCs, and as such, the proposed autocrine 
release of BMP-2 appears to be TNF-dependent. It is possible, therefore, that smooth muscle 
BMP-2 signalling may only occur in inflamed areas of vasculature affected by atherosclerosis, 
as previously reported by Simões Sato et al. (2014). The opposite trends, however, were 
observed in ALP, Runx2 and Sox9 mRNA expression following TNF + RANKL exposure. 
While the inclusion of RANKL significantly downregulated TNF-induced pro-calcific gene 
expression, no change was noted in ALP activity, again highlighting divergent responses at a 
transcriptional and translational level common throughout this study. As seen with OPG 
regulation in Chapter 3, pro-calcific gene regulation may involve a bimodal response to these 
stimuli, with an initial upregulation caused by TNF/RANKL activation followed by a 
subsequent downregulation as part of a natural protective mechanism.  
Also of relevance, co-incubation with RANKL results in a reduction of smooth muscle OPG 
release, exerting the opposite effect to TNF but exerting a similar effect to RANKL exposure 
alone. Of note, we have confirmed in Chapter 3 that this finding is not due to RANKL:OPG 
ELISA interference, and so we propose that during inflammation, the presence of RANKL 
renders the smooth muscle cell layer more susceptible to calcification. While this observation 
was of minimal relevance in Chapter 3 (where we considered an intact endothelial barrier), this 
data is particularly pertinent in areas of vasculature affected by EC dysfunction/atherosclerosis. 
With the exception of OPG, however, the presence of RANKL does not significantly affect 
TNF-induced pro-calcific indices, and the two proteins do not appear to function 
synergistically in the promotion of VC, despite previous reports of synergy during 
osteoclastogenesis (Fuller et al., 2002; Yamashita et al. 2015).  
 
4.4.5.3 The Effects of TRAIL on VC Indices under Inflammatory Conditions in HASMCs 
In Chapter 3, it was found that while TRAIL attenuates RANKL-induced pro-calcific signalling 
in the endothelium, its protective influence in the smooth muscle cell layer is minimal. TRAIL 
has, however, been shown to exert anti-calcific effects under pro-inflammatory atherosclerotic 
conditions in vitro and in vivo (di Bartolo et al., 2011; di Bartolo et al., 2013; Liu et al., 2014), 
and as such, it remains to be determined if TRAIL can attenuate pro-calcific signalling in 
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HASMCs during inflammation. Interestingly, TRAIL was found to exert similar effects to 
RANKL in the presence of TNF at an mRNA level, reversing TNF-induced downregulation 
of BMP-2, and downregulating multiple pro-calcific genes. These trends are not maintained at 
a protein level, however, and so this finding is of minimal physiological relevance. TRAIL did, 
however, reduce ALP activity in VSMC-conditioned media, thereby reducing extracellular 
matrix calcification in the vascular media (Orimo, 2010). Furthermore, TRAIL co-incubation 
under inflammatory conditions significantly reduced OPG release; as for RANKL, this 
observation cannot be attributed to OPG:TRAIL interference, but does indicate that this effect 
is not RANKL-specific (and perhaps a phenomenon induced by high concentrations of 
extracellular OPG decoy receptors). Physiologically, the smooth muscle cell layer is rendered 
more susceptible to vascular injury following reduced OPG release, and as such, TRAIL does 
not appear to exert anti-calcific effects on the vasculature via OPG regulation under 
inflammatory conditions. Overall, TRAIL does not exert a strong vasoprotective influence on 
the medial arterial layer in areas of dysfunctional endothelium, suggesting that the 
aforementioned TRAIL protection in atherosclerosis may be exerted via a different mechanism. 
 
4.4.5.4 The Effects of Hyperglycemia on VC Indices in HASMCs 
Like TNF, hyperglycemia is well recognized in its pathological role in T2DM and has been 
long associated with CVD and arterial hardening (Liu et al., 2010; Stabley and Towler, 2017). 
Elevated glucose has been shown to elicit pro-calcific effects in VSMCs in vitro (Chen et al.,  
2006; Liu et al., 2010), but to date, such a wide range of pro-calcific indices have not been 
profiled in HASMCs under hyperglycemic conditions. In this respect, and unsurprisingly, 
several key pro-calcific indices were found to be upregulated in response to moderate and 
severe hyperglycemia. Most relevantly, active ALP and BMP-2 release were significantly 
induced following glucose treatment, suggesting that during T2DM (permitting glucose 
transport across the EC monolayer) HASMCs secrete autocrine factors that promote medial 
calcification. In agreement with this finding, BMP-2 has previously been shown to be induced 
in HASMCs following hyperglycemic treatment (Liu et al., 2010), and Al-Aly et al. (2007) 
noted that hyperglycemia and calcification progressed alongside activation of the BMP-2 
pathway in vivo. Additionally, ALP activity (and mRNA) have also been shown to be induced 
following glucose treatment in HASMCs (Chen et al., 2006; Liu et al., 2010), and thus 
hyperglycemia may contribute to explaining the elevated circulating levels of both BMP-2 and 
ALP observed in T2DM patients (Rao and Morghom, 1986; Zhang et al., 2015).  
 170 
It should be noted, however, that BMP-2 transcript expression was significantly downregulated 
under hyperglycemic conditions. Contrastingly, BMP-2 mRNA has previously been shown to 
be upregulated following exposure to high glucose (Liu et al., 2010), however, this finding 
followed only 24 hours’ incubation. The observed decrease in BMP-2 mRNA at 72 hours is 
less easily explained, and may suggest that the autocrine secretion of BMP-2 from HASMCs 
is short-lived; as mentioned, HAECs are considered to be the primary source of secretory BMP-
2 in the vasculature (Davenport et al., 2016; Osako et al., 2010). Also of interest, Sox9 
chondrocytic transcription factor appears to be a key driver of pro-calcific indices in HASMCs 
in response to high glucose, particularly under severe hyperglycemic conditions. As noted in 
Chapter 3, both Runx2 and Sox9 modulate a similar range of osteochondroblastic genes, and it 
has been thought in recent years that VC may more closely resemble chondrogenesis (Speer et 
al., 2009). Indeed, previous research has implicated both Runx2 and Sox9 in HASMC trans-
differentiation induced by hyperglycemia (Alesutan et al., 2017; Bessueille et al., 2015; 
Leopold, 2015), but we propose a more pronounced role for Sox9 in this process.  
Interestingly, OPG production and release were significantly elevated under hyperglycemic 
conditions, again as a potential cardioprotective response to injurious stimuli and contributing 
to elevated circulating OPG during T2DM (Bjerre, 2013; Secchiero et al., 2006). In contrast to 
TNF-exposure, however, OPG mRNA expression was downregulated alongside this increase 
in protein levels. With regard to the literature, a dose-dependent increase in OPG mRNA has 
been associated with 48-hour high glucose treatment in VSMCs (Chang et al., 2015), while in 
longer-term exposures (2 weeks), no change in OPG mRNA was detected (Hadi and Suwaidi, 
2007). This finding may suggest that the observed induction in OPG release/production is time-
dependent, with an initial upregulation of OPG mRNA subsequently followed by a reversal 
and ultimate loss of this effect (a phenomenon also observed in Chapter 3). As noted, 
transcriptional and translational pathways are often distinct from one another (Carmody and 
Wente, 2009; Greenbaum et al., 2003), but it is as of yet unclear whether OPG acts primarily 
as an early-stage marker of VC or plays a longer-term role in vasoprotection.  
 
4.4.5.5 The Effects of RANKL on VC Indices under Hyperglycemic Conditions in HASMCs 
There is minimal evidence in the literature regarding the role of RANKL under hyperglycemic 
conditions, despite being recognised as a key promoter of VC (Collin-Osdoby, 2004); as such, 
the effects of RANKL on the smooth muscle cell layer remain to be defined. Interestingly, 
glucose-induced BMP-2 release remained unaffected by RANKL co-incubation, however, 
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RANKL completely recovered BMP-2 downregulation at a transcriptional level. It is unclear 
as of yet what the significance of this is, but it is possible that RANKL may promote the longer-
term maintenance of autocrine BMP-2 signalling within the HASMC layer; indeed, RANKL 
also induces the production of intracellular BMP-2 in the presence of glucose. With the 
exception of BMP-2, RANKL does not appear to have a synergistic effect on pro-calcific 
indices under hyperglycemic conditions in the smooth muscle cell layer, but rather reduces the 
transcription of pro-calcific genes, perhaps as part of a compensatory mechanism designed to 
prevent VC. Furthermore, RANKL significantly induced OPG mRNA expression while 
simultaneously decreasing OPG release, despite having minimal effect on intracellular protein 
expression. Thus, in the presence of RANKL, the vasculature may be rendered more 
susceptible to injury. As a final note, RANKL does not appear to function via NF-κB signalling 
in HASMCs under hyperglycemic conditions, and rather the activation of these pathways are 
more relevant to RANKL-induced pro-calcific signalling in areas of healthy/intact 
endothelium. The mechanism by which RANKL functions in the presence of glucose remains 
to be delineated, but this data further supports our hypothesis that RANKL exerts its pro-calcific 
function predominantly via endothelial signalling, and not directly on HASMCs.  
 
4.4.5.6 The Effects of TRAIL on VC Indices under Hyperglycemic Conditions in HASMCs 
Again, there is limited data to consider regarding the role of TRAIL in smooth muscle under 
hyperglycemic conditions. As noted, TRAIL has been known to exert a protective influence 
under hyperglycemic conditions in vivo (Liu et al., 2014), but it is unclear if this protection is 
mediated via modulation of pro-calcific indices or if this effect occurs in HASMCs. 
Interestingly, TRAIL exerts similar effects to RANKL on the vasculature at an mRNA level in 
the downregulation of pro-calcific genes; TRAIL does not affect the measured pro-calcific 
indices at a protein level, however, and as such, does not appear to exert a protective influence 
under hyperglycemic conditions in HASMCs. Furthermore, TRAIL-induced canonical NF-κB 
activation observed in healthy VSMCs does not occur during hyperglycemia, indicating that 
high glucose mediates pro-calcific indices via a distinct and unrelated mechanism. Like 
RANKL, TRAIL was also found to downregulate OPG release while simultaneously inducing 
its expression. Thus, while this effect may render the vasculature prone to damage, it seems to 
be relevant to both soluble OPG receptors rather than being RANKL- or TRAIL-specific. This 
finding may also contribute to explaining the contrasting data with regard to the role of TRAIL 
in the vasculature discussed in Chapter 3.  
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4.4.5.7 HASMC Monoculture: Summary  
As summarised in Table 4.3 and Figure 4.13 below, it is clear that both RANKL and TRAIL 
exert some function in the medial smooth muscle layer under inflammatory and hyperglycemic 
conditions, however, these effects appear less potent than those observed in the endothelium. 
RANKL did not synergistically promote any of the measured pro-calcific indices under 
inflammatory conditions, and while TRAIL slightly reduced TNF-induced ALP release, a 
strong protective influence on HASMCs was not observed. Similarly, while both moderate and 
severe hyperglycemia promoted many pro-calcific genes/proteins, RANKL did not accelerate 
this effect, nor did TRAIL protect from it. Interestingly, although TNF may also exert its 
function via NF-κB signalling in HASMCs, TRAIL co-incubation did not attenuate non-
canonical activation in this case; this finding may suggest that TRAIL only attenuates this 
pathway in the endothelium (as a similar finding was observed in Chapter 3). Overall, it is clear 
that RANKL and TRAIL exert their respective pro-calcific and protective functions 
predominantly via endothelial signalling under pathological conditions. Therefore, it is hoped 
that the inclusion of this paracrine contribution in co-culture may shed additional light on the 









Figure 4.13. Summary of the key findings following smooth muscle exposure to RANKL/TRAIL +/- TNF 
(inflammation) and high glucose. RANKL did not further promote any of the measured pro-calcific indices 
mediated by TNF or glucose treatment. TRAIL was found to exert a slight protective influence (green arrow) via 
downregulation of both glucose- and TNF-induced Runx2/Sox9 mRNA expression, and also slightly reduced 



















4.5 HAEC:HASMC Co-culture  
Finally, a co-culture model was employed to facilitate 
paracrine communication between the endothelium and 
smooth muscle cell (Figure 4.14). Following treatment 
of HAECs with TNFα or glucose in the absence and 
presence of RANKL/TRAIL, conditioned media from 
the subluminal compartment was assessed for paracrine 
signalling molecules, while underlying HASMCs were 
monitored for pro-calcific gene and protein expression. 
Once again, only the key findings from the following 
investigations will be discussed in-text, while the reader will be directed to the relevant figure 
panels. No notable trends were observed in cases where data is not presented.  
 
4.5.1 The Effects of TNFα and Glucose on Pro-Calcific Targets in Co-culture  
Following endothelial treatment with TNFα, no pro-calcific genes were upregulated in 
HASMCs, but rather a downregulation was observed in Runx2 and OPG mRNA (Figure 
4.15A). TNFα treatment also induced the release of all measured extracellular indices into the 
subluminal compartment (Figure 4.15B), while intracellular BMP-2 and OPG in the underlying 
HASMCs were also elevated (Figure 4.15C). Both NF-B pathways were activated in 
HASMCs following HAEC treatment (Figure 4.15D). With regard to endothelial glucose 
treatment, smooth muscle ALP/Sox9 mRNA levels were upregulated following severe 
hyperglycemia, while Runx2/OPG mRNA were downregulated (Figure 4.16A). High glucose 
also stimulated the release of BMP-2, ALP and IL-6 into the subluminal compartment (Figure 
4.16B), while intracellular OPG levels in the underlying HASMCs was reduced (Figure 4.16C). 
Hyperglycemic treatment did not activate NF-B in the underlying HASMCs (Figure 4.16D).  
 
4.5.2 The Effects of RANKL and TRAIL under Inflammatory Conditions in Co-culture 
At an mRNA level, both RANKL and TRAIL downregulated TNFα-induced Runx2 and OPG, 
but upregulated BMP-2 mRNA in the underlying HASMCs (Appendix 4.11A). At a protein 
level, RANKL co-treatment further promoted TNFα-induced BMP-2 release into the 
subluminal space, while also further driving smooth muscle OPG. TRAIL, on the other hand, 
Figure 4.14. The co-culture model. HAECs in 
semi-permeable transwell inserts, suspended 
above a confluent smooth muscle layer were 
exposed to soluble factors (i.e. RANKL/TRAIL 












































Figure 4.15. The effects of TNF on pro-calcific indices in co-cultured HASMCs. HAECs were exposed to TNF⍺ (100 
ng/mL) for 72 hours, and the underlying HASMCs harvested for analysis. (A) (i) ALP, (ii) Runx2, (iii) OPG and (iv) Sox9 
mRNA were assessed by RT-qPCR, employing GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP, (iii) OPG and 
(iv) IL-6 release, and (C) intracellular (i) BMP-2, (ii) ALP and (iii) OPG protein levels were quantified by ELISA and 
enzyme assay where appropriate. (D) (i) Canonical and (ii) non-canonical NF-κB activation were determined by Western 
blotting, quantified by scanning densitometry and normalised to GAPDH. Blots are representative. Absolute values for 
media and protein lysate analyses are normalised to 105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p < 
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Figure 4.16. The effects of glucose on pro-calcific indices in co-cultured HASMCs. HAECs were exposed to glucose 
(15-30 mM) for 72 hours, and the underlying HASMCs harvested for analysis. (A) (i) ALP, (ii) Runx2, (iii) OPG and (iv) 
Sox9 mRNA were assessed by RT-qPCR, employing GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP, (iii) OPG 
and (iv) IL-6 release, and (C) intracellular (i) BMP-2, (ii) ALP and (iii) OPG protein levels were quantified by ELISA and 
enzyme assay where appropriate. (D) (i) Canonical and (ii) non-canonical NF-κB activation were determined by Western 
blotting, quantified by scanning densitometry and normalised to GAPDH. Blots are representative (control bands previously 
presented in Figure 4.15). Absolute values for media and protein lysate analyses are normalised to 105 cells and total protein 
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significantly reduced TNFα-mediated BMP-2/ALP release, further promoted OPG release, and 
reduced HASMC BMP-2 production (Figure 4.17A, B). Both ligands significantly reduced 
smooth muscle NF-B/p52 activation (Appendix 4.13). Supporting data is presented in 
Appendix 4.11 and 4.13. 
 
4.5.3 The Effects of RANKL and TRAIL under Hyperglycemic Conditions in Co-culture 
Following hyperglycemic treatment, RANKL further promoted glucose-induced BMP-2/ALP 
release into the subluminal space, while TRAIL completely attenuated the release of both 
paracrine elements. TRAIL also promoted OPG release, and smooth muscle intracellular OPG 
in the presence of hyperglycemia (Figure 4.18B, C). Also of interest, at an mRNA level, TRAIL 
attenuated glucose-induced ALP/Sox9 transcript expression (Figure 4.18A). Additional data is 
presented in Appendix 4.12 and 4.13.  
Figure 4.17. The effects of TNF +/- RANKL/TRAIL on pro-calcific indices in co-cultured HASMCs. 
HAECs in transwell inserts were exposed to TNF⍺ (100 ng/mL) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 
72 hours, and HASMCs in the subluminal compartment were harvested for analysis. (A) (i) BMP-2, (ii) ALP 
activity and (iii) OPG release were quantified by ELISA and enzyme assay where appropriate, normalised to 105 
cells. (B) Intracellular (i) BMP-2, (ii) ALP activity and (iii) OPG in the underlying HASMCs were assessed 
similarly, normalised to total cellular protein. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control 
unless otherwise stated; bars indicate statistical significance between treatment groups.  
(i)  (ii)  (iii)  



























Figure 4.18. The effects of glucose +/- RANKL/TRAIL on pro-calcific indices in co-cultured HASMCs. 
HAECs in transwell inserts were exposed to glucose (15-30 mM) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) 
for 72 hours, and HASMCs in the subluminal compartment were harvested for analysis. (A) mRNA expression 
of (i) ALP and (ii) Sox9 were analysed by RT-qPCR employing GAPDH as an endogenous control. (B) (i) 
BMP-2, (ii) ALP activity and (iii) OPG release in the subluminal compartment, and (C) intracellular OPG in 
HASMCs were quantified by ELISA or enzyme activity assay where appropriate. Media and lysate analyses 
were normalised to 105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p < 0.001 compared 
to untreated control unless otherwise stated; bars indicate statistical significance between treatment groups.  
A 
(i)  (ii)  
B 
C 
(i)  (ii)  
(iii)  
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4.5.4 HAEC:HASMC Co-culture: Summary of Results  
RANKL and TRAIL exerted a number of effects on VC-related indices under inflammatory 
and hyperglycemic conditions in co-culture, both in the subluminal space and in the underlying 
HASMCs. These results are summarised below in Table 4.4.  
 
 
Inflammation   RANKL TRAIL 
BMP-2 mRNA ↑ ↑↑ ↑↑↑ 
 Extracellular Protein ↑ ↑↑ − 
 Intracellular Protein ↑ ↑ − 
ALP mRNA − ↑ ↓ 
 Extracellular Activity ↑↑ ↑↑ ↑ 
 Intracellular Activity − ↑ − 
OPG Extracellular Protein ↑ ↑δ ↑↑ 
 Intracellular Protein ↑ ↑↑ ↑ 
IL-6 mRNA  ↑ ↑ ↑↑ 
Sox9 mRNA − ↑ − 
NF-κB (p52/p100) Activation ↑↑ ↑ ↑ 
 
Hyperglycemia      
BMP-2 mRNA − − ↓ 
 Extracellular Protein ↑ ↑↑ − 
 Intracellular Protein ↑ ↑↑ ↑ 
ALP mRNA ↑ ↑ ↓ 
 Extracellular Activity ↑ ↑↑ − 
 Intracellular Activity − ↑δ − 
OPG mRNA ↓ ↓↓ ↓↓ 
 Extracellular Protein − − ↑ 
 Intracellular Protein − − ↑ 
IL-6 mRNA  ↓ − − 
 Extracellular Protein ↑ ↑ − 
Sox9 mRNA ↑ ↑↑ − 
 ↑, upregulation; ↑↑/↑↑↑, further upregulation relative to corresponding treatment conditions; ↓, downregulation; 
↓↓, further downregulation relative to corresponding treatment conditions; −, no change; δ, not significant. 
 
Table 4.4. The effects of TNFα or glucose +/- RANKL or TRAIL in co-cultured HASMCs.  
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4.5.5 Co-culture: Discussion   
Co-culture models have previously been employed to investigate the paracrine contribution of 
various cell types to VSMC calcification, overcoming important limitations of traditional 
monoculture (Davenport et al., 2016; Deuell et al., 2012; Osako et al., 2010; Shin et al., 2004). 
Despite this, few studies consider the effects of inflammation and hyperglycemia on the 
progression of VC in co-culture, and the contributory effects of RANKL and TRAIL have not 
been considered in these models. As highlighted in Chapter 3, the vascular endothelium can 
exert strong pro-calcific effects via paracrine signalling on underlying HASMCs, the location 
of medial calcification in vivo. Furthermore, RANKL and TRAIL can influence these signals 
to promote or prevent VC respectively, and as such, likely contribute to EC:VSMC 
communication in the presence of TNF or high glucose. In this study, it must also be taken 
into account that both ligands may also act directly on the underlying HASMCs in co-culture, 
as TNF can promote endothelial permeability (Royall et al., 1989) and glucose may transfer 
to the subluminal compartment via active transport (Viator and Fouty et al., 2009). As such, 
communication in the subluminal space under pathological conditions may involve both 
paracrine (endothelial) and autocrine (smooth muscle) signalling that jointly mediate VC.  
 
4.5.5.1 The Effects of TNF on VC Indices in Co-culture 
Following endothelial treatment with TNF, paracrine/autocrine signalling in the subluminal 
space and pro-calcific mRNA/protein expression in the underlying HASMCs were assessed. 
As noted, TNF is elevated in atherosclerotic lesions (Barath et al., 1990), and can penetrate 
damaged endothelium to act directly on HASMCs (Zhang et al., 2009). TNF has been 
previously employed in EC/VSMC co-culture, and has been shown to increase endothelial 
permeability in these models (Chu et al., 2018; Kerkar et al., 2006; Lodi et al., 2012). TNF 
has also been shown to promote VSMC calcification (Liu et al., 2010; Tintut et al., 2000), and 
as such, we investigated the effects of this cytokine on pro-calcific EC:VSMC signalling in 
areas of the vasculature affected by atherosclerosis.  
Following analysis, TNF was found to exert strong pro-calcific effects on the vast majority of 
pro-calcific indices in co-culture. Of particular interest to paracrine signalling, the release of 
BMP-2/ALP were induced in the subluminal space. While unsurprising given the pro-calcific 
effects of TNF noted in the literature (Illiandri et al., 2016), this finding is of particular 
relevance to the progression of VSMC calcification in areas of damaged or dysfunctional 
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endothelium. As noted, both proteins have been shown to drive medial VC, and ALP is 
involved in extracellular matrix calcification in the smooth muscle layer (Davenport et al., 
2016; Osako et al., 2010; Schoppet and Shanahan, 2008). It should be highlighted, however, 
that TNF, while eliciting endothelial paracrine signalling, may also directly induce pro-
calcific autocrine signals within the underlying HASMCs; thus, both HAECs and HASMCs 
may contribute to elevated levels of BMP-2/ALP in the subluminal space. Interestingly, BMP-
2 mRNA/protein were upregulated in the underlying smooth muscle cells, which supports a 
role for HASMC BMP-2 signalling in damaged vasculature. To further support this point, both 
canonical and non-canonical NF-B activation was observed in HASMCs following 
endothelial exposure to TNF, pathways previously implicated in BMP-2 signalling and VC 
(Panizo et al., 2009, Suryavanasgi and Kulkarni, 2017, Zhan et al., 2014, Zhao et al., 2012).  
OPG release was also elevated in the subluminal space following TNF exposure, as was 
intracellular OPG in the underlying HASMCs. OPG mRNA levels, however, do not coincide 
with this release, but given the deviating responses between OPG transcriptional and 
translational levels to date, this finding is difficult to interpret accurately. Nonetheless, this data 
further supports the hypothesis that in areas of damaged endothelium (such as that present 
during atherosclerosis) inflammation may drive the release of OPG as a natural 
cardioprotective mechanism in response to vascular injury, ultimately increasing circulatory 
OPG (Abedin et al., 2007; O’Sullivan et al., 2010; Schoppet et al., 2003).  
As a final consideration, a significant amount of  IL-6 release into the subluminal space in co-
culture was observed, and as noted, the pro-calcific functions have been widely reported (Al-
Aly, 2008; Illiandri et al., 2016; Shao et al., 2010). As a potential explanation for this, Wallace 
and Truskey (2010) have previously hypothesised (based on EC:VSMC co-culture models) 
that smooth muscle cells under pathological conditions induce an activated pro-inflammatory 
state in endothelial cells, and suggest based on pertinent evidence that they may be centrally 
involved in the progression of atherosclerotic disease (Chiu et al., 2007; Rainger and Nash, 
2001).  Thus, while endothelial paracrine signalling is the core focus of current vascular 
research, the importance of smooth muscle signalling to the endothelium should not be 
overlooked in future studies. In this respect, we hypothesise that in areas of inflamed 
endothelium/atherosclerosis, both cell types drive the production of pro-calcific signals that 
drive medial VC (McCullough et al., 2008), and contribute to elevated circulating BMP-2/ALP 
often accompanying vascular pathologies (Rao and Morghom, 1986; Zhang et al., 2015).  
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4.5.5.2 The Effects of RANKL on VC Indices under Inflammatory Conditions in Co-culture 
Several authors have recognised the comparable effects of RANKL and TNF, and have 
considered inter-related functions for these proteins in co-culture models. In this respect, it has 
been noted that RANKL-induced pro-calcific activity in smooth muscle is dependent on TNF 
(Deuell et al., 2012), while RANKL-induced TNF has been considered an autocrine factor in 
osteoclastic differentiation (Nakao et al., 2007). As such, the pro-calcific effects of RANKL 
under inflammatory conditions were next assessed.  
Following the addition of RANKL, a significant increase in BMP-2 release was measured in 
the subluminal compartment compared to TNF treatment alone, likely a combination of both 
paracrine and autocrine signalling. A similar trend was observed in ALP activity following 
TNF + RANKL exposure, but the effects of RANKL did not significantly elevate these levels 
beyond that of TNF treatment. Despite this, ALP was significantly upregulated in the 
underlying HASMCs, suggesting that RANKL may be necessary to induce smooth muscle 
ALP production in the vasculature, and reinforcing a key observation from Chapter 3. As a 
pertinent finding of this chapter, we therefore highlight the ability of RANKL to function 
alongside TNF to induce BMP-2 paracrine signalling (and to a lesser extent ALP activity), 
further enhancing VSMC calcification and matrix mineralisation (Davenport et al., 2016; 
Osako et al., 2010; Schoppet and Shanahan, 2008). Also of interest, while TNF alone has no 
effect on Sox9 expression, RANKL promoted this chondrocytic transcription factor both alone 
and in the presence of inflammation; this observation may indicate that the induction of Sox9 
in co-cultured HASMCs is RANKL-specific, and may be associated with the aforementioned 
upregulation of ALP. The TNF-specific downregulation of Runx2, however, remains 
unaffected by RANKL, and as such, further implicates chondrocytic rather than osteocytic 
regulation during VC (Speer et al., 2009). As a final note, the addition of RANKL under 
inflammatory conditions slightly promoted OPG production, despite RANKL treatment alone 
reducing it. As a potential explanation, this effect may result from residual RANKL traversing 
the damaged endothelial monolayer and acting directly on underlying HASMCs (a direct effect 
observed in Section 4.4). 
 
4.5.5.3 The Effects of TRAIL on VC Indices under Inflammatory Conditions in Co-culture 
There is limited literature to draw on regarding the role of TRAIL under inflammatory 
conditions in vitro, but the anti-atherosclerotic and anti-calcific effects of this ligand have been 
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highlighted in vivo (di Bartolo et al., 2013; Liu et al., 2014; Secchiero et al., 2006). Therefore, 
this study is the first of its nature to consider the combined effects of TRAIL + TNF in a 
vascular setting, and even more pertinently, in co-culture, adding to the pathophysiological 
relevance of these findings. 
Firstly, TRAIL was found to exert a clear protective effect by attenuating TNF-induced pro-
calcific autocrine/paracrine signalling, as it significantly reduced BMP-2/ALP release into the 
subluminal space, emulating its protective influence on RANKL-induced pro-calcific 
signalling identified in Chapter 3. It must be noted that, in the aforementioned HAEC studies, 
this trend was also observed alongside an increase in non-canonical NF-B activation, 
suggesting that this pathway may also be involved in the regulation of endothelial paracrine 
signalling under inflammatory conditions. While TRAIL has been found to prevent endothelial 
BMP-2 release, it also decreases TNF-induced BMP-2 production in co-cultured HASMCs, 
indicating a protective role for TRAIL in both cell types during inflammation. Furthermore, 
TRAIL slightly promotes TNF-induced OPG release, that (given the significantly higher OPG 
production in smooth muscle compared to endothelial cells (Davenport et al., 2018)) can be 
primarily attributed to the HASMC layer. Again, this trend is not recapitulated at an mRNA 
level; thus, the bimodal regulation of OPG observed in Chapter 3 remains prominent under 
inflammatory conditions.  
 
4.5.5.4 The Effects of Hyperglycemia on VC Indices in Co-culture 
As discussed, circulating glucose can be transported through the endothelial monolayer via 
active GLUT-1 transport (Viator and Fouty et al., 2009) to act directly on underlying HASMCs 
in vivo, and as such, vascular issues that are common during T2DM may result from both EC 
and VSMC autocrine/paracrine signalling. The effects of hyperglycemia have previously been 
studied in EC:VSMC co-culture, but these studies focus on proliferation and inflammation and 
have not been completed in aortic models to date (Tarallo et al., 2012; Zitman-Gal et al., 2015). 
Thus, as we investigate the effects of high glucose on pro-calcific vascular signalling for the 
first time, it must be noted that there is limited data with which to compare these novel results.  
Unsurprisingly, a number of pro-calcific indices were upregulated under hyperglycemic 
conditions, most relevantly BMP-2/ALP in the subluminal space. As noted, these pro-calcific 
autocrine/paracrine signals are likely generated by both HAECs and HASMCs, contributing to 
elevated circulating BMP-2/ALP during T2DM (Rao and Morghom, 1986; Zhang et al., 2015). 
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Furthermore, IL-6 release within the subluminal space was elevated during hyperglycemia, as 
previously observed in co-culture (Zitman-Gal et al., 2015), which may further promote the 
aforementioned pro-calcific signals (Kurozumi et al., 2016). Also, despite the role of IL-6 as a 
well-known inducer of NF-B activation (Brasier, 2010), this co-culture model further supports 
the observation that high glucose does not promote VC via NF-B signalling.  
As a further note, the upregulation of Sox9 transcription factor alongside the downregulation 
of Runx2 again implicates chondrocytic rather than osteoblastic regulation during glucose-
induced pro-calcific signalling. As discussed, both factors have been shown to exert similar 
pro-calcific effects (Luo et al., 1997; Speer et al., 2009; Tyson et al., 2003), and this finding 
supports a key novel finding of Chapter 3 (in which RANKL-induced Sox9 was identified in 
co-cultured HASMCs). As an additional interesting finding, high glucose was found to 
decrease OPG mRNA/protein in co-cultured HASMCs, while OPG release remained 
unaffected, despite circulating OPG widely known to be increased during type-2 diabetes 
(Bjerre, 2013; Secchiero et al., 2006). Therefore, from the current data, it appears that 
hyperglycemia itself does not induce OPG release in areas of healthy vasculature; rather this 
circulating OPG may be the result of glucose-induced secretion in areas of damaged 
endothelium, or induced by inflammatory cytokines that often accompany hyperglycemia in 
these patients (Esposito et al., 2002).  
 
4.5.5.5 The Effects of RANKL on VC Indices under Hyperglycemic Conditions in Co-culture 
To our knowledge, no studies to date have considered the effects of RANKL under 
hyperglycemic conditions in vascular cell co-culture models. As such, the finding that RANKL 
exerts an additive effect on glucose-induced BMP-2/ALP pro-calcific paracrine signalling, 
promoting underlying HASMC calcification, is particularly novel. Moreover, the upregulation 
of Sox9 in the underlying HASMC layer, alongside decreased Runx2 expression, further 
suggests that both hyperglycemia and RANKL promote chondrocytic rather than osteoblastic 
pro-calcific signalling in smooth muscle (Speer et al., 2009). Indeed, RANKL and glucose also 
exerted an additive effect on this transcription factor in co-cultured HASMCs, in a similar 
manner to BMP-2/ALP release. Again, pro-calcific IL-6 levels (Hénaut and Massy, 2018) 
remain unchanged in the presence of RANKL, and as such, the aforementioned promotion of 
BMP-2, ALP and Sox9 are RANKL-specific, emulating trends observed in Chapter 3.  
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As another interesting observation, while a decrease in OPG mRNA was observed, no effects 
were noted in OPG release levels; thus, glucose appears to interrupt RANKL-induced OPG 
secretion in co-culture. We therefore propose that, under healthy conditions, OPG may be 
released as a natural cardioprotective mechanism in response to its pro-calcific ligand; under 
hyperglycemic conditions, however, the vasculature is left open to injury and may be more 
susceptible to RANKL-induced pro-calcific effects. This finding also further supports the 
proposition that inflammatory rather than hyperglycemic processes may be more responsible 
for the increase in circulatory OPG release noted during early T2DM (Secchiero et al., 2006). 
 
4.5.5.6 The Effects of TRAIL on VC Indices under Hyperglycemic Conditions in Co-culture 
Similarly, with regard to TRAIL, no studies to our knowledge have investigated the effects of 
this ligand on the vasculature under hyperglycemic conditions, and as such, there no data 
available with which to compare these results. In a significant and novel finding of this chapter, 
however, TRAIL was found to completely attenuate glucose-induced BMP-2/ALP release into 
the subluminal space, thus preventing pro-calcific effects in the underlying HASMCs 
(Davenport et al., 2016; Schoppet and Shanahan, 2008). Of particular relevance, we 
highlighted both in Chapter 3 and in inflammatory models in the current study that non-
canonical NF-B activation may be centrally involved in pro-calcific signalling, and that 
TRAIL may exert its protective effects via attenuation of this pathway. In this case, however, 
TRAIL exerts protective effects in the absence of non-canonical activation, and thus TRAIL-
mediated protection during hyperglycemia must progress via a different mechanism. We 
propose that, given strong evidence in the literature that high glucose induces oxidative stress 
(Fiorentino et al., 2013), the vasoprotective effects of TRAIL may be due to the proposed anti-
oxidant properties of this ligand (Forde et al., unpublished observations). TRAIL is indeed well 
known as a pleiotropic molecule (Forde et al., 2016), and its vascular function likely involves 
multiple interrelated mechanisms which remain to be fully delineated (see Chapter 5).  
Also of interest, the observed TRAIL protection during hyperglycemia may be mediated in part 
by a reduction in pro-calcific IL-6 release, known to promote VC (Hénaut and Massy, 2018). 
Indeed, the interrelated roles of both hyperglycemia and inflammation have recently been noted 
by Chu et al. (2018), who highlighted (in an EC:VSMC co-culture model) the importance of 
reduced cytokine release in the prevention vascular disorders, further supporting the key role 
of paracrine signalling in vascular protection (Chu et al., 2018). TRAIL-induced OPG release 
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from HASMCs may also contribute to these vasoprotective effects, however, it must be 
considered that this effect may be more accurately described as a short-term cardioprotective 
response, contributing to the proposed role for OPG as a biomarker of vascular injury 
(Secchiero et al., 2006). It is unlikely that OPG is fully responsible for the protective effects of 
TRAIL noted above, given that RANKL exerts its pro-calcific function even in the presence of 
excess OPG.  
 
4.5.5.7 Co-culture: Summary  
As summarised in Table 4.4, the employed inflammatory and hyperglycemic co-culture models 
further enforce the key findings from Chapter 3: RANKL promotes pro-calcific signalling via 
the induction of paracrine BMP-2/ALP release, while TRAIL exerts a protective influence via 
the attenuation of pro-calcific signalling under pathological conditions. It is likely that these 
effects are mediated at both an endothelial and smooth muscle level, secreting proteins that 
ultimately drive VC. Moreover, RANKL and TRAIL modulate the release of their own decoy 
receptor, OPG, which may further contribute to these effects. Given the physiological relevance 
of this co-culture model, these novel findings provide significant evidence to implicate 
RANKL and TRAIL in the progression and prevention of VC, respectively, under pathological 












Figure 4.19. Summary of the key HASMC responses following endothelial exposure to RANKL/TRAIL +/- 
TNF (inflammation) and high glucose in co-culture. RANKL was found to further upregulate (red arrow) a 
number of pro-calcific indices when compared to TNF or glucose treatment alone. TRAIL was found to reduce 




















4.6 Summary and Conclusions 
In summary, this chapter profiles the effects of RANKL and TRAIL on pro-calcific signalling 
in the presence of inflammation and hyperglycemia, pathological conditions common during 
T2DM/CVD. Within the realm of VC, this is undoubtedly the most comprehensive study to 
date to be completed in primary human vascular cell mono- and co-culture models, and the 
first to combine known mediators of VC with these pathological stimuli. As noted, given the 
likelihood of endothelial dysfunction and glucose transport within these models, we build on 
the data observed in healthy vasculature in Chapter 3 to now consider both paracrine and 
autocrine signals that may regulate calcification in VSMCs under pathological conditions. 
Firstly, we have confirmed the pro-calcific effects of TNF and high glucose in the vascular 
intima and media across a wide range of indices, somewhat clarifying the pro-calcific 
signalling processes that occur during these pathologies. Of interest, the pro-calcific and the 
protective effects of RANKL and TRAIL respectively during these pathological conditions 
were particularly obvious in EC:VSMC co-culture. Most prevalently, RANKL exerted an 
additive effect on both TNF and glucose-induced BMP-2/ALP paracrine/autocrine signalling 
in the subluminal space, while TRAIL significantly attenuated BMP-2/ALP release induced by 
these stimuli. We suggest, therefore, that RANKL may function alongside inflammation and 
hyperglycemia to promote medial VC via BMP-2/ALP pro-calcific signalling (Davenport et 
al., 2016; Osako et al., 2010), while we highlight for the first time the protective influence of 
TRAIL on pro-calcific signalling under these conditions. These effects may be mediated via 
the non-canonical NF-B signalling pathway under inflammatory conditions, previously 
implicated in RANKL/TRAIL function in Chapter 3. However, we can conclude that RANKL- 
and TRAIL-induced pro-calcific and protective effects respectively appear to be mediated by 
a different mechanism during hyperglycemia, which remains to be investigated.  
Overall, therefore, we have profiled for the first time the pro-calcific effects of RANKL and 
the protective effects of TRAIL in physiologically relevant co-culture models, delineating the 
relevant signalling processes that exist under pathological conditions common during 
T2DM/CVD. These findings add significant and novel knowledge to the field of VC research, 
particularly with respect to the roles of RANKL and TRAIL, and most importantly emphasise 
the translational value of TRAIL as a potential therapeutic for cardiovascular complications 
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5.1 Introduction  
5.1.1 Background and Hypothesis Development 
The cellular mechanisms by which RANKL and TRAIL exert their function, while clarified in 
other areas of research, remain largely undefined in a vascular context. RANKL is known to 
activate both canonical and non-canonical NF-B signalling via its cell surface receptor, 
RANK, and both pathways play important roles in osteoclastogenesis (Beristain et al., 2012; 
Boyce et al., 2015). However, the specific involvement of these pathways has not yet been 
clarified in VC, and although research points to a pro-calcific role for non-canonical activation 
in smooth muscle (Panizo et al., 2009), the data presented in Chapter 3 is the first to implicate 
this pathway in endothelial pro-calcific signalling. Furthermore, RANKL has been shown to 
induce oxidative stress, a key promoter of VC (Byon et al., 2008; Thummuri et al., 2017), 
which may suggest that multiple mechanisms contribute to its pro-calcific vascular function.  
TRAIL has also been associated with many pathways in its role as a pleiotropic molecule 
(Forde et al., 2016). However, like RANKL, its precise mechanism(s) of action in the 
vasculature remain largely unspecified, particularly with respect to VC protection (di Bartolo 
et al., 2013; Secchiero et al., 2006). In Chapters 3 and 4, novel evidence suggested that TRAIL 
may attenuate non-canonical NF-B signalling induced by pro-calcific stimuli (RANKL, 
TNF⍺) acting upon the endothelium. Moreover, TRAIL also attenuated glucose-induced pro-
calcific signalling in the absence of non-canonical activation, suggesting that additional 
mechanism(s) of TRAIL protection may exist. Pertinently, recent evidence has emerged within 
our research group that TRAIL may exert anti-oxidant effects in the endothelium (Forde et al., 
unpublished observations). Indeed, RANKL, TNF⍺ and glucose are all known promoters of 
oxidative stress (Chen et al., 2008; Li et al., 2017; Thummuri et al., 2017), and as such, further 
clarification of the anti-oxidant role for TRAIL in VC is merited.  
In the current chapter, an effort will be made to shed additional light on the mechanisms by 
which RANKL and TRAIL exert their respective pro-calcific and protective influences on the 
vasculature. In consideration of the key findings of Chapters 3 and 4, we propose that non-
canonical NF-B signalling and oxidative stress pathways may together regulate the effects 
of RANKL and TRAIL in the vascular endothelium. Given the complex roles for both ligands 
in vivo, and the wide range of pathways with which they interact (Beristain et al., 2012; Forde 
et al., 2016), an attempt will also be made to identify novel participants that may influence 
RANKL/TRAIL function during VC.  
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5.1.2 Study Aims 
As noted, the precise mechanisms underlying RANKL-induced pro-calcific signalling and 
TRAIL-mediated protection have yet to be fully defined in a vascular setting, although 
evidence points to the involvement of non-canonical NF-B signalling and oxidative stress. 
We therefore once again employ primary human vascular cells in both mono- and co-culture 
models in an attempt to provide novel insights into the pathways activated by these proteins 
during VC. Given the pertinent role for EC paracrine signalling in RANKL/TRAIL function 
identified in Chapters 3 and 4, a focus on the endothelium will be maintained.  
Three main study objectives were developed, carried out in tandem but arranged in the 
following order for clarity:  
1. To identify novel VC participants that may aid in delineating the mechanisms 
responsible for RANKL-induced calcification and TRAIL-mediated protection. 
2. To investigate the involvement of oxidative stress in endothelial VC regulation, 
with respect to RANKL-induced pro-oxidant signalling and TRAIL-mediated anti-
oxidant protection.   
3. To specify the role for endothelial non-canonical NF-B activation in RANKL-
induced pro-calcific signalling, thus clarifying the importance of TRAIL-mediated 
attenuation of this pathway.  
 
5.1.3 Study Overview  
Given the comprehensive nature of this study, the specific experimental approach/research 
background for each aim is described in the relevant sections. A brief overview is summarised 
overleaf in Figure 5.1, with the above objectives determining the three key investigations:  
 
5.1.3.1 Identification of Novel VC Targets  
To aid in the understanding of the mechanisms responsible for RANKL-induces pro-calcific 
signalling and TRAIL-mediated protection, novel participants in the VC process were 
investigated. Following a combination of bioinformatics and literature analyses, any proteins 
identified as potential contributors to the VC process would be assessed under all experimental 



























Figure 5.1. Schematic representation of the experiments and techniques employed in Chapter 5. 
Experimental models from Chapters 3 employing RANKL and TRAIL, and from Chapter 4 incorporating 
the pathological stimuli TNF⍺ and glucose, were employed where deemed necessary for the current series 
of experiments. HAEC/HASMC monoculture and HAEC:HASMC co-culture models were 
employed/modified where required, indicated above by the relevant colour code. Three mechanistic routes 
were investigated; the identification of novel targets, oxidative stress pathways, and the non-canonical 
NF-B signalling pathway. Experimental targets were analysed by RT-qPCR, Western blotting, ELISA, 
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5.1.3.2 Investigating the Role of Oxidative Stress in VC Regulation 
As noted, recent evidence points to a pro-oxidant and anti-oxidant role for RANKL and TRAIL 
respectively, however, the precise role(s) for oxidative stress in VC remain to be delineated. 
The following experiments were carried out to clarify the involvement of pro-/anti-oxidant 
events in RANKL/TRAIL function in the endothelium:  
(i) The expression of SOD1 and SOD2 in HAECs, contributors to the regulation of 
cytoplasmic and mitochondrial ROS respectively, known for their cardioprotective 
effects (Fukai and Ushio-Fukai, 2011); these proteins were assessed under all 
conditions employed in Chapters 3 and 4.  
(ii) The expression of pro-/anti-oxidant genes in HAECs in response to RANKL +/- 
TRAIL, including: 
 
a.  the pro-oxidant genes gp91-phox and p47-phox (referred to as gp91 and p47 
from this point onward), subunits of the superoxide generator NADPH oxidase; 
b. eNOS, with cardioprotective functions ascribed to its synthesis of NO 
(Förstermann et al., 1994);  
c. HMOX1, induced in response to oxidative stress and believed to be protective 
(Gozzelino et al., 2010).  
(iii) The effects of N-acetyl-L-cysteine (NAC) anti-oxidant treatment on RANKL pro-
calcific function, to determine if pro-calcific and pro-oxidant pathways are inter-
dependent in the endothelium. 
(iv) The effects of TRAIL on RANKL-induced ROS, to determine if the potential anti-
oxidant effects of TRAIL may contribute to TRAIL-mediated protection from 
RANKL pro-calcific signalling.  
 
5.1.3.3 Clarifying the Role of Endothelial Non-canonical NF-B Signalling during VC 
In order to assess the importance of non-canonical NF-B activation for RANKL-induced pro-
calcific signalling, co-cultured HAECs were subject to siRNA knockdown of a key component 
of the non-canonical pathway, namely p100/p52. Endothelial paracrine signalling, alongside 
all pro-calcific indices in HASMCs assessed in Chapters 3 and 4, were analysed. Furthermore, 
given the potential interlinked roles for pro-calcific and pro-oxidant signalling in response to 
RANKL, a range of targets associated with oxidative stress were also assessed.  
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5.1.4 Experimental Design 
For the identification of novel targets involved in VC signalling, bioinformatics analyses were 
conducted using two databases: the Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) and the Biological General Repository for Interaction Datasets (BioGRID). Proteins 
interacting with RANKL, TRAIL and any of the measured pro-calcific indices were of interest, 
alongside any predicted interactions determined via STRING computational prediction or text 
mining methods (Szklarczyk et al., 2016). Target(s) identified were first analysed at both an 
mRNA level (via RT-qPCR) and protein level (via Western blotting) in HAEC/HASMC 
monocultures grown in standard 6-well culture dishes. Second, HAEC:HASMC co-culture was 
implemented, whereby HAECs in the luminal compartment were treated in semi-permeable 
transwell inserts, and confluent HASMCs in the subluminal compartment were harvested for 
analysis in response to endothelial paracrine signalling (Figure 5.2). Potential target(s) were 
assessed following exposure to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL), and either  
RANKL (25 ng/mL) or TRAIL (5 ng/mL) under inflammatory (100 ng/mL TNF⍺) or 
















RANKL +/- TRAIL 
RANKL/TRAIL +/- TNF⍺ 
RANKL/TRAIL +/- Glucose 
Figure 5.2. Representation of the transwell co-culture model employed for novel VC 
target analysis. HAECs in the luminal compartment were exposed to soluble factors for 72 
hours. The HASMC transcriptome and proteome were harvested and analysed for mRNA 
and protein expression by RT-qPCR and Western blotting respectively. Image adapted from 
Harper et al., 2017.  
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In consideration of the observed contribution of the endothelium to VC signalling in Chapters 
3 and 4, the potential role for oxidative stress in RANKL/TRAIL regulation was assessed only 
in HAEC monoculture. SOD1 and SOD2 gene expression (via RT-qPCR) and protein 
expression (via Western blotting) was assessed following exposure to RANKL +/- TRAIL, and  
RANKL or TRAIL under inflammatory or hyperglycemic conditions for 72 hours. For the 
analysis of pro/anti-calcific gene expression, HAECs were exposed to RANKL +/- TRAIL for 
72 hours prior to analysis by RT-qPCR.  
To investigate the effects of NAC on RANKL function, HAECs were exposed to RANKL (25 
ng/mL) +/- NAC (5 mM, t - 1 hours) for 72 hours prior to gene and protein expression analysis 
by RT-qPCR and ELISA/Western blotting, respectively. NAC has been successfully employed 
at 5 mM concentration to achieve a potent anti-oxidant effect in endothelial cells, and has been 
shown to be optimally functional at scavenging its target (O2
-) in these cells when added 1 hour 
prior to treatment (Guinan et al., 2013). All pro-calcific and pro-oxidant genes/proteins were 
assessed (where deemed necessary) as previously described, to investigate the potential inter-
related mechanisms of VC and oxidative stress (BMP-2, ALP, Runx2, IL-6, OPG, NF-B/p52, 
SOD1/2, gp91, p47, eNOS, HMOX1). As a positive control, the effects of NAC on 100 ng/mL 
TNF⍺, a known pro-oxidant stimulus (Chen et al., 2008), was included to ensure NAC exerted 
the desired anti-oxidant effects in the employed cell model. For ROS analyses, the effects of 
RANKL +/- TRAIL were assessed by fluorescence microscopy (Section 2.2.6.2) and flow 
cytometry (Section 2.2.7.2) following 24 and 72 hours’ incubation. Once again, the effects of 
NAC on TNF⍺-induced ROS formation was assessed as a positive control for ROS 
induction/depletion (Chen et al., 2008).  
To clarify the role of non-canonical NF-B signalling in HAECs, siRNA knockdown of the 
p100 subunit (the precursor to p52) was carried out, according to the method described in 
Section 2.2.2.4. Following thorough transfection optimisation, HAECs were subject to non-
targetting siRNA/NFB2 gene knockdown in transwell inserts for 48 hours. Following 6 hours’ 
recovery in fresh media, transwell inserts were transferred to a 6-well culture dish containing 
confluent HASMCs, and HAECs subject to RANKL exposure for 72 hours. Conditioned media 
from the subluminal compartment, HAECs and HASMCs were harvested and analysed for pro-
calcific and pro-oxidant indices where necessary. All relevant controls, including untransfected 
cells and non-targetting siRNA treatments, were included as required.  
All studies presented in this chapter are conducted to n = 3 independent experiments. 
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5.2 Identification and Analysis of a Novel VC Target  
Prior to the investigation of oxidative stress and non-canonical NF-B signalling, novel 
participants in the VC process that may potentially contribute to delineating the overlapping 
pathways involved in RANKL-induced pro-calcific signalling and TRAIL-mediated protection 
were considered. In this respect, bioinformatics and literature analyses were employed to 
identify novel protein interactions not yet assessed in the context of VC, as described in detail 
in Section 2.2.8.  
 
5.2.1 Target Identification  
In order to identify novel targets, the STRING database (version 10.0) was first employed 
within which experimentally determined protein interactions and text mining predictions are 
recorded (Szklarczyk et al., 2016). Proteins interacting with RANKL, TRAIL and their soluble 
decoy receptor OPG were primarily assessed. Searches were conducted in accordance with the 
criteria detailed in Section 2.2.8 within both homo sapiens and mus musculus species databases 
in order to incorporate interactions that may not yet be identified in human studies. The primary 






RANKL OPG TRAIL 
OPG RANKL OPG 
RANK TRAIL Caspase 3, 8, 10 
PTH TGFβ-1 DcR1, DcR2 
TRACP5 PTH DR4, DR5 
TRAF6 TRACP5 FADD 
BMP-2 IL-18  
STAT3   
FADD, fas-associated protein with death domain; PTH, parathyroid hormone; TRACP5, tartrate-resistant acid 
phosphatase 5; TRAF, TNF receptor associated factor; TGF, transforming growth factor; STAT3, signal 
transducer and activator of transcription 3. 
Table 5.1. Key protein interactions and potential interactions with RANKL, OPG and TRAIL identified 
using the STRING database (version 10.0). 
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Following further analyses according to the same search criteria, only TRACP5 (identified as 
a potential interactant for both RANKL and OPG via STRING analysis) was found to also 
associate with the previously identified pro-calcific paracrine proteins BMP-2 and ALP. 
Moreover, following additional protein interaction analysis using the BioGRID database 
(version 3.4.142), TRACP5 was also listed as a potential interactant with TRAIL. As such, the 
target TRACP5 was subject to functional analysis using the Universal Protein (UniProt) 
database (entry P13686). Several key functions of interest, overlapping with those of RANKL, 
TRAIL, OPG and other pro-calcific indices, were computationally inferred: 
(i) Regulation of bone morphogenesis, predominantly bone resorption; 
(ii) Osteoclast differentiation and activation; 
(iii) BMP signalling; 
(iv) OPN/BSP dephosphorylation; 
(v) Negative regulation of NO biosynthesis; 
(vi) Regulation of IL-1β; 
(vii) Superoxide anion (O2-) generation; 
(viii) Response to L-ascorbic acid. 
Thus, the investigation of a potential role for TRACP5 in the development and progression of 
VC was clearly warranted on a bioinformatics basis, with protein interactions and overlapping 
functions with key VC-related indices identified. Following an extensive literature review, 
discussed in detail in Section 5.2.5, several key studies also supported the potential 
involvement of TRACP5 in the VC process: 
(i) While primarily expressed in bone, TRACP5 is also expressed in heart tissue, and 
increased expression of TRACP5 has been identified in atherosclerotic lesions 
compared to normal regions of human aorta (Timofeeva et al., 2009);  
(ii) TRACP5 is upregulated in the artery of obese pigs, coinciding with the induction 
of pro-inflammatory, pro-oxidant and NF-B pathways (Padilla et al., 2013);  
(iii) RANKL induces TRACP5 expression in osteoclastogenesis, which can be 
attenuated by statin treatment (Nakashima and Haneji, 2013); 
(iv) TRACP5 co-localises with OPG/RANKL in chondrocytes (Solberg et al., 2015); 
(v) Recombinant TRAIL injection decreases circulating TRACP5 levels in vivo (Zauli 
et al., 2008); 
(vi) TRACP5 can be activated by oxidative stress in chondrocytes (Seol et al., 2009). 
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Given the apparent role for TRACP5 in bone morphogenesis and oxidative stress, this evidence 
further supports a potential role for this protein in VC, not yet investigated to date. Although 
the primary role for TRACP5 appears to be bone resorption, rather than formation, the similar 
paradoxical function of RANKL (i.e., exerting osteoclastic effects in bone and osteoblastic 
effects in vasculature) cannot be ignored; therefore, the role of TRACP5 in RANKL/TRAIL-
mediated VC was next investigated. 
 
5.2.2 The Effects of RANKL +/- TRAIL on TRACP5 Expression 
First, the effects of RANKL +/- TRAIL on TRACP5 expression in both mono- and co-culture 
were assessed. In HAEC monoculture, 25 ng/mL RANKL increased TRACP5 mRNA 
expression, and also induced TRACP5 protein expression, significantly at 5 ng/mL. TRAIL 
was found to significantly decrease TRACP5 mRNA expression both alone and in combination 
with 5 ng/mL RANKL, while also decreasing RANKL-induced TRACP5 protein expression 
(Figure 5.3A). In HASMC monoculture, RANKL treatment was found to dose-dependently 
induce TRACP5 transcript expression; while TRAIL also slightly, but significantly, increased 
TRACP5 mRNA, it also significantly reduced RANKL-induced TRACP5 expression at 25 
ng/mL. No effects, however, were noted in TRACP5 protein expression in HASMCs (Figure 
5.3B), nor were any effects noted at an mRNA or protein level in co-cultured HASMCs (Figure 
5.3C). The calcification inducer, β-glycerophosphate, was found to increase TRACP5 
mRNA/protein expression in HAECs (Appendix 5.1A (i), (iv)) and HASMCs (data not shown).   
 
5.2.3 The Effects of RANKL/TRAIL on TRACP5 Expression during Inflammation 
Following TNF⍺ exposure, TRACP5 mRNA expression was significantly reduced in both 
HAECs and HASMCs in monoculture, while it was significantly upregulated in co-cultured 
HASMCs (Figure 5.4A-C (i)). The addition of RANKL further downregulated TRACP5 
mRNA in HASMC monoculture, while TRAIL somewhat recovered the TNF⍺-induced 
downregulation of TRACP5 mRNA in the same model (Figure 5.4B (i)). Interestingly, TRAIL 
further upregulated TNF⍺-induced TRACP5 mRNA in co-cultured HASMCs (Figure 5.4C (i)). 
TRACP5 protein remained unaffected by TNF⍺ treatment in both mono- and co-culture, and 
the addition of RANKL did not exert any effect on TRACP5 protein expression under 
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inflammatory conditions. TRAIL, however, significantly upregulated TRACP5 protein 
expression in all models employed (Figure 5.5A-C (i)).  
 
5.2.4 The Effects of RANKL/TRAIL on TRACP5 Expression during Hyperglycemia 
To ensure that the observed effects under hyperglycemic treatment were glucose-specific, an 
osmotic control was first employed;  mannitol (30 mM) had no effect on TRACP5 protein 
mRNA/protein expression in HAECs (Appendix 5.1A (i)) or HASMCs (data not shown). At 
an mRNA level, high glucose significantly downregulated TRACP5 mRNA in HAECs (at 30 
mM) and HASMCs, while dose-dependently upregulating TRACP5 mRNA in co-cultured 
HASMCs (Figure 5.4A-C (ii)). Interestingly, following RANKL addition, TRACP5 transcript 
expression was significantly upregulated under hyperglycemic conditions in HAECs (Figure 
5.4A (ii)). High levels of glucose had no effect on TRACP5 protein expression in mono- or co-
culture (Figure 5.5A-C (ii)). Exposure to TRAIL (but not RANKL) under hyperglycemic 
conditions, however, significantly promoted TRACP5 protein expression in both endothelial 
and smooth muscle monoculture. Neither ligand exerted any effects on TRACP5 protein 


















































Figure 5.3. The effects of RANKL +/- TRAIL on TRACP5 expression. (A) HAECs and (B) HASMCs were exposed 
to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours, prior to harvesting and analysis of TRACP5 (i) mRNA 
and (ii) protein expression. (C) HAECs in the luminal compartment in co-culture were exposed to the same conditions, 
and the underlying HASMCs harvested and assessed for TRACP5 (i) mRNA and (ii) protein expression. Gene 
expression was analysed by RT-qPCR employing GAPDH as an endogenous control, while protein expression was 
assessed by Western blotting, quantified by scanning densitometry and normalised to GAPDH. Blots are representative. 
* p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical 































(i)  (ii)  
(i)  (ii)  
(i)  (ii)  
Figure 5.4. The effects of RANKL/TRAIL on TRACP5 mRNA expression under inflammatory and 
hyperglycemic conditions. (A) HAECs and (B) HASMCs were exposed to (i) TNF⍺ (100 ng/mL) or (ii) 
glucose (15-30 mM) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours, prior to analysis of TRACP5 
mRNA expression. (C) HAECs in the luminal compartment in co-culture were exposed to the same 
conditions, and the underlying HASMCs harvested and assessed for TRACP5 mRNA expression. TRACP5 
levels were determined by RT-qPCR, employing GAPDH as an endogenous control. * p < 0.05; ** p < 0.01; 
*** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance 

































(i)  (ii)  
(i)  (ii)  
(i)  (ii)  
Figure 5.5. The effects of RANKL/TRAIL on TRACP5 protein expression under inflammatory and hyperglycemic 
conditions. (A) HAECs and (B) HASMCs were exposed to (i) TNF⍺ (100 ng/mL) or (ii) glucose (15-30 mM) +/- RANKL 
(25 ng/mL) or TRAIL (5 ng/mL) for 72 hours, prior to analysis of TRACP5 protein expression. (C) HAECs in the luminal 
compartment in co-culture were exposed to the same conditions, and the underlying HASMCs harvested and assessed for 
TRACP5 protein expression. TRACP5 levels were determined by Western blotting, quantified by scanning densitometry 
and normalised to GAPDH. Blots are representative. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control 




5.2.5 Discussion: TRACP5 Analysis   
It is now known that RANKL and TRAIL play central roles in the regulation of VC. However, 
much remains to be delineated regarding the precise molecular signalling processes and 
mechanisms underpinning these functions. The key aim of this investigation, given the 
integrated roles for these ligands identified previously, was to identify novel targets that may 
aid in the understanding of RANKL-induced calcification and TRAIL-mediated protection. 
Following in-depth bioinformatics and literature analyses, TRACP5 was identified as a 
potential interactant with RANKL/TRAIL, with multiple associated functions in bone 
morphogenesis and oxidative stress. Hence, this protein was assessed in both mono- and co-
culture, following exposure to RANKL, TRAIL and pathological stimuli employed in previous 
chapters. 
 
5.2.5.1 Identification of a Novel VC Target: TRACP5  
Following bioinformatics analyses, a number of proteins that may potentially interact with 
RANKL, TRAIL and their common decoy receptor OPG were identified. As expected, 
RANKL and TRAIL were associated with their membrane and decoy receptors, while TRAIL’s 
primary role as an apoptosis-inducing ligand was highlighted in its interaction with caspase 
proteins (Li and Yuan, 2008). The interaction between RANKL and TRAF6 is also well-
established, with TRAF6 known to mediate RANKL-induced signals such as NF-B in bone 
(Armstrong et al., 2002). Interestingly, text mining analyses revealed a potential interaction of 
RANKL/OPG with PTH; indeed, PTH has been implicated in the development of VC, 
particularly associated with renal failure (Neves et al., 2007), but no studies to date have 
identified a link between PTH and TRAIL function. Of additional note, despite reports of 
TRAIL-mediated vasoprotection in previous studies (di Bartolo et al., 2011; Liu et al., 2014; 
Secchiero et al., 2006), TRAIL has not yet been associated with any VC-related indices via 
bioinformatics. This finding emphasizes the novelty of the studies presented in Chapters 3 and 
4, and indicates that TRAIL may indirectly mediate pro-calcific pathways (via mechanism(s) 
that remain to be determined) rather than through direct interaction with pro-calcific proteins. 
Highlighting the importance of a comprehensive bioinformatics strategy, BioGRID  analysis 
suggested that TRACP5, identified as a potential interactant with RANKL/OPG via STRING 
text mining, also interacted in some way with TRAIL; furthermore, TRACP5 was associated 
with many of the same pathways/processes central to RANKL/TRAIL function in vivo.  
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5.2.5.2 The Function of TRACP5 in Bone and Vasculature 
Several functions of TRACP5 identified in the UniProt and BioSystems databases overlap with 
that of RANKL and TRAIL, potentially implicating this protein in VC pathogenesis. TRACP5 
is known to be expressed in a number of cell types in vivo, in particular osteoclasts and activated 
macrophages, but has also been identified in the heart, among other organs and tissues 
(Hayman et al., 2000). In this case, the role for TRACP5 in osteoclasts, regulating bone 
resorption, was of particular interest. TRACP5 shares this primary function with that of 
RANKL, but the role for TRACP5 in the vasculature remains understudied. Given the 
paradoxical role for RANKL in bone and vasculature (i.e. resorbing bone while promoting 
VC), the potential for TRACP5 to exert similar pro-calcific effects could not be disregarded. 
Indeed, TRACP5 is also expressed in osteoblasts (Solberg et al., 2014) and has been suggested 
(through bioinformatics) to regulate osteoblast differentiation/activation. In fact, Lau and 
Baylink (2003) have previously identified two distinct isoenzymes of TRACP5, one with 
osteoclastic and one with osteoblastic function, further indicating a dual role for this protein.   
Moreover, computational analysis associated TRACP5 function with BMP receptor signalling. 
Again, the primary function for BMPs are that of bone morphogenesis, striking a balance 
between formation and resorption (Paul et al., 2009), but their role in the regulation of VC has 
now been well established (Davenport et al., 2016; Osako et al., 2010; Panizo et al., 2009). 
BMPs (2-7) have previously been shown to promote the formation of TRACP5-positive 
multinucleated osteoclasts in bone (Paul et al., 2009), and as such, BMP signalling in the 
vasculature may also promote TRACP5 expression. Furthermore, bioinformatics analyses also 
identified a role for TRACP5 in extracellular matrix mineralisation, although it is not specified 
whether positive or negative; this function is likely linked to OPN/BSP dephosphorylation, a 
key process necessary for osteoclast migration (Ek-Rylander et al., 1994) but also responsible 
for the release of free phosphate into the extracellular space in a mechanism similar to that of 
ALP (Linder et al., 2017).  
Within the literature, there are several studies that suggest a role for TRACP5 in the promotion 
of bone formation. In this respect, TRACP5-deficient mice have been found to develop delayed 
cartilaginous mineralisation alongside severe osteopetrosis, while TRACP5-overexpressing 
mice develop mild osteoporosis and increased osteoblastic activity (Hayman et al., 1996; Angel 
et al., 2000). These effects would appear to contradict the osteoclastic function of TRACP5, 
suggesting once again a potential dual function for this protein in bone morphogenesis. 
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Evidence also points to an integrated role for TRACP5 and RANKL/TRAIL, relevant to both 
bone and vasculature. RANKL has been found to induce TRACP5 expression in osteoclasts 
(Nakashima and Haneji, 2013), while statin treatment was found to attenuate this effect, again 
highlighting the link between bone turnover and cardiovascular health. TRACP5 has also been 
found to co-localise with OPG/RANKL in chondrocytes (Solberg et al., 2015), of particular 
interest given the proposition that chondrocytic (rather than osteoblastic) signalling events 
mediate VC (Speer et al., 2009). TRACP5 expression has also been associated with NF-B 
activation, a pathway which plays a key role in bone resorption (Abu-Amer, 2013) but also 
contributes to pro-calcific signalling (Zhao et al., 2012). With regard to TRAIL, recombinant 
injection has been found to decrease circulating TRACP5 levels in vivo (Zauli et al., 2008), 
coinciding with the previous observation that TRAIL delivery exerts a cardioprotective effect 
in murine models (Liu et al., 2014; Secchiero et al., 2006). Of further note, TRACP5 is thought 
to respond to L-ascorbic acid, a strong pro-calcific agent employed to promote osteoblastic 
differentiation (Ciceri et al., 2012). Overall, therefore, there is strong evidence to suggest a 
pro-calcific role for TRACP5 in the regulation of VC.   
Finally, following bioinformatics analyses, TRACP5 function was also associated with the 
promotion of oxidative stress, known to be involved in RANKL’s vascular function and 
implicated in the pathogenesis of VC (Byon et al., 2008; Thummuri et al., 2017). Like RANKL, 
TRACP5 is known to promote ROS generation in vivo (Halleen et al., 1999), and as such 
promotes a pro-oxidant environment. Consistent with this is the finding that TRACP5 
negatively regulates NO, an anti-oxidant signalling molecule centrally involved in 
cardioprotection (Hummel et al., 2006; Nasseem, 2005; Räisänen et al., 2005). Furthermore, 
TRACP5 has been shown to be activated by oxidative stress in chondrocytes (Seol et al., 2009), 
potentially suggesting a reciprocal regulatory mechanism between the two. Indeed, the 
aforementioned upregulation of arterial TRACP5, associated with NF-B signalling, was also 
found to coincide with pro-oxidant pathways (Padilla et al., 2013). Therefore, the hypothesised 
pro-calcific role for TRACP5 in the vasculature may, like RANKL, be accentuated by 
coexistent pro-oxidant effects. As recent evidence suggests an anti-oxidant role for TRAIL in 
the vasculature (Forde et al., unpublished observations), it may also be possible that TRAIL 




5.2.5.3 The Effects of RANKL +/- TRAIL on TRACP5 Expression  
Firstly, the expression of TRACP5 was investigated in vascular cells in mono- and co-culture 
following exposure to RANKL +/- TRAIL to determine if these ligands may regulate TRACP5 
expression during VC. As mentioned, TRACP5 has been found to be upregulated in 
atherosclerotic lesions compared to normal artery (Timofeeva et al., 2009), but its expression 
has not yet been confirmed in HAECs or HASMCs; thus, the first novel finding of note is that 
TRACP5 is expressed at both an mRNA and protein level in both aortic ECs and VSMCs. 
Following exposure to RANKL/TRAIL, the finding that RANKL promoted both TRACP5 
mRNA and protein expression in HAECs was particularly noteworthy, given the prominent 
role for the endothelium in pro-calcific signalling identified in Chapters 3 and 4. As mentioned, 
RANKL has been claimed to induce TRACP5 expression in osteoclasts (Nakashima and 
Haneji, 2013), but this finding has not yet been confirmed in vascular cells; thus, we highlight 
for the first time the presence of RANKL-mediated TRACP5 regulation in the endothelium, 
coinciding with pro-calcific BMP-2/ALP paracrine signalling and non-canonical NF-B 
activation also induced by RANKL. With regard to the latter, TRACP5 has, unsurprisingly, 
been associated with NF-B activation in its role in osteoclastogenesis (Abu-Amer, 2013), but 
whether or not TRACP5 activates NF-B within a vascular context remains to be determined. 
It is likely, however, given the potential for TRACP5 to exert pro-calcific effects as discussed 
in Section 5.2.5.2, that RANKL-induced TRACP5 expression may further contribute to 
signalling events (e.g. NF-B activation, matrix mineralisation) during VC pathogenesis. 
Even more interesting is the observed ability of TRAIL to completely attenuate RANKL-
induced TRACP5 mRNA/protein in HAECs. As noted, TRAIL exerts protective effects at an 
endothelial level in the prevention of RANKL-induced pro-calcific BMP-2/ALP and non-
canonical NF-B signalling. Given that TRACP5 is simultaneously attenuated suggests that 
TRACP5 expression may be mediated via the same pathway(s) that regulate other RANKL-
induced pro-calcific signals (eg. NF-B). In support of this, circulatory TRACP5 levels have 
been shown to be reduced following TRAIL delivery (Zauli et al., 2008). This finding also 
adds further validation to the protective nature of TRAIL in the vasculature, for which the 
mechanism(s) remain to be explored in the following sections; TRACP5 does, however, 
interact with both oxidative stress and NF-B pathways (Halleen et al., 1999), which will be 
investigated as potential targets for TRAIL-mediated protection in Sections 5.3 and 5.4 
respectively.  
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While a similar trend in TRACP5 expression was observed at an mRNA level in HASMCs, 
TRACP5 was not regulated at a protein level. The promotion and prevention of TRACP5 
transcript expression by RANKL and TRAIL respectively, however, suggests a role for 
TRACP5 in smooth muscle during VC. By way of explanation, TRACP5 protein expression 
has been shown to be upregulated in late stage (but not early stage) calcification induced by 
RANKL in monocyte precursor cells (Nie et al., 2015); as such, TRACP5 protein responses 
may vary across cell types, taking longer to exert a functional response in smooth muscle 
compared to endothelium. Finally, RANKL and TRAIL had no effect on TRACP5 regulation 
in co-culture. Thus, endothelial paracrine signalling does not mediate TRACP5 expression in 
HASMCs, but rather direct RANKL treatment of vascular cells.   
 
5.2.5.4 The Effects of RANKL/TRAIL on TRACP5 Expression during Inflammation 
The regulation of TRACP5 under pathological conditions is less easily explained. Despite the 
well-established pro-calcific, pro-oxidant and pro-inflammatory roles for TNF⍺, this cytokine 
did not exert any effect on TRACP5 protein expression in HAECs, HASMCs or HASMCs in 
co-culture. Contrastingly, TNF⍺ has previously been shown to promote TRACP5 expression 
in osteoclastogenesis (Azuma et al., 2000), again highlighting the conflicting regulation of this 
protein in bone and vasculature. Moreover, while RANKL treatment alone promoted TRACP5 
protein expression in HAECs, this effect was not sustained under inflammatory conditions, 
while TRAIL treatment significantly upregulated TRACP5 in the presence of TNF⍺. While 
difficult to interpret, these findings further support a key observation of Chapter 4 that the 
effects of RANKL and TRAIL vary significantly under healthy and pathological conditions.  
Interestingly, both TNF⍺ and RANKL share many of the same functions and activate similar 
signalling pathways in bone and vasculature (Al-Aly, 2008; Azuma et al., 2000; di Bartolo and 
Kavurma, 2014; Wada et al., 2006), and as such it is unclear why the presence of TNF⍺ 
attenuates RANKL-induced TRACP5 expression. By way of potential explanation, IL-6 pro-
inflammatory cytokine is widely known to be induced following TNF⍺ treatment (Modur et 
al., 1996), a trend confirmed in HAECs and HASMCs in Chapter 4. Interestingly, IL-6 directly 
inhibits differentiation of osteoclast progenitor cells by inhibiting specific components of 
RANK signalling pathways (IB, c-Jun N-terminal kinase), despite being widely considered a 
promoter of osteoclast activity (Yoshitake et al., 2008). Thus, Yoshitake and colleagues 
highlight a potential multifunctional role for IL-6 during osteoclast differentiation, which may 
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also extend to the vasculature, with IL-6 potentially attenuating RANKL-induced TRACP5 
expression while maintaining its pro-calcific function via uninhibited pathways.  
The observed upregulation of TRACP5 by TRAIL is also contradictory to our hypothesis; 
however, a potential explanation for this may lie with the regulation of TRAIL surface 
receptors. Previous research within our group, in accordance with the literature, have shown 
that TNF⍺ promotes the expression of DR5 in endothelial cells (Sheikh et al., 1998), and as 
such, it is possible that DR5 mediates additional signalling events in vascular cells; indeed, 
TRAIL has been found to induce osteoclastic activity and TRACP5 expression in 
monocyte/macrophage precursor cells (Yen et al., 2008). While this explanation is speculative, 
it is well known that TRAIL-mediated signalling can exert both pathological and protective 
effects under specific conditions (Forde et al., 2016), and thus it is possible that TRAIL 
promotes TRACP5 in the presence of inflammation. As suggested in previous chapters, this 
finding further implies that the vasoprotective effects of TRAIL may be most pertinent 
specifically during RANKL-induced calcification in areas of healthy, rather than 
atherosclerotic, vasculature.  
 
5.2.5.5 The Effects of RANKL/TRAIL on TRACP5 Expression during Hyperglycemia 
Once again, RANKL and TRAIL exert drastically different effects in the vasculature under 
hyperglycemic compared to normoglycemic conditions. Glucose-induced IL-6 may in part 
contribute to a reduction in RANKL-induced TRACP5 expression (Yoshitake et al., 2008), 
previously suggested in Section 5.2.5.4., but this cytokine is released to a much lesser extent 
under hyperglycemic compared to inflammatory conditions. There is no further evidence to 
our knowledge to support the apparent “protective” effects of glucose on RANKL-induced 
TRACP5 expression. In fact, hyperglycemia in T2DM has been associated with osteoporosis 
(Starup-Linde and Vestergaard, 2015), and has been shown to promote VC (Besueille et al., 
2015), suggesting a paradoxical role in bone and vasculature similar to that of RANKL.  
With regard to TRAIL, no evidence to our knowledge suggests that glucose regulates the 
expression of TRAIL receptors, and so the previously suggested upregulation of DR5 resulting 
in TRAIL-induced TRACP5 expression cannot be supported in this case. As noted, the 
pleiotropic role of TRAIL is well documented (Forde et al., 2016), and our data suggests that 
it may exert different effects under normal and pathological conditions. It must be noted, 
however, that the varying trends between mRNA and protein levels may hinder our 
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understanding of TRACP5 regulation in the vasculature. It is known that mRNA and protein 
trends do not always coincide (Carmody and Wente, 2009; Greenbaum et al., 2003), which 
seems particularly true for TRACP5 under pathological conditions, making the longer-term 
effects of RANKL/TRAIL treatment difficult to determine. Furthermore, it is possible that the 
apparent upregulation of TRACP5 observed following exposure to TRAIL may actually 
represent a blockade of TRACP5 release, rather than an increase in expression, similar to that 
observed with BMP-2 in Chapter 3. These explanations require further experimentation, but 
given the convincing evidence to support TRAIL protection, should not be disregarded. 
 
5.2.5.6 TRACP5: Summary of Results  
Following thorough analyses, we confirm that TRACP5 (despite its primary role in 
osteoclastogenesis) is expressed in vascular tissue, and suggest that it may be involved in 
RANKL-induced calcification and TRAIL-mediated protection in healthy vasculature 
(particularly the endothelium). Whether or not TRACP5 is mediated by the same proposed 
pathways as other pathological stimuli (i.e., NF-B, redox signalling), or if extracellular 
TRACP5 may contribute to VC, remains to be determined (Figure 5.6). The effects of 
RANKL/TRAIL on TRACP5 expression were altered under inflammatory and hyperglycemic 
conditions, however, further experimentation is required to explain these discrepancies. 
Overall, however, we find that TRACP5, like RANKL, may exert paradoxical roles in bone 










Figure 5.6. Representation of the key findings of TRACP5 investigations. Endothelial cell (upper layer) 
exposure to RANKL activates non-canonical NF-B and may also induce reactive oxygen species (ROS) 
generation. This leads to TRACP5 production, alongside BMP-2/ALP pro-calcific signalling, to induce 
calcification in the underlying (lower layer) smooth muscle. TRAIL co-incubation blocks this process thereby 
preventing calcification. It remains to be determined if TRACP5 is also released in a paracrine manner, or 






5.3 Identifying the Role of RANKL/TRAIL in Endothelial Oxidative Stress  
Oxidative stress plays a key role in many vascular processes, and has long been implicated in 
vasculopathies associated with CVD/T2DM (Higashi et al., 2009; Pitocco et al., 2013). As 
oxidative stress is a major contributor to endothelial dysfunction/VC (Silva et al., 2012; Singh 
et al., 2010), and given the profound role for the endothelium in VC signalling identified in 
Chapters 3 and 4, oxidative stress was deemed a valid target in the investigation of 
RANKL/TRAIL functional mechanisms. Indeed, RANKL has been shown to induce oxidative 
stress, which has been implicated in the promotion of VC (Byon et al., 2008; Thummuri et al., 
2017), while recent evidence points to an anti-oxidant role for TRAIL in the endothelium 
(Forde et al., unpublished observations). Moreover, TRACP5, a potential player in the VC 
process identified in Section 5.2.1, is thought to interact with RANKL/TRAIL function and is 
known to regulate oxidative stress (Seol et al., 2009). This finding further highlights the 
potential for the involvement of pro/anti-oxidant mechanisms in RANKL/TRAIL-mediated 
VC processes. In this section, a number of targets related to oxidative stress will be assessed, 
as listed in Section 5.1.3.2, while experimental approaches incorporating the anti-oxidant NAC 
will also be employed.  
 
5.3.1 The Expression of SOD1/SOD2 in HAECs  
First, the expression of SOD1/SOD2 in HAECs exposed to RANKL +/- TRAIL, and 
RANKL/TRAIL under inflammatory and hyperglycemic conditions, will be assessed. As 
discussed, SOD1 and SOD2 are involved in the conversion of superoxide radicals (O2
-) into 
less damaging species in the cytosol and mitochondria respectively, and as such are known 
exert cardioprotective effects in the vasculature (Fukai and Ushio-Fukai, 2011). The expression 
of SOD1/SOD2 was only assessed in HAECs, given the prominent role for the endothelium in 
VC regulation identified in previous chapters and in the relevant literature.  
 
5.3.1.1 The Effects of RANKL +/- TRAIL on SOD1/SOD2 Expression 
At an mRNA level, 25 ng/mL RANKL significantly downregulated SOD1 transcript 
expression by approximately 30%. TRAIL, on the other hand, significantly induced SOD1 














At a protein level, RANKL dose-dependently increased SOD1 protein expression (with a 
significant upregulation observed at 25 ng/mL), while TRAIL induced a non-significant up-
regulation of SOD1. SOD1 protein expression remained significantly upregulated in the 
presence of RANKL (5-25 ng/mL) + TRAIL (Figure 5.7B). Furthermore, β-glycerophosphate 
significantly induced SOD1 expression at both an mRNA and protein level (Appendix 5.1A 
(ii), (v)). Regarding SOD2, RANKL dose-dependently downregulated mRNA levels while 
TRAIL significantly increased its expression. SOD2 transcription levels returned to baseline, 
however, in the presence of both RANKL and TRAIL (Appendix 5.2). SOD2 protein 
expression remained undetectable by Western blotting under these conditions (data not shown), 
but its production was significantly induced following exposure to β-glycerophosphate 
(Appendix 5.1A (vi)).  
 
5.3.1.2 The Effects of RANKL/TRAIL on SOD1/SOD2 Expression during Inflammation 
Following exposure to TNF⍺, SOD1 mRNA expression was significantly upregulated; while 
the addition of RANKL slightly (but significantly) decreased its expression, SOD1 remained 
upregulated to the same extent in the presence of TRAIL (Appendix 5.3A (i)). TNF⍺ also 
upregulated SOD1 a protein level, while the addition of both RANKL and TRAIL (separately) 
reduced this effect by approximately 30% (Appendix 5.4A (i)). SOD2 transcript expression 
A B 
Figure 5.7. The effects of RANKL +/- TRAIL on SOD1 expression in HAECs. HAECs were exposed to 
RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours, prior to harvesting and analysis of SOD1 (A) mRNA 
and (B) protein expression. Gene expression was analysed by RT-qPCR employing GAPDH as an endogenous 
control, while protein expression was assessed by Western blotting, quantified by scanning densitometry and 
normalised to GAPDH. Blots are representative. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated 





was upregulated to a major extent (~60-fold) under inflammatory conditions, and again, while 
TRAIL had no effect on this, RANKL exposure slightly reduced these expression levels 
(Appendix 5.3B (i)). TNF⍺ also increased SOD2 protein expression ~5-fold, while the separate 
addition of RANKL and TRAIL reduced this expression by 40-45% (Appendix 5.4B (i)).  
 
5.3.1.3 The Effects of RANKL/TRAIL on SOD1/SOD2 Expression during Hyperglycemia 
Prior to glucose treatment, HAECs were again exposed to mannitol osmotic control to ensure 
that any observed effects on SOD expression were glucose-specific; as such, mannitol had no 
effect on SOD1/SOD2 expression at an mRNA (data not shown) or protein level (Appendix 
5.1B (ii), (iii)). Following hyperglycemic treatment, SOD1 mRNA expression was dose-
dependently upregulated, and no significant effects were noted following treatment with 
RANKL or TRAIL (Appendix 5.3A (ii)). SOD1 protein expression was elevated following 
both moderate and severe glucose treatment; while RANKL treatment did not significantly 
affect this trend, the addition of TRAIL partially reduced this effect (Appendix 5.4A (ii)). 
SOD2 mRNA expression was also upregulated following both moderate and severe 
hyperglycemic treatment. RANKL treatment completely attenuated this effect, while TRAIL 
further promoted SOD2 transcript expression, particularly in the presence of moderate 
hyperglycemia (Appendix 5.3B (ii)). Contrastingly, at a protein level, SOD2 remained 
undetectable following both RANKL and TRAIL treatment under hyperglycemic conditions.  
 
5.3.2 The Effects of RANKL +/- TRAIL on Pro-/Anti-oxidant Gene Expression in HAECs  
A range of redox genes (gp91, eNOS, HMOX1) were next assessed in HAECs exposed to 
RANKL +/- TRAIL to further investigate the role of oxidative stress in RANKL/TRAIL 
function. Interestingly, neither ligand had any notable effects on gp91 mRNA (only a slight 
decrease of approximately 20% was noted with 5 ng/mL RANKL), but 25 ng/mL RANKL 
significantly upregulated p47 transcript expression by ~1.4-fold. Furthermore, the addition of 
TRAIL non-significantly attenuated this effect (Figure 5.8A). Regarding anti-oxidant genes, 
RANKL significantly increased and TRAIL decreased eNOS expression; during co-exposure, 
however, RANKL and TRAIL at these concentrations exerted a synergistic effect on eNOS 
transcription levels. Moreover, TRAIL (in both the presence and absence of RANKL) 



















5.3.3 The Effects of the Anti-Oxidant NAC on Pro-calcific Signalling in HAECs  
While studies describing the effects of RANKL and TRAIL on the aforementioned targets may 
be useful in delineating the pro/anti-calcific effects of these ligands, a functional study may be 
more beneficial in clarifying the role of oxidative stress in the endothelium during VC. As such, 
the anti-oxidant NAC was employed in HAEC monoculture, both alone and in combination 
with RANKL, to determine (i) if the pro-calcific effects of RANKL are dependent on pro-
oxidant mechanisms, and (ii) if TRAIL exerts similar effects to a well-established anti-oxidant. 
Furthermore, TNF⍺, a strong pro-oxidant/pro-calcific stimulus, was also co-treated with NAC 
to ensure the desired anti-oxidant effect was achieved. A wide range of genes/proteins were 
assessed in an attempt to clarify the inter-related roles of oxidative stress and VC.   
A 
B 
(i)  (ii)  
(i)  (ii)  
Figure 5.8. The effects of RANKL +/- TRAIL on pro/anti-oxidant mRNA expression in HAECs. HAECs 
were exposed to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours, prior to analysis of (A) (i) gp91 
and (ii) p47 pro-oxidant genes, and (B) (i) eNOS and (ii) HMOX1 anti-oxidant genes. Gene expression was 
analysed by RT-qPCR employing GAPDH as an endogenous control * p < 0.05; ** p < 0.01 compared to 





5.3.3.1 The Effects of NAC on the Pro-calcific and Pro-oxidant Actions of RANKL   
With regard to the pro-calcific effects of RANKL identified in Chapters 3 and 4, again no 
effects were noted on BMP-2 and ALP mRNA expression after 72 hours; NAC, however, both 
alone and in combination with RANKL, significantly downregulated BMP-2/ALP mRNA 
(Figure 5.9A). No changes were noted following NAC treatment in Runx2 or IL-6 transcript 
expression (data not shown). Furthermore, co-incubation with NAC completely attenuated 
RANKL-induced BMP-2/ALP release (Figure 5.9C). NAC also significantly attenuated 
intracellular ALP activity induced by RANKL (Figure 5.9B), but did not affect intracellular 
BMP-2 production (data not shown). Furthermore, the addition of NAC significantly increased 
both OPG production and release, both alone and when co-treated with RANKL (data not 
shown). No effects were noted in IL-6 release levels (data not shown). While the canonical NF-
B pathway was not assessed (given the focus on pro-calcific signalling), RANKL-induced 
non-canonical activation was also attenuated by NAC (Figure 5.9D).  
 
5.3.3.2 The Effects of NAC on the Pro-oxidant and Pro-calcific Actions of TNF⍺ 
With regard to oxidative stress, NAC was found to significantly reduce TNF⍺-induced p47 and 
gp91 gene expression (data not shown). Regarding pro-calcific indices, at an mRNA level, 
TNF⍺-induced ALP, BMP-2, Runx2 and IL-6 were all significantly reduced by the co-addition 
of NAC (data not shown). This trend was reflected at a protein level, where BMP-2 and ALP 
release (induced by TNF⍺) were significantly attenuated, and IL-6 release significantly reduced 
by NAC (Appendix 5.5A). Similarly, NAC attenuated TNF⍺-induced intracellular BMP-2 
protein levels and ALP activity (Appendix 5.5B). Non-canonical NF-B activation was, 
however, only slightly reduced by NAC addition (Appendix 5.5C). Moreover, NAC was found 
to further promote TNF⍺-induced OPG production and release when compared to TNF⍺ 
treatment alone (data not shown).  
 
5.3.4 The Effects of TRAIL on RANKL-induced ROS Generation in HAECs  
Finally, the effects of RANKL and TRAIL on endothelial ROS production were assessed in an 
effort to further clarify the role of oxidative stress during VC. Again, HAECs were treated with 
RANKL (25 ng/mL) both alone and in combination with TRAIL (5 ng/mL), and DHE staining 




















fluorescence microscopy (Section 2.2.6.2). These experiments were conducted at both 24 and 
72 hours to investigate the potential for time-dependent ROS generation in response to RANKL 
and TRAIL. HAECs were also treated with TNF⍺ +/- NAC for 24 hours to ensure that ROS 
production/depletion could be successfully detected. Following treatment, RANKL was found 
to time-dependently induce ROS production, and while TRAIL alone had no effect, its co-
addition significantly reduced RANKL-induced ROS after 72 hours (and non-significantly at 
24 hours) (Figure 5.10A, B). TNF⍺, a recognised pro-oxidant stimulus, increased ROS 
generation, while NAC anti-oxidant treatment significantly reduced TNF⍺-induced ROS 
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Figure 5.9. The effects of RANKL +/- NAC on gene/protein expression in HAECs. HAECs were exposed to 
RANKL (25 ng/mL) +/- NAC (5 mM) for 72 hours prior to analysis. (A) mRNA expression levels of (i) BMP-2 and 
(ii) ALP were analysed by RT-qPCR employing GAPDH as an endogenous control. (B) intracellular ALP activity and 
(C) (i) BMP-2 and (ii) ALP release were assessed by ELISA and enzyme assay where appropriate, normalized to 105 
cells (media) and total protein (lysate). (D) Non-canonical NF-B activation was assessed by Western blotting, 
quantified by scanning densitometry and normalised to GAPDH. Blots are representative. * p < 0.05; ** p < 0.01; *** 
p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance between 





























A: 24 hours B: 72 hours 
PE-Texas Red (ROS) PE-Texas Red (ROS) 
(i)  (i)  
(ii)  (ii)  
Control RANKL TRAIL RANKL + TRAIL 
C: 72 hours 
(i)  
(ii)  
Figure 5.10. The effects of RANKL +/- TRAIL on ROS generation in HAECs. HAECs were exposed to 
RANKL (25 ng/mL) +/- TRAIL (5 ng/mL) for 24 and 72 hours prior to analysis. DHE stain (3 µM) was 
added 30 minutes prior to the end of the incubation period; DAPI was added 3 minutes prior to analysis for 
fluorescence microscopy only. (A, B) ROS generation was measured by flow cytometry, quantified by 
histogram area; presented histograms are representative. (C) (i) ROS generation via DHE staining and (ii) 
DAPI nuclear counterstain were visualised using a Nikon Eclipse Ti fluorescence microscope at 24 hours. 
Images (40X magnification) are representative. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated 





5.3.5 Discussion: Oxidative Stress  
To reiterate, oxidative stress is exerted in vivo by the generation of ROS, by-products of 
metabolism resulting from the reduction of oxygen (Bayir, 2005). ROS levels are mediated by 
pro-oxidants (e.g. NADPH oxidase) and anti-oxidants (e.g. SOD, NO) in the modulation of 
multiple cellular processes (Rahal et al., 2014), and the accumulation of ROS (above levels 
required to mediate these processes) exerts pathological effects on cells. Relevant to this study, 
oxidative stress has been associated with CVD/T2DM, and is known to promote endothelial 
dysfunction (Higashi et al., 2009; Kayama et al., 2015; Pitocco et al., 2013). As such, the 
previously observed regulation of redox pathways by RANKL and TRAIL may partly explain 
the observed pro-calcific and protective effects of these ligands in the vasculature (Byon et al., 
2008; Forde et al., unpublished observations; Thummuri et al., 2017). In further support of this 
theory, TRACP5, identified as a potential contributor to VC in Section 5.2 and known to drive 
oxidative stress (Seol et al., 2009), was regulated by RANKL/TRAIL treatment in HAECs. 
Thus, given the central role for the endothelium in the regulation of vascular paracrine 
signalling, HAECs were employed in an attempt to clarify the mechanisms by which RANKL 
and TRAIL exert their respective functions during VC. 
 
5.3.5.1 The Effects of RANKL +/- TRAIL on SOD1/SOD2 Expression 
Firstly, the effects of RANKL and TRAIL on endothelial SOD1/SOD2 expression were 
investigated. As noted, SOD enzymes catalyse superoxide dismutation, i.e., the conversion of 
superoxide anions into less harmful compounds, and as such are potent anti-oxidants (Ighodaro 
and Akinloye, 2017; Zhang et al., 2003). SOD1, accounting for the vast majority of SOD 
activity, is responsible for scavenging cytosolic ROS, while SOD2 exerts this function 
exclusively in the mitochondria (Zelko et al., 2002). Of relevance, cytosolic and mitochondrial 
ROS have been associated with vascular dysfunction (Faraci and Didion, 2004; Madamanchi 
et al., 2007), and both SOD1 and SOD2 have been shown to exert a cardioprotective influence 
on the vessel wall (Ohashi et al., 2006; Tribble et al., 1999). SOD3, a third isoform (responsible 
for the dismutation of extracellular ROS) was not assessed in this study. Like SOD1 and SOD2, 
SOD3 is known to play a role in the mediation of vascular oxidative stress, however it is not 
believed to be expressed by endothelial cells (Faraci and Didion, 2004; Fukai et al., 2002).  
A significant and novel finding of the current study was the decrease observed in SOD1 and 
SOD2 mRNA expression following RANKL treatment. No studies to our knowledge have yet 
 216 
assessed the effect of RANKL on SOD expression, despite RANKL being a known promoter 
of oxidative stress (Thummuri et al., 2017). Interestingly, the NF-B family of transcription 
factors are established regulators of SOD expression, likely explaining the mechanism by 
which RANKL modulates these genes (Miao and St. Clair, 2010). While at an mRNA level the 
effects of RANKL may appear pro-oxidant, SOD1 protein expression was dose-dependently 
induced. By way of explanation, alongside the RANKL-induced downregulation of SOD 
mRNA, it is possible that the observed increase in SOD1 translation may represent a natural 
protective mechanism to counteract RANKL-induced oxidative stress. In support of this 
theory, TNF⍺ (a potent pro-oxidant cytokine) has previously been shown to induce SOD2 
protection (Warner et al., 1991), but this trend has not yet been associated with SOD1.  
Following TRAIL treatment, SOD1 and SOD2 mRNA were upregulated, and protein levels of 
SOD1 also trended upwards. While there is limited literature available to compare TRAIL-
mediated SOD expression, conflicting research within our own group suggests that TRAIL had 
no effect on SOD1/SOD2 transcription/translation (Forde et al., unpublished observations). In 
this particular instance, however, a higher dose of TRAIL (100 ng/mL) over a shorter 
incubation period (24 hours) was employed, potentially suggesting time- or dose-dependent 
regulation. Research presented in Chapter 3 indeed supports this proposition. Higher 
concentrations of TRAIL were found to induce the release of pro-inflammatory and pro-calcific 
proteins in HAECs (Section 3.2.1), possibly revealing that TRAIL exerts pathological effects 
at higher doses. Moreover, the TRAIL-induced inflammatory response was previously reported 
to be both time- and dose-dependent (Zoller et al., 2017), again highlighting the pleiotropic 
nature of TRAIL and potentially explaining the above discrepancies in SOD expression. 
Overall, as both RANKL and TRAIL induce SOD1 expression to a similar extent, this is likely 
not the mechanism responsible for TRAIL-mediated protection in the endothelium. With 
regard to SOD2, it has been confirmed within our research group that SOD2 protein remains 
undetectable in response to TRAIL treatment in HAECs (Forde et al., unpublished 
observations). Indeed, low expression levels of SOD2 have been reported in HUVECs and 
BAECs (Valle et al., 2005), and it has been reported that it is not uncommon for SOD2 mRNA 
and protein levels to deviate (Vogel et al., 2011). Moreover, the short half-life of SOD2 and its 
complex post-translational regulation make these trends difficult to decipher (Kim et al., 2011; 
Knirsch et al., 2001; Miao and St. Clair, 2009). However, the lack of detectable protein 
expression also suggests that SOD2 does not mediate RANKL or TRAIL function in HAECs.  
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5.3.5.2 The Effects of RANKL/TRAIL on SOD1/SOD2 Expression during Inflammation 
 Studies have shown that endothelial dysfunction is mediated by TNF⍺-induced oxidative 
stress (Chen et al., 2008) while other pro-inflammatory cytokines (e.g. IL-6) induced by TNF⍺ 
further promote EC injury (Wassmann et al., 2004). Circulating levels of these cytokines are 
known to be elevated during CVD/T2DM (Olson et al., 2012; Levine et al., 1990) contributing 
to a pro-calcific, pro-oxidant vascular environment. Thus, the effects of RANKL and TRAIL 
on TNF⍺-induced oxidative stress, such as that present during atherosclerosis, were next 
assessed to determine if either ligand mediates redox pathways under pathological conditions.  
Interestingly, both SOD1 and SOD2 mRNA/protein levels were upregulated following TNF⍺ 
exposure in HAECs. As mentioned, TNF⍺ has previously been shown to induce SOD2 
expression in ECs (Forde et al., unpublished observations; He et al., 2004), but conflicting data 
suggests that TNF⍺ actually downregulates SOD1 mRNA/protein expression (Afonso et al., 
2006; Dschietzig et al., 2012). These studies were, however, conducted in malignant cell lines 
of minimal physiological relevance to the natural vascular environment. Previous research 
within our own group has also indicated that TNF⍺ exerts negligible effects on SOD1 
regulation in HAECs following 24 hours’ exposure. This finding suggests that the observed 
induction of SOD1 may only activate under chronic (>24 hour) conditions, potentially 
explaining the conflicting evidence presented above. Additionally, given the pro-oxidant role 
for TNF⍺, one would expect this cytokine to downregulate anti-oxidant SOD enzymes. 
However, this data supports the suggestion that SOD is upregulated by pro-oxidant stimuli as 
part of an intrinsic cardioprotective mechanism, emulating its natural function in vivo. 
Following RANKL addition, SOD1/SOD2 mRNA and protein expression were slightly 
reduced compared to treatment with TNF⍺ alone. There are, as of yet, no relevant studies with 
which to compare this finding, but it may suggest that the presence of RANKL dampens the 
natural anti-oxidant response of HAECs. TRAIL addition had no effect at an mRNA level, but 
slightly downregulated both SOD proteins in a similar manner to RANKL. Given these 
findings, that TRAIL does not exert its protective influence via the upregulation of SOD in 
inflamed endothelium.  
 
5.3.5.3 The Effects of RANKL/TRAIL on SOD1/SOD2 Expression during Hyperglycemia 
Hyperglycemia is also considered a strong stimulus for oxidative stress and is a recognized 
promoter of ROS generation and endothelial dysfunction (Yano et al., 2004). As noted, 
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elevated blood glucose is one of the key hallmarks of T2DM, and VC is known to be 
particularly prevalent among diabetic patients (Stabley and Towler, 2017). As such, 
hyperglycemia (like RANKL and TRAIL) likely contributes to the regulation of the pro-
calcific and pro-oxidant vascular environment during T2DM. The effects of RANKL/TRAIL 
on HAECs in the presence of elevated glucose were therefore assessed to investigate whether 
or not these ligands mediate redox signalling pathways under hyperglycemic conditions. In this 
model, hyperglycemia was found to promote SOD1 expression as previously reported in 
vascular cells (Mahavadi et al., 2017; Patel et al., 2013). Interestingly, genetic disruption of 
SOD1 has been shown to induce glucose intolerance (Muscogiuri et al., 2013), and SOD1 
overexpression attenuates hyperglycemia-induced pathologies (Coucha et al., 2015), providing 
strong evidence that glucose-induced SOD1 represents the cardioprotective anti-oxidant 
mechanism previously hypothesised. Regarding SOD2, while upregulated at a transcriptional 
level, SOD2 protein again remained undetectable. In support of this finding, the transcriptional 
upregulation of SOD2 under hyperglycemic conditions observed by Valle and colleagues was 
not accompanied by a concurrent increase in protein (Valle et al., 2005).  
With regard to RANKL treatment, no significant effects were noted in the presence of glucose, 
suggesting that RANKL does not modulate hyperglycemia-induced SOD expression during 
T2DM; however, this is the first study of its nature to date, and there is no evidence with which 
to compare this finding. Following TRAIL treatment, despite the non-significant increase 
observed in SOD1 mRNA, SOD1 protein was reduced when compared to hyperglycemia alone. 
Again, SOD2 protein remained undetectable (despite an upregulation of mRNA following 
moderate hyperglycemia). There is some evidence, albeit minimal, with which this data can be 
compared. An upregulation has previously been noted in SOD2 mRNA expression following 
TRAIL treatment under hyperglycemic conditions (Liu et al., 2014) in conjunction with an 
increase in total SOD activity. Although we observed a decrease in SOD1 protein production 
(and undetectable SOD2 protein) compared to high-glucose alone, it must be noted that SOD 
activity and SOD protein expression may not coincide (indeed, enzyme activity can be 
mediated by a number of additional factors, e.g. levels of pro-inflammatory mediators) 
(Demerdash et al., 2017). It is unlikely, however, based on the presented data, that TRAIL 
exerts a strong protective influence on HAECs under hyperglycemic conditions via the 




5.3.5.4 The Effects of RANKL +/- TRAIL on Pro-/Anti-oxidant Gene Expression in HAECs  
Next, representative pro-oxidant and anti-oxidant genes were assessed in HAECs exposed to 
RANKL and TRAIL, to further investigate if the respective pro-calcific/protective effects of 
these ligands may be mediated (at least in part) by the regulation of redox pathways. Given that 
neither RANKL nor TRAIL appeared to exert these effects via the regulation of SOD1/SOD2, 
but TRAIL was found to attenuate RANKL-induced TRACP5 in endothelial cells (a known 
catalyst for ROS generation), this experiment was conducted in the RANKL +/- TRAIL model 
only. As such, we investigate the effects of RANKL and TRAIL on the expression of oxidative 
stress-related genes in HAECs under physiological conditions.   
Firstly, the pro-oxidant genes p47 and gp91 were assessed in HAECs following exposure to 
RANKL +/- TRAIL. These genes encode two phox subunits of NADPH oxidase (NOX) 
enzymes, a major source of ROS in endothelial cells (Pitocco et al., 2013). Unsurprisingly 
therefore, NADPH oxidases have been associated with the progression of CVD/T2DM (Cave 
et al., 2006; Fulton and Barman, 2016, Meyer and Schmitt, 2000). Specifically, gp91 (NOX2) 
mRNA expression has been positively correlated with atherosclerosis severity (Sorescu et al., 
2002) and relevant to this study has also been shown to promote RANKL-induced osteoclast 
differentiation (Kang and Kim, 2016). The p47 subunit, involved in NOX1/NOX2 signalling, 
has also been implicated in intimal calcification (Barry-Lane et al., 2001) and is induced in 
endothelial cells under pro-inflammatory conditions common during VC (Li et al., 2002).  
In the current study, RANKL was found to upregulate p47 mRNA at the higher concentration 
of 25 ng/mL. While research linking RANKL with this subunit is lacking, p47 has previously 
been implicated in the inhibition of early bone development, emulating the natural resorptive 
effects of RANKL (Chen et al., 2015), and TNF⍺ has been shown to upregulate p47 (Li et al., 
2002), also known to exert pro-calcific effects on the vasculature. Deletion of p47 has also been 
found to protect against atherosclerotic calcification (Barry-Lane et al., 2001; Vendrov et al., 
2007) further implicating this subunit in the progression of vascular pathologies. Taken 
together, this data may suggest that p47-mediated NOX pathways (NOX1 and NOX2) may be 
involved in RANKL function in the endothelium. Of note, NOX1 is not believed to be 
expressed in ECs (Pendyala et al., 2009) potentially implicating the NOX2 pathway as a source 
of RANKL-induced endothelial ROS. Indeed, gp91 also modulates the NOX2 pathway, 
previously shown to promote atherosclerosis (Sorescu et al., 2002) and RANKL-induced 
osteoclast differentiation (Kang and Kim, 2016). As such, the lack of upregulation of gp91 
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mRNA may be explained at a translational level, or may suggest that RANKL-induced p47 
mediates the NOX2 pathway by promoting p47/gp91 assembly at the plasma membrane. Of 
further relevance, the upregulation of p47 mRNA by RANKL was completely attenuated by 
TRAIL. There is, however, no evidence to date to suggest that TRAIL exerts protective effects 
via NOX blockade; in contrast, TRAIL’s apoptotic function has been positively associated with 
NOX1-induced superoxide production in tumour cells via DR4/DR5 signalling (Park et al., 
2012). However, endothelial resistance to TRAIL-induced apoptosis can be mediated by the 
expression of DcR1/DcR2 (Zhang et al., 2000), and TRAIL is now widely accepted to exert 
pleiotropic effects in vivo via both death and decoy receptors (Forde et al., 2016). Given the 
pro-calcific/pro-oxidant effects of RANKL and the anti-calcific/anti-oxidant effects of TRAIL 
observed in this model to date, we present novel evidence to suggest that the effects of these 
ligands may be mediated (in part) by the NOX2 pathway in endothelial cells.  
The next gene involved in the mediation of redox signalling assessed in this study was eNOS, 
one of three NO synthase (NOS) isoforms. eNOS is primarily (but not exclusively) expressed 
in endothelial cells (Förstermann et al., 2012) and plays a complex role in the regulation of 
ROS. Under basal conditions, eNOS produces NO, a free radical responsible for the regulation 
of vascular homeostasis, VSMC proliferation and vasodilation among other functions (Sena et 
al., 2013). As such, eNOS is generally considered to exert protective effects on the vasculature. 
Under pathological conditions, however, eNOS can become “uncoupled”, and produce 
superoxide instead of NO (Yang et al., 2009). eNOS uncoupling is prevalent in cardiovascular 
diseases and diabetes (Guzik et al., 2002; Yang et al., 2009), particularly under oxidative stress, 
thereby contributing to vascular ROS. Indeed, under these conditions, the role of eNOS may 
be altered, but constitutively expressed eNOS under physiological conditions is generally 
considered cardioprotective (Albrecht et al., 2003).  
Interestingly, RANKL at 25 ng/mL was found to upregulate eNOS mRNA. Given the proposed 
cardioprotective nature of eNOS, and the downregulation of eNOS observed during pro-
calcific events (Banquet et al., 2013, Oemar et al., 1998), this result was surprising. By way of 
comparison, Min and colleagues (2007) have identified an increase in eNOS activity following 
RANKL treatment, but no change in eNOS mRNA/protein; however, this group stimulated 
HUVECs for only 30 minutes, likely explaining this discrepancy. Min et al. suggest that 
RANKL-induced eNOS/NO may play a role in the development of atherosclerosis via the 
promotion of vascular permeability; however, their analysis does not address the 
cardioprotective effects of eNOS in healthy vasculature. Therefore, we propose that RANKL-
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induced eNOS may represent endothelial switching from a healthy to a pro-oxidant state, 
increasing oxidative stress and upregulating eNOS as previously described (Ding et al., 2007). 
As such, RANKL treatment may provide the pro-oxidant environment necessary for eNOS 
uncoupling and eNOS-mediated ROS generation (Yang et al., 2009).  
Following TRAIL treatment, a slight downregulation in eNOS mRNA was observed, also in 
contrast with previous studies (Forde et al., unpublished observations; Zauli et al., 2003). 
However, these studies employed TRAIL at 20-fold higher concentrations at varying time 
points, and as noted, the effects of TRAIL on ECs are likely time- and dose-dependent. 
Following treatment with RANKL, however, the mRNA expression of eNOS was 
synergistically induced. This novel finding may suggest that TRAIL upregulates eNOS in an 
effort to counteract coexisting RANKL-induced p47 expression and ultimately ROS 
generation. Interestingly, Liu et al. (2014) note that TRAIL recovers eNOS activity in aortic 
cells under hyperglycemic conditions, further suggesting that TRAIL-induced eNOS may be 
dependent on a pro-oxidant, pathological environment. Protein analyses are required to confirm 
this hypothesis, but preliminary data suggests that the protective effects of TRAIL on RANKL-
mediated pro-calcific/oxidant effects may involve the upregulation of eNOS.   
Finally, HMOX1, an enzyme known to exert anti-oxidant effects on the vasculature in response 
to oxidative stress and inflammation (True et al., 2007) was assessed. HMOX1 catalyses the 
degradation of heme, a potent pro-oxidant (Jeney et al., 2002), exerting a range of 
cardioprotective effects (Araujo et al., 2012; Juan et al., 2001). As expected, RANKL did not 
regulate HMOX1 in the current model. TRAIL, on the other hand, was a potent inducer of 
HMOX1, both alone and in the presence of RANKL. Interestingly, carbon monoxide, a by-
product of HMOX1 activity, has previously been shown to prevent RANKL-induced 
osteoclastic differentiation via NF-B (Bak et al., 2017), and may possibly partly explain the 
TRAIL-mediated attenuation of RANKL effects. Overall, following gene expression analyses 
of redox genes in the endothelium, it appears that RANKL may modulate its pro-oxidant effects 
in the vasculature via upregulation of p47/NOX2 signalling, and that TRAIL may exert its anti-
oxidant effects via attenuation of RANKL-induced p47, alongside the upregulation of eNOS 
and HMOX1 under pathological conditions. Protein analyses are required to confirm these 
findings, but the observed pro-/anti-oxidant effects of RANKL and TRAIL likely contribute to 
the respective pathological and protective effects during VC.  
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5.3.5.5 The Effects of NAC on the Pro-calcific and Pro-oxidant Actions of RANKL  
As noted, RANKL has been shown to exert pro-oxidant effects on the vasculature, and 
pathological conditions such as EC dysfunction and VC are associated with an increase in 
oxidative stress (Silva et al., 2012; Singh et al., 2010). NAC, a well-known anti-oxidant often 
used in vitro as a negative regulator of oxidative stress (Nedeljkovic et al., 2013), was next 
employed to further delineate the consequences of RANKL’s pro-oxidant influence on the 
endothelium. In this way, following NAC blockade of pro-oxidant signalling by RANKL, a 
range of pro-calcific indices were assessed to determine if RANKL-induced redox pathways 
are involved in the promotion of VC.  
Interestingly, the addition of NAC was found to significantly reduce BMP-2/ALP mRNA 
following 72 hours’ incubation, indicating that (even in the absence of RANKL) attenuation of 
pro-oxidant pathways may exert anti-calcific protective effects on the vasculature. In 
accordance with this finding, co-treatment with NAC completely attenuated BMP-2 release 
and reduced extracellular ALP activity (alongside complete attenuation of intracellular ALP 
activity). Thus, we present novel evidence that RANKL-induced oxidative stress may mediate 
endothelial pro-calcific paracrine signalling, ultimately regulating VC in the underlying 
HASMC layer (Davenport et al., 2016; Osako et al., 2010). Indeed, the attenuation of BMP-2 
mRNA expression by NAC has been reported in human epithelial cells, while BMP-2/ALP-
induced mineralization (alongside ROS generation) has been blocked by NAC in pre-
osteoblasts (Gustafsson et al., 2005; Mandal et al., 2011). NAC treatment has also been 
associated with reduced circulating ALP in vivo (Maheswari et al., 2014) and has been found 
to attenuate dimethylnitrosamine-induced ALP in rats (Priya et al., 2011).  
Furthermore, the NAC-mediated reduction in BMP-2/ALP was accompanied by attenuation of 
RANKL-induced non-canonical NF-B signalling. We suggest in Chapter 3 that the non-
canonical pathway may be responsible for the pro-calcific effects of RANKL, given its 
previous associations with VC (Panizo et al., 2009), and that TRAIL-mediated vasoprotection 
may involve blockade of this pathway. Interestingly, NF-B activation and oxidative stress are 
known to intersect, and ROS intermediates have been shown to activate NF-B (Bonizzi et al., 
1999; Morgan and Liu, 2011). Thus, while RANKL is known to activate NF-B directly, 
RANKL-induced oxidative stress may also promote this effect, and the anti-oxidant role of 
TRAIL may be responsible for the attenuation of NF-B (and ultimately pro-calcific 
signalling). In further support of this proposition, NAC has been shown to attenuate NF-B 
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and protect from diabetes in vivo (Ho et al., 1999), and more specifically, to prevent NF-B 
induced by TNF⍺ (known to exert pro-calcific effects) (Oka et al., 2000). Indeed, the 
similarities in the effects of TRAIL and this anti-oxidant on RANKL-induced pro-calcific 
signalling cannot be ignored. Thus, NF-B and redox pathways likely exert interlinking 
functions in the regulation of VC, jointly regulated by RANKL and TRAIL.  
 
5.3.5.6 The Effects of NAC on the Pro-calcific and Pro-oxidant Actions of TNF⍺ 
To ensure NAC was exerting the desired anti-oxidant effect on HAECs, TNF⍺, a known pro-
oxidant stimulus, was employed. Given that TNF⍺ is known to activate p47/NOX2 signalling 
(Kim et al., 2007; Li et al., 2005), it was no surprise that p47/gp91 mRNA expression was 
elevated following treatment; furthermore, the observed blockade of this upregulation by NAC 
suggested a successful anti-oxidant effect was achieved. On an additional note, an interesting 
observation was made regarding the effect of NAC on TNF⍺-induced pro-calcific indices. In 
this respect, NAC co-incubation significantly attenuated/reduced all measured pro-calcific 
indices upregulated by TNF⍺ at both an mRNA and protein level. However, this finding was 
accompanied by only a slight decrease in non-canonical NF-B activation, unlike the complete 
attenuation observed following RANKL + NAC treatment. As noted, NAC has previously been 
shown to attenuate NF-B signalling, in particular that induced by TNF⍺ (Oka et al., 2000). 
However, these authors demonstrate NAC-mediated attenuation of the canonical signalling 
pathway by Western blotting (p50/p65 subunits) and do not attempt to specify the precise 
effects of NAC on non-canonical activation. As such, this finding may suggest that anti-calcific 
effects in the vasculature under inflammatory conditions may be mediated primarily via anti-
oxidant pathways, rather than attenuation of non-canonical NF-B signalling.  
 
5.3.5.7 The Effects of TRAIL on RANKL-induced ROS Generation in HAECs  
As a final attempt to clarify the role of oxidative stress in the regulation of VC by RANKL and 
TRAIL, a functional analysis to quantify ROS generation was employed. Indeed, data 
presented up to this point supports a pro-oxidant role for RANKL and suggests that TRAIL-
mediated vasoprotection may involve anti-oxidant signalling. However, whether this proposed 
anti-oxidant effect of TRAIL exerts a protective effect on RANKL-induced pro-calcific 
signalling remains to be confirmed. In this respect, ROS levels (assessed by DHE staining) 
were quantified/visualised following endothelial exposure to RANKL +/- TRAIL. TNF⍺ +/- 
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NAC, defined pro-oxidant and anti-oxidant stimuli respectively (Chen et al., 2008; Nedeljkovic 
et al., 2013), were also incorporated into this experiment as a positive control to ensure the 
generation/attenuation of ROS could be successfully detected. Furthermore, ROS generation 
was assessed at both 24 and 72 hours to identify potential time-dependent redox signalling.   
Firstly, TNF⍺ was confirmed to induce ROS generation at 24 hours, while NAC addition 
attenuated this effect. TNF⍺ can induce both mitochondrial and NOX-mediated oxidative stress 
(Chen et al., 2008), and NAC has been found to attenuate TNF⍺-mediated ROS generation in 
ECs (Szotowski et al., 2007). Thus, both the induction and attenuation of ROS were 
successfully detected, verifying the suitability of the employed methodological approach. 
While oxidative stress has long been associated with VC (Agharazii et al., 2015; Towler, 2008), 
no direct evidence yet suggests that ROS is mediated by RANKL in the vasculature. As such, 
the observed time-dependent induction of endothelial ROS following RANKL treatment is 
particularly significant. In support of this finding, there is compelling evidence that RANKL-
mediated ROS is centrally involved in osteoclastogenesis (Kim et al., 2010; Lee et al., 2005; 
Thummuri et al., 2017). In a particularly relevant study, Lee and colleagues (2005) demonstrate 
that RANKL-induced ROS promotes the osteoclastic differentiation of bone marrow 
monocyte-macrophage lineage cells, and further suggest that this ROS generation is dependent 
on NADPH oxidases (consistent with our previous finding that RANKL upregulates p47). 
Moreover, blockade of NOX (and treatment with NAC) both exert similar effects in the 
attenuation of RANKL-induced osteoclastic function, further implicating NOX signalling in 
RANKL function as previously hypothesised (Lee et al., 2005).  
As discussed in Chapter 1, RANKL is widely known to exert its function via RANK binding 
and NF-B activation in bone and vasculature. Of relevance, an overlap between NF-B and 
ROS signalling in the context of VC has previously been highlighted by Al-Aly and co-workers 
(2011). Unsurprisingly, these authors propose a pathological role for ROS in the vasculature, 
emphasising the therapeutic potential for anti-oxidants during VC treatment. Al-Aly et al. rely 
heavily on a study by Zhao and co-workers in this conclusion (2011), who present pertinent 
evidence that β-glycerophosphate, a potent inducer of calcification, promotes ROS generation 
in bovine VSMCs alongside canonical NF-B activation. Thus, taking this data together, it 
appears likely that RANKL mediates ROS in the promotion of VC, supporting the data 
presented and endorsing a role for NF-B in this process.  
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Unlike RANKL, TRAIL had no independent effect on ROS generation in HAECs, and this 
finding has been confirmed within our own research group by Forde et al. (unpublished 
observations). While there is little research to date attempting to clarify the effects of TRAIL 
on ROS generation in untransformed cells, contrasting evidence exists in malignant cells. In 
this respect, TRAIL-induced apoptosis is claimed to be mediated by oxidative stress, with 
compelling evidence that TRAIL enhances ROS-mediated apoptosis via upregulation of DR4 
and DR5 (Jung et al., 2005; Lee et al., 2002; Park et al., 2012; Yodkeeree et al., 2009). As no 
researchers outside of our own group have yet assessed the effects of TRAIL on primary 
HAECs, we propose that ROS-induced apoptosis by TRAIL does not progress under healthy, 
physiological conditions in these cells. As an interesting observation, TRAIL has been shown 
to induce NOX4 signalling in an in vivo murine model; however, unlike NOX1 and NOX2, 
NOX4 has been associated with a number of protective functions, including the expression of 
anti-oxidant genes (eNOS, HMOX1) (Schröder et al., 2012), and in one particular study, 
neovascularisation following ischemic injury (di Bartolo et al., 2015). Thus, the regulation of 
oxidative stress by TRAIL may not be clear-cut, and instead may involve a complex balance 
of redox pathways emulating its pleiotropic function.  
Following co-treatment, TRAIL significantly reduced RANKL-induced ROS at 72 hours. This 
novel finding is particularly pertinent given the coinciding attenuation of RANKL-induced pro-
calcific signalling and non-canonical NF-B activation observed in Chapter 3. Thus, as 
RANKL/NF-B has previously been associated with ROS generation, we present the strongest 
evidence to date that TRAIL may exert an anti-calcific effect on the vasculature via a reduction 
in RANKL-induced ROS. In support of this finding, previous studies have revealed that TRAIL 
may attenuate ROS during VC pathogenesis. Research within our group suggests that TRAIL 
may significantly reduce both TNF⍺- and hyperglycemia-induced ROS in HAECs (Forde et 
al., unpublished observations), well known promoters of VC (Besueille et al., 2015; Chen et 
al., 2008; Yano et al., 2004). Indeed, TRAIL has also been shown to reduce hyperglycemia-








5.3.5.8 Summary: Oxidative Stress  
Overall, it is clear that both RANKL and TRAIL mediate redox signalling pathways in their 
role in the endothelium. From this data, it is unlikely that SOD enzymes, in the dismutation of 
ROS, are responsible for these effects, but the upregulation of pro-oxidant (NOX) and anti-
oxidant (eNOS, HMOX1) genes by RANKL and TRAIL respectively may contribute to these 
effects. Furthermore, NAC was found to attenuate RANKL-induced pro-calcific signalling and 
non-canonical NF-B activation, supporting an anti-oxidant role of TRAIL in the mediation of 
RANKL-induced VC and revealing a potential mechanism by which TRAIL blocks the pro-
calcific effects of RANKL. Finally, TRAIL co-incubation reduced RANKL-induced ROS, 
confirming a functional anti-oxidant effect on the endothelium. It is therefore our assertion that 
TRAIL regulates anti-oxidant genes in the endothelium, attenuating NF-B activation and pro-















Figure 5.11. Representation of the key findings of redox investigations. Endothelial cell (upper layer) 
exposure to RANKL induces p47 mRNA expression, and may also promote NADPH oxidase 2 (NOX2) 
generation of reactive oxygen species (ROS). ROS may also contribute to the induction of endothelial 
pro-calcific paracrine signalling (e.g., BMP-2, ALP) to the underlying smooth muscle (bottom layer), 
thereby promoting calcification. Co-incubation with TRAIL attenuates RANKL-induced p47 and 
upregulates the anti-oxidant HMOX1, and therefore may also reduce NOX2 generation of ROS. The anti-
oxidant influence of TRAIL may also attenuate pro-calcific paracrine signalling, thereby protecting from 






5.4 Investigating the Role of Non-canonical NF-B Activation in HAECs 
Finally, the non-canonical NF-B pathway was investigated to further delineate its role in pro-
calcific signalling. As noted, RANKL is known to activate NF-B via the RANK receptor, and 
the non-canonical pathway has previously been implicated in smooth muscle calcification 
(Beristain et al., 2012; Boyce et al., 2015; Panizo et al., 2009). Furthermore, endothelial non-
canonical NF-B signalling has been associated with the pro-calcific effects of RANKL in 
Chapters 3 and 4, while the co-addition of TRAIL attenuated RANKL-induced non-canonical 
activation. This follow-on study now aims to fully clarify the RANKL/TRAIL-mediated 
signalling processes that can be attributed to non-canonical NF-B during VC. In this regard, 
HAECs were subject to siRNA knockdown of the NFB2 gene, which encodes the p52 
precursor protein, p100, and is therefore an effective method of attenuating the non-canonical 
NF-B pathway. Following optimisation, HAECs were co-cultured with HASMCs in the 
presence of RANKL (Figure 5.12), and a range of pro-calcific indices monitored. Moreover, 
given the inter-related roles for oxidative stress and pro-calcific signalling identified in 











5.4.1 Optimisation of siRNA Knockdown  
Firstly, to ensure valid results, an in-depth optimisation process was developed prior to co-
culture analyses. To assess reagent toxicity and ensure robust gene knockdown, HAECs were 
BMP-2 IL-6 ALP 
Runx2 Sox9  
OPG 
 
RANKL +/- TRAIL 
NF-κB p52/p100 
siRNA knockdown 
Figure 5.12. Representation of the transwell co-culture model employed following endothelial NF-κB 
p52/p100 knockdown. HAECs in semi-permeable transwell inserts were subject to NFκB2 siRNA 
knockdown for 48 hours, prior to suspension above the confluent smooth muscle layer. HAECs in the 
luminal compartment were exposed to RANKL (5-25 ng/mL) for 72 hours prior to analysis of smooth 
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Figure 5.13. Optimisation of NF-κB2 siRNA knockdown. (A) HAECs were subject to GAPDH knockdown for 
48 hours across a range of DharmaFECT™ volumes and siRNA concentrations; GAPDH expression levels were 
determined by RT-qPCR, employing 18S as an endogenous control. (B) HAECs were subject to NFκB2 siRNA 
knockdown across a range of DharmaFECT™ volumes and siRNA concentrations; (i) viability was assessed by 
ADAM™ counter and (ii) NFκB2 mRNA expression levels were determined by RT-qPCR, employing 18S as an 
endogenous control. (C) HAEC NFκB2 mRNA expression was similarly assessed following (i) NFκB2 and (ii) non-
targetting siRNA knockdown for 48 hours in transwell inserts. (D) NF-κB p52/p100 protein expression was assessed 
by Western blotting following 72 hours’ knockdown with (i) NFκB2 and (ii) non-targetting siRNA in transwell 
inserts. Protein expression was quantified by scanning densitometry and normalised to GAPDH. Blots are 





subject to pre-validated GAPDH siRNA knockdown across concentration and reagent volume 
ranges (25-50 nM; 2.5-10 µL DharmaFECT™ per well) as recommended by the manufacturer. 
A concentration of 50 nM siRNA achieved optimal GAPDH gene knockdown after 48 hours 
when combined with higher volume of DharmaFECT™ reagent (Figure 5.13A); HAEC 
viability was maintained above 85% in all cases (data not shown). Following successful siRNA 
silencing of a pre-validated target, DharmaFECT™ reagents were deemed suitable for gene 
knockdown in primary HAECs. With regard to NFB2 knockdown, the same range of siRNA 
concentrations and reagent volumes were assessed. Again, a combination of 50 nM siRNA + 10 
µL DharmaFECT™ was deemed optimal, with viability maintained above 89% (Figure 5.13B). 
NFB2 knockdown efficiency was also comparable in transwell inserts, while scrambled non-
targetting siRNA (nt-siRNA) had no effect on NFB2 expression under the same conditions, 
confirming target specificity (Figure 5.13C). At a protein level, approximately 45-48% 
knockdown of p52 and its precursor p100 was achieved following NFB2 knockdown, while 
scrambled nt-siRNA had no significant effects on p52/p100 protein expression (Figure 5.13D).  
 
5.4.2 The Effects of NF-B/p52 Knockdown on Pro-Calcific Indices in HAECs 
Following endothelial NFB2 knockdown in transwell inserts, no significant effects were 
noted in BMP-2, ALP or Runx2 mRNA levels, however, IL-6 transcript expression was 
significantly upregulated (data not shown). NFB2 silencing did not affect BMP-2, ALP or 
OPG release, but significantly reduced IL-6 levels in the conditioned media (Appendix 5.7A 
(i)). Intracellularly, NFB2 siRNA knockdown in HAECs significantly decreased BMP-2 
production by approximately 70%, but had no effect on ALP activity (Appendix 5.7B (i)). 
Furthermore, NFB2 knockdown had no effect on OPG release or protein expression in 
HAECs (data not shown), nor did it affect activation of the canonical NF-B pathway 
(Appendix 5.7C (i)). Following scrambled nt-siRNA treatment, no effects were noted at an 
mRNA expression level for any of the measured indices (data not shown). The endothelial 
release profile also remained unaffected (Appendix 5.7A (ii)); nt-siRNA treatment, however, 
slightly but significantly induced intracellular ALP activity (Appendix 5.7B (ii)). Again, no 
effects were noted in OPG production/release (data not shown) or canonical NF-B activation 
(Appendix 5.7C (ii)) following nt-siRNA treatment.  
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5.4.3 The Effects of NF-B/p52 Knockdown on Pro-Calcific Indices in Co-culture 
Following siRNA knockdown in transwell inserts, HAECs were co-cultured with HASMCs for 
a further 72 hours in the presence and absence of RANKL (5-25 ng/mL) before assessing a 
range of pro-calcific indices in the underlying HASMCs. Prior to analysis, it was confirmed 
that endothelial treatment with nt-siRNA had no effect on the measured indices in HASMCs, 
apart from a slight increase in IL-6 release (data not shown). At an mRNA level, the previously 
identified upregulation of ALP/Sox9 in co-cultured HASMCs following endothelial RANKL 
treatment were completely attenuated by NFB2 knockdown; furthermore, Sox9 mRNA levels 
were reduced to below baseline (Figure 5.14A). Runx2 mRNA levels were slightly but 
significantly downregulated in co-cultured HASMCs following NFB2 knockdown in HAECs, 
while the RANKL-induced downregulation of OPG/IL-6 mRNA were completely recovered.  
Regarding protein release, RANKL-induced BMP-2 secretion into the subluminal space was 
completely attenuated following HAEC NFB2 knockdown, and extracellular ALP activity 
(induced by 25 ng/mL RANKL) was significantly reduced (Figure 5.14B (i), (ii)). Interestingly, 
OPG secretion was induced following NFB2 silencing in HAECs, while RANKL treatment 
dose-dependently decreased this release (Figure 5.14B (iii)). NFB2 knockdown did not affect 
RANKL-induced IL-6 secretion (Appendix 5.8B). Intracellularly, RANKL-induced OPG 
production was reduced following knockdown of endothelial NFB2 (Appendix 5.8C), as was 
RANKL-induced ALP activity, at the higher concentration of 25 ng/mL (Figure 5.14C).  
 
5.4.4 The Effects of NF-B/p52 Knockdown on Pro/Anti-Oxidant Indices in HAECs 
Finally, the effects of endothelial NFB2 knockdown on pro- and anti-calcific indices were 
assessed, namely SOD1/2, gp91, p47, eNOS and HMOX1, in the endothelial monolayer 
following RANKL exposure. In this respect, neither mock-transfected (nt-siRNA) nor NFB2-
silenced HAECs responded differently in the mRNA expression of these genes than that 
previously observed in response to RANKL (data not shown). SOD2 protein remained 
undetectable, while HAECs treated with nt-siRNA exerted the same increase in SOD1 protein 
expression as previously reported. Interestingly, following NFB2 gene silencing, SOD1 
protein expression was upregulated to the same extent in both untreated and RANKL-treated 



























Figure 5.14. The effects of RANKL following endothelial siRNA knockdown in co-cultured HASMCs. HAECs 
were subject to nt-siRNA/NFκB2 knockdown in transwell inserts for 48 hours, prior to co-culture with confluent 
HASMCs. HAECs in the luminal compartment were then treated with RANKL (5-25 ng/mL) for 72 hours prior to 
analysis of protein/mRNA responses in the underlying HASMCs. (A) (i) ALP and (ii) Sox9 mRNA expression levels 
were determined by RT-qPCR, employing GAPDH as an endogenous control. (B) (i) BMP-2, (ii) ALP and (iii) OPG 
release in the subluminal space, alongside (C) intracellular ALP activity, were assessed by ELISA and enzyme assay 
where appropriate; media and lysate analysis were normalised to 105 cells and total protein respectively. * p < 0.05; 
** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance 
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5.4.5 Discussion: Non-canonical NF-B Activation  
To reiterate, RANKL is known to exert its osteoclastic functions in bone via NF-κB signalling 
(Beristain et al., 2012; Boyce et al., 2015), and has been shown to induce pro-calcific effects 
in VSMCs both directly via NF-κB activation (Panizo et al., 2009) and indirectly via 
endothelial paracrine signalling (Davenport et al., 2016; Osako et al., 2010). In Chapter 3, we 
identified the non-canonical NF-κB pathway in particular as a potential mediator of RANKL-
induced pro-calcific effects, in agreement with Panizo et al. (2009), who have previously 
associated this pathway with VC progression in smooth muscle. Furthermore, we noted that 
TRAIL co-incubation could attenuate non-canonical signalling alongside blockade of 
endothelial paracrine signalling. Indeed, the protective influence of TRAIL in the vasculature 
has been noted previously (di Bartolo et al., 2013), while TRAIL has been shown to interfere 
with RANKL signalling in bone (Zauli et al., 2004; Zauli et al., 2008). Despite this evidence, 
no studies to date have associated RANKL/TRAIL signalling with non-canonical NF-κB 
activation in the endothelium, or assessed the implications of this in the pathogenesis of VC.  
Furthermore, evidence suggests an anti-oxidant role for TRAIL in HAECs in vitro (Forde et 
al., unpublished observations), a consideration thoroughly explored in Section 5.3. However, 
while TRAIL reduces RANKL-induced ROS generation, it does not completely attenuate it, 
unlike the complete blockade of pro-calcific signalling/non-canonical NF-κB observed in 
Chapter 3; thus, TRAIL-mediated protection cannot be wholly attributed to the regulation of 
ROS. Interestingly, redox signalling and NF-κB activation are known to reciprocally intersect 
(Morgan and Liu, 2011), and Zhao and colleagues have presented pertinent evidence describing 
the dual activation of ROS and NF-κB following VC induction (2011). Indeed, we have 
observed that the anti-oxidant NAC can attenuate pro-calcific signalling and non-canonical 
NF-κB, suggesting that the proposed anti-oxidant nature of TRAIL may be responsible for the 
attenuation of non-canonical signalling. Thus, we aimed to determine the importance of non-
canonical signalling in RANKL/TRAIL-mediated VC, delineating if this pathway is central to 
the regulation of VC or merely a side-effect of redox signalling.  
In this respect, the NFκB2 gene was subject to siRNA silencing in co-cultured HAECs. NFκB2 
codes for the p100 fragment, and thus the cleaved p52 product, ultimately involved in nuclear 
translocation during non-canonical activation. A range of pro-calcific/pro-oxidant indices were 
assessed in HAECs and HASMCs following treatment with RANKL in co-culture, in an effort 
to determine the significance of non-canonical NF-κB activation during VC pathogenesis.   
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5.4.5.1 The Effects of NF-B/p52 Knockdown on the Expression of Pro-Calcific Indices  
Firstly, comprehensive control studies confirmed the employed siRNA pool was specific for 
the NFκB2 gene, and knockdown did not exert adverse effects on transfected HAECs or on co-
cultured HASMCs. Firstly, NF-B/p52 knockdown was found to significantly reduce 
endothelial BMP-2 production, further implicating this pathway in the regulation of BMPs as 
first suggested by Panizo et al. (2009). Importantly, NFκB2 silencing had no effect on total or 
phosphorylated levels of p65, thus ruling out off-target effects. By way of knockdown 
efficiency, close to 90% and 50% NFκB2 gene silencing and p52/p100 protein knockdown, 
respectively, were achieved, alongside minimal effects on cell viability. Indeed, recent studies 
have successfully achieved knockdown of NF-κB pathways in various cell types (including 
vascular cells), achieving comparable levels of knockdown to that observed in this case 
(Hénaut et al., 2016; Patel et al., 2017; Wang et al., 2016). Given the complex nature of NF-
κB signalling, and its role in many physiological processes including cell survival (Papa et al., 
2004), it was of major concern that complete p52/p100 knockdown may inadvertently exert 
pathological effects on HAECs. As such, the protein knockdown efficiency achieved was 
considered acceptable for the purpose of assessing the resulting influence on pro-calcific 
indices.  
Following mock transfection (scrambled, nt-siRNA) and NFκB2 silencing, HAECs in co-
culture were exposed to RANKL (5-25 ng/mL) for 72 hours. A range of pro-calcific indices in 
both the subluminal space and the underlying HASMCs were assessed to determine the 
contribution of endothelial non-canonical activation in the progression of VC. As observed and 
discussed in Chapter 3, RANKL treatment of mock-transfected HAECs in co-culture led to 
pro-calcific effects in both the subluminal space (increased ALP, BMP-2 release) and in the 
underlying HASMCs (increased ALP, Sox9 mRNA, ALP activity, decreased OPG 
mRNA/release). Following NFκB2 silencing, however, RANKL treatment of transfected 
HAECs in co-culture had a much less potent pro-calcific influence on the underlying HASMCs, 
with many of the aforementioned effects completely attenuated.  
Firstly, the attenuation of BMP-2 release and the decrease in extracellular ALP activity is of 
particular relevance to this study. As noted, BMP-4 regulation has previously been associated 
with non-canonical activation in VSMCs (Panizo et al., 2009), but to date, no studies have 
specifically associated BMP-2 release with this pathway. While extracellular ALP is not 
completely attenuated, it must be considered that only ~50% p52/p100 protein knockdown was 
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achieved, and smooth muscle ALP release also likely contributes to this trend; indeed, a similar 
trend in ALP activity was observed in the underlying HASMCs. Therefore, non-canonical NF-
κB activation may be responsible for BMP-2/ALP endothelial paracrine signalling, and in turn 
the regulation of smooth muscle ALP, ultimately contributing to smooth muscle calcification.  
In the underlying HASMCs, the attenuation of RANKL-induced ALP and Sox9 mRNA, 
alongside a reduction in Runx2 mRNA, suggests that endothelial NF-κB signalling (and 
paracrine communication) is required for smooth muscle pro-calcific gene expression. In fact, 
both Runx2 and Sox9, osteoblastic and chondroblastic transcription factors respectively, are 
responsible for the regulation of a wide range of genes during VC (including ALP) (Akiyama, 
2008; Fujita et al., 2004), and in the absence of endothelial NFκB2 are now reduced to below 
baseline. Interestingly, Runx2 and Sox9 transcription factors have been shown to mediate 
BMP-2-induced gene expression (Jang et al., 2012; Pan et al., 2008), and thus the observed 
attenuation of BMP-2 paracrine signalling may be responsible for this observation.  
It is also apparent that non-canonical NF-κB activation influences vascular OPG regulation, 
and in particular is involved in RANKL-mediated regulation of its own decoy receptor. In this 
regard, NF-κB mediates the RANKL-induced downregulation of smooth muscle OPG mRNA, 
and the accumulation of intracellular OPG. Interestingly, OPG release was significantly 
induced following NFκB2 silencing, however this did not affect the RANKL-mediated 
reduction in OPG; As such, this OPG release may represent the previously hypothesised 
cardioprotective response to vascular stress, rather than a RANKL/NFκB2-dependent 
mechanism involving ALP/BMP-2 signalling.  
As discussed in our publication of this study (Harper et al., 2018), there is minimal data to 
which we can compare these findings outside of our own results. Indeed, it was suggested in 
Chapter 3 that pro-calcific events may be mediated by non-canonical rather than canonical NF-
κB activation in endothelial cells, as the calcification inducer β-glycerophosphate was only 
found to activate the former pathway. Furthermore, the aforementioned study by Panizo et al. 
(2009), central to our hypothesis, has implicated this pathway in BMP signalling in VSMCs, 
while Zhan and colleagues (2014) have observed the attenuation of VC via blockade of 
RANKL/NF-κB (but not specifically non-canonical signalling) by GLP-1RA treatment. Of 
further note, NF-κB has also been considered a potential therapeutic target in the management 
of diabetic microvascular complications (Suryavanashi et al., 2017), but again neither 
canonical nor non-canonical signalling pathways are favoured in this suggestion. In endothelial 
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cells, the role of NF-κB (but not specifically non-canonical signalling) in the regulation of 
paracrine signalling has been previously noted. In this respect, the knockdown of canonical 
NF-κB in ECs has consequences for VSMC proliferation (Patel et al., 2017), further 
highlighting the importance of NF-κB for vascular paracrine communication. In this study, we 
now present novel evidence that endothelial non-canonical NF-κB signalling is required for 
pro-calcific paracrine communication in VSMCs, thereby playing a central role in the 
pathogenesis of medial VC.  
 
5.4.5.2 The Effects of NF-B/p52 Knockdown on Anti-oxidant Expression  
Finally, the effects of non-canonical NF-κB knockdown on oxidative stress indices were 
assessed in order to determine if this pathway mediates redox pathways in ECs. In this respect, 
the previous section has clarified that non-canonical NF-κB is responsible for pro-calcific 
paracrine signalling, but it has also been observed that RANKL and TRAIL mediate endothelial 
oxidative stress. The bi-directional relationship between NF-κB and redox signalling is 
complex; ROS can induce NF-κB, and the resulting upregulated genes can then reciprocally 
regulate ROS (Morgan and Liu, 2011). Indeed, several processes that mediate oxidative stress 
also regulate NF-κB (including pro-inflammatory cytokines) (Brand et al., 1996). Furthermore, 
NF-κB can exert both pro- and anti-oxidant effects, and is known to mediate NOX (Anrather 
et al., 2006) as well as SODs/HMOX1 (Djavaheri-Mergny et al., 2004; Lavrovsky et al., 1994; 
Rojo et al., 2004), potent pro- and anti-oxidant genes respectively. Moreover, TRACP5, 
identified in Section 5.2 as a potential regulator of VC, is also known to induce oxidative stress 
(Halleen et al., 1999). Thus, the inter-regulation between endothelial non-canonical NF-κB and 
oxidative stress during VC requires clarification.  
To reiterate, a key aim of this Chapter is to delineate the mechanism(s) by which TRAIL exerts 
its protective function in the vasculature, identified in Chapter 3. The majority of evidence 
presented in this chapter points to a role for redox pathways in the regulation of non-canonical 
NF-κB (i.e., the anti-oxidant NAC was found to attenuate non-canonical activation). Thus, we 
propose that TRAIL may exert anti-calcific effects in the endothelium via anti-oxidant 
signalling, blocking non-canonical NF-κB activation and ultimately pro-calcific paracrine 
signalling. As such, this investigation serves to confirm the hypothesis that redox pathways 
mediate NF-κB in the promotion of VC, rather than vice-versa. In this case, a range of pro-
oxidant and anti-oxidant genes were assessed in endothelial cells following NFκB2 silencing 
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and RANKL exposure. Compared to mock-transfected cells, no changes were noted at an 
mRNA level in any of the measured oxidative stress indices in HAECs following NFκB2 
knockdown. RANKL exposure exerted the same trends on these indices (SOD1, SOD2, gp91, 
p47, eNOS, HMOX1) as previously identified in Section 5.3, thus remaining unaffected by 
NFκB2 silencing. This finding therefore confirms that RANKL-induced non-canonical NF-κB 
activation induces pro-calcific signalling in HAECs, but does not regulate the measured redox 
genes (which remained unaffected by NFκB2 knockdown).  
Overall, therefore, while non-canonical NF-κB is required for endothelial pro-calcific paracrine 
signalling, it is not required for RANKL-mediated oxidative stress. Indeed, the stimulus that 
causes NF-κB to regulate redox genes appears to be cell-specific, and relies on a number of 
environmental factors (Morgan and Liu, 2011; Perkins et al., 2006). What we can conclude 
from this study is that RANKL-induced pro-calcific signalling is reliant on non-canonical NF-
κB activation, and the concurrent induction of oxidative stress is not mediated by this pathway. 
However, TRAIL-mediated anti-oxidant signalling can attenuate non-canonical NF-κB, 















5.5 Summary and Conclusions   
While RANKL is known to exert is osteoclastic function via NF-κB signalling, its mechanism 
in the vasculature remains largely unclarified. This statement is even more true for TRAIL, 
known to activate multiple pathways in its pleiotropic functions in vivo, none of which have 
yet been experimentally associated with its protective role in the vasculature. Research from 
Chapter 3 suggests that RANKL may exert its pro-calcific function via non-canonical NF-κB 
activation, subsequently blocked by TRAIL; however, it has also been suggested that RANKL 
and TRAIL can exert pro-oxidant and anti-oxidant effects respectively. In this study, the 
regulation of non-canonical NF-κB/redox signalling by RANKL/TRAIL in the vasculature 
were clarified, and potential novel targets that may be involved in RANKL/TRAIL function 
were investigated. 
Firstly, TRACP5, a protein with a central role in osteoclastogenesis, was identified as a 
potential contributor to VC pathogenesis. Our data provides strong evidence that TRACP5 is 
mediated by RANKL/TRAIL in the vasculature, and therefore may be pertinent in delineating 
the mechanisms underlying VC. Of additional note, TRACP5 is also known to exert pro-
oxidant effects, known to drive VC, thereby further supporting a role for RANKL and TRAIL 
in vascular redox signalling.  
Following analysis of a number of oxidative stress targets, the proposed pro-oxidant and anti-
oxidant roles for RANKL and TRAIL respectively were confirmed, with RANKL upregulating 
the p47 subunit of NADPH oxidase, and TRAIL promoting HMOX1 expression. Furthermore, 
the TRAIL-dependent promotion of eNOS expression in the presence of RANKL, and the 
simultaneous reduction in RANKL-induced ROS further supports an anti-oxidant role for 
TRAIL in the mediation of VC.  
Finally, the anti-oxidant NAC was also found to attenuate RANKL-induced pro-calcific 
signalling alongside non-canonical NF-κB activation, emulating the effects of TRAIL observed 
in Chapter 3 and supporting a role for oxidative stress in the regulation of pro-calcific non-
canonical NF-κB signalling. Indeed, following siRNA silencing of the NFκB2 gene, it was 
confirmed that the non-canonical NF-κB pathway in endothelial cells is responsible for 
EC:VSMC pro-calcific paracrine communication. Thus, we can conclude that TRAIL may also 
exert its protective effects on the endothelium via attenuation of RANKL-induced non-
canonical NF-κB activation. In this way, we shed additional light on the mechanisms of 
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RANKL and TRAIL-mediated pro-calcific and protective effects during VC, respectively, 






































6.1 Final Summary  
Recent evidence now points to a role for RANKL, TRAIL and their common decoy receptor 
OPG in VC pathogenesis, a major cause of cardiovascular morbidity and mortality among type-
2 diabetics. The primary role for RANKL in vivo is in the promotion of bone resorption, while 
for TRAIL it is the induction of apoptosis (Kim et al., 2004; Wada et al., 2006). In the 
vasculature, however, these ligands appear to exert the opposite effect, with RANKL driving 
calcification (a process analogous to bone formation), and TRAIL exerting a cardioprotective 
effect in the vasculature by preventing VC. Despite this evidence, however, the precise 
signalling pathways and mechanisms exerting the effects of RANKL and TRAIL in a vascular 
setting remain largely undefined within the scientific literature. Of interest, much evidence now 
highlights the therapeutic potential for TRAIL in preventing or regressing VC in vivo (di 
Bartolo et al., 2013). As such, if the precise molecular events and mechanisms underpinning 
the VC process (and TRAIL protection in particular) can be defined, this may aid in the 
development of a novel treatment to ultimately reduce the morbidity and mortality associated 
with CVD/T2DM worldwide.  
Interestingly, recent research has identified a pro-calcific role for RANKL both directly in 
VSMCs (Panizo et al., 2009) and via endothelial paracrine signalling, promoting calcification 
in the underlying smooth muscle layer (Davenport et al., 2016; Osako et al., 2010). 
Furthermore, previous limited studies have indicated that TRAIL may have the ability to 
attenuate RANKL’s effects in osteoclastogenesis (Zauli et al., 2004; Zauli et al., 2008). 
Therefore, we hypothesised that TRAIL may exert its protective effects in the vasculature via 
attenuation of RANKL-induced pro-calcific signalling (Study 1). The key findings from Study 
1 are summarised in Section 6.1.1. Secondly, we noted that the vast majority of studies to date 
regarding the role of RANKL and TRAIL in the vasculature have been carried out in “healthy”, 
non-pathological models in vitro. In reality, however, VC progresses alongside known 
pathological stimuli such as hyperglycemia (a key circulatory hallmark of T2DM) and 
inflammation (present during atherosclerosis) (McCullough et al., 2008). Thus, we investigated 
the effects of RANKL and TRAIL (separately) on the vasculature in the presence of these 
pathological stimuli, to determine if these ligands retained their respective pro-calcific and 
protective effects under these conditions. In this respect, we hypothesised that RANKL may 
promote, and TRAIL may prevent, pro-calcific events induced by inflammation/hyperglycemia 
(Study 2). The key findings from Study 2 are summarised in Section 6.1.2. 
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Although the mechanisms underpinning RANKL-induced osteoclastogenesis and TRAIL-
mediated apoptosis are well defined, the precise signalling pathways activated by these ligands 
in the vasculature remain unclear. Interestingly, both NF-κB signalling and oxidative stress 
have been implicated in the pathogenesis of VC, rendering these pathways of particular interest 
(Byon et al., 2008; Zhao et al., 2012). Indeed, it is known that RANKL activates NF-κB 
signalling in the vasculature, but (as RANKL is one of few ligands known to activate the non-
canonical NF-κB pathway), it has not yet been clarified which NF-κB pathway is responsible 
for RANKL-mediated pro-calcific effects. Furthermore, an anti-oxidant role for TRAIL in the 
vasculature has been proposed (Zauli et al., 2003), but whether or not this pathway exerts an 
anti-calcific effect on the vasculature remains to be determined. As such, we chose to further 
investigate these pathways in vitro, with a hypothesis that RANKL and TRAIL may mediate 
their respective pro-calcific and anti-calcific effects (at least in part) via NF-κB signalling 
and/or oxidative stress (Study 3). We also considered and assessed additional contributors to 
the VC process, not yet identified to date, in an effort to shed additional light on VC from a 
mechanistic perspective. The key findings from Study 3 are summarised in Section 6.1.3. 
To examine these hypotheses, primary human endothelial and smooth muscle cells were 
assessed both in monoculture and co-culture. The employed co-culture model more closely 
resembles the structure of the vasculature, incorporating endothelial paracrine communication 
(the cells in contact with circulating proteins in vivo) to the underlying smooth muscle layer 
(the location of medial VC in vivo). Furthermore, the widest range of VC-related indices to 
date were assessed, and a number of common confounders employed in the literature were 
eliminated (Davenport et al., 2016; Olesen et al., 2012). In this respect, these studies comprise 
the most physiologically relevant and comprehensive investigation of its nature to date, 
providing valuable insight into the molecular processes and signalling pathways driving the 
VC process, and aiding our understanding of this complex pathology.  
 
6.1.1 Study 1: Key Findings  
In study 1, we investigated the hypothesis that TRAIL may attenuate RANKL-induced pro-
calcific signalling in the vasculature. In endothelial cell monoculture, it was found that RANKL 
induced both BMP-2 and ALP paracrine signalling, previously observed by Davenport et al. 
(2016). We further highlighted an increase in both intracellular BMP-2/ALP. Most pertinently, 
co-incubation with TRAIL completely attenuated endothelial BMP-2/ALP release, alongside 
intracellular ALP activity, highlighting a protective role for this ligand in the attenuation of 
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RANKL-mediated pro-calcific signalling. Interestingly, RANKL also induced both canonical 
and non-canonical NF-κB activation in endothelial cells, while TRAIL completely attenuated 
RANKL-induced non-canonical signalling, potentially implicating this pathway as the 
mechanism by which RANKL exerts its pro-calcific effects in the vasculature. In smooth 
muscle cell monoculture, RANKL was found to exert direct pro-calcific effects via the 
induction of ALP release, osteoblastic Runx2 mRNA expression, and decreasing 
cardioprotective OPG release. Minimal protective effects of TRAIL were noted in smooth 
muscle cells, however, indicating that TRAIL may only exert its protective effects via 
endothelial paracrine signalling, and not at the level of the underlying VSMCs.  
In co-culture models, endothelial exposure to RANKL induced a number of pro-calcific effects 
in the underlying smooth muscle cells. In this respect, RANKL promoted the expression of 
ALP and Sox9 mRNA, whilst decreasing OPG mRNA. All three transcriptional changes, 
however, were attenuated by TRAIL co-treatment, as was RANKL-induced intracellular ALP 
activity. Once again, co-exposure with TRAIL completely attenuated RANKL-induced BMP-
2/ALP paracrine signalling, suggesting that the observed effects of RANKL and TRAIL in 
smooth muscle are primarily mediated by endothelial communication. Of additional interest, 
RANKL was found to induce smooth muscle OPG release in co-culture, despite a decrease 
being observed in smooth muscle monoculture. This finding may suggest that, in areas of intact 
(healthy) endothelium, the vasculature exerts a natural cardioprotective mechanism to protect 
from RANKL-induced calcification, while in areas of damaged or dysfunctional endothelium 
(for example, atherosclerotic plaque) OPG levels are reduced, rendering the vessel susceptible 
to further damage. Furthermore, RANKL appears to induce Runx2 osteoblastic transcription 
factor when in direct contact with VSMCs, while upregulating Sox9 chondrogenic 
transcription factor expression via endothelial signalling; thus, we propose that RANKL may 
drive both osteoblastic and chondrocytic differentiation, determined by the integrity of the 
endothelium. Overall, however, we highlight for the first time the pro-calcific effects of 
RANKL-mediated endothelial paracrine signalling on underlying VSMCs, and the ability of 
TRAIL to attenuate RANKL-induced calcification in a vascular setting.  
 
6.1.2 Study 2: Key Findings  
In study 2, we investigated the role of RANKL and TRAIL under pathological conditions 
(inflammation, hyperglycemia) common during T2DM. In both mono- and co-culture, as 
expected, the employed pathological stimuli (TNFα, glucose) were found to induce a wide 
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range of pro-calcific effects on endothelial and smooth muscle cells. In endothelial cell 
monoculture, RANKL was found to further promote TNFα-induced BMP-2 release and (non-
significantly) extracellular ALP; moreover, these effects were exerted alongside an increase in 
non-canonical NF-κB activation, potentially implicating this pathway in the regulation of 
TNFα-mediated pro-calcific signalling. In smooth muscle cells, RANKL exerted minimal 
effects on TNFα-induced pro-calcific signalling, but again endothelial BMP-2/ALP paracrine 
signalling was promoted by RANKL in co-culture, alongside intracellular smooth muscle ALP 
activity. With regard to TRAIL, non-canonical NF-κB activation was significantly attenuated 
in the endothelial layer under inflammatory conditions, and TRAIL co-treatment was also 
found to significantly reduce TNFα-induced BMP-2/ALP release and intracellular BMP-2 in 
co-culture. Thus, RANKL and TRAIL (respectively) promote and prevent TNFα-induced 
endothelial BMP-2/ALP release and non-canonical NF-κB activation, highlighting a role for 
these ligands in paracrine communication under inflammatory conditions, and further 
implicating NF-κB signalling in VC pathogenesis. 
Under hyperglycemic conditions, RANKL further promoted endothelial BMP-2 release and 
(non-significantly) ALP activity, while also upregulating Runx2 mRNA expression. In 
HASMC monoculture, RANKL exerted minimal pro-calcific effects, but in co-culture, 
RANKL again promoted glucose-induced BMP-2/ALP paracrine signalling while upregulating 
smooth muscle Sox9 mRNA. Again, TRAIL exerted minimal direct effects on smooth muscle 
cells, but significantly reduced glucose-induced BMP-2/ALP paracrine signalling in co-
culture. Furthermore, this effect was accompanied by a decrease in smooth muscle ALP and 
Sox9 mRNA, and an increase in cardioprotective OPG release (compared to glucose treatment 
alone). As an additional significant finding, under hyperglycemic conditions, the observed pro-
calcific endothelial paracrine signalling was not accompanied by an increase in the activation 
of either NF-κB pathway; therefore, RANKL and TRAIL exert their respective functions via 
an unrelated (unknown) mechanism in the presence of elevated glucose. Furthermore, in all 
cases, the mRNA expression trends of both RANKL and TRAIL are particularly similar, 
decreasing a number of pro-calcific markers. While this finding may contribute to explaining 
the protective nature of TRAIL, it is unclear as of yet what the significance of this is for 
RANKL, as this ligand exerts simultaneous pro-calcific effects at a protein level; therefore, 
further experimentation is required to delineate these trends. Overall, however, it is clear that 
both RANKL and TRAIL promote and prevent glucose-induced pro-calcific paracrine 
signalling, respectively, via a mechanism unrelated to non-canonical NF-κB. 
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6.1.3 Study 3: Key Findings  
In study 3, we investigated the key molecular mechanisms underpinning VC, focusing on 
oxidative stress and non-canonical NF-κB signalling. Furthermore, we investigated new targets 
as of yet unrelated to VC, that may aid in delineating the molecular events and signalling 
mechanisms behind this process. With respect to the latter, TRACP5, a protein central to bone 
resorption, was identified and assessed as a potential contributor to VC pathogenesis. Our 
findings suggest that TRACP5 may be involved in RANKL/TRAIL-mediated pro-calcific 
signalling in the endothelium, given that RANKL promotes, and TRAIL attenuates, the 
TRACP5 expression. Further research is therefore warranted to delineate the precise role of 
this enzyme during VC, and to investigate its contribution to the calcification process. 
Secondly, a number of pro- and anti-oxidant targets were assessed to determine the role of 
oxidative stress in RANKL/TRAIL-mediated endothelial paracrine signalling. SOD1, a potent 
anti-oxidant enzyme, was elevated in response to both RANKL and TRAIL, and therefore does 
not appear to be responsible for the observed effects of RANKL and TRAIL in endothelial 
cells. Interestingly, RANKL was found to upregulate p47 mRNA, a central subunit involved 
in NOX2 ROS generation, while also significantly inducing intracellular ROS levels. Thus, 
RANKL appears to exert a net pro-oxidant effect on the endothelium, which may contribute to 
RANKL-induced pro-calcific signalling. TRAIL, on the other hand, completely attenuated 
RANKL-induced p47 mRNA expression while upregulating the anti-oxidant HMOX1 mRNA, 
and co-treatment with RANKL + TRAIL significantly induced eNOS mRNA expression. 
Furthermore, these effects were accompanied by a decrease in RANKL-induced intracellular 
ROS levels. Therefore, TRAIL exerts a net anti-oxidant effect on the endothelium, which may 
contribute to TRAIL-mediated endothelial protection.  
To better understand the pro-oxidant and anti-oxidant nature of RANKL and TRAIL, 
respectively, NAC was employed to determine the effects of anti-oxidant treatment on 
RANKL-induced pro-calcific signalling. Interestingly, NAC treatment was found to completely 
attenuate endothelial pro-calcific paracrine signalling and non-canonical NF-κB activation, 
suggesting that anti-oxidant mechanisms may mediate calcification upstream of NF-κB. 
Indeed, the effects of NAC were similar to that of TRAIL co-treatment, further suggesting that 
TRAIL may exert an anti-oxidant effect on endothelial cells to prevent pro-calcific signalling.  
To better understand the importance of non-canonical NF-κB signalling in this process, a key 
element of this pathway was subject to siRNA knockdown. It was determined that non-
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canonical activation is indeed necessary for RANKL-induced endothelial pro-calcific 
signalling, and the induction of pro-calcific events in the underlying smooth muscle. However, 
NF-κB/p52 knockdown did not affect any of the measured redox indices in endothelial cells; 
therefore, it can be concluded that RANKL-induced oxidative stress activates non-canonical 
NF-κB and subsequent pro-calcific endothelial paracrine signalling in the mediation of VC. 
Furthermore, the anti-calcific nature of TRAIL may be dependent on anti-oxidant signalling, 
potentially explaining its protective effects under inflammatory (NF-κB-dependent) and 
hyperglycemic (NF-κB-independent) conditions. The proposed effects of RANKL and TRAIL 
under physiological and pathological conditions from a mechanistic perspective are 
















Figure 6.1. Visual interpretation of the key findings from Studies 1-3. (A) Under physiological conditions, our 
data suggests that RANKL induces oxidative stress (via NOX2/p47) upstream of non-canonical NF-κB activation 
(NF-κB/p52) in endothelial cells. This activation results in endothelial paracrine signalling (BMP-2/ALP) driving 
pro-calcific effects in the underlying smooth muscle cells. When co-incubated with TRAIL, this oxidative stress 
is reduced (via a NOX2/eNOS-dependent mechanism), non-canonical NF-κB signalling is attenuated, and the 
subsequent paracrine signalling/smooth muscle calcification prevented. (B) Under inflammatory conditions (TNFα 
exposure), we suspect that RANKL further promotes TNFα-induced oxidative stress in endothelial cells, thereby 
driving non-canonical NF-κB activation and pro-calcific paracrine signalling/smooth muscle calcification. TRAIL, 
however, likely exerts an anti-oxidant effect on the endothelium, preventing TNFα-induced non-canonical NF-κB 
activation and the downstream pro-calcific cascade. (C) Under hyperglycemic conditions (glucose exposure), we 
suspect that RANKL amplifies the pro-oxidant influence of hyperglycemia, thereby accentuating pro-calcific 
paracrine signalling via an (as yet) unknown mechanism. These paracrine signals then drive chondrocytic (Sox9) 
differentiation in the underlying smooth muscle cells. We also propose that TRAIL exerts an anti-oxidant effect 
under hyperglycemic conditions, thereby preventing glucose-induced paracrine signalling via an unknown 
mechanism. Glucose-induced pro-calcific effects in the underlying smooth muscle layer are therefore reduced. 
Thus, RANKL and TRAIL may promote and prevent, respectively, pro-calcific signalling events mediated by 
pathological stimuli. RANKL, receptor activator of NF-κB ligand; TRAIL, tumour necrosis factor-related 
apoptosis-inducing ligand; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; BMP, bone 
morphogenetic protein;  ALP, alkaline phosphatase; OPG, osteoprotegerin; Sox9, sex determining region Y box-
9; Runx2, runt-related transcription factor 2. Purple text, hypothesised event: data not shown experimentally in the 
current thesis. 
 
A: Physiological conditions B: Inflammatory conditions C: Hyperglycemic conditions 
RANKL TRAIL 
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6.2 Future Directions  
Despite the comprehensive nature of this study, there are several questions that remain 
unanswered regarding the role of RANKL and TRAIL, and their mechanisms of action, in the 
vasculature. In this respect, a common trend throughout this research was the divergent 
responses of mRNA and protein, a likely contributor to the conflicting evidence identified in 
the literature to date. It is well known that mRNA and protein trends do not always coincide 
(Carmody and Wente, 2009; Greenbaum et al., 2003), and indeed, protein measurements more 
accurately represent the functional outcome of RANKL/TRAIL treatment. However, the 
longer-term effects of the diverging mRNA responses on vascular cells remain to be clarified 
to determine if these protein responses are retained. In particular, the bimodal response of OPG 
identified in Chapter 3, and the complex trends identified in the regulation of this ligand 
throughout this thesis, requires further clarification. Indeed, a key limitation of this study is the 
employment of only one endothelial cell and one smooth muscle cell donor; thus, repeat 
experiments with multiple cell donors may shed additional light on these discrepancies.  
From a mechanistic perspective, the effects of RANKL and TRAIL on oxidative stress under 
pathological conditions remain to be fully delineated. We propose in Figure 6.1 that RANKL 
promotes, and TRAIL reduces, ROS generation induced by hyperglycemia and inflammation. 
Recent research within our group indeed suggests that TRAIL (at 100 ng/mL) can reduce both 
TNFα- and glucose-induced ROS (Forde et al., unpublished observations), but additional 
experiments are required to confirm this at 5 ng/mL, and to investigate the effects of RANKL 
under these conditions. Furthermore, the specific redox mechanism(s) by which RANKL and 
TRAIL mediate pro-calcific signalling under hyperglycemic conditions are of particular 
interest, as non-canonical NF-κB signalling was not observed in these models. As an additional 
oversight of this study, only SOD mRNA/protein expression were assessed following 
endothelial exposure to the aforementioned stimuli. To further clarify the role of SOD1/2 in 
the regulation of calcification, SOD enzyme activity should also be assessed, which may 
provide additional mechanistic information into the role of oxidative stress in VC.  
Furthermore, clarification is required regarding the regulation of RANK and TRAIL receptors 
during RANKL/TRAIL-mediated VC. It has been considered that TRAIL may exert its 
protective effects on RANKL-induced pro-calcific signalling via the downregulation of RANK 
in endothelial cells, although preliminary evidence at an mRNA level suggests that this is not 
the case (data not shown). Despite this, RANK and TRAIL receptors will be assessed at a 
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protein level (via receptor quantification/flow cytometry) to determine the potential influence 
of receptor regulation during VC. Indeed, following these mechanistic investigations, 
additional pathways associated with RANKL/TRAIL signalling (e.g. MAPK, ERK) may be 
investigated to determine their contribution to VC regulation.  
Of note, it is known that VC progresses under both hyperglycemic and inflammatory conditions 
in vivo (Olson et al., 2012), and in the presence of a complex balance of soluble factors 
including RANKL and TRAIL. Moreover, multiple cell types contribute to VC, including the 
release of pro-inflammatory cytokines from immune cells at atherosclerotic sites (Gotsman et 
al., 2008). The inclusion of all of these factors would be too complex in vitro, and as such, a 
murine model of diabetic calcification would be ideal for future VC investigations (such as that 
employed by Liu et al. (2014)). Additionally, in vivo models incorporate the physiological 
element of shear stress exerted on the vasculature by the flow of blood, which may potentially 
alter the effects observed for RANKL and TRAIL under static conditions in vitro. Within a 
diabetic murine model, the precise effects of recombinant RANKL and TRAIL under 
pathological conditions may be more accurately determined, and may shed light on the 
potential therapeutic value for TRAIL during VC.  
Finally, the role for TRACP5 as a potential contributor to RANKL/TRAIL function in VC 
warrants further investigation. In this regard, whether or not TRACP5 is actively involved in 
the progression of calcification/pro-calcific signalling remains to be determined (e.g. via 
TRACP5 siRNA knockdown). Furthermore, extracellular TRACP5 measurements in vitro, not 
assessed in the current investigation, may highlight a role for this enzyme as a circulatory 
biomarker for VC, as TRACP5 has previously been identified as a marker of bone pathologies 
(Seol et al., 2009). Interestingly, two circulatory isoforms of TRACP5 have been identified 
(Halleen et al., 2009), and the relevance of each to VC pathogenesis remain to be defined.  
On a similar note, the potential for TRAIL as a circulatory biomarker for cardiovascular 
complications during T2DM has been investigated within our own research group by Forde et 
al. (unpublished observations). Indeed, circulating TRAIL levels were found to accurately 
distinguish between patients with newly diagnosed T2DM, and diabetic patients with 
underlying CVD complications. Further collaborative research is now underway to design and 
implement a mass spectrometry immunoassay to examine specific circulatory isoforms of 
TRAIL (and related VC indices), adding further value to T2DM/CVD diagnostics in the 
prevention of diabetic cardiovascular events.  
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6.3 Concluding Remarks 
Overall, this research has provided valuable insight into the roles of RANKL and TRAIL in 
the pathogenesis of VC from both a molecular signalling and mechanistic perspective, 
clarifying much debate remaining in the literature. We highlight the significance of endothelial 
paracrine signalling in the mediation of VC, and the importance of incorporating vascular cell 
communication in vitro. We report that RANKL-induced pro-calcific effects are exerted 
predominantly at an endothelial level, and that RANKL can also promote VC in the presence 
of pathological stimuli common during T2DM. Significantly, we present novel evidence that 
TRAIL exerts a protective, anti-calcific effect on the vasculature via the attenuation of 
RANKL-induced endothelial paracrine signalling, and also reduces the potent pro-calcific 
effects induced by pathological stimuli. Furthermore, this research provides important insight 
into the mechanisms underpinning VC in vascular cells; in this respect, we implicate for the 
first time the non-canonical NF-κB pathway as a key driver of endothelial pro-calcific 
signalling. Furthermore, we show that RANKL exerts a pro-oxidant effect on the vasculature 
in the promotion of VC, while TRAIL exerts an anti-oxidant effect on the vasculature in the 
prevention of VC; moreover, these effects appear to be upstream of NF-κB signalling, 
subsequently activated by RANKL and attenuated by TRAIL. Therefore, while this research 
provides necessary clarification regarding the complex signalling events underpinning VC, we 
also highlight the therapeutic value of TRAIL in this context, potentially reducing the growing 
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Therapy Mode of Action Results To Date References 
    
OPG/RANKL/TRAIL-Related Therapies 
Denosumab* Neutralizes RANKL; prevents phenotypic 
transformation of vascular cells. 
Decreased aortic VC in a murine study; no 
effect on calcification in a human sub-
analysis of a larger trial. 
Helas et al., 2009 
Samelson et al., 2014 
Recombinant OPG 
Therapy 
Neutralizes RANKL; prevents phenotypic 
transformation of vascular cells. 
Inhibited VC in a murine study. Morony et al., 2008 
TRAIL Administration Unclear Reduced atherosclerosis progression in a 
murine model; protected against diabetic 
vascular injury in a rat model.  
Secchiero et al., 2006 
Liu et al., 2014  
    
Osteoporosis Therapies 
Bisphosphonates Prevents calcium and phosphate release from 
bone; inhibits crystal nucleation and 
propagation. 
Suppressed calcification in a rat model; 
conflicting data in human studies. 
Persy et al., 2006 
Nitta et al., 2004 
Toussaint et al., 2010  
Teriparatide Upregulates circulating concentrations of 
osteopontin, a calcification inhibitor. 
Decreased valve calcification in murine 
studies. 
Shao et al., 2003 
    
Cardiovascular Disease Therapies 
Statins  Prevent dyslipidemia and inflammation, risk 
factors for VC.  
Protective effects on VC in a rat model; 
conflicting data in human studies. 
Novaro et al., 2001 
Iijima et al., 2014 
Loomba and Arora, 2010 
Puri et al., 2015 
Endothelin Receptor 
Agonists 
Reduces hypertension, a risk factor for VC. Significantly reduced VC in a rat model.  Essalihi et al., 2004 
Antibody to IL-1β Reduces inflammation, a risk factor for VC. Attenuated calcification in a murine model. Awan et al., 2015 
    
    
Appendix 1.1. Therapies under investigation for the inhibition/reversal of VC.  
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T2DM Therapies 
Exenatide (GLP-1RA) Enhances glucose-dependent insulin secretion to 
reduce T2DM symptoms. 
Attenuated VSMC calcification in vitro; no 
in vivo studies completed to date. 
Zhan et al., 2014 
Liraglutide (GLP-1RA) Enhances glucose-dependent insulin secretion to 
reduce T2DM symptoms. 
No decrease in calcification noted in one 
prospective observational study to date.  
Davenport et al., 2015 
    
Chronic Kidney Disease Therapies 
Phosphate binders Decreases circulating concentrations of 
phosphate. 
Conflicting data, but favouring reduced 
progression of calcification with non-
calcium based phosphate binders. 
Jamal et al., 2013 
Calcimimetics Lower circulating calcium levels. Reduced mortality in uremic rats; reduced 
VC in humans in combination with low-dose 
vitamin D. 
Jung et al., 2012 
Raggi et al., 2011 
Rodriguez et al., 2008 
Vitamin D Receptor 
Agonists 
Mechanism not fully understood, but shown to 
increase osteopontin expression. 
Significantly reduced aortic calcification in 
a murine model. 
Lau et al., 2012 
Vitamin K Upregulates production of MGP, which binds 
calcium ions. 
Prevented arterial calcification in a rat 
model; slowed the progression of CAC in 
healthy older adults with pre-existing CAC 
in one human study. 
Shea et al., 2009 
Spronk et al., 2003 
Sodium Thiosulfate Chelates calcium, reduces inflammation. Prevented calcification in a uremic rat 
model; uncertain if suitable for VC 
treatment in humans. Recognised treatment 
for calciphylaxis. 
Auriemma et al., 2011 
Mathews et al., 2011 
Pasch et al., 2008 
CAC, coronary artery calcification; GLP-1RA, glucagon-like peptide-1 receptor agonist; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa-beta ligand; T2DM, 
type-2 diabetes mellitus; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand; VC, vascular calcification; VSMC, vascular smooth muscle cell. *Denosumab can be 
classified as both an OPG/RANKL/TRAIL-related and osteoporosis therapy. Harper et al., 2016.  
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BSP (murine) 95 








Prior to gene expression analysis, all primer sets were assessed for primer efficiency (Section 
2.2.3.8). It was ensured that all efficiency values fell between the accepted range of 90-105% 
as specified by the MIQE guidelines. 































Appendix 2.2. Typical standard curves for ELISA and alizarin red S staining. (A) In order to enable 
protein quantification, standard curves were included for ELISA experiments. Fresh standard curves were 
included for each ELISA run, with representative curves for (i) BMP-2, (ii) OPG, (iii) IL-6, (iv) RANKL 
and (v) TRAIL presented above. (B) For quantification of alizarin red S stain for calcium deposition, a 




























Appendix 3.1. RANKL and TRAIL release and intracellular protein expression in HAEC and HASMC 
monoculture. (A, B) RANKL and TRAIL release and (D, E) intracellular protein concentrations were 
determined by ELISA; (C) lysates were also analysed by Western blotting. HAECs (A, D) and HASMCs (B, 
E) were exposed to 25 ng/mL RANKL or 5 ng/mL TRAIL for 72 hours prior to analysis. Absolute values 
normalised to 105 cells (release) or mg total protein (lysate). * p < 0.05 compared to untreated control.  






























Appendix 3.2. The effects of RANKL and TRAIL on endothelial barrier function and smooth muscle 
phenotype in monoculture. (A) Percentage trans-endothelial exchange (TEE) of  FITC-dextran from the 
luminal to the subluminal compartment as determined by permeability assay (t = 3 hours). HAECs were 
subject to 72-hour RANKL (25 ng/mL) or TRAIL (5 ng/mL) exposure prior to barrier analysis. Results 
presented as fold change to untreated control. (B) HASMCs were subject to RANKL (25 ng/mL) or TRAIL 
(5 ng/mL) treatment for 72 hours prior to mRNA analysis of (i) SMα-actin, (ii) SM22α, (iii) BSP and (iv) 
OCN levels by RT-qPCR. Results presented as fold change to untreated control; 18S was employed as an 
endogenous control.  
A: HAEC 
B: HASMC 



























Appendix 3.3. Methodological validation. (A) Amplification curves for endogenous controls (18S, GAPDH) 
employed in qPCR. HAECs and HASMCs were exposed to RANKL (25 ng/mL) and TRAIL (5 ng/mL)  for 
72 hours prior to analysis. Samples were assayed in duplicate; control, RANKL and TRAIL amplification 
curves are overlapping. (B) OPG concentrations as determined by ELISA for HASMC-conditioned media 
(CM) and HASMC CM spiked with recombinant RANKL (25 ng/mL) and TRAIL (5 ng/mL). (C) RANKL 
and TRAIL concentrations as determined by ELISA for HASMC CM and HASMC CM spiked with 
recombinant OPG (20 ng/mL). ELISA results are presented as pg/mL absolute concentrations. (D) Percentage 
trans-endothelial exchange of recombinant RANKL and TRAIL from the luminal to the subluminal 

















A: 18S; HASMC   
B: 18S; HAEC 
C: GAPDH; HASMC 



























Appendix 3.4. Pro-calcific mRNA expression and OPG protein production in HAEC monoculture. 
HAECs were exposed to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours. (A) (i) BMP-2, (ii) ALP, 
(iii) Runx2 and (iv) IL-6 mRNA expression levels were determined by RT-qPCR, with GAPDH employed 
as an endogenous control. (B) OPG (i) release and (ii) intracellular production were analysed by ELISA; 




(iii)  (iv)  
(ii)  



























Appendix 3.5. Non-canonical NF-κB activation and pro-calcific gene expression in HAECs at various 
time points. (A) HAECs were exposed to 25 ng/mL RANKL over a 0-24 hour time course. Lysates were 
assessed for non-canonical NF-κB activation by Western blotting, and analysed by scanning densitometry 
normalised to GAPDH. Blots are representative. (B) HAECs were exposed to 25 ng/mL RANKL for 0, 24 
and 72 hours. (i) BMP-2, (ii) ALP and (iii) Runx2 mRNA expression was evaluated by RT-qPCR, with 
GAPDH employed as a reference gene. * p < 0.05; ** p < 0.01 compared to the 0-hour time point.  
A 



























Appendix 3.6. HAEC responses to β-glycerophosphate exposure. HAECs were treated with 10 mM β-
glycerophosphate for 72 hours. (A) Lysates were analysed for (i) canonical and (ii) non-canonical NF-κB 
activation by Western blotting, quantified by scanning densitometry and normalised to GAPDH. Blots are 
representative. (B) Conditioned media was assayed for (i) BMP-2 release by ELISA and (ii) ALP activity by 
enzyme activity assay. Absolute values are normalised to 105 cells. * p < 0.05; ** p < 0.01; *** p < 0.001 
































Appendix 3.7. Pro-calcific mRNA expression and protein production in HASMC monoculture. 
HASMCs were exposed to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours. (A) (i) ALP, (ii) BMP-
2 and (iii) IL-6 mRNA expression levels were determined by RT-qPCR, with GAPDH employed as an 
endogenous control. (B) Intracellular ALP activity was determined via enzyme assay while (C) (i) BMP-2 
and (ii) IL-6 release were quantified by ELISA. Absolute values for media and lysate are and normalised to 
105 cells and total protein respectively. * p < 0.05; ** p < 0.01 compared to untreated control unless otherwise 
stated; bars indicate statistical significance between treatment groups.  
A 
B 
(i)  (ii)  
(iii)  
(i)  



























Appendix 3.8. Expression of mRNA indices in HASMCs over a 72-hour time course. (A) HASMCs were 
exposed to RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 0, 24 and 72 hours. (i) BMP-2, (ii) ALP and (iii) 
Sox9 mRNA levels were investigated by RT-qPCR in response to RANKL, while (iv) BMP-2 and (v) Runx2 
mRNA levels were analysed in response to TRAIL. (B) HASMCs were exposed to RANKL (25 ng/mL) or 
TRAIL (5 ng/mL) for 0, 24, 48 and 72 hours. OPG mRNA was analysed by RT-qPCR in response to (i) 
RANKL and (ii) TRAIL. GAPDH was employed as a reference gene. * p < 0.05; ** p < 0.01 compared to 




(i)  (ii)  (iii)  
(iv)  (v)  



























Appendix 3.9. HASMC responses to β-glycerophosphate exposure. HASMCs were treated with 10 mM β-
glycerophosphate for 72 hours. (A) Pro-calcific transcripts (i) BMP-2, (ii) ALP, (iii) Runx2 and (iv) Sox9 were 
analysed. (B) Conditioned media was assayed for (i) BMP-2 release by ELISA and (ii) ALP activity by enzyme 
activity assay. (C) Lysates were analysed for (i) BMP-2 and (ii) ALP activity by ELISA and enzyme assay 
respectively. (D) OPG (i) mRNA, (ii) release and (iii) intracellular protein were analysed by RT-qPCR and 
ELISA where appropriate. GAPDH was employed as a reference gene for all RT-qPCR analyses. Absolute 
values are normalised to 105 cells and total cell protein for extra- and intracellular analyses respectively. * p < 




(i)  (ii)  (iii)  (iv)  
(i)  (ii)  (iii)  




























Appendix 3.10. HASMC responses to BMP-2 +/- noggin exposure. HASMCs were exposed to BMP-2 (5 
ng/mL) and/or noggin (100 ng/mL) for 72 hours. (A) mRNA transcripts were assessed for (i) ALP, (ii) Runx2 
and (iii) Sox9 by RT-qPCR, employing GAPDH as a reference gene. (B) Conditioned media was assessed for 
ALP activity via enzyme assay, normalising to 105 cells. (C) Intracellular (i) ALP and (ii) BMP-2 were 
analysed by activity assay and ELISA respectively, normalising to total cell protein. (D) Canonical and non-
canonical NF-κB activation were monitored by Western blotting and analysed by scanning densitometry, 
normalised to GAPDH. Blots are representative. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated 
control unless otherwise stated; bars indicate statistical significance between treatment groups.  
A 
(i)  
(ii)  (i)  





























Appendix 3.11. HASMC gene expression, protein production and NF-κB activation following 
endothelial treatment in co-culture. HAECs in transwell inserts were exposed to RANKL (5-25 ng/mL) 
+/- TRAIL (5 ng/mL) for 72 hours. In the underlying co-cultured HASMCs, (A) (i) BMP-2 and (ii) Runx2 
mRNA expression levels were determined by RT-qPCR, with GAPDH employed as an endogenous control. 
(B) Intracellular BMP-2 was quantified by ELISA, normalised to total protein levels. (C) (i) Canonical and 
(ii) non-canonical NF-κB activation was analysed by Western blotting and quantified by scanning 
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Appendix 3.12. HASMC responses post-exposure to HAEC-conditioned media following endothelial 
RANKL treatment. HAECs were treated with 25 ng/mL RANKL for 72 hours; HAEC conditioned media 
was then transferred to reporter HASMCs in culture for a further 72 hours. (A) Extracellular (i) BMP-2, (ii) 
ALP activity and (iii) OPG were measured by ELISA (BMP-2, OPG) and activity assay (ALP), normalised 
to 105 cells (HASMCs). (B) Intracellular (i) BMP-2, (ii) ALP activity and (iii) OPG were quantified in a 
similar manner, normalised to total cell protein. (C) (i) Canonical and (ii) non-canonical NF-κB activation 
was analysed by Western blotting and quantified by scanning densitometry, normalised to GAPDH. Blots are 
representative. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to control (0 ng/mL RANKL) HAEC-
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Appendix 3.13. HASMC responses in co-culture following endothelial RANKL treatment, +/- noggin. 
HAECs in transwell inserts were exposed to RANKL (5-25 ng/mL) for 72 hours, +/- noggin (100 ng/mL) in 
the subluminal compartment. (A) mRNA transcripts for (i) ALP and (ii) OPG were analysed in co-cultured 
HASMCs by RT-qPCR, normalised to GAPDH. (B) Extracellular (i) ALP activity and (ii) OPG release were 
quantified by activity assay and ELISA respectively, normalised to 105 cells (HASMCs). (C) Intracellular (i) 
ALP activity and (ii) OPG were quantified in a similar manner, normalised to total cell protein. * p < 0.05; 
** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical 





































Appendix 3.14. Osteogenic differentiation of MC3T3-E1 and HASMC, and alizarin red S staining of 
HASMCs in mono- and co-culture. MC3T3-E1 and HASMCs were exposed to osteogenic differentiation 
media for 21 days prior to analysis.  (A) Pro-calcific markers (i) ALP and (ii) Runx2, and osteogenic 
differentiation markers (iii) BSP and (iv) OCN were assessed by RT-qPCR in MC3T3-E1 cells; GAPDH was 
employed as an endogenous control. (B) Extracellular ALP activity was monitored at 7, 14 and 21 days’ 
differentiation via activity assay for (i) MC3T3-E1 and (ii) HASMCs. (C) HASMCs in (i) monoculture and 
(ii) co-culture were exposed to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for the final 72 hours of 
differentiation, prior to alizarin red S staining and quantification by absorbance. * p < 0.05; ** p < 0.01; *** 
p < 0.001 compared to control (undifferentiated cells).  
A 
B 
(i)  (ii)  (iii)  (iv)  
(i) MC3T3-E1  (ii) HASMC  
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Appendix 4.1. RANKL and TRAIL expression in HAECs and HASMCs exposed to TNF⍺ or glucose. 
HAECs and HASMCs were exposed to TNF⍺ (100 ng/mL) or glucose (30 mM) for 72 hours. (A) HASMC 
RANKL mRNA expression was analysed by RT-qPCR, employing 18S as an endogenous control. TRAIL 
release from (B) HAECs and (C) HASMCs were quantified by ELISA, normalised to 105 cells. Intracellular 
RANKL and TRAIL from (D) HAECs and (E) HASMCs were quantified by ELISA, normalised to total 



























Appendix 4.2. The effects of TNF⍺ and glucose on endothelial barrier function and smooth muscle 
phenotype in monoculture. (A) Percentage trans-endothelial exchange (TEE) of  FITC-dextran from the 
apical to the basolateral compartment as determined by permeability assay (t = 3 hours). HAECs were subject 
to 72-hour TNF⍺ (100 ng/mL) or glucose (30 mM) exposure prior to barrier analysis. Results presented as 
fold change to untreated control. (B) HASMCs were subject to TNF⍺ (100 ng/mL) or glucose (30 mM) 
treatment for 72 hours prior to mRNA analysis of (i) SMα-actin, (ii) SM22α, (iii) BSP and (iv) OCN levels 
































(i)  (ii)  (iii)  (iv)  
B 
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Appendix 4.3. The effect of mannitol exposure on pro-calcific indices in HAECs. HAECs were exposed 
to mannitol (30 mM) for 72 hours prior to analysis. (A) (i) BMP-2, (ii) ALP, (iii) Runx2 and (iv) IL-6 mRNA 
expression was determined by RT-qPCR, employing GAPDH as a reference gene. (B) Extracellular (i) BMP-
2, (ii) OPG, (iii) ALP activity and (iv) IL-6 in the conditioned media and (C) intracellular (i) BMP-2, (ii) OPG 
and (iii) ALP activity were determined by ELISA and enzyme assay as appropriate. (D) (i) Canonical and (ii) 
non-canonical NF-κB activation were determined by Western blotting, quantified by scanning densitometry 
and normalised to GAPDH. Blots are representative. Media and lysate analyses are normalised to 105 cells 



























Appendix 4.4. The effects of TNF⍺ +/- RANKL/TRAIL on pro-calcific indices in HAEC monoculture. 
HAECs were exposed to TNF⍺ (100 ng/mL) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) 
mRNA expression of (i) BMP-2 and (ii) IL-6 were analysed by RT-qPCR employing GAPDH as an 
endogenous control. (B) (i) OPG and (ii) IL-6 release and (C) intracellular (i) OPG and (ii) ALP activity were 
determined by ELISA and enzyme assay as appropriate, and normalised to 105 cells (media) or total cell protein 
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Appendix 4.5. The effects of glucose +/- RANKL/TRAIL on pro-calcific indices in HAEC monoculture. 
HAECs were exposed to glucose (15-30 mM) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) 
mRNA expression of BMP-2 was analysed by RT-qPCR employing GAPDH as an endogenous control. (B) 
(i) OPG and (ii) IL-6 release, and (C) intracellular (i) BMP-2, (ii) ALP activity and (iii) OPG were determined 
by activity assay and ELISA as appropriate, normalised to 105 cells (media) or total cell protein (lysate). * p 
< 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate 
statistical significance between treatment groups.  
A B (i)  
(ii)  C (i)  
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Appendix 4.6. The effects of TNF⍺ and glucose +/- RANKL/TRAIL on NF-κB activation in HAEC 
monoculture. HAECs were exposed to TNF⍺ (100 ng/mL) or glucose (15-30 mM) +/- RANKL (25 ng/mL) 
or TRAIL (5 ng/mL) for 72 hours. (A) Representative blots for NF-κB activation are presented for all 
conditions tested. (B) Canonical NF-κB activation was assessed following exposure to TNF⍺ +/- 
RANKL/TRAIL, and (C) (i) Canonical and (ii) non-canonical NF-κB activation was assessed following 
exposure to glucose +/- RANKL/TRAIL. NF-κB activation was determined by Western blotting, quantified 
by scanning densitometry and normalised to GAPDH. Absolute values are normalised to total protein. ** p < 
0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance 
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Appendix 4.7. The effect of mannitol exposure on pro-calcific indices in HASMCs. HASMCs were 
exposed to mannitol (30 mM) for 72 hours prior to analysis. (A) (i) BMP-2, (ii) ALP, (iii) Runx2, (iv) OPG, 
(v) Sox9 and (vi) IL-6 mRNA expression was determined by RT-qPCR, employing GAPDH as a reference 
gene. (B) (i) BMP-2, (ii) ALP activity, (iii) OPG, (iv) IL-6 in the conditioned media, and (C) intracellular (i) 
BMP-2, (ii) OPG and (iii) ALP activity were determined by ELISA and enzyme assay as appropriate. (D) (i) 
Canonical and (ii) non-canonical NF-κB activation was determined by Western blotting, quantified by 
scanning densitometry and normalised to GAPDH. Blots are representative. Media and lysate analyses are 



























Appendix 4.8. The effects of TNF⍺ +/- RANKL/TRAIL on pro-calcific indices in HASMC monoculture. 
HASMCs were exposed to TNF⍺ (100 ng/mL) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours. (A) 
(i) BMP-2, (ii) OPG and (iii) IL-6 mRNA expression was assessed by RT-qPCR, employing GAPDH as a 
reference gene. (B) (i) BMP-2 and (ii) IL-6 release and (B) intracellular (i) BMP-2, (ii) ALP activity and (iii) 
OPG were analysed by ELISA and enzyme assay as appropriate. Absolute values normalised to 105 cells. * p 
< 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control.  
B 
(i)  (ii)  
(iii)  
C 
(i)  (ii)  



























Appendix 4.9. The effects of glucose +/- RANKL/TRAIL on pro-calcific indices in HASMC 
monoculture. HASMCs were exposed to glucose (15-30 mM) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) 
for 72 hours. (A) mRNA expression of (i) BMP-2 and (ii) IL-6 were analysed by RT-qPCR employing GAPDH 
as an endogenous control. (B) (i) BMP-2 and (ii) ALP activity were assessed in the conditioned media, and 
(C) intracellular (i) BMP-2 and (ii) OPG were determined by ELISA and activity assay as appropriate. Media 
and lysate analyses were normalised to 105 cells and total protein respectively. * p < 0.05; ** p < 0.01; *** p 
< 0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance between 
treatment groups.  
A 
(i)  (ii)  
(i)  (ii)  
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Appendix 4.10. The effects of TNF⍺ and glucose +/- RANKL/TRAIL on NF-κB activation in HASMC 
monoculture. HASMCs were exposed to TNF⍺ (100 ng/mL) or glucose (15-30 mM) +/- RANKL (25 ng/mL) 
or TRAIL (5 ng/mL) for 72 hours. (A) Representative blots for NF-κB activation are presented for all 
conditions tested. (B) Canonical NF-κB activation was assessed following exposure to TNF⍺ +/- 
RANKL/TRAIL, and (C) (i) canonical and (ii) non-canonical NF-κB activation was assessed following 
exposure to glucose +/- RANKL/TRAIL. NF-κB activation was determined by Western blotting, quantified 
by scanning densitometry and normalised to GAPDH. Absolute values are normalised to total protein. * p < 
0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical 



























Appendix 4.11. The effects of TNF⍺ +/- RANKL/TRAIL on pro-calcific indices in co-cultured HASMCs. 
HAECs in transwell inserts were exposed to TNF⍺ (100 ng/mL) +/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) 
for 72 hours, and the underlying HASMCs harvested for analysis. (A) mRNA expression of (i) BMP-2, (ii) 
ALP, (iii) Runx2, (iv) Sox9, (v) OPG and (vi) IL-6 were analysed by RT-qPCR employing GAPDH as an 
endogenous control. (B) IL-6 release levels were determined by ELISA, normalised to 105 cells. * p < 0.05; 
** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical 
significance between treatment groups.  
(iv)  (v)  (vi)  
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Appendix 4.12. The effects of glucose +/- RANKL/TRAIL on pro-calcific indices in co-cultured 
HASMCs. HAECs in transwell inserts were exposed to glucose (15-30 mM) +/- RANKL (25 ng/mL) or 
TRAIL (5 ng/mL) for 72 hours, and the underlying HASMCs harvested for analysis. (A) mRNA expression 
of (i) BMP-2, (ii) Runx2 and (iii) OPG were analysed by RT-qPCR employing GAPDH as an endogenous 
control. (B) IL-6 release and (C) intracellular (i) BMP-2 and (ii) ALP activity were determined by ELISA and 
activity assay where appropriate, and normalised to 105 cells (media) or total protein (lysate). * p < 0.05; ** p 
< 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate statistical 
significance between treatment groups.  
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(i)  (ii)  
(iii)  B 
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Appendix 4.13. The effects of TNF⍺ and glucose +/- RANKL/TRAIL on NF-κB activation in co-cultured 
HASMCs. HAECs were exposed to TNF⍺ (100 ng/mL) or glucose (15-30 mM) +/- RANKL (25 ng/mL) or 
TRAIL (5 ng/mL) for 72 hours, and the underlying HASMCs harvested for analysis. (A) Representative blots 
for NF-κB activation are presented for all conditions tested. (B) (i) Canonical and (ii) non-canonical NF-κB 
activation was assessed following exposure to TNF⍺ +/- RANKL/TRAIL, and (C) (i) canonical and (ii) non-
canonical NF-κB activation was assessed following exposure to glucose +/- RANKL/TRAIL. NF-κB 
activation was determined by Western blotting, quantified by scanning densitometry and normalised to 
GAPDH. Absolute values are normalised to total protein. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to 
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Appendix 5.1. The effects of β–glycerophosphate and mannitol on TRACP5, SOD1 and SOD2 
expression in HAECs. HAECs were exposed to (A) 10 mM β–glycerophosphate for 72 hours prior to analysis 
of (i) TRACP5, (ii) SOD1 and (iii) SOD2 mRNA expression via RT-qPCR employing 18S as an endogenous 
control, or (iv) TRACP5, (v) SOD1 and (vi) SOD2 protein expression via Western blotting. (B) HAECs were 
exposed to 30 mM mannitol prior to analysis of (i) TRACP5, (ii) SOD1 and (iii) SOD2 protein expression by 
Western blotting. Blots are normalised to GAPDH, quantified by scanning densitometry where possible. 



























Appendix 5.2. The effects of RANKL +/- TRAIL on SOD2 mRNA expression in HAECs. HAECs were 
exposed to RANKL (5-25 ng/mL) +/- TRAIL (5 ng/mL) for 72 hours prior to analysis. SOD2 gene expression 
was analysed by RT-qPCR employing GAPDH as an endogenous control. * p < 0.05; ** p < 0.01; *** p < 
0.001 compared to untreated control.   
  
  
Appendix 5.3. The effects of RANKL/TRAIL on SOD1/SOD2 mRNA expression under inflammatory 
and hyperglycemic conditions. HAECs were exposed to (i) TNF⍺ (100 ng/mL) or (ii) glucose (15-30 mM) 
+/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours, prior to analysis of (A) SOD1 and (B) SOD2 mRNA 
expression. SOD1/SOD2 levels were determined by RT-qPCR, employing GAPDH as an endogenous control. 
* p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise stated; bars indicate 



































Appendix 5.4. The effects of RANKL/TRAIL on SOD1/SOD2 protein expression under inflammatory 
and hyperglycemic conditions. HAECs were exposed to (i) TNF⍺ (100 ng/mL) or (ii) glucose (15-30 mM) 
+/- RANKL (25 ng/mL) or TRAIL (5 ng/mL) for 72 hours, prior to analysis of (A) SOD1 and (B) SOD2. 
Protein expression levels were determined by Western blotting, quantified by scanning densitometry and 
normalised to GAPDH. Blots are representative. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated 
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Appendix 5.5. The effects of TNF⍺ +/- NAC on mRNA and protein expression levels in HAECs. HAECs 
were exposed to TNF⍺ (100 ng/mL) +/- NAC (5 mM) for 72 hours prior to analysis. (A) Release levels of (i) 
BMP-2, (ii) ALP and (iii) IL-6, and (B) intracellular levels of (i) BMP-2 and (ii) ALP were determined by 
ELISA and enzyme activity where appropriate. Media and lysate values are normalised to 105 cells and total 
protein respectively. (C) Non-canonical NF-B activation was determined by Western blotting, quantified by 
scanning densitometry and normalised to GAPDH. Blots are representative. * p < 0.05; ** p < 0.01; *** p < 
0.001 compared to untreated control unless otherwise stated; bars indicate statistical significance between 
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Appendix 5.6. The effects of TNF⍺ +/- NAC on ROS generation in HAECs. HAECs were exposed to 
TNF⍺ (100 ng/mL) +/- NAC (5 mM) for 24 hours prior to analysis. DHE stain (3 µM) was added 30 minutes 
prior to the end of the incubation period; DAPI was added 3 minutes prior to analysis for fluorescence 
microscopy only. (A) ROS generation was measured by flow cytometry, quantified by histogram area; 
presented histograms are representative. (B) (i) ROS generation via DHE staining and (ii) DAPI nuclear 
counterstain were visualised using a Nikon Eclipse Ti fluorescence microscope. Images (40X 
magnification) are representative. ** p < 0.01; *** p < 0.001 compared to untreated control unless otherwise 
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Appendix 5.7. The effects of siRNA knockdown on pro-calcific indices in HAECs. HAECs were subject to (i) 
NFκB2 or (ii) non-targeting siRNA knockdown for 72 hours prior to analysis. (A) HAEC release profile of pro-
calcific indices, and (B) intracellular BMP-2/ALP were assessed by ELISA and enzyme assay where appropriate. 
(C) Canonical NF-κB activation was determined by Western blotting, quantified by scanning densitometry and 















































Appendix 5.8. The effects of RANKL following endothelial siRNA knockdown in co-cultured 
HASMCs. HAECs were subject to nt-siRNA/NFκB2 knockdown in transwell inserts for 48 hours, prior 
to co-culture with confluent HASMCs. HAECs in the luminal compartment were then treated with 
RANKL (5-25 ng/mL) for 72 hours prior to analysis of protein/mRNA responses in the underlying 
HASMCs. (A) (i) Runx2, (ii) OPG and (iii) IL-6 mRNA expression levels were determined by RT-qPCR, 
employing GAPDH as an endogenous control. (B) IL-6 release in the subluminal space, alongside (C) 
intracellular OPG, were assessed by ELISA; media and lysate analysis were normalised to 105 cells and 
total protein respectively. * p < 0.05; ** p < 0.01; *** p < 0.001 compared to untreated control unless 
otherwise stated; bars indicate statistical significance between treatment groups.  
  
  
  
